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Summary 
Epilepsy  is  a  common  and  serious  but  treatable  neurological  disorder.  Current  treatment 
is  limited  by  high  rates  of  adverse  drug  effects  and  lack  of  complete  seizure  control  in  a 
significant  proportion  of  patients.  Epilepsy  is  suitable  for  pharmacogenetic  exploration 
because  response  to  antiepileptic  drug  (AED)  treatment  can  be  quantified  and  adverse 
effects  can  be  assessed  by  several  measures.  Furthermore,  there  is  substantial 
knowledge  of  the  pharmacodynamics  and  pharmacokinetics  of  AEDs  and  some 
candidate  genes  implicated  in  the  disorder  have  been  identified.  However,  recent  studies 
examining  the  association  of  particular  genes  and  their  genetic  variants  with  seizure 
control  and  adverse  drug  effects  have  not  provided  definitive  conclusions. 
Commonly,  pharmacogenetic  studies  focus  primarily  on  single  nucleotide 
polymorphisms,  which  are  single  base  variations  in  the  sequence  of  genes.  This  form  of 
genetic  variant  has  the  potential  to  influence  the  structure  and/or  function  of  the  proteins 
those  genes  encode.  Candidate  genes  for  pharmacogenetic  studies  in  epilepsy  are  those 
that  encode  proteins  directly  involved  in  the  pharmacokinetics  (drug  metabolizing 
enzymes  (DMEs),  drug  transporters  (DTPs)  and  pharmacodynamics  (voltage-gated 
sodium  channels,  y-aminobutyric  acid  receptors  (GABA)  of  AED  action.  These 
principals  have  been  applied  to  this  research  programme,  investigating  the  influence  of 
genetic  variability  on  the  clinical  pharmacology  of  carbamazepine  (CBZ)  and 
lamotrigine  (LTG). 
Although  many  genes  could  influence  response  to  these  drugs,  obvious  candidates  are 
known.  CBZ  and  LTG  target  the  a-subunit  of  the  voltage-gated  sodium  channels.  CBZ 
metabolism  involves  several  DMEs  such  as  CYP3A4,  CYP3A5,  CYPIA2,  microsomal 
epoxide  hydrolase  (mEH)  and  UGT2B7,  and  LTG  is  a  probable  substrate  of  P- 111 
glycoprotein  (P-gp).  Common  polymorphisms  in  genes  encoding  these  proteins  were 
examined  as  initial  genetic  factors  that  may  influence  the  response  to  CBZ  and  LTG 
monotherapy.  These  polymorphisms  include  CYP3A4  g.  -392A>G,  CYP3A5 
g.  6986A>G,  CYP1A2  g.  5734C>A,  EPHX1  c.  337T>C,  EPHX1  c.  416A>G,  UGT2B7 
c.  802C>T,  ABCBI  c.  1236C>T,  ABCBI  c.  2677G>T/A,  ABCBI  c.  3435C>T  and 
SCN2A  c.  56G>A. 
The  prevalence  of  these  common  polymorphisms  was  evaluated  in  a  400-strong  study 
population  from  a  single  research  unit.  The  polymorphisms  were  identified  by 
polymerase  chain  reaction-restriction  fragment  length  polymorphism  (PCR-RFLP),  with 
the  exception  of  EPHX1  c.  337  >C,  which  was  identified  by  direct  sequencing  assay. 
Genotype  distribution  of  each  polymorphism  was  examined  for  Hardy-Weinberg 
equilibrium  (HWE).  Minor  allele  frequency  ranged  between  3.5%  (CYP3A4  -392G) 
and  48.0%  (ABCB  1  1236T).  Allele  and  genotype  distributions  were  comparable  to 
published  data  for  other  Caucasian  populations.  All  genotype  distributions  were 
consistent  with  HWE.  As  such,  no  apparent  systematic  error  in  the  genotyping  assay 
was  identified. 
The  influence  of  common  polymorphisms  in  DME  and  sodium  channel  genes  on  the 
optimal  dose  of  CBZ  was  assessed  in  a  cohort  of  70  patients.  Optimal  dose  in  this  study 
was  defined  as  the  final  dose  given  to  a  patient  that  successfully  maintained  optimal 
seizure  control  without  intolerable  side  effects.  Several  basic  clinical  factors  such  as  age 
and  gender  were  also  examined  as  potential  predictors.  The  effect  of  predictors  on  the 
optimal  dose  of  CBZ  was  investigated  using  linear  regression  analysis.  This  study 
revealed  that  age  and  common  polymorphisms  in  the  EPHX  1  gene  (c.  337T>C  and 
c.  416A>G)  are  potential  predictors  for  optimal  dose  of  CBZ.  The  significant  effects  of 
EPHX  1  variants  may  be  explained  by  their  significant  contribution  to  the  inactivation  of iv 
CBZ.  These  potential  predictors  explain  approximately  15%  of  the  inter-individual 
variation  in  CBZ  dose  requirements. 
The  prevalence  of  common  polymorphisms  in  genes  that  encode  CBZ-related  DMEs 
was  examined  in  an  effort  to  identify  a  unique  adverse  effect  profile.  A  total  of  14  out  of 
104  patients  receiving  CBZ  monotherapy  experienced  at  least  one  intolerable  adverse 
effect  which  led  to  withdrawal  of  treatment.  Of  these,  9  patients  experienced  central 
nervous  system  (CNS)-related  effects  and  5  patients  experienced  idiosyncratic 
reactions.  The  variant  allele  distributions  were  compared  between  patients  who 
experienced  the  adverse  effects  and  those  who  did  not  by  an  appropriate  contingency 
table  test.  There  was  no  significant  difference  in  allele  distributions  between  these 
groups,  either  for  CNS-related  effects  or  idiosyncratic  reactions.  These  preliminary 
findings  suggest  that  common  polymorphisms  in  DME  genes  do  not  form  a  unique 
profile  which  increases  the  risk  of  developing  intolerable  CBZ  adverse  effects. 
The  prevalence  of  common  polymorphisms  in  ABCB  1  and  SCN2A  genes  was 
investigated  between  seizure  free  and  non-seizure  free  patients  who  received  LTG 
monotherapy  as  the  first  AED  treatment.  A  total  of  79  patients  were  involved  in  this 
study  cohort.  Of  these,  39  patients  had  reached  seizure  free  status  within  the  first  year  of 
treatment.  Differences  in  the  distribution  of  gene  variants  were  examined  by  logistic 
regression  analysis.  No  difference  was  observed  in  the  distribution  of  these 
polymorphisms  between  the  two  groups,  whether  analysed  by  allele,  genotype, 
haplotype  or  diplotype  frequency.  It  is  unlikely  that  common  polymorphisms  in  ABCB1 
and  SCN2A  genes  influence  the  expression  and/or  activity  of  their  respective  proteins  to 
the  level  at  which  they  can  dictate  response  to  LTG  therapy. V 
The  influence  of  common  polymorphisms  in  ABCB  1  and  SCN2A  genes  on  the  optimal 
dose  of  LTG  was  assessed  in  a  cohort  of  94  patients.  Optimal  dose  in  this  study  was 
defined  as  the  final  dose  given  to  the  patients  that  successfully  maintained  seizure 
freedom  for  at  least  1  year  with  LTG  monotherapy.  Several  basic  clinical  factors  such  as 
age  and  gender  were  also  examined  as  potential  predictors.  The  effect  of  predictors  on 
the  optimal  dose  of  LTG  was  investigated  using  linear  regression  analysis.  This  study 
revealed  that  gender  and  common  polymorphisms  in  the  ABCB  1  gene  (c.  1236C>T  and 
c.  3435C>T)  are  potential  predictors  for  optimal  dose  of  LTG.  These  predictors  explain 
approximately  17%  of  the  inter-individual  variation  in  LTG  dose  requirement.  These 
findings  further  highlight  the  potential  role  of  P-gp  in  the  management  of  epilepsy 
The  final  study  investigated  the  influence  of  ABCB  1  c.  1236C>T  and  ABCB  1 
c.  3435C>T  polymorphisms  on  the  pharmacokinetics  of  LTG.  A  total  of  156  blood 
samples  from  50  patients  receiving  LTG  monotherapy  were  available  for  analysis.  The 
influence  of  ABCB1  variants  was  evaluated  by  population  pharmacokinetics.  This 
approach  successfully  estimated  the  oral  clearance  of  LTG  monotherapy  at  steady-state. 
However,  the  absorption  rate  constant  (Ka)  and  volume  of  distribution  (Vd)  of  LTG 
were  poorly  estimated.  The  inclusion  of  common  polymorphisms  in  the  ABCB  1  gene  in 
the  pharmacokinetic  model  did  not  improve  the  estimation  of  oral  clearance.  This  may 
indicate  that  common  variants  of  ABCB  I  do  not  influence  clearance  of  LTG. 
In  conclusion,  these  results  suggest  that  optimal  doses  of  CBZ  and  LTG  are  associated 
with  polymorphisms  in  genes  involved  in  their  respective  pharmacokinetics.  Common 
genetic  polymorphisms  of  other  DMEs  that  are  responsible  for  CBZ  metabolism  did  not 
significantly  associate  with  CBZ  dose  and  none  were  associated  with  CBZ  adverse 
effects.  Polymorphisms  in  the  ABCB  1  gene  may  not  be  useful  in  predicting  response  to 
LTG  treatment  and  did  not  influence  the  oral  clearance  of  LTG.  The  present  study  is vi 
preliminary  but  provides  encouragement  for  future  investigation,  particularly,  large 
scale  studies  of  multiple  polymorphisms  and  combinations  thereof  which  attempt  to 
identify  a  panel  of  genotypes  that  can  be  used  as  predictors  of  an  individual  patient's 
response  to  AED  treatment. vii 
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GENERAL  INTRODUCTION Chapter  1:  General  Introduction 
1.1  Epilepsy 
1.1.1  History  of  epilepsy 
The  word  `epilepsy'  originates  from  a  Greek  word,  epilambanein,  which  means  'to 
seize'  or  `to  attack'  (World  Health  Organization,  2001),  and  the  term'epilepsia'  is  used 
to  denote  a  seizure.  In  ancient  times,  epilepsy  or  an  epileptic  attack  was  depicted  as  an 
abrupt  suspension  or  seizing  of  a  person's  senses  (Gastaut  &  Broughton,  1972).  The 
basic  concepts  of  epilepsy  in  ancient  Indian  medicine  were  identified  during  the  Vedic 
period  in  4500-1500  BC.  The  complete  Ayurvedic  medical  system,  Charaka  Samhit, 
described  epilepsy  as'apasmara'  which  means  `loss  of  consciousness'.  A  description  of 
epilepsy  was  also  found  in  a  Babylonian  textbook  of  medicine  dating  as  far  back  as 
1067  BC,  and  which  emphasized  the  supernatural  nature  of  epilepsy  (Pierce,  2002).  A 
later  description  of  epilepsy  appeared  in  the  Hippocratic  text  entitled  "On  the  Sacred 
Disease".  In  describing  epilepsy,  Hippocrates  wrote  the  following  statement: 
"It  is  thus  with  regard  to  the  disease  called  Sacred:  it  appears  to  me 
to  be  nowise  more  divine  nor  more  sacred  than  other  diseases,  but 
has  a  natural  cause  from  the  originates  like  other  affections 
(Hippocrates,  400  B.  C.  E.  )" 
Hippocrates  has  highlighted  the  fact  that  epilepsy  is  just  one  kind  of  brain  disorder.  This 
notion  has  countered  the  superstitious  thought  that  epilepsy  is  a  curse  or  a  prophetic 
power.  Galen  (AD  130-200)  described  three  types  of  fits,  and  suggested  that  epilepsy 
was  a  brain  disorder  related  to  an  accumulation  of  "thick  humours"  (Pierce,  2002). 
Later,  in  the  19th-century,  John  Hughlings  Jackson  deduced  the  basic  pathophysiology 
of  epileptic  seizures  through  his  clinical  observation  (Hogan  &  Kaiboriboon,  2003). Chapter  1:  General  Introduction 
Jackson's  contributions  to  the  field  of  epilepsy  continue  to  be  recognised  in  modern 
medical  sciences. 
1.1.2  Epilepsy  and  its  syndromes 
Epilepsy  is  one  of  the  most  important  clinical  syndromes,  with  a  prevalence  range  of  3 
to  7.3  per  1000  population  (Wright  et  al.,  2000;  Al  Rajeh  et  al.,  2001;  Oun  et  al.,  2003; 
Hui  &  Kwan,  2004).  It  is  a  difficult  disorder  to  control  (Spear,  2001)  and  may  even 
cause  sudden  unexplained  death  (Pedley  &  Hauser,  2002).  The  term  epilepsy  refers  to 
the  recurrence  of  seizures  from  all  types  of  pathological  states  or  diseases  (Janz,  1985). 
The  International  League  Against  Epilepsy  (ILAE)  and  the  International  Bureau  for 
Epilepsy  (IBE)  consensus  defined  an  epileptic  seizure  and  epilepsy  as  follows: 
"An  epileptic  seizure  is  a  transient  occurrence  of  signs  and/or 
symptoms  due  to  abnormal  excessive  or  synchronous  neuronal 
activity  in  the  brain  (Fisher  et  al.,  2005)" 
"Epilepsy  is  a  disorder  of  the  brain  characterized  by  an  enduring 
predisposition  to  generate  epileptic  seizures  and  by  the 
neurobiologic,  cognitive,  psychological,  and  social  consequences  of 
this  condition.  The  definition  of  epilepsy  requires  the  occurrence  of 
at  least  one  epileptic  seizure  (Fisher  et  al.,  2005)" 
Seizures  occur  due  to  a  sudden,  excessive,  rapid  discharge  in  the  grey  matter  of  some 
part  of  the  brain;  this  might  spread  further  all  over  the  brain,  to  produce  generalised 
syndromes.  The  brain's  electrical  discharge  may  result  in  an  almost  instantaneous  loss 
of  consciousness,  alteration  of  perception  or  impairment  of  psychic  function,  convulsive Chapter  1:  General  Introduction  4 
movement,  disturbance  of  sensation,  or  some  combination  thereof  (Victor  &  Ropper, 
2001). 
Epilepsy  syndromes  are  commonly  characterised  by  their  clinical  presentation  such  as 
seizure  type,  age  at  onset,  brain  electrical  pattern,  causal  factors  and  trend  of  genetic 
inheritance  (Brodie  &  French,  2000).  Generally,  epilepsy  syndromes  are  widely 
grouped  into  idiopathic,  cryptogenic  and  symptomatic  (Commission,  1989;  Brodie  & 
French,  2000).  Idiopathic  or  primary  epilepsies  are  epileptic  syndromes  with  an 
unknown  cause  except  perhaps  a  genetic  one;  cryptogenic  epilepsies  are  epileptic 
syndromes  with  uncertain  nature  of  origin  and  the  seizures  may  be  the  only  sign  of  brain 
abnormalities;  meanwhile  symptomatic  or  secondary  epilepsies  are  epileptic  syndromes 
with  clearly  known  causes  (Victor  &  Ropper,  2001;  Brodie  et  al.,  2005).  Epilepsy 
treatment  decisions  are  based  principally  on  the  type  of  epilepsy  syndrome  and  the 
kinds  of  seizures  that  occur. 
1.1.3  Classification  of  seizures 
The  present  commonly  used  classification  was  proposed  by  the  ILAE  more  than  twenty 
years  ago  (TABLE  1.1;  Commission,  1981)  using  clinical  description  and 
electroencephalogram  (EEG)  characteristics.  The  limitations  of  this  classification  are 
becoming  increasingly  apparent  with  advances  in  imaging  technology  and 
neurophysiology.  Nevertheless,  the  present  system  has  gained  widespread  acceptance 
and  provides  an  effective  means  of  communication  among  clinicians. 
The  current  classification  divides  seizures  broadly  into  partial  and  generalised.  Partial 
seizures,  also  called  focal,  are  those  seizures  that  begin  in  a  focal  region  of  the  cortex  in Chapter  1:  General  Introduction  5 
one  hemisphere.  Based  on  the  symptoms  of  the  seizures,  partial  seizures  can  be 
subdivided  into  simple  partial  seizures  and  complex  partial  seizures. 
TABLE  1.1.  International  classification  of  epileptic  seizure.  Adapted  from 
Commission  (1981). 
Partial  (focal)  seizures  (seizures  beginning  locally) 
A  Simple  (consciousness  not  impaired) 
i  With  motor  symptoms 
ii  With  somatosensory  or  special  sensory  symptoms 
iii  With  autonomic  symptoms  or  signs 
iv  With  psychic  symptoms 
B  Complex  (with  impaired  consciousness) 
i  Simple  partial  onset  followed  by  impairment  of 
consciousness 
ii  Impaired  consciousness  at  onset 
C  Partial  seizures  evolving  into  secondary  generalised  seizures 
II  Generalised  seizures  (convulsive  or  non-convulsive) 
A  Absence  seizures 
i  Typical  (petit  mal) 
ii  Atypical 
B  Myoclonic  seizures 
C  Clonic  seizures 
D  Tonic  seizures 
E  Tonic-clonic  seizures 
F  Atonic  seizures 
III  Unclassified  seizures 
Simple  partial  seizures  have  no  impact  on  the  level  of  consciousness.  Depending  on  the 
area  of  the  brain  affected,  these  seizures  could  be  expressed  as  shaking  of  a  small  part  of 
the  body,  an  unusual  tingling  or  numbness  of  a  localised  body  part,  or  even  an  unusual Chapter  1:  General  Introduction  6 
smell,  visual  hallucination,  or  ill-defined  feeling.  Complex  partial  seizures  occur  when 
the  abnormal  electrical  activity  involves  parts  of  the  brain  that  affect  level  of 
consciousness.  Thus,  the  critical  feature  of  a  complex  partial  seizure  is  that  the  person 
has  altered  consciousness,  so  that  he  may  be  confused  or  staring  unresponsively.  There 
may  also  be  subtle,  repetitive  and  stereotypical  movements  of  the  face  or  extremities. 
Sometimes  a  complex  partial  seizure  can  start  in  just  one  area  and  spread  throughout  the 
entire  brain,  resulting  in  a  generalised  tonic-clonic  seizure.  This  seizure  type  is  known 
as  complex  partial  with  secondary  generalisation. 
Generalised  seizures  are  caused  by  abnormal  electrical  activity  that  occurs  over  the 
entire  brain  simultaneously.  This  group  of  seizures  affect  the  level  of  awareness  and 
muscle  movement  of  all  extremities.  Absence  seizures  are  also  known  as  "petit  mal". 
They  are  described  as  staring  spells.  These  seizures  typically  start  in  childhood  and  are 
often  outgrown  by  adolescence,  although  adults  can  occasionally  have  absence  seizures. 
Myoclonic  seizures  are  characterized  by  sudden  brief  jerks  of  a  single  muscle  or  muscle 
group.  It  may  appear  as  if  sufferers  have  been  startled  and  you  may  also  see  the  head  or 
body  suddenly  bend  forward  or  backward.  Atonic  seizures  are  also  very  sudden  brief 
seizures,  but  they  involve  loss  of  all  muscle  tone.  The  patient  will  suddenly  go  limp  and 
fall  to  the  ground.  There  is  a  significant  risk  of  head  injury  during  the  fall.  Tonic 
seizures  involve  stiffening  of  parts  of  the  body  or  the  entire  body.  Unlike  tonic-clonic 
seizures,  there  is  no  progression  to  a  clonic  phase.  Tonic-clonic  seizures  are  also  known 
as  "grand  mal".  They  generally  start  with  a  tonic  phase  with  stiffening  of  the  entire 
body.  The  eyes  may  roll  back  in  the  head,  the  back  arches,  and  arms  and  legs  stiffen. 
The  clonic  part  is  described  as  rhythmic  jerking  of  the  entire  body.  Once  the  seizure  is 
over,  the  patient  may  feel  worn  out  and  may  even  sleep  for  a  period  of  time.  They  may 
also  experience  some  confusion. Chapter  1:  General  Introduction 
1.1.4  Diagnosis  of  epilepsy 
The  diagnosis  procedure  aims  to  determine  whether  the  patient  has  epilepsy,  and  if  so, 
the  syndromic  classification  and  underlying  aetiology.  Epilepsy  may  be  difficult  to 
diagnose  in  the  early  stages  especially  in  the  absence  of  a  witnessed  account.  It  is 
imperative  that  the  physician  obtains  a  complete  patient  history,  including  details  of 
birth,  childhood,  family  history,  and  medication  regimen;  a  thorough  medical  history, 
including  illnesses  of  the  nervous  system;  and  a  thorough  history  of  drug  and  alcohol 
use.  A  detailed  description  of  the  seizures  is  important  to  distinguish  seizure  types. 
The  primary  tool  in  the  diagnosis  of  epilepsy  is  the  EEG  (King  et  al.,  1998),  which 
measures  electrical  activity  in  the  brain.  Seizure  disorders  produce  characteristic 
patterns  in  an  EEG  test.  In  patients  with  partial  epilepsy,  the  EEG  may  also  help  to 
localise  the  area  of  seizure  onset.  Inpatient  video-EEG  monitoring  is  used  to  localise 
seizure  onset  in  patients  undergoing  evaluation  for  epilepsy  surgery.  It  is  also  used  to 
confirm  epilepsy  when  the  diagnosis  is  uncertain.  Neuroimaging  approaches  are  another 
means  to  identify  any  underlying  epileptogenic  structural  abnormalities  and  are 
indicated  in  patients  suspected  to  have  localisation-related  epilepsy.  Magnetic  resonance 
imaging  (MRI)  is  undoubtedly  the  investigation  of  choice  (Duncan,  1997).  However, 
computer  tomography  should  be  used  in  preference  to  MRI  in  patients  with  cardiac  pace 
makers,  metal  aneurysm  clips,  or  severe  claustrophobia,  or  when  MRI  is  not  available. 
Imaging  techniques  that  show  cerebral  function  play  a  growing  role  in  the  evaluation  of 
epilepsy.  These  techniques  include  functional  MRI,  magnetoencephalography,  magnetic 
resonance  spectroscopy,  single  photon  emission  computed  tomography,  and  positron 
emission  tomography  (Duncan  1997).  Making  an  accurate  diagnosis  of  an  epileptic 
syndrome  may  allow  the  clinician  to  define  the  likely  prognosis,  provide  appropriate 
counselling  and  choose  the  most  appropriate  treatment  (Brodie  &  French,  2000). Chapter  1:  General  Introduction  $ 
1.2  Treatment  of  Epilepsy 
Treatment  approaches  for  the  epilepsies  can  include  pharmacotherapy  using  AEDs, 
neurosurgical  procedures,  removal  of  causative  and  precipitating  factors,  and  regulation 
of  physical  and  mental  activities  (Victor  &  Ropper,  2001).  AED  treatment  is  the 
commonest  initial  approach  to  treat  epilepsy.  AEDs  can  reduce  or  stop  seizures 
altogether.  Some  patients  with  epilepsy  do  not  respond  to  several  AEDs  and  in  this 
situation  those  with  partial  epilepsy  might  be  considered  for  surgery.  Another  option  for 
patient  who  are  resistant  to  AEDs  is  vagal  nerve  stimulation  (Brodie  et  al.,  2005). 
1.2.1  History  of  antiepileptic  drug  development 
The  first  effective  agent  in  the  treament  of  epilepsy  was  bromide  (Pearce,  2002). 
However,  the  usage  of  bromide  was  limited  due  to  an  association  with  frequent  side 
effects.  In  1912,  phenobarbital  (PB)  was  introduced  as  a  better-tolerated  antiepileptic 
agent.  In  subsequent  years,  Merritt  and  Putnam  introduced  a  new  non-sedating  AED, 
phenytoin  (PHT;  Merritt  &  Putnam,  1938).  Since  its  introduction,  PHT  has  been  a  first- 
line  medication  for  the  prevention  of  partial  and  tonic-clonic  seizures,  and  the  acute 
treatment  of  seizures  and  status  epilepticus.  In  1953,  CBZ  was  synthesised  at  the  Geigy 
laboratory  by  Schindler  and  Blattner  (Schmutz,  1985).  It  was  originally  developed  as  an 
antipsychotic  and  its  antiepileptic  properties  were  not  observed  clinically  until  1963 
(Brodie  &  Dichter,  1997).  Sodium  valproate  (VPA)  was  serendipitously  discovered  in 
1963  by  Pierre  Eymard,  when  it  was  used  as  a  solvent  in  testing  other  potential  AEDs 
(Brodie  &  Dichter,  1997).  Since  the  introduction  of  VPA,  many  new  AEDs  have  been 
developed  and  marketed  (FIGURE  1.1).  Generally,  AEDs  can  be  divided  into  two 
generations,  the  established  AEDs  and  the  modem  AEDs.  The  modern  AEDs  are Chapter  1:  General  Introduction 
believed  to  possess  better  efficacy  and  tolerability  profiles  than  their  established 
counterparts. 
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FIGURE  1.1.  Year  of  introduction  of  antiepileptic  drugs  to  the  clinical 
management  of  epilepsy  in  the  United  Kingdom. 
1.2.2  Indications  of  antiepileptic  drugs 
Starting  treatment  with  an  AED  is  a  major  event  for  the  patient  and  should  not  be 
undertaken  without  careful  evaluation.  AED  therapy  is  long  term,  usually  for  at  least 
three  years  and,  depending  on  circumstances,  sometimes  for  life.  The  modem  AEDs 
complement  established  AEDs  that  are  well  known  to  most  clinicians.  In  addition  to Chapter  1:  General  Introduction  10 
providing  more  options  for  the  adjunctive  treatment  of  seizures,  some  of  these  new 
compounds  have  been  approved  for  monotherapy  (TABLE  1.2). 
TABLE  1.2.  Approved  indications  for  antiepileptic  drugs. 
Partial  Broad  Infantile  Absence 
Drug  seizure"  spectrumb  spasms  only 
Established  AEDs 
Carbamazepine  + 
Ethosuximide 
Phenobarbitone  ++ 
Phenytoin  + 
Valproic  acid  +++ 
New  AEDs 
Gabapentin  + 
Lamotrigine  ++ 
Levetiracetam  ++ 
Oxcarbazepine  + 
Pregabalin`  + 
Tiagabine`  + 
Topiramate  ++ 
Vigabatrin°  ++ 
Zonisamide°  +++ 
+ 
a  Including  secondarily  generalised 
b  Most  seizure  types,  including  partial,  absence,  myoclonic,  tonic  and  both 
primary  and  secondarily  generalised  tonic-clonic 
Licensed  as  adjunctive  treatment/add-on  therapy  only 
(Kwan  et  al.,  2001;  Perucca,  2001;  Bazil  &  Pedley,  2003) 
One  of  the  advantages  of  using  established  AEDs  is  that  their  spectrum  of  efficacy, 
adverse-effect  profiles,  drug-drug  interactions,  and  idiosyncrasies  are  relatively  well Chapter  1:  General  Introduction  11 
known.  Although  some  side  effects  of  the  established  AEDs  may  be  undesirable,  they 
are  usually  predictable.  AEDs  are  generally  chosen  according  to  seizure  type.  LTG, 
controlled-release  CBZ,  topiramate  or  VPA  are  first-line  monotherapy  options  for 
partial  seizures.  For  generalised  seizures,  LTG,  topiramate  or  VPA  are  the  options  and, 
as  these  drugs  are  broad  spectrum,  they  may  also  be  used  when  there  is doubt  about  the 
classification  (Kwan  et  al.,  2001;  Perucca,  2001;  Bazil  &  Pedley,  2003).  Broad 
spectrum  AEDs  usually  cover  partial,  absence,  myoclonic,  tonic  and  both  primary  and 
secondarily  generalised  tonic-clonic  seizures.  Although  as  effective  as  other  established 
AEDs,  PHT  is  no  longer  considered  as  a  first-line  treatment  because  of  its  side  effect 
profile  when  employed  on  a  chronic  basis  and  its  saturation  kinetics,  which  require 
routine  monitoring  of  its  plasma  concentrations. 
1.2.3  Mechanisms  of  action  of  antiepileptic  drugs 
Experimental  studies  (both  in  vitro  and  in  vivo)  together  with  clinical  observations  have 
contributed  to  understanding  of  the  mechanisms  of  action  of  AEDs.  However,  current 
knowledge  on  mechanisms  of  action  is  of  limited  application  in  the  initiation  of  therapy 
for  individual  patients.  This  is  because  of  a  poor  understanding  of  seizure 
pathophysiology.  Therefore,  most  first  line  drugs  are  usually  chosen  on  the  basis  of 
available  clinical  evidence  (Perucca,  2001).  Knowledge  of  mechanisms  of  action  can 
have  an  important  role  in  determining  which  AEDs  to  add-on  in  those  patients  who  fail 
to  respond  to  the  first  drug  (Deckers  et  al.,  2000).  Combining  AEDs  with  different 
mechanisms  of  action  can  improve  the  percentage  of  patients  with  controlled  seizures, 
possibly  up  to  20  percent  (Stephen  &  Brodie,  2002).  The  recent  influx  of  newer  AEDs 
into  clinical  practice  may  elevate  knowledge  of  mechanisms  of  action  amongst  other 
potentially  important  drug  selection  criteria,  particularly  in  the  absence  of  sufficient 
clinical  evidence  or  experience  (Brodie,  1999;  Kwan  et  al.,  2001). Chapter  1:  General  Introduction  12 
The  mechanisms  of  action  of  AEDs  are  presented  in  TABLE  1.3.  Three  mechanisms 
have  been  proposed  to  explain  the  effects  of  AEDs:  modulation  of  voltage-dependent 
ion  channel  (sodium,  calcium,  potassium),  potentiation  of  GABA-mediated  inhibitory 
neurotransmission  and  inhibition  of  glutamate-mediated  excitatory  neurotransmission 
(Meldrum,  2001).  The  opening  of  voltage-gated  sodium  channels  is  responsible  for  the 
upstroke  of  the  neuronal  action  potential  and  these  proteins  essentially  control  the 
intrinsic  excitability  of  the  nervous  system  (Clare  et  al.,  2000).  Sodium  channels  cycle 
between  functional  states  (open,  closed,  inactivated)  within  a  matter  of  milliseconds. 
This  character  is  important  in  producing  the  rapid  burst  of  action  potentials  during 
normal  neuronal  transmission,  and  particularly  in  the  production  of  epileptic  discharges 
(Kwan  et  al.,  2001).  Many  AEDs  such  as  PHT,  CBZ  and  LTG  block  the  neuronal 
voltage-gated  sodium  channels  as  their  principal  antiseizure  action  (Tunnicliff,  1996; 
White,  1999). 
The  key  structure  and  sequence  homology  of  voltage-dependent  calcium  channels  are 
shared  with  sodium  channels  (Anderson  &  Greenberg,  2001).  Low  and  high  activation 
thresholds  are  used  to  widely  categorise  calcium  channels.  L-type  calcium  channels  are 
expressed  in  muscle,  brain  and  endocrine  cells.  N-,  P/Q-  and  R-  type  calcium  channels 
are  found  mainly  in  neurones.  All  of  these  channels  require  a  strong  depolarization  (i.  e. 
high  threshold)  to  be  activated.  T-type  calcium  channels  are  low  threshold  channels  and 
are  found  in  various  cell  types  (Ertel  et  al.,  2000).  The  rhythmic  3-Hz  spike-and-wave 
discharge  that  is  present  in  generalised  absence  seizures  is  believed  to  be  a  product  of 
activation  of  these  low-threshold  T-type  calcium  channels  (Sohal  &  Huguenard,  2001). 
Blockade  of  the  voltage-dependent  calcium  channels  in  a  subtype-specific  manner 
explains  the  effects  of  several  AEDs.  For  example,  LTG  reduces  N-  and  P-type  calcium 
currents,  diminishing  repetitive  neuronal  firing,  and  consequently  controlling  seizure, 
without  affecting  L-type  calcium  currents  (Pisani  et  al.,  2004). Chapter  1:  General  Introduction 
TABLE  1.3.  Proposed  mechanisms  of  antiepileptic  drugs. 
13 
I  Na+  1  Ca  T  K+  T  inhibitory  j  excitatory 
Drug  channels  channels  channels  transmission  transmission 
Established  AEDs 
Carbamazepine  +++ 
Ethosuximide  +++ 
Phenobarbital  +  +++  + 
Phenytoin  +++ 
Valproic  acid  ++  ++  + 
New  AEDs 
Felbamate  ++  ++  ++  ++ 
Gabapentin  +  +++  + 
Lamotrigine  +++  + 
Levetiracetam  +++  ++ 
Oxcarbazepine  +++  ++ 
Tiagabine  +++ 
Topiramate  ++  ++  ++  ++ 
Vigabatrin  +++ 
Zonisamide  ++  ++ 
+++  =  primary  action,  ++  =  probable  action  and  +=  possible  action  (Kwan  et  al., 
2001;  Madeja  et  al.,  2003). 
The  tetrameric  structure  of  neuronal  voltage-gated  potassium  channels  is  derived  from 
the  association  of  large  protein  complexes.  Their  monomers  are  related  to  sodium  and 
calcium  channel  subunits  (Anderson  &  Greenberg,  2001).  Activation  of  potassium 
channels  suppresses  the  generation  of  action  potentials  (Spitzer  et  al.,  2002).  Studies 
have  reported  levetiracetam  (Madeja  et  al.,  2003)  and  retigabine  (Rundfeldt,  1999) 
activate  potassium  channel  conductance  as  one  of  their  mechanisms  of  antiseizure 
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GABA  is  the  principal  inhibitory  neurotransmitter  in  mammalian  brain  and  is  released 
at  up  to  40%  of  all  synapses  (Olsen  &  Avoli,  1997).  Insufficiency  of  GABAergic 
neurones  has  been  proposed  as  a  mechanism  of  seizure  generation  (Loscher  &  Schmidt, 
2002).  GABA-related  mechanisms,  such  as  the  promotion  of  GABA  synthesis,  increase 
in  GABA  release,  facilitation  of  GABA  receptors  and  a  decrease  in  GABA  inactivation 
are  associated  with  AEDs  such  as  VPA,  gabapentin,  vigabatrin  and  tiagabine  (Errante  et 
al.,  2002). 
The  complementary  neurotransmitter  to  GABA  is  glutamate,  which  is  the  principal 
excitatory  neurotransmitter  in  the  mammalian  CNS  (Meldrum  et  al.,  1999).  Seizures 
have  been  associated  with  glutamatergic  system  abnormalities,  including  over- 
activation  of  glutamatergic  transmission  and  defective  ionotropic  and  metabotropic 
glutamate  receptor  properties  (Meldrum  et  al.,  1999).  None  of  the  licensed  AEDs  act 
solely  on  the  glutamatergic  neurones,  but  glutamate  receptor  blockade  is  associated  with 
some  AEDs  (Meldrum,  2001).  For  example,  felbamate  and  topiramate  are  believed  to 
act  on  the  NMDA-  and  AMPA-subtypes  of  glutamate  receptors,  respectively  (Harty  & 
Rogawski,  2000;  Kaminski  et  al.,  2004). 
1.2.4  Clinical  pharmacokinetics  of  antiepileptic  drugs 
Evidence  supporting  the  relationship  between  plasma  drug  concentration  and  clinical 
response  to  established  AEDs  is  available  to  aid  dosage  individualization  (Perucca, 
1999;  Affolter  et  al.,  2003).  Drug  therapeutic  ranges  were  derived  from  population 
pharmacokinetic  studies  using  statistical  concepts  in  which  most  of  the  patients 
demonstrated  an  acceptable  clinical  response  with  no  intolerable  side  effects  (Patsalos, 
2001).  Nevertheless,  some  patients  may  demonstrate  good  seizure  control  below  the 
minimum  limit  of  the  therapeutic  range,  and  intoxication  may  also  be  present  in  some Chapter  1:  General  Introduction  15 
patients  with  plasma  drug  concentrations  within  the  therapeutic  range  (Browne,  1998). 
Hence,  the  therapeutic  range  is  regarded  as  a  guide  to  AED  dosage,  and  an  individual 
patient's  clinical  conditions  should  always  be  considered  in  cases  of  poor  response  or 
intolerable  side  effects. 
To  achieve  optimal  control  of  seizures,  AEDs  must  be  well  absorbed  from  the 
gastrointestinal  tract,  distributed  into  body  tissues,  and  reach  sufficient  concentration  in 
the  brain.  Almost  all  AEDs  have  more  than  90  percent  oral  bioavailability,  with  the 
exception  of  gabapentin  and  vigabatrin  (TABLE  1.4).  Interestingly,  some  AEDs  such  as 
PHT  are  not  only  well  absorbed  in  the  small  intestine  but  absorption  also  extends  up  to 
the  colonic  region  (Stevenson  et  al.,  1997).  After  the  absorption  phase,  AEDs  are 
distributed  into  body  compartments  depending  on  their  physicochemical  properties.  In 
the  blood,  AEDs  such  as  PHT,  VPA  and  tiagabine  are  highly  bound  to  plasma  proteins. 
AEDs  with  this  characteristic  have  a  higher  risk  for  drug  interactions  through 
competitive  depletion  from  the  site  of  protein  binding.  This  is  clearly  observed  in 
polytherapy  regimens  comprising  PHT  and  VPA.  One  should  aim  for  a  lower  plasma 
concentration  of  PHT  when  used  concomitantly  with  VPA,  because  of  plasma  protein 
binding  displacement  (Perucca  et  al.,  1980b;  Patsalos  &  Perucca,  2003).  Reduced 
binding  to  plasma  proteins  may  shorten  the  AED  half-life,  requiring  a  more  frequent 
dosing  schedule  as  noted  with  the  newer  AED,  gabapentin  (Perucca,  2001). 
The  magnitude  and  duration  of  the  antiepileptic  actions  of  AEDs  are  predominantly 
determined  by  dose  and  pharmacokinetic  profile  (Perucca,  1999).  The  AED  dose  and 
pharmacokinetic  profile  are  in  turn  influenced  by  enzymatic  biotransformation  and  drug 
transporters  (Browne,  1998;  Kim,  2002a;  Ramachandran  &  Shorvon,  2003).  Most 
AEDs  undergo  enzymatic  biotransformation  to  form  a  more  water-soluble  compound 
before  being  excreted  by  the  kidney.  Nevertheless,  some  AEDs  can  be  excreted  in  an Chapter  1:  General  Introduction  16 
unchanged  form  or  with  only  minor  enzymatic  action,  for  example  gabapentin, 
topiramate  and  vigabatrin  (Patsalos,  1999). 
TABLE  1.4.  The  pharmacokinetics  of  antiepileptic  drugs. 
Usual 
Plasma  effective 
protein  plasma 
Bioavailability  binding  t%  concentration  T,,,,,, 
Drug  (%)  (%)  (h)  (µmoVl)  (h)  Route  of  elimination 
Established  AEDs 
Carbamazepine  89'  75  8-22  Up  to  50  4-8  >90%  hepatic 
Ethosuximide  <5  60  Up  to  700  3-7  65%  hepatic 
Phenobarbital  >_  90  45  100  Up  to  170  2-8  >90%  hepatic 
Phenytoin  90  90-95  22  Up  to  80  3-8  >90%  hepatic 
Valproic  acid  >_  90  80-90  15-20  Up  to  700  3-8  >95%  hepatic 
New  AEDs 
Felbamate  >_  80  20-25  14-23  125-250  2-6  60%  hepatic  (oxidation),  renal  excretion 
Gabapentin  <60  <5  5-7  70-120  2-3  >95%  renal  excretion 
Lamotrigine  98  55  15-30b  10-60  2-5  >90%  hepatic  (glucuronide  conjugation) 
Levetiracetam  >_  90  <10  6-8  35-120  1  >65%  renal  excretion 
Oxcarbazepine  40  8-15  50-140  3-13  >90%  hepatic  (glucuronide  conjugation) 
Tiagabine  >_  90  96  4-13  50-250  I  >90%  hepatic  (oxidation) 
Topiramate  >_  80  13  20-30  15-60  4-10  Renal  excretion,  30%  hepatic  (oxidation) 
Vigabatrin  >_  60  0  5-8  6-278  1  Renal  excretion 
Zonisamide  2:  90  50  50-70  45-180  2-6  70%  hepatic  (glucuronide  conjugation, 
acetylation,  oxidation) 
aextended  release  formulation;  bcomedication  with  VPA  and  enzyme  inducers. 
(Patsalos,  1999;  Perucca,  1999;  Perucca,  2001;  Ramsay  &  Wilder,  2002;  Bazil  & 
Pedley,  2003) 
Biotransformation  occurs  mainly  through  an  oxidation  process  and  takes  place  primarily 
in  the  liver  with  the  involvement  of  DMEs  such  as  cytochrome  P450  (CYP450) 
isoenzymes,  hydrolases  and  conjugating  enzymes.  More  than  12  isoenzymes  of  CYP450 
are  involved  in  drug  metabolism.  Metabolism  of  AEDs  is  predominantly  driven  by  a 
variety  of  CYP450  subfamilies,  including  CYP1A,  CYP2A,  CYP2B,  CYP2C,  CYP2D, 
CYP2E  and  CYP3A  (Ramachandran  &  Shorvon,  2003),  mEll  and  conjugating  enzymes 
such  as  UDP-glucuronosyltransferases  (UGTs;  TABLE  1.5).  The  reaction  catalysed  by Chapter  1:  General  Introduction  17 
CYP450s  involves  the  oxidation  of  AEDs  where  there  is  a  heterocyclic  ring,  an 
aromatic  ring,  an  alkane,  or  an  alkene  substituent.  CYP450  metabolism  converts  AEDs 
into  more  water-soluble  compounds,  which  are  more  easily  conjugated  and  excreted 
from  the  body.  CYP450  metabolism  also  converts  some  AEDs,  such  as  CBZ,  PB  and 
PHT,  to  intermediate  epoxide  metabolites.  Many  of  these  epoxide  metabolites  are 
reactive  and  can  covalently  bind  to  cell  macromolecules,  resulting  in  cytotoxicity 
(Madden  et  al.,  1996).  Detoxification  of  these  reactive  epoxide  metabolites  is  mediated 
by  mEH.  mEH  converts  epoxides  to  trans-dihydrodiols  which  can  be  conjugated  and 
excreted  from  the  body.  Conjugation  of  AEDs  or  AED  metabolites  is  predominantly 
mediated  by  UGT  isoenzymes  in  a  process  known  as  glucuronidation.  Glucuronidation 
involves  chemical  binding  of  a  substance  to  glucuronic  acid  via  a  glycosidic  bond.  The 
resulting  glucuronide  metabolite  is  typically  much  more  water  soluble  than  the  original 
substance.  Examples  of  AEDs  that  are  mainly  metabolised  through  glucuronidation  are 
VPA  and  LTG  (Staines  et  al.,  2004). 
In  order  to  understand  drug  disposition,  DMEs  cannot  be  studied  in  isolation, 
particularly  where  the  roles  of  DTPs  have  been  reported  to  be  significant  (Kim,  2002a; 
Kim,  2002b).  Drug  movement  across  tissue  compartments  habitually  occurs  in  two 
directions;  influx  and  efflux.  Specific  DTPs  are  responsible  for  carrying  out  both  of 
these  functions  in  a  concentration-dependent  manner  (Roden,  2001).  The  most 
commonly  recognised  efflux  transporter  is  P-gp.  Several  AEDs,  such  as  PHT  and  LTG, 
have  been  shown  to  be  transported  by  P-gp  (Potschka  &  Loscher,  2001;  Potschka  et  al., 
2002).  P-gp  can  be  found  in  various  body  tissues  such  as  the  intestinal  lining,  liver  and 
brain.  Variation  in  P-gp  activities  may  be  present  and  can  potentially  affect  drug 
pharmacokinetics.  It  has  been  demonstrated  that  variation  in  the  expression  of  duodenal 
P-gp  correlates  with  the  variation  in  plasma  digoxin  concentrations  (Hoffmeyer  et  al., 
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barrier  (BBB),  blood-cerebrospinal  fluid  barrier  and  various  parts  of  the  brain  could  also 
alter  the  elimination  process  of  AEDs  (Mcfadyen  et  al.,  1998;  de  Lange  &  Danhof, 
2002).  Therefore,  variation  in  the  expression  and  function  of  DMEs  and  DTPs  may 
consequently  influence  the  response  to  AED  treatment. 
TABLE  1.5.  Antiepileptic  drugs  and  their  related  hepatic  drug  metabolizing 
enzymes. 
Drug 
Metabolizing 
Enzyme 
Antiepileptic  Drug 
CBZ  ESM  PB  PHT  VPA  TGB  TPM  LTG  ZNS 
CYP  1  A2  ++ 
CYP2C9  ++  ++  + 
CYP2C  19  ++  ++++ 
CYP2D6  ++ 
CYP3A4  ++  ++  +  ++  ++ 
CYP3A5  +  +?  ++ 
mEH  +  +?  +? 
UGT  1  A4  ++ 
UGT1A6  &  1A9  ++ 
UGT2B7  +  ++ 
CYP,  cytochrome  P450;  mEH,  microsomal  epoxide  hydrolase;  UGT,  UDP- 
glucuronosyltransferase;  CBZ,  carbamazepine;  ESM,  ethosuximide;  PB, 
phenobarbital;  PHT,  phenytoin;  VPA,  valproic  acid;  TGB,  tiagabine;  TPM, 
topiramate;  LTG,  lamotrigine;  ZNS,  zonisamide;  ++,  major  involvement; 
significant  involvement;  +7,  potential  involvement.  (Adapted  from  Ramachandran 
&  Shorvon,  2003). Chapter  1:  General  Introduction  19 
1.2.5  Variability  in  the  response  to  antiepileptic  drug  treatment 
The  majority  of  epilepsy  patients  receive  AEDs  as  the  main  treatment  modality. 
However,  response  to  AED  therapy  remains  poor,  despite  the  ever-expanding  list  of 
modern  AEDs,  introduced  in  the  last  decade  and  designed  to  possess  improved  efficacy 
and  fewer  side  effects.  Poor  responders  to  AED  treatment  account  for  about  30  percent 
of  epilepsy  patients  (Kwan  &  Brodie,  2000),  and  only  small  numbers  of  them  have 
shown  clinically  significant  improvement  with  the  introduction  of  additional  AEDs 
(Ramachandran  &  Shorvon,  2003).  Patients  with  uncontrolled  epilepsy  not  only  suffer 
from  health  implications  but  also  psychosocial  and  socioeconomic  consequences. 
Despite  the  relative  importance  of  uncontrolled  seizures  in  a  large  fraction  of  epilepsy 
patients,  the  cellular  basis  of  pharmacoresistance  has  so  far  remained  elusive.  Two 
major  hypotheses  have  been  proposed  to  explain  poor  responsiveness  to  AED  therapy; 
(1)  alteration  in  AED  targets  such  as  decreased  sensitivity  of  ion  channels  and 
neurotransmitter  receptors,  and  (2)  modification  in  AED-related  DMEs  and  DTPs 
resulting  in  decreased  absorption,  increased  metabolism  or  decreased  uptake  into  the 
brain  (Bazil  &  Pedley,  2003;  Ramachandran  &  Shorvon,  2003;  Remy  &  Beck,  2006). 
Any  one  of  these  alterations  may  be  the  result  of  variation  in  genes  that  express  the 
corresponding  proteins  (Roden,  2001;  Spear,  2001;  Ramachandran  &  Shorvon,  2003; 
Remy  &  Beck,  2006). 
1.3  Pharmacogenetics 
Interindividual  variation  in  the  response  to  drugs  is  an  important  clinical  issue.  Such 
variation  ranges  from  resistance  to  treatment  to  adverse  drug  reactions  and  drug-drug 
interactions.  It  is  now  clear  that  much  of  the  individuality  in  drug  response  is  inherited Chapter  1:  General  Introduction  20 
(Hartl  &  Orel,  1992).  This  genetically  determined  variability  in  drug  response  defines 
the  research  area  known  as  pharmacogenetics  (Vogel,  1959).  Pharmacogenetic  studies 
create  an  opportunity  to  explore  individualisation  in  drug  therapy,  a  concept  of  tailored 
drug  type  and  dosage  to  individuals  based  not  only  on  traditional  clinical  factors  but 
also  on  their  genetic  profiles  (Kruglyak,  1999). 
1.3.1  Human  genetics 
The  genome  of  an  organism  is  its  whole  hereditary  information.  The  human  genome  is 
stored  in  23  pairs  of  chromosomes.  A  chromosome  is  a  single  large  macromolecule  of 
deoxyribonucleic  acid  (DNA),  and  is  the  basic  'unit'  of  DNA  in  a  cell.  DNA  consists  of 
two  associated  polynucleotide  strands  that  wind  together  in  a  helical  fashion.  It  is  often 
described  as  a  double  helix.  The  DNA  is  a  long  chain  of  nucleotides  which  consist  of 
deoxyribose  (a  pentose  sugar),  phosphoric  acid  and  4  organic  nitrogenous  bases  (purines 
-  Adenine  (A)  and  Guanine  (G),  or  pyrimidines  -  Cytosine  (C)  and  Thymidine  (T)).  The 
human  genome  contains  approximately  3.2  billion  base  pairs  that  are  specifically 
arranged  according  to  the  function  of  a  gene  and  genetic  ancestry.  A  gene  is  a  relatively 
small  segment  of  DNA  that  codes  for  the  synthesis  of  a  specific  protein.  Genes  consist 
of  a  long  strand  of  DNA  that  contains  a  promoter,  which  controls  the  activity  of  a  gene, 
and  exons,  coding  sequences  which  determine  what  the  gene  produces.  Genes  also 
contain  introns,  non-coding  regions  that  do  not  code  for  the  gene  products,  but 
sometimes  regulate  gene  expression.  Exons  and  introns  are  arranged  alternate  to  each 
other. 
Protein  synthesis  is  a  2-part  process  that  involves  a  second  type  of  nucleic  acid  known 
as  ribonucleic  acid  (RNA).  The  first  process  in  protein  synthesis  is  called  transcription. 
In  this  step,  the  double  DNA  strands  unzip  from  each  other  and  a  single  strand  of Chapter  1:  General  Introduction  21 
messenger  RNA  (mRNA)  is  then  made  by  pairing  up  mRNA  bases  with  the  exposed 
DNA  nucleotide  bases.  Splicing  is  a  modification  of  genetic  information  after 
transcription,  in  which  introns  are  removed  and  exons  are  joined.  Splicing  prepares 
precursor  mRNA  in  eukaryotes  to  produce  mature  mRNA.  The  second  process  in 
protein  synthesis  is  translation.  After  the  mature  mRNA  is  manufactured,  it  leaves  the 
cell  nucleus  and  travels  to  a  cellular  organelle  called  the  ribosome.  In  the  ribosome,  the 
mRNA  code  is  translated  into  a  transfer  RNA  (tRNA)  code  which,  in  turn,  is  transfered 
into  a  protein  sequence.  In  this  process,  each  set  of  3  mRNA  bases,  known  as  a  codon, 
will  pair  with  a  complimentary  tRNA  base  triplet  called  an  anticodon.  Each  tRNA  is 
specific  to  an  amino  acid  and  as  tRNA's  are  added  to  the  sequence,  amino  acids  are 
linked  together  by  peptide  bonds,  eventually  forming  a  protein  that  is  later  released  by 
the  ribosome. 
1.3.2  Glossary  of  genetics 
The  commonly  used  terms  in  pharmacogenetics  include  allele,  genotype,  haplotype, 
diplotype  and  phenotype  (Guttmacher  &  Collins,  2002).  Alleles  are  alternative  forms  of 
a  gene  at  a  particular  locus,  or  location,  on  a  chromosome.  Different  alleles  produce 
variation  in  inherited  characteristics  such  as  hair  colour  or  blood  type.  In  an  individual, 
one  form  of  the  allele  (dominant)  may  be  expressed  more  than  another  form  (recessive). 
A  single  allele  for  each  gene  locus  is inherited  from  each  parent.  A  pair  of  alleles  forms 
the  genotype.  Genotype  is  the  genetic  constitution  of  an  organism  or  cell  at  a  particular 
locus.  Usually,  in  a  pair  of  alleles,  each  individual  can  be  assigned  to  one  of  3  possible 
genotypes. 
Haplotype  may  refer  to  only  one  locus  or  to  an  entire  genome.  Haplotype  represents  a 
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inherited  together.  A  diploid  is  a  full  set  of  genetic  material  consisting  of  paired 
chromosomes.  The  diploid  human  genome  has  46  chromosomes.  Phenotype  is  an 
observable  characteristic  of  an  organism  produced  by  the  organism's  genotype 
interacting  with  the  environment.  This  contrasts  with  genotype,  which  is  an  organism's 
genetic  composition. 
1.3.3  Genetic  variations  among  humans 
Even  though  the  DNA  sequence  between  humans  is  99.9%  identical,  millions  of  base 
pair  differences  are  still  present  (Kruglyak  &  Nickerson,  2001).  Genetic  variations 
occur  as  a  result  of  insertions,  deletions,  simple  tandem  repeats  (STRs)  and  single 
nucleotide  polymorphisms  (SNPs)  of  the  DNA  sequence.  In  insertion  variations,  a  few 
base  pairs  are  inserted  into  a  genetic  sequence.  This  can  happen  due  to  slipping  of  DNA 
polymerase.  Insertions  in  the  coding  region  of  a  gene  may  alter  splicing  of  the  mRNA  or 
cause  a  frameshift,  both  of  which  may  significantly  alter  the  gene  product.  A  sequence 
deletion  is  a  variation  in  which  a  part  of  a  chromosome  or  a  sequence  of  DNA  is 
missing.  Any  number  of  nucleotides  can  be  deleted,  from  a  single  base  to  an  entire  piece 
of  chromosome.  Deletion  of  a  number  of  base  pairs  that  is  not  evenly  divisible  by  three 
will  lead  to  a  frameshift  mutation,  causing  all  of  the  codons  occurring  after  the  deletion 
to  be  read  incorrectly  during  translation,  producing  a  severely  altered  and  potentially 
non-functional  protein.  A  STR  in  DNA  is  a  class  of  polymorphism  that  occurs  when  a 
pattern  of  two  or  more  nucleotides  are  repeated  and  the  repeated  sequences  are  directly 
adjacent  to  each  other. 
The  most  common  type  of  genetic  variation  is  the  SNP,  of  which  there  are  an  estimated 
1.4  million  candidates  in  the  human  genome  (Kruglyak  &  Nickerson,  2001).  A  SNP  is  a 
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between  members  of  a  species.  For  a  variation  to  be  considered  a  SNP,  it  must  occur  in 
at  least  1%  of  the  population.  The  estimated  frequency  of  SNPs  in  the  human  genome  is 
1  per  1000  bases  (Wang  &  Moult,  2001).  Commonly,  each  SNP  is  represented  by  two 
alleles.  However,  SNPs  with  more  than  2  alleles  are  also  present.  SNPs  may  fall  within 
promoter  regions,  coding  sequences,  noncoding  regions,  or  in  the  intergenic  regions 
between  genes.  SNPs  within  a  coding  sequence  may  change  the  amino  acid  sequence  of 
the  protein  that  is  produced.  A  SNP  that  does  not  change  the  polypeptide  sequence  is 
termed  a  synonymous  SNP.  If  a  different  polypeptide  sequence  is  produced  they  are 
termed  as  non-synonymous  SNPs  (Guttmacher  &  Collins,  2002).  SNPs  in  coding  and 
regulatory  regions  are  the  most  likely  to  affect  gene  function  (Chakravarti,  1998). 
Approximately  50%  of  coding  SNPs  are  non-synonymous,  and  about  80%  of  these  non- 
synonymous  SNPs  have  been  associated  with  disease  through  alteration  in  protein 
stability  (Wang  &  Moult,  2001).  Nevertheless,  SNPs  that  are  not  in  coding  regions  may 
still  have  consequences  for  gene  splicing  and  transcription  factor  binding.  Interestingly, 
some  SNPs  may  simply  serve  as  markers  for  the  unidentified  susceptible 
polymorphisms  rather  than  ascribing  a  causative  role  (Chakravarti,  1998;  Carlson  et  al., 
2003).  In  many  pharmacogenetic  studies,  SNPs  are  commonly  used  as  phenotype 
markers  (Davidson,  2000).  SNPs  can  be  identified  using  several  analytical  assays  such 
as  polymerase  chain  reaction-restriction  fragment  length  polymorphisms  (PCR-RFLP) 
and  direct  sequencing. 
1.3.4  Nomenclature  of  genetic  sequence  variations 
A  nomenclature  system  has  been  suggested  to  standardise  the  description  of 
polymorphisms  in  DNA  and  protein  sequences  (den  Dunnen  &  Antonarakis,  2001). 
Variations  are  described  at  the  most  basic  level  using  either  a  genomic  or  a 
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because  it  includes  multiple  transcription  initiation  sites  (promoters),  alternative 
splicing,  and  multiple  translation  initiation  sites  (ATG-codons).  A  complementary  DNA 
reference  sequence  is  used  when  the  entire  genomic  sequence  is  not  known. 
To  avoid  confusion  in  the  description  of  a  sequence  change,  a  letter  indicating  the  type 
of  reference  sequence  is  used,  for  example;  'g.  '  for  a  genomic  sequence  (e.  g.  g.  54A>T), 
'c.  '  for  a  complemetary  DNA  sequence  (e.  g.  c.  54A>T)  and  'p.  '  for  a  protein  sequence 
(e.  g.  p.  R54K).  At  the  DNA  level,  nucleotides  are  designated  by  the  bases;  A  (adenine), 
C  (cytosine),  G  (guanine)  and  T  (thymidine).  Nucleotide  changes  are  indicated  by  a 
number  which  denotes  the  position  of  the  substitution  in  the  DNA  sequence  counted 
from  the  first  coding  nucleotide.  Substitutions  are  designated  by  a  `>'  character.  For 
example,  65A>C  denotes  that  at  nucleotide  65  an  A  residue  changed  to  C.  Two 
polymorphisms  in  one  variant  are  described  as  "first  change  +  second  change",  for 
example,  69A>C+102G>C  denotes  an  A  to  C  transition  at  nucleotide  69  and  aG  to  C 
transition  at  nucleotide  102  in  the  same  variant.  For  the  purposes  of  standardisation, 
alleles  of  a  SNP  are  represented  by  the  position  of  the  SNP  and  base  of  the  allele,  for 
example,  alleles  of  the  c.  89A>G  substitution  are  denoted  as  89A  and  89G.  Genotypes  of 
a  SNP  are  represented  by  the  position  of  the  SNP  and  the  pair  of  allele  bases,  for 
example,  genotypes  of  c.  89A>G  substitution  are  denoted  as  89A/A,  89A/G  and  89G/G. 
1.3.5  History  of  pharmacogenetics 
Inherited  characteristics  that  were  first  observed  by  Mendel  (Hartl  &  Orel,  1992),  have 
now  evolved  to  a  more  complex  and  applied  discipline  known  as  pharmacogenetics. 
The  earliest  documented  evidence  of  individual  differences  in  drug  metabolism  can  be 
traced  back  to  the  ancient  Greeks  (Pirmohamed,  2001).  Sir  Archibald  Garrod,  an 
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description  of  "an  inborn  error  of  metabolism"  (Garrod,  1902).  An  incident  that 
occurred  during  World  War  II  further  highlighted  the  diversity  of  pharmacogenetic 
disorders.  Service  personnel  deployed  in  regions  with  high  malarial  risk  were  given  a 
prophylactic  antimalarial  drug,  primaquine.  After  the  drug  was  taken,  approximately 
10%  of  the  African-American  servicemen  were  diagnosed  with  acute  anemia.  The 
affected  individuals  were  found  to  harbour  some  mutations  in  the  gene  expressing 
glucose  6-phosphate  dehydrogenase  (Carson  et  al.,  1956).  At  the  end  of  World  War  II, 
medicine  entered  the  antibiotic  era,  and  isoniazid  was  introduced  to  treat  tuberculosis.  It 
was  noted  that  some  individuals  who  took  isoniazid  rapidly  developed  a  peripheral 
neuropathy.  This  was  later  proven  to  be  associated  with  genetically  polymorphic  N- 
acetyltransferase,  an  enzyme  responsible  for  the  metabolism  of  isoniazid  (Kalow  & 
Staron,  1957).  In  the  post-war  years,  Motulsky  and  Kalow,  who  were  interested  in 
genetically  determined  differences  in  drug  metabolism,  wrote  extensive  reviews  on 
heredity  and  response  to  drugs  (Motulsky,  1957;  Kalow,  1962).  This  laid  the 
foundations  for  `pharmacogenetics',  a  term  coined  by  Friedrich  Vogel  of  Heidelberg  in 
1959  (Vogel,  1959). 
The  discovery  of  polymorphic  hydroxylation  of  debrisoquine  in  man  has  strengthened 
the  promising  future  of  pharmacogenetics  for  medicine  and  science  (Mahgoub  et  al., 
1977).  Further  polymorphisms  relating  to  other  cytochrome  enzymes  were  discovered  in 
subsequent  decades.  Now,  the  Human  Genome  Project  and  other  research  endeavors  are 
providing  information  that  allows  a  better  understanding  of  the  underlying  causes  of 
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1.4  Pharmacogenetics  of  antiepileptic  drugs 
Epilepsy  itself  has  been  linked  to  at  least  33  chromosome  regions  (Prasad  et  al.,  1999). 
On  the  basis  of  prior  knowledge  of  AED  pharmacodynamics  and  pharmacokinetics, 
candidate  genes  and  SNPs  for  AED  pharmacogenetic  study  can  be  identified. 
Accordingly,  genes  that  have  a  potential  pharmacogenetic  impact  in  epilepsy  are 
divided  into  four  groups;  (i)  genes  that  characterize  a  subclass  of  the  epilepsy,  (ii)  genes 
for  ion  channel  and  AED  receptors,  (iii)  genes  that  encode  pharmacokinetic-related 
proteins  associated  with  AED  efficacy,  and  (iv)  genes  which  are  associated  with  AED 
toxicity  (Spear,  2001).  Interindividual  variations  in  genes  located  on  or  related  to 
regions  that  express  drug  receptors,  ion  channels,  DMEs  and  DTPs  may  influence  the 
response  to  AED  treatment  (Spear,  2001;  Holmes,  2002;  Clancy  &  Kass,  2003; 
Ramachandran  &  Shorvon,  2003;  Ma  et  al.,  2004). 
1.4.1  Pharmacogenetics  of  antiepileptic  drugs:  The  influence  of 
pharmacodynamic  genes 
Most  forms  of  human  idiopathic  epilepsy  have  been  associated  with  genetic  variation  in 
ion  channels.  These  include  generalised  epilepsy  with  febrile  seizure  plus  (GEFS+)  and 
severe  myoclonic  epilepsy  of  infancy  (SMEI)  that  were  linked  to  sodium  channel 
subunit  (SCNIA  and  SCN2A,  respectively)  variation  (Ceulemans  et  al.,  2004;  Kamiya 
et  ah,  2004)  and  some  idiopathic  generalised  epilepsy  syndromes  that  have  been 
associated  with  voltage-gated  potassium  channel  (Chioza  et  al.,  2002)  and  calcium 
channel  gene  polymorphisms  (Chioza  et  al.,  2001).  Most  AEDs  are  believed  to  act  on 
ion  channels  to  modulate  the  excitability  of  neurones.  Therefore,  it  is  possible  that  there 
are  associations  between  channel  abnormalities  and  drug  responsiveness  in  epilepsy. 
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subunits.  These  transcriptional  changes  most  probably  affect  both  the  density  of  ion 
channels  in  the  neuronal  membrane,  as  well  as  the  shape  of  multi-subunit  channel 
complexes.  Other  post-transcriptional  modifications  of  ion  channel  proteins  that  are 
induced  by  seizures  may  also  affect  AED  sensitivity  (Remy  &  Beck,  2006). 
Reversal  of  excessive  neuronal  hyperexcitability  can  be  achieved  by  AED  binding  to  its 
recognition  site  in  the  domain  IV,  segment  6  region  of  the  voltage-gated  sodium  channel 
(Ramachandran  &  Shorvon,  2003).  Alteration  of  this  important  binding  site  could 
potentially  result  in  drug  non-responsiveness.  This  postulated  mechanism  is  supported 
by  the  phenotypic  difference  between  SMEI  and  GEFS+.  Most  patients  with  SMEI 
carry  a  truncating  mutation  which  leads  to  a  short  Na￿1.1  sodium  channel  a-subunit 
protein  and  most  likely  causes  a  loss  of  function  (Ceulemans  et  al.,  2004).  In  these 
patients,  protein  truncation  might  result  in  destruction  of  the  drug  binding  site  and 
thereby  explain  resistance  to  AEDs  acting  on  the  sodium  channel.  On  the  other  hand, 
GEFS+  is  a  more  benign  phenotype  which  results  from  a  few  SNPs  in  sodium  channel 
genes,  but  a  nonetheless  fully  expressed  protein  (Ceulemans  et  al.,  2004).  Compared  to 
SMEI,  GEFS+  is  associated  with  a  better  response  to  AEDs. 
Other  than  treatment  response,  variability  in  the  function  of  ion  channels  may  also 
influence  the  amount  of  AED  required  to  achieve  optimal  seizure  control.  It  has  been 
demonstrated  that  an  intronic  polymorphism  IVS5  -91G>A  in  the  SCNIA  gene  is 
associated  with  maximum  doses  of  CBZ  and  PHT  (Tate  et  al.,  2005).  Maximum  doses 
of  CBZ  averaged  1313,1225,  and  1083  mg  for  individuals  with  IVS5  -91A/A,  A/G,  and 
GIG  genotype,  respectively;  maximum  doses  of  PHT  averaged  373,340,  and  326  mg, 
for  individuals  with  IVS5  -91A/A,  A/G,  and  GIG  genotype,  respectively,  suggesting  a 
trend  towards  reduction  in  maximum  dose  according  to  genotype.  This  polymorphism 
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disrupts  the  consensus  sequence  of  fetal  exon  5N,  possibly  reducing  the  expression  of 
this  exon  relative  to  the  adult  exon  5A.  Analysis  of  SCNIA  c.  DNA  from  adult  human 
brain  tissue  of  individuals  with  epilepsy  showed  some  degree  of  association  between  the 
IVS5  -91G>A  genotypes  and  the  SCNIA  expression  (Tate  et  al.,  2005).  Therefore, 
genetic  variability  in  ion  channels  not  only  explains  epileptogenesis  but  may  also 
influence  drug  responsiveness  and  dosing  requirements  due  to  subtle  alteration  of  the 
channel  structure. 
1.4.2  Pharmacogenetics  of  antiepileptic  drugs:  The  influence  of 
pharmacokinetic  genes 
Investigation  of  AED  pharmacogenetic-pharmacokinetic  association  can  be  approached 
from  two  directions;  (1)  genes  encoding  DTPs  and  (2)  genes  encoding  DMEs.  Although 
pharmacogenetic  studies  examining  the  influence  of  DTP  polymorphisms  directly  on 
AED  pharmacokinetics  are  limited,  some  studies  have  explored  the  association  between 
DTP  gene  polymorphisms  and  the  response  to  AED  treatment  (Siddiqui  et  al.,  2003; 
Tan  et  al.,  2004a;  Hung  et  al.,  2005;  Sills  et  al.,  2005;  Kim  et  al.,  2006;  Seo  et  al., 
2006a).  The  most  studied  DTP  gene  is  ABCB  1,  a  gene  responsible  for  encoding  the 
efflux  transporter,  P-gp.  P-gp  is  believed  to  be  a  contributor  to  pharmacoresistance  in 
epilepsy,  as  several  AEDs  have  been  demonstrated  to  be  transported  by  P-gp  (Potschka 
et  al.,  2002)  and  over-expression  of  P-gp  has  been  identified  in  medically  intractable 
epileptic  brain  tissue  (Marchi  et  al.,  2004).  Variability  in  P-gp  expression  may  be  the 
result  of  polymorphisms  in  the  ABCB  1  gene  and  has  been  postulated  to  result  in 
interindividual  variation  in  the  response  to  AED  treatment.  One  study  has  demonstrated 
that  patients  with  drug-resistant  epilepsy  are  more  likely  to  carry  the  ABCBI  3435C/C 
genotype  than  the  3435T/T  genotype  (Siddiqui  et  al.,  2003).  Further  studies  examining 
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in  the  ABCB  1  gene  may  be  more  useful  in  predicting  response  to  AED  treatment  (Hung 
et  al.,  2005;  Seo  et  al.,  2006a).  However,  other  investigations  have  failed  to  confirm  the 
original  association  between  the  ABCB  1  c.  3435C>T  polymorphisms  and  drug-resistant 
epilepsy  (Tan  et  al.,  2004a;  Sills  et  al.,  2005;  Kim  et  al.,  2006).  As  such,  the  functional 
significance  of  ABCB  1  gene  polymorphisms  in  the  response  to  AED  treatment  remains 
elusive. 
The  second  dimension  of  AED  pharmacogenetic-pharmacokinetic  association  studies  is 
that  related  to  DMEs.  Among  the  DMEs  that  mediate  metabolism  of  AEDs,  only 
isoforms  of  CYP2C  have  been  studied  in  depth.  (Prasad  et  al.,  1999;  Clancy  &  Kass, 
2003;  Ramachandran &  Shorvon,  2003).  CYP2C9  has  two  functionally  important 
polymorphisms,  the  c.  430C>T  and  c.  1075A>C  substitutions  (Scordo  et  al.  2004). 
Lower  CYP2C9  activity  is  associated  with  the  430T+1075C  variant.  In  a  single  dose 
study  using  300  mg  PHT,  there  was  a  significant  difference  in  trough  PHT 
concentrations  between  the  variants  of  CYP2C9  (Aynacioglu  et  al.,  1999).  Compared 
with  the  CYP2C9  430C/C+1075A/A  variant,  the  greatest  difference  in  trough  PHT 
concentrations  was  demonstrated  in  individuals  carrying  the  CYP2C9  430T/T+1075A/C 
variant  (95%  Cl:  0.78  -  2.20;  Aynacioglu  et  al.,  1999).  In  a  different  study,  the  PHT  0- 
96  hour  AUC  after  a  single  dose  was  also  significantly  higher  in  patients  carrying  the 
430T+1075C  variant  than  in  individuals  homozygous  for  the  430C  and  1075A  alleles. 
Overall,  carriers  of  the  430T+1075C  variant  have  1.8  to  2.7-fold  higher  PHT  AUC  than 
other  genetic  variants  (Caraco  et  al.,  2001). 
In  addition,  the  maximal  elimination  rate  of  PHT  was  shown  to  be  lower  in  individuals 
with  the  1075C  allele  compared  to  those  with  the  1075A  allele  (Odani  et  al.,  1997),  and 
this  may  explain  the  association  between  higher  plasma  PHT  concentrations  and  the 
CYP2C9  1075C  allele  (Brandolese  et  al.,  2001;  Soga  et  al.,  2004).  Carriers  of  the Chapter  1:  General  Introduction  30 
430T+1075C  variant  have  also  been  shown  to  have  a  higher  plasma  PHT  concentration 
(Caraco  et  al.,  2001),  which  corresponded  with  a  mean  PHT  dose  that  was  30%  lower  in 
a  group  of  patients  with  the  430T+1075C  variant  compared  to  those  with  the 
430C+1075A  variant  (199  ±38.6  mg  versus  287  ±80.7  mg,  respectively).  This 
difference  in  PHT  dose  between  variant  groups  was  most  evident  in  patients  with  PHT 
steady-state  plasma  concentrations  within  the  therapeutic  range  (10  -  20  mg/l;  van  der 
Weide  et  al.,  2001).  A  trend  confirming  that  the  PHT  dose  is  associated  with  CYP2C9 
variants  was  also  demonstrated  in  the  prevalence  profile  of  the  variants;  CYP2C9 
430T+1075C  alleles  were  present  in  62.5%  of  the  low-dose  group,  32.4%  of  the 
standard-dose  group  and  0%  of  the  high-dose  group  (van  der  Weide  et  al.,  2001).  A 
study  on  maximum  dose  of  AEDs  has  also  demonstrated  that  carriers  of  CYP2C9 
430T+1075C  variant  received  significantly  lower  PHT  and  CBZ  doses  (Tate  et  al., 
2005). 
1.4.3  Antiepileptic  drugs  as  drugs  of  pharmacogenetic  interest 
A  drug  with  pharmacogenetic  interest  is  one  that  is  likely  to  demonstrate  significant 
inter-individual  variability  in  mortality,  morbidity,  quality  of  life  impact  and  the  risk  of 
severe  adverse  effects.  In  addition  to  these  criteria,  the  frequency  of  drug  prescription 
and  the  number  of  exposed  patients  should  also  be  considered  (Kim  et  a!.,  2007).  Drugs 
that  are  frequently  prescribed  may  also  be  drugs  of  pharmacogenetic  interest  because  a 
larger  population  of  patients  is  at  risk  of  suffering  therapeutic  failure  or  severe  adverse 
effects. 
The  exciting  pharmacogenetic  findings  in  relation  to  PITT  metabolism  have  a  limited 
clinical  application  since  this  drug  is  no  longer  employed  as  a  first  line  agent  in  most 
European  countries,  especially  for  the  chronic  treatment  of  epilepsy  (National  Institute Chapter  1:  General  Introduction  31 
for  Health  and  Clinical  Excellence,  2004).  However,  a  number  of  other  AEDs  is 
available  for  further  exploration.  VPA,  CBZ  and  LTG  are  the  three  most  commonly 
prescribed  AEDs  by  clinicians  in  the  UK  (Morgan  et  al.,  2004).  The  Standard  and  New 
Antiepileptic  Drug  (SANAD)  study  has  demonstrated  that  the  best  AED  for  newly 
diagnosed  idiopathic  generalised  epilepsy  is  VPA,  whereas  CBZ  and  LTG  are  the  drugs 
of  choice  for  patients  with  partial  epilepsy  (Marson  et  al.,  2007a;  Marson  et  al.,  2007b). 
The  Epilepsy  Unit  at  the  Western  Infirmary  is  a  tertiary  referral  centre  for  adults  with 
new-onset  and  pre-existing  seizure  disorders  and,  as  such,  has  a  population  which  is 
predominated  with  partial  or  localisation-related  epilepsy.  Given  that  these  patients  are 
most  commonly  treated  with  CBZ  and  LTG,  that  these  drugs  have  a  common 
pharmacodynamic  target,  and  that  their  pharmacokinetic  and  metabolic  profiles  are  well 
established,  it  is  reasonable  to  focus  on  these  two  important  AEDS. 
1.5  Carbamazepine 
1.5.1  History  and  indications 
CBZ  was  first  synthesised  in  the  laboratories  of  J.  R.  Geigy  A.  G.  by  Schindler  and 
Blattner  in  1957  (Schmutz,  1985).  Theoblad  and  Kunz  reported  its  initial  spectrum  of 
anticonvulsant  activity  six  years  after  CBZ  had  been  discovered  (Schmutz,  1985).  CBZ 
or  5H-dibenz-[b,  f]azepine-5-carboxamide  (Himes  et  al.,  1981)  has  been  used  as  an  AED 
for  many  decades.  It  is  effective  in  the  treatment  of  simple  partial,  complex  partial  and 
generalised  tonic-clonic  seizures.  It  is  ineffective  and  may  even  be  deleterious  in 
generalised  absence  seizures  (Liporace  et  al.,  1994;  Kochen  et  ah,  2002).  Other 
indications  for  CBZ  include  the  treatment  of  neuropathic  pain,  such  as  trigeminal 
neuralgia,  and  psychiatric  disorders,  such  as  manic-depressive  illness  and  aggression 
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Several  mechanisms  have  been  proposed  to  explain  the  anticonvulsant  activity  of  CBZ. 
Its  principal  mechanism  is  on  neuronal  ion  channels  to  prevent  the  generation  of  high- 
frequency  repetitive  firing.  CBZ  blocks  voltage-gated  sodium  channels  and  L-type 
calcium  channels  (Ambrosio  et  al.,  1999),  and  potentiates  potassium  channel 
conductance  (Schmidt  &  Eiger,  2004),  which  consequently  suppresses  the  generation  of 
high  frequency  action  potentials.  CBZ  binds  to  the  inactivated  state  of  the  voltage-gated 
sodium  channel  and  changes  the  gating  conformation  in  a  voltage-,  frequency-  and 
time-dependent  manner  (Courtney,  1975;  Kuo,  1998;  Kwan  et  al.,  2001).  It  binds  to  a 
common  receptor  site  located  on  the  extracellular  portion  of  the  sodium  channel.  The 
common  binding  site  contains  two  phenyl  groups,  which  are  probably  part  of  the  side 
chain  groups  of  aromatic  amino  acids  constituting  the  channel.  The  two  phenyl  rings  in 
CBZ  bind  to  corresponding  phenyl  groups  in  the  receptor.  Other  mechanisms  of  action 
reported  for  CBZ  include  modulation  of  synaptic  transmission  and  neurotransmitter 
receptors  such  as  the  purine,  monoamine,  acetylcholine  and  N-methyl-D-aspartate 
(NMDA)  receptors  (Brodie  &  Dichter,  1997;  Kwan  et  al.,  2001;  Bazil  &  Pedley,  2003; 
Schmidt  &  Eiger,  2004).  However,  these  mechanisms  are  not  as  clear  as  the  first 
mechanism. 
1.5.3  Clinical  pharmacokinetics 
CBZ  is  absorbed  relatively  slowly  from  the  gastrointestinal  tract;  however,  its  oral 
bioavailability  is  high  (>70%).  The  irregular  and  delayed  absorption  is  due  to  its  poor 
dissolution  in  gastrointestinal  fluid,  and  also  alteration  of  gastrointestinal  motility  by  its 
weak  anticholinergic  properties.  After  a  single  oral  dose,  peak  plasma  CBZ 
concentrations  are  achieved  within  4  to  8  hours  (Spina,  2002).  In  the  blood,  CBZ  is  75% Chapter  1:  General  Introduction  33 
bound  to  albumin,  and  to  a  lesser  degree  to  a,  -acid  glycoprotein.  In  terms  of 
physicochemistry,  CBZ  is  neutral  and  highly  lipophilic,  making  it  easy  to  cross  cell 
membranes.  CBZ  rapidly  distributes  to  various  organs  and  body  tissues.  In  single-dose 
studies  employing  healthy  volunteers  and  patients,  the  Vd  for  CBZ  has  been  estimated  at 
between  0.79  and  1.86  1/kg  (Spina,  2002).  The  biotransformation  of  CBZ  occurs  mainly 
in  the  liver,  involving  multiple  DMEs  such  as  the  CYP450s,  hydrolases  and  conjugating 
enzymes.  CBZ  does  not  undergo  significant  enterohepatic  metabolism  (Spina,  2002).  In 
humans,  less  than  2%  of  CBZ  is  eliminated  unchanged  in  the  urine  and  approximately 
70%  of  its  oral  dose  is  renally  excreted  (Bertilsson  et  al.,  1997). 
1.5.4  Metabolism  of  carbamazepinc 
Multiple  isoforms  of  CYP450  enzymes  may  be  involved  in  the  metabolism  of  a  single 
AED.  CYP450-related  metabolism  has  a  significant  influence  on  the  plasma 
concentrations  of  CBZ.  CBZ  metabolism  is  mediated  by  CYPIA2,  CYP2B6,  CYP2C8, 
CYP2C9  and  CYP3A4,  with  the  latter  being  identified  as  the  primary  isoenzyme 
(Pearce  et  al.,  2002;  Tredger  &  Stoll,  2002).  The  phase  1  metabolism  of  CBZ  produces 
four  major  metabolites;  CBZ-10,11-epoxide  (CBZ-E);  2-hydroxy-CBZ;  3-hydroxy- 
CBZ;  and  CBZ-acridan  (Bernus  et  al.,  1996).  Thereafter,  mEH  converts  CBZ-E  to 
CBZ-  10,11  -diol,  prior  to  conjugation  and  excretion  from  the  body.  A  significant  amount 
of  CBZ  (15%)  is  subject  to  direct  N-glucuronidation,  with  UGT2B7  identified  as  the 
key  enzyme  (Staines  et  al.,  2004).  Most  other  products  of  phase  1  metabolism  are  also 
conjugated  with  glucuronides  (Maggs  et  al.,  1997;  FIGURE  1.2). 
The  intermediate  metabolite,  CBZ-E  is  known  to  be  pharmacologically  active.  It  is  often 
associated  with  rash  and  other  side  effects  of  CBZ  (Ramsay  &  Wilder,  2002).  The  rate 
of  CBZ  epoxidation  is believed  to  correlate  with  the  content  of  microsomal  CYP3A4  in Chapter  1:  General  Introduction  34 
human  liver  (Kerr  et  al.,  1994),  while  inhibition  of  CYP3A4  by  drug  such  as 
ketoconazole  can  suppress  CBZ-E  formation  by  up  to  94%  (Pelkonen  et  al.,  2001). 
These  findings  suggest  that  CYP3A4  is  the  principal  catalyst  of  CBZ-E  formation  in 
human  liver.  A  minor  role  of  CYP2C8  in  CBZ  epoxidation  has  also  been  demonstrated 
(Kerr  et  al.,  1994;  Pelkonen  et  al.,  2001).  A  study  using  cultures  of  COS-7  cells  has 
shown  that  the  activity  of  CYP3A5  is  approximately  one  third  that  of  CYP3A4  with 
regard  to  the  formation  of  CBZ-E  (Ohmori  et  al.,  1998).  Another  investigation  using 
baculovirus-infected  insect  cells  and  human  liver  microsomes  has  shown  similar  levels 
of  activity,  with  the  CYP3A5/CYP3A4  ratio  of  intrinsic  clearance  in  the  convertion  of 
CBZ  to  CBZ-E  approaching  1.0  (Huang  et  al.,  2004).  These  investigators  also  reported 
that  the  CYP3A4  and  CYP3A5  Michaelis-Menten  constant  values  were  248  and  338 
µM,  and  the  maximum  rate  of  metabolism  values  were  4.87  and  5.98  nmollmin/nmol, 
respectively.  These  observations  indicate  a  potentially  important  role  of  CYP3A5 
enzyme  in  the  in  vivo  metabolism  of  CBZ. 
The  conversion  of  CBZ  to  hydroxy-CBZ  metabolites  is  the  second  most  important 
metabolic  pathway  after  epoxidation.  The  hydroxylation  process  is  mediated  by 
multiple  CYP450s,  including  CYP3A4/5  and  CYPIA2  (Pelkonen  et  al.,  2001;  Pearce  et 
al.,  2002;  Spina,  2002).  Each  of  these  CYP450s  has  a  specific  site  of  action  on  the  CBZ 
molecule,  corresponding  to  the  1-,  2-,  3-,  or  4-  positions  of  the  aromatic  ring  (FIGURE 
1.3;  Spina,  2002),  however,  the  most  common  metabolites  are  2-hydroxy-CBZ  and  3- 
hydroxy-CBZ  (Pearce  et  al.,  2002). 
CBZ  induces  the  CYP450  isoenzymes  that  are  involved  in  its  own  metabolism.  CBZ 
may  increase  the  amount  of  CYP3A4  protein  and  its  corresponding  activity  up  to  3-  to 
4-fold  (Wolbold  et  al.,  2003).  CBZ  induces  CYP3A4  activity  to  a  greater  extent  than 
other  CYP450  isoenzymes  such  as  CYP2CI9  (Bertilsson  et  al.,  1997).  As  CBZ  is Chapter  1:  General  Introduction  35 
primarily  metabolised  by  CYP3A4,  this  effect  will  automatically  accelerate  its  own 
metabolism  in  a  process  known  as  autoinduction  (Tredger  &  Stoll,  2002),  and  give  a 
unique  time-dependent  character  to  the  pharmacokinetics  of  CBZ  (Bialer  et  al.,  1998). 
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action.  Modified  from  Himes  et  al.  (1981),  Pelkonen  et  al.  (2001)  and  Spina 
(2002). 
1.5.5  Effects  of  autoinduction  on  carbamazepine  pharmacokinetics 
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Autoinduction  of  CBZ  metabolism  involves  steroid  and  nuclear  receptors  such  as  the 
constitutive  androstane  receptor  (CAR)  and  pregnane  X  receptor  (PXR;  Fuhr,  2000). 
The  involvement  of  PXR  is  crucial  at  the  transcription  level  of  CYP3A4  mRNA 
(Wolbold  et  al.,  2003).  In  addition  to  PXR  and  CAR,  the  human  glucocorticoid  receptor 
(GR)  has  also  been  described  as  a  contributor  to  CYP3A4  induction  by  its  involvement 
in  the  GR-PXR/CAR-cytochrome  P450  cascade  (Dvorak  et  al.,  2003;  Pascussi  et  al., 
2003).  Both  GR  and  PXR  have  been  reported  to  contribute  to  the  transcriptional 
regulation  of  the  CYP3A4  gene  mediated  by  a  large  number  of  xenobiotics  (El-Sankary 
et  al.,  2001).  Although  it  is  recognised  that  PXR  plays  a  significant  role  in  the 
transcriptional  phase  of  CYP3A4,  genetic  variability  in  the  PXR  gene  does  not  explain 
the  variation  in  CYP3A4  expression  (Schuetz,  2003)  or  activity  (Zhang  et  al.,  2001). Chapter  1:  General  Introduction  37 
Autoinduction  of  CBZ  metabolism  is  a  dose  dependent  process  (Liu  &  Delgado,  1994). 
Steady-state  clearance  of  CBZ  varies  between  31  to  110  ml/min  depending  on  the 
maintenance  dose  and  increases  linearly  with  dose  increment  (Kudriakova  et  al.,  1992). 
The  ratio  of  CBZ-E  to  CBZ  ranges  between  0.09  ±0.02  at  100  mg/day  and  0.21  ±0.06  at 
1200  mg/day  (Kudriakova  et  al.,  1992).  Dose  effects  on  these  ratios  are  more 
predominant  at  a  lower  dosage  range.  Surprisingly,  age  does  not  influence  the  degree  of 
CBZ  autoinduction,  despite  clear  differences  in  metabolic  capacity  between  young  and 
elderly  subjects  (Battino  et  al.,  2003). 
The  effects  of  autoinduction  on  CBZ  concentrations  are  critical.  Observed 
concentrations  of  CBZ  are  50%  lower  than  expected  concentrations  at  day-4  of  therapy, 
with  observed  concentrations  falling  further  during  extended  follow-up  (Eichelbaum  et 
al.,  1975).  This  drop  in  CBZ  plasma  concentrations  can  be  detrimental  to  seizure  control 
(Macphee  &  Brodie,  1985). 
CBZ  has  been  employed  as  a  reference  drug  in  many  comparative  clinical  trials  of  novel 
AEDs  for  the  treatment  of  partial  seizures  and  generalised  tonic-clonic  seizures  in  either 
adult  or  pediatric  subjects  (Brodie  et  al.,  1995;  de  Silva  et  al.,  1996;  Reunanen  et  al., 
1996;  Tanganelli  &  Regesta,  1996;  Chadwick,  1999;  Vasudev  et  al.,  2000;  Kwan  & 
Brodie,  2001;  Marson  et  al.,  2002;  Fakhoury  et  al.,  2004).  Due  to  the  effects  of 
autoinduction,  the  dose  of  CBZ  has  to  be  adjusted  (Tanganelli  &  Regesta,  1996;  Arroyo 
&  Sander,  1999;  Fakhoury  et  al.,  2004).  Dose  titration  often  results  in  a  2-  or  more-fold 
higher  dose  at  the  end  of  study  than  the  initial  target  dose.  In  a  study  of  childhood 
epilepsy,  the  median  doses  of  CBZ  at  the  start  of  therapy  and  after  3  years  on  therapy 
were  200  mg/day  (50  -  400  mg/day)  and  400  mg/day  (150  -  1000  mg/day),  respectively 
(de  Silva  et  al.,  1996).  The  range  of  maximum  dose  was  reported  to  be  wider  in  CBZ- 
treated  subjects  (200  -  1400  mg/day)  compared  with  other  AEDs  (Chadwick,  1999). Chapter  1:  General  Introduction  38 
This  range  is  similar  to  that  reported  as  the  final  dose  required  (200  -  1600  mg/day)  to 
achieve  full  seizure  control  (Kwan  &  Brodie,  2001).  In  clinical  studies,  some  subjects 
receive  a  significantly  higher  dose  of  CBZ  by  the  end  of  the  study  period,  however, 
mean  CBZ  and  CBZ-E  plasma  concentrations  do  not  differ  when  measured  routinely 
over  a  four  week  period  (Schmidt  &  Eiger,  2004)  or  even  up  to  48  weeks  (Brodie  et  al., 
1995;  Hogan  et  al.,  2003).  This  is  a  demonstration  of  how  the  effect  of  autoinduction 
can  influence  plasma  concentrations  of  CBZ  over  an  extended  period  of  time.  These 
studies  have  also  shown  that  the  degree  of  CYP3A4  metabolic  capacity  among  patients 
is  varied  and  may  partly  associate  with  interindividual  genetic  variability. 
1.5.6  Concentration-response  relationship 
The  association  between  plasma  CBZ  concentrations  and  clinical  response  has  been 
investigated  comprehensively  in  seizure  disorders.  The  therapeutic  range  for  CBZ 
plasma  concentrations  has  been  suggested  at  4  to  12  mg/l  (Bialer  et  al.,  1998),  although 
minor  variations  on  this  range  have  been  proposed  in  numerous  other  studies  (Hvidberg, 
1985;  Brodie  et  al.,  1995;  de  Silva  et  al.,  1996;  Arroyo  &  Sander,  1999;  Dickinson  et 
al.,  1999). 
Plasma  concentrations  of  CBZ  in  excess  of  10  to  12  mg/1  are  likely  to  produce  adverse 
effects.  However,  minor  signs  of  toxicity  may  also  be  apparent  at  lower  concentrations. 
Interestingly,  some  patients  are  able  to  tolerate  higher  levels  of  CBZ  without  obvious 
deleterious  consequences.  A  relationship  between  fluctuations  in  plasma  CBZ 
concentration  and  the  emergence  of  intermittent  side  effects  has  also  been  described 
(Bialer  et  al.,  1998).  Optimal  CBZ  concentrations  vary  widely  among  patients,  with 
lowest  concentrations  of  approximately  1  to  6  mg/l  required  for  minimal  effectiveness Chapter  1:  General  Introduction  39 
(Bialer  et  a1.,  1998).  However,  CBZ  concentrations  lower  than  a  threshold  of  4  to  6  mg/1 
may  not  be  able  to  control  seizures  in  difficult  to  treat  epilepsy  (Bialer  et  al.,  1998). 
1.5.7  Side  effects  and  adverse  reactions 
Most  AEDs  have  the  potential  to  cause  side  effects  or  adverse  events.  CNS  related 
events  represent  more  than  60%  of  overall  reported  side  effects  or  adverse  reactions  of 
AEDs  (Chadwick,  1999;  Carpay  et  al.,  2005).  Up  to  80%  of  patients  on  AEDs 
experience  at  least  one  adverse  event  (Chadwick,  1999).  Adverse  events  are  the  most 
common  reason  for  AED  withdrawal  in  many  clinical  trials  (Reunanen  et  al.,  1996; 
Fakhoury  et  al.,  2004).  The  most  common  side  effects  of  CBZ  are  CNS  related,  for 
example  drowsiness,  dizziness,  asthenia,  headache,  weakness  and  somnolence  (Brodie 
et  al.,  1995;  Reunanen  et  al.,  1996;  Tanganelli  &  Regesta,  1996;  Vasudev  et  al.,  2000; 
Hogan  et  al.,  2003). 
CBZ  is  also  associated  with  severe  cutaneous  reactions  such  as  Stevens-Johnson 
syndrome,  toxic  epidermal  necrolysis  and  generalised  rash  (Rzany  et  al.,  1999).  This 
phenomenon  has  been  associated  with  the  production  of  reactive  iminoquinone,  which 
is  an  intermediate  metabolite  in  CBZ  metabolism  (Ju  &  Uetrecht,  1999).  The  initial 
cutaneous  reactions  may  indicate  a  potentially  life-threatening  reaction  known  as 
anticonvulsant  hypersensitivity  syndrome  (Svensson  et  al.,  2000.  ).  Rash  is  experienced 
by  3.4  to  10  percent  of  patients  on  CBZ  (Reunanen  et  al.,  1996;  Chadwick,  1999; 
Hogan  et  al.,  2003)  and  is  one  of  the  most  significant  adverse  events  leading  to  CBZ 
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1.5.8  Potential  factors  that  influence  the  variability  in  clinical 
pharmacology  of  carbamazepinc 
Various  factors  contribute  to  variability  in  pharmacokinetics  and  pharmacodynamics, 
which  may  consequently  affect  the  efficacy  and  toxicity  of  CBZ.  These  factors  include 
patient  age,  organ  function,  drug  formulation,  concomitant  medications  and  genetic 
status.  Age  reflects  body  composition  and  function.  The  weight-related  Vd  of  lipophilic 
drugs  is  usually  higher  in  adults  than  in  children  because  of  the  greater  proportion  of  fat 
per  kg  of  body  weight  (Thomson,  2004).  Indeed,  it  has  been  reported  that  the  Vd  of  CBZ 
is  strongly  associated  with  body  weight  and  demonstrates  an  increase  when  comparing 
children  to  adults  (Reith  et  al.,  2001).  Clearance  of  CBZ  also  increases  linearly  with 
body  weight  and  nonlinearly  with  age.  With  respect  to  body  weight,  infants  have  a 
higher  clearance  than  older  children  (Delgado  Iribarnegaray  et  al.,  1997;  Reith  et  al., 
2000)  and  the  tl/2  of  CBZ  is  very  short  in  young  children.  CBZ  is  more  rapidly 
metabolized  to  CBZ-E  in  children  than  in  adults.  This  is  in  accordance  with 
conventional  wisdom  which  suggest  that,  biotransformation  occurs  at  a  faster  rate  in 
children  than  in  adults  (Gilman  et  al.,  2003;  Perucca,  2006).  Thus,  children  may  require 
a  higher  dose  of  CBZ  per  kg  of  body  weight  than  adults. 
The  effect  of  hepatic  impairment  on  the  pharmacokinetics  of  CBZ  is  not  known.  Given 
that  CBZ  is  primarily  metabolized  in  the  liver,  it  is  important  to  exercise  caution  when 
initiating  CBZ  in  patients  with  hepatic  dysfunction.  The  effect  of  renal  impairment  on 
the  pharmacokinetics  of  CBZ  is  similarly  unknown. 
Plasma  CBZ  concentrations  can  be  influenced  by  drug  interactions.  These  are  often 
pharmacokinetic  rather  than  pharmacodynamic  in  origin,  and  result  from  induction  or 
inhibition  of  DMEs  (Patsalos,  1999;  Perucca,  2001;  Bazil  &  Pedley,  2003).  The  CBZ-E Chapter  1:  General  Introduction  41 
to  CBZ  ratio  may  be  significantly  increased  by  the  concomitant  administration  of 
enzyme-inducing  AEDs  (PHT  and  PB)  or  decreased  by  enzyme  inhibitors  (VPA).  The 
metabolism  of  CBZ  can  also  be  inhibited  by  a  variety  of  therapeutic  agents,  including 
macrolide  antibiotics,  anti-fungals,  anti-virals,  and  anti-hypertensive,  all  leading  to  an 
increased  CBZ  plasma  concentration.  Such  drug-induced  changes  in  CBZ  kinetics  are 
particularly  pronounced  in  children  (Battino  et  al.,  1995). 
Genetic  polymorphisms  which  result  in  the  production  of  proteins  with  altered  activity 
may  also  have  major  implications  for  the  variability  in  CBZ  pharmacokinetics  and 
pharmacodynamics.  These  proteins  include  DMEs  and  ion  channels.  CBZ  metabolism 
involves  many  DMEs  (FIGURE  1.2;  Pelkonen  et  al.,  2001).  Common  polymorphisms 
in  genes  encoding  these  enzymes  have  been  associated  with  several  functional  variants. 
Any  such  change  in  the  activity  of  DMEs  may  consequently  influence  the  plasma  and 
brain  concentrations  of  CBZ.  This  may  in  turn  increase  the  risk  of  treatment  failure  or 
the  precipitation  of  adverse  effects  with  CBZ  treatment.  Blockade  of  voltage-gated 
sodium  channels  is  the  principal  mechanism  of  CBZ  action  (Courtney,  1975;  Kuo, 
1998;  Kwan  et  al.,  2001)  and  polymorphisms  in  the  genes  which  encode  these  proteins 
have  been  associated  with  defective  channel  structure  and  several  forms  of  epilepsy  in 
children  (Meisler  &  Kearney,  2005).  These  genetic  variants  may  influence  the  binding 
site  for  CBZ  and  the  sensitivity  of  the  channel  to  blockade.  As  such,  they  have  the 
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1.6  Lamotrigine 
1.6.1  Indication  and  efficacy 
LTG  (3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine)  is  a  modified  derivative  of 
pyrimethamine,  an  antifolate  compound  (FIGURE  1.4).  It  was  approved  for  the  clinical 
management  of  seizures  in  the  United  Kingdom  in  1991.  LTG  was  initially  introduced 
as  an  adjunctive  agent,  but  was  subsequently  proven  to  be  effective  as  monotherapy  in 
the  treatment  of  both  partial  seizures  and  primary  generalised  seizures  in  newly 
diagnosed  and  refractory  epilepsy  patients  (Beghi,  2004).  Patients  with  juvenile 
myoclonic  epilepsy  have  also  benefited  from  LTG  monotherapy  (Schimschock  et  al., 
2005).  Outwith  epilepsy,  LTG  is  employed  as  a  mood  stabiliser  in  depression  (Herman, 
2004).  The  effectiveness  of  LTG  monotherapy  is  comparable  to  that  of  CBZ 
monotherapy  (Nieto-Barrera  et  al.,  2001;  Kaminow  et  al.,  2003).  However,  LTG  has 
better  tolerability  and  a  better  health  related  quality  of  life  measures  than  CBZ  (Gillham 
et  al.,  2000;  Nieto-Barrera  et  al.,  2001).  Up  to  40%  of  patients  who  are  refractory  to 
other  AEDs  may  respond  to  LTG  (Knoester  et  al.,  2005).  LTG  is  also  effective  as  an 
alternative  AED  for  patients  who  experience  intolerable  adverse  effects  (Knoester  et  al., 
2005). 
1.6.2  Mechanism  of  action 
LTG  was  identified  during  the  screening  of  antifolates  as  putative  antiepileptic  agents 
(Ragsdale  &  Avoli,  1998).  However,  its  anticonvulsant  activity  does  not  correlate  with 
its  weak  inhibition  of  dihydrofolate  reductase,  an  enzyme  involved  in  folate  bio- 
synthesis  (Bazil  &  Pedley,  2003).  LTG  acts  mainly  by  prolonging  the  inactivation  of 
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in  a  voltage-  and  frequency-dependent  manner  (Cheung  et  al.,  1992;  Ragsdale  &  Avoli, 
1998;  Kwan  et  al.,  2001).  These  actions  resemble  those  of  the  established  AEDs,  PHT 
and  CBZ.  LTG  also  acts  on  L-,  N-,  and  P-  subtypes  of  calcium  channels  to  reduce  post- 
synaptic  depolarisation  (Wegerer  et  al.,  1997;  Perucca,  2001).  Blockade  of  voltage- 
gated  sodium  and  calcium  channels  by  LTG  is  also  believed  to  prevent  the  release  of 
glutamate,  the  principle  excitatory  neurotransmitter  in  mammalian  brain  (Patsalos, 
1999;  Bazil  &  Pedley,  2003).  LTG  has  been  demonstrated  to  decrease  spontaneous 
glutamate  release  and  to  increase  GABA  release  in  rat  entorhinal  cortex  (Cunningham 
&  Jones,  2000).  This  wide  range  of  pharmacological  effects  may  explain  the  broad 
spectrum  of  clinical  activity  observed  with  LTG 
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FIGURE  1.4.  Chemical  structure  of  lamotrigine.  Arrow  shows  the  main  position 
of  glucuronidation. 
1.6.3  Clinical  pharmacokinetics 
LTG  is  rapidly  and  completely  absorbed  following  oral  administration  and  reaches  peak 
plasma  concentrations  at  I  to  3  hours  after  administration  (T,  ￿.;  Patsalos,  1999;  Bazil  & 
Pedley,  2003;  Doose  et  al.,  2003).  The  oral  bioavailability  approaches  98%  (Patsalos, 
1999;  Bazil  &  Pedley,  2003;  Doose  et  al.,  2003).  LTG  absorption  is  not  significantly Chapter  1:  General  Introduction  44 
influenced  by  the  presence  of  food  in  the  gastrointestinal  tract  (Patsalos,  1999).  The 
constant  rate  of  absorption  has  been  estimated  at  3.18  1/h.  The  Vd  and  tin  are  not  dose- 
dependent,  and  Vd  has  been  estimated  at  approximately  1.14  to  1.36  Vkg  (Cohen  et  a!., 
1987;  Ramsay  et  al.,  1991;  Hussein  &  Posner,  1997;  Wooton  et  al.,  1997).  LTG  is 
approximately  55%  bound  to  human  plasma  proteins.  Thus,  any  interaction  with  other 
therapeutic  agents  through  displacement  from  protein  binding  sites  is  regarded  as 
insignificant. 
In  healthy  volunteers,  the  total  apparent  and  renal  clearances  of  LTG  have  been 
estimated  at  approximately  0.5  and  0.043  ml/min/kg,  respectively  (Cohen  et  al.,  1987; 
Wooton  et  al.,  1997).  The  t112  of  LTG  ranges  from  23  to  36  hours  (Cohen  et  al.,  1987; 
Jawad  et  al.,  1987;  Rambeck  &  Wolf,  1993;  Wooton  et  al.,  1997;  Patsalos,  1999).  In 
patients  with  epilepsy,  concomitant  administration  of  LTG  with  enzyme-inducing  AEDs 
(PHT,  CBZ,  primidone  or  PB)  decreases  the  mean  LTG  tin  to  14  hours  (Jawad  et  al., 
1987;  Ramsay  et  al.,  1991).  In  contrast,  concomitant  administration  of  LTG  with 
enzyme-inhibiting  AEDs  (VPA)  significantly  increases  the  ti/2  of  LTG  (30  -  90  hours; 
Jawad  et  al.,  1987;  Patsalos,  1999;  Perucca,  2001;  Bazil  &  Pedley,  2003).  Doses  may  be 
adjusted  accordingly  but  the  dosing  interval  is  unchanged  as  the  relationship  between 
LTG  dose  and  concentration  remains  linear  in  both  monotherapy  and  polytherapy 
(Armijo  et  al.,  1999).  Other  than  concomitant  AEDs,  several  other  factors  may  also 
influence  LTG  concentrations.  Oral  contraceptives  can  reduce  LTG  concentration 
through  induction  of  the  glucuronidation  process  (Sabers  et  al.,  2001)  and  pregnancy  is 
associated  with  a  decrease  in  LTG  concentrations,  especially  in  the  second  and  third 
trimesters  (Tran  et  al.,  2002;  Petrenaite  et  al.,  2005).  Severe  liver  disease,  such  as 
cirrhosis,  may  reduce  the  elimination  of  LTG  and  potentially  increase  plasma 
concentrations  (Marcellin  et  al.,  2001).  A  modest  autoinduction  with  LTG  has  been 
demonstrated  and  is  complete  within  2  weeks  of  LTG  initiation.  As  a  result,  the Chapter  1:  General  Introduction  45 
systemic  clearance  is  increased  by  an  average  of  17%  and  the  tin  decreased  from  27.6  to 
23.5  hours  (Hussein  &  Posner,  1997). 
LTG  undergoes  2-N-glucuronidation  mainly  by  UGTIA4  (FIGURE  1.4;  Magdalou  et 
al.,  1992;  Rambeck  &  Wolf,  1993;  Vashishtha  et  al.,  2001).  Glucuronide  conjugates  are 
the  primary  (90%)  excreted  form  of  LTG.  Approximately  70%  of  oral  LTG  doses  are 
recovered  in  the  urine  (Cohen  et  al.,  1987).  The  pharmacokinetic  profiles  of  LTG  did 
not  differ  between  healthy  volunteers  and  patients  with  chronic  renal  failure,  suggesting 
that  renal  impairment  has  little  or  no  effect  on  LTG  plasma  concentrations  (Wooton  et 
al.,  1997). 
1.6.4  Concentration  -  response  relationship 
Patients  with  focal  and  generalised  epilepsies  are  known  to  possess  a  lower  resting 
motor  threshold  (RMT;  Tergau  et  al.,  2003).  RMT  is  an  indicator  of  the  level  of  motor 
cortex  excitability.  A  study  performed  in  healthy  volunteers  demonstrated  a  positive 
linear  correlation  between  LTG  plasma  concentrations  and  RMT  (Tergau  et  al.,  2003), 
suggesting  that  LTG  significantly  influences  the  excitability  of  the  motor  cortex  in  a 
concentration-dependent  manner  and  that  higher  LTG  concentrations  may  be  associated 
with  better  seizure  control.  However,  there  are  no  clinical  studies  which  have 
successfully  reproduced  this  relationship  in  the  epilepsy  population.  There  is  no  known 
association  between  LTG  plasma  concentration  and  the  percentage  reduction  in  seizure 
frequency  (Mahmood  et  al.,  1998)  or  total  seizure  control  (Kilpatrick  et  a!.,  1996).  The 
literature  is,  however,  less  clear  with  regard  to  the  relationship  between  LTG 
concentration  and  toxicity  (Kilpatrick  et  al.,  1996;  Hirsch  et  al.,  2004).  Concentrations 
of  LTG  higher  than  the  recommended  therapeutic  range  (1.5  -  10  mg/1)  are  often  well 
tolerated  and  may  provide  better  efficacy  (Hirsch  et  a!.,  2004),  but  those  greater  than  20 Chapter  1:  General  Introduction  46 
mg/I  have  been  reported  to  produce  adverse  effects  in  more  than  50%  of  patients 
(Hirsch  et  al.,  2004). 
There  is  no  evidence  to  support  the  appropriateness  of  monitoring  plasma  LTG 
concentration  in  association  with  seizure  control.  However,  it  may  be  useful  in  patients 
treated  with  polytherapy,  especially  when  adding  or  removing  concomitant  AEDs  as 
LTG  concentrations  are  influenced  by  enzyme  inducers  such  as  NIT,  CBZ  and  PB  and 
enzyme  inhibitors  like  VPA  (Perucca,  2001;  Bazil  &  Pedley,  2003).  Significant  changes 
in  plasma  LTG  concentrations  as  a  result  of  the  withdrawal  of  concomitant  agents  may 
be  detrimental  to  seizure  control  or  increase  the  risk  of  adverse  effects. 
1.6.5  Adverse  effects 
The  typical  adverse  effects  experienced  with  LTG  are  similar  to  those  of  CBZ  (Brodie 
et  al.,  1999;  Kaminow  et  al.,  2003).  However,  the  number  of  patients  who  experience 
adverse  effects  with  LTG  is  relatively  low  compared  to  established  drugs,  such  as  CBZ 
and  VPA  (Nieto-Barrera  et  al.,  2001;  Kaminow  et  al.,  2003).  Although  the  incidence  of 
rash  is  higher  with  LTG  than  with  CBZ,  the  percentage  of  patients  with  intolerable 
rashes  that  lead  to  drug  withdrawal  is  lower  (Brodie  et  al.,  1999;  Kaminow  et  al.,  2003; 
Faught  et  al.,  2004).  This  was  paralleled  with  a  lower  number  of  drop-outs  for  the  LTG 
group  compared  to  the  CBZ  group  in  a  head  to  head  monotherapy  trial  (Brodie  et  al., 
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1.6.6  Potential  factors  that  influence  the  variability  in  clinical 
pharmacology  of  lamotrigine 
Numerous  factors  can  lead  to  variability  in  pharmacokinetics  and  pharmacodynamics, 
and  consequently  affect  the  efficacy  and  toxicity  of  LTG.  These  include  patient  age, 
organ  function,  underlying  diseases,  drug  formulation,  concomitant  medications  and 
genetic  status.  Body  composition  and  function  are  reflected  by  age.  The  weight-related 
Vd  of  lipophilic  drugs  is  usually  higher  in  adults  than  in  children  because  of  the  greater 
proportion  of  fat  per  kg  of  body  weight  (Thomson,  2004).  However,  the  weight- 
normalised  Vd  for  LTG  in  children  aged  between  2  to  12  years  is  higher  than  that 
reported  in  adults  (Chen  et  al.,  1999).  There  is  no  clear  explanation  for  this  observation. 
LTG  metabolism  is  mainly  mediated  by  glucuronidation  in  the  liver.  The  rate  of 
glucuronidation  is  known  to  be  lower  in  infants  aged  between  7  and  24  months  than  in 
older  children  or  adults  (Strassburg  et  al.,  2002).  Hence,  children  under  2  years  may 
exhibit  a  lesser  degree  of  LTG  metabolism.  Interestingly,  the  weight-normalised 
clearance  of  LTG  is  higher  in  children  aged  between  2  and  12  years  than  in  adults  (Chen 
et  al.,  1999).  This  is  in  accordance  with  the  observation  that,  in  older  children,  DMEs 
mature  rapidly  and  biotransformation  occurs  at  a  faster  rate  than  in  adults  (Gilman  et  al., 
2003;  Perucca,  2006).  Thus,  children  may  require  a  higher  dose  of  LTG  per  kg  of  body 
weight  than  adults.  LTG  metabolism  can  also  be  affected  by  severe  liver  disease,  such 
as  cirrhosis  (Marcellin  et  al.,  2001),  whereas  renal  impairment  does  not  directly  affect 
plasma  LTG  concentrations  but  may  influence  the  excretion  of  glucuronide  metabolites 
of  LTG  (Wooton  et  al.,  1997).  Plasma  LTG  concentrations  can  also  be  influenced  by 
drug  interactions.  These  are  often  a  result  from  induction  or  inhibition  of  DMEs  (Jawad 
et  al.,  1987;  Ramsay  et  al.,  1991;  Armijo  et  al.,  1999;  Patsalos,  1999;  Perucca,  2001; 
Bazil  &  Pedley,  2003).  It  is  well  known  that  the  concomitant  use  of  LTG  and  enzyme- Chapter  1:  General  Introduction  48 
inducing  AEDs  such  as  PB,  PHT  and  CBZ  may  reduce  plasma  LTG  concentrations 
(Jawad  et  al.,  1987;  Ramsay  et  al.,  1991),  whereas  the  interaction  between  LTG  and 
VPA  may  result  in  increase  of  plasma  LTG  concentrations  (Armijo  et  al.,  1999). 
Dosage  adjustment  of  LTG  may  be  required  when  introducing  or  withdrawing  these 
concomitant  AEDs. 
Genetic  polymorphisms  which  result  in  the  production  of  proteins  with  altered  activity 
may  have  major  implications  for  the  variability  in  LTG  pharmacokinetics  and 
pharmacodynamics.  These  proteins  include  DMEs,  DTPs  and  specific  subunits  of 
neuronal  ion  channels.  Polymorphisms  in  UGT  genes  can  influence  the  activity  of 
glucuronidation  enzymes  (Sawyer  et  al.,  2003;  Thibaudeau  et  al.,  2006),  and  any  such 
change  in  the  activity  of  UGTs  involved  in  LTG  metabolism  may  consequently  affect 
plasma  and  brain  drug  concentrations.  This  may  increase  the  risk  of  treatment  failure  or 
the  precipitation  of  adverse  effects  with  LTG  treatment.  LTG  is  believed  to  be  a 
substrate  for  P-gp  (Potschka  et  al.,  2002).  Polymorphisms  in  the  ABCB  I  gene  which 
encodes  P-gp  can  alter  the  expression  and  function  of  P-gp  (Hoffineyer  et  al.,  2000). 
This  protein  is  expressed  in  various  body  tissues,  including  the  intestine,  liver,  kidney 
and  brain  (Kim,  2002a;  Marchi  et  al.,  2004).  Variability  in  the  ABCB1  gene  has  the 
potential  to  influence  the  absorption,  distribution,  and  elimination  of  LTG. 
Polymorphisms  in  the  pharmacodynamic  targets  of  LTG  may  also  have  an  impact  on  its 
efficacy.  Blockade  of  voltage-gated  sodium  channels  is  the  principal  mechanism  of 
LTG  action  (Cheung  et  al.,  1992;  Ragsdale  &  Avoli,  1998;  Kwan  et  al.,  2001)  and 
polymorphisms  in  the  genes  which  encode  the  principal  protein  subunits  of  these 
channels  have  been  associated  with  defective  channel  structure  and  several  forms  of 
epilepsy  in  children  (Meisler  &  Kearney,  2005).  These  genetic  variants  have  the 
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pharmacological  blockade.  As  such,  they  might  contribute  to  interindividual  variability 
in  the  clinical  efficacy  and  toxicity  of  the  drug. 
1.7  Drug  metabolising  enzyme,  drug  transporter  protein 
and  sodium  channel  genes  and  their  common 
polymorphisms 
In  accordance  to  the  aims  of  this  project,  special  attention  is  given  to  DMEs  that  are 
involved  in  CBZ  metabolism,  P-gp  that  has  been  reported  to  transport  LTG,  and 
voltage-gated  sodium  channels  which  are  blocked  by  CBZ  and  LTG  in  exerting  their 
antiepileptic  effects.  Common  polymorphisms  in  these  DME,  P-gp  and  voltage-gated 
sodium  channel  genes  are  described  in  this  section.  Published  studies  examining  these 
gene  variants  in  association  with  AED  responsiveness  are  limited.  As  such,  studies 
investigating  other  pharmacological  agents  are  presented  to  illustrate  the  functional 
relevance  of  these  gene  variants.  The  common  polymorphisms  examined  throughout 
this  research  programme  are  listed  in  TABLE  1.6.  These  are  the  most  widely  recognised 
genetic  polymorphisms  of  the  respective  proteins  at  the  time  this  project  was  planned. 
1.7.1  Cytochrome  P450:  History  and  structure 
In  1940s,  cytochrome  P450  monooxygenase  was  first  systematically  documented  in 
studies  exploring  the  in  vivo  metabolic  pathway  of  compounds  in  animals  (Schenkman, 
1993).  Extended  work  through  the  1960s  by  many  investigators  revealed  the  presence  of 
mixed  function  oxidase  in  the  process  of  drug  and  xenobiotic  oxidation.  In  1958, 
Garfinkel  and  Klingenberg  identified  and  reported  CYP450  as  a  new  pigment  in 
mammalian  liver  microsomes  (Lipscomb  &  Gunsalus,  1973;  Sato  et  al.,  1973).  When Chapter  1:  General  Introduction  50 
treated  with  carbon  monoxide,  the  reduced  form  of  the  pigment  demonstrated  an 
unusually  strong  absorption  band  at  450  nm.  For  that  reason,  the  pigment  was  known  as 
Pigment-450  (P450;  Sato  et  al.,  1973).  Most  of  these  pigments  are  present  in  a 
membrane-bound  state  of  several  tissues,  for  example,  in  the  liver,  kidney,  adrenal 
cortex,  intestinal  mucosa  and  several  endocrine  glands  (Sato  et  al.,  1973).  CYP450s  are 
named  with  the  root  CYP  derived  from  CYtochrome  P450  followed  by  an  Arabic 
numeral  denoting  the  gene  family,  a  letter  for  the  subfamily  and  another  numeral 
designating  the  gene  number  (Gonzalez,  1993).  Human  CYP450  has  more  than  30 
isoforms. 
CYP450  has  a  molecular  weight  of  about  57  000  Daltons  (-500  residues)  and  contains 
one  equivalent  of  ß-type  haem  per  polypeptide.  The  overall  hydrophobicity  of  CYP450 
is  about  36%,  and  this  gives  a  significant  non-polar  property  to  the  molecule. 
Computational  modelling  of  CYP450  suggests  the  existence  of  an  a-helix  and  a  ß-strand 
in  the  molecule.  The  structure  undergoes  `open'  and  `closed'  transitions  to  facilitate 
substrate  binding  and  product/metabolite  release  (FIGURE  1.5;  Black,  1993).  Further 
investigations  in  3-dimensional  models  have  demonstrated  that  CYP450  structure  is 
specific  for  certain  substrates  (Guengerich,  1987). Chapter  1:  General  Introduction 
TABLE  1.6.  Single  nucleotide  polymorphisms  in  selected  drug  metabolising 
enzyme,  drug  transporter  protein  and  sodium  channel  genes. 
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Single  nucleotide  Amino  acid  dbSNP  reference 
Protein  Gene  polymorphism  substitution  number 
CYP3A4  CYP3A4  g.  -392A>G  -  rs2740574 
CYP3A5  CYP3A5  g.  6986A>G  Splicing  defect  rs776746 
CYP1A2  CYPIA2  g.  5734C>A  -  rs762551 
mEH  EPHXI  c.  337T>C  Y11311  rs1051740 
c.  416A>G  H  139R  rs2234922 
UGT2B7  UGT2B7  c.  802C>T  H268Y  rs7439366 
P-gp  ABCB  1  c.  1236C>T  G412G  rs  1128503 
c.  2677G>T/A  A893S/T  rs2032582 
c.  3435C>T  111451  rs1045642 
Na"1.2  SCN2A  c.  56G>A  R19K  rs17183814 
mEH  =  microsomal  epoxide  hydrolase;  P-gp  =  P-glycoprotein;  Na,,  1.2  =  voltage- 
gated  sodium  channel  alpha-2  subunit;  amino  acid  code,  A=  Alanine,  G= 
Glycine,  H=  histidine,  I=  Isoleucine,  K=  lysine,  R=  arginine,  S=  Serine,  T= 
Threonine,  Y=  tyrosine;  dbSNP  =  SNP  database  from  National  Center  for 
Biotechnology  Information  available  at  http:  //www.  ncbi.  nlm.  nih.  gov/. Chapter  I:  General  Introduction 
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FIGURE  1.5.  A  schematic  view  of  the  secondary  structure  of  the  ('YI13A4 
protein.  The  thick  arrow  shows  the  substrate  pocket.  Adapted  G-om  Williams  'i  at. 
(2004). 
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1.7.2  Cytochrome  P450  3As 
1.7.2.1  Functions  and  tissue  distribution  of  CYP3As 
Almost  50%  of  all  clinically  used  drugs  arc  mctabolised  by  ('YP3A  isolorms,  mainly 
CYP3A4  and  CYP3A5  (Kuehl  et  (il.,  2001;  Tredger  &  Stoll,  2002;  Schuct/  ct  al.,  2004). 
Both  CYP3As  are  also  involved  in  the  metabolism  of  more  than  50%  of  Al:  I)s.  Other 
than  xcnobiotics,  CYP3A  also  catalyses  the  metabolism  of  endogenous  substances  such 
as  steroids,  fatty  acids  and  prostagladins  (Ohmori  et  al.,  199  8).  ('YP3A  proteins  are 
present  in  many  tissues  throughout  the  body.  CYP3A  expression  is  greatest  in  the  liver, 
which  is  the  main  organ  of  drug  elimination.  On  average,  ('YP3A  comprises  30  to  40% 
of  total  hepatic  CYP450  (Shimada  et  al.,  1994).  In  the  small  intestine,  ('YP3A  can  be 
found  in  the  villus  epithelium  (Paine  et  al.,  I997).  CYP3A  hepatic  expression  shows  a 
variation  as  much  as  40-1old  among  surgically  excised  and  organ  donated  livers  (I,  amba Chapter  I:  General  Introduction  53 
et  al.,  2002a;  Ozawa  et  al.,  2004).  A  large  interindividual  variability  has  also  been 
reported  for  the  CYP3A  content  in  the  small  intestine  (Paine  et  al.,  1997;  I.  own  ct  al., 
1994). 
The  CYP3A4  isoform  is  the  dominant  CYP3A  enzyme  in  the  adult  liver.  In  contrast, 
CYP3A5  is  expressed  mainly  in  the  gastrointestinal  tract.  Nevertheless,  the  CYP3A5 
isoform  can  also  be  detected  in  other  tissues  throughout  the  body,  such  as  adrenal  gland, 
lung,  prostate  and  kidney  (Kolars  et  a!.,  1994;  Lown  el  al.,  1994;  (icrvot  et  a!.,  1996; 
1  laehner  et  al.,  1996;  Ilukkanen  et  al.,  2001;  Koch  et  a!.,  2002). 
1.7.2.2  CYP3A  gene  locus 
The  CYP3A  gene  locus  is  located  on  position  g22.  I  ol'chromosome  7  (()rawa  cf  (Il., 
2004).  Duplication  of  an  ancestral  CYP3A  gene  cassette  of  40-55  kb  forms  the  CYP3A 
locus.  Each  of  the  CYP3A  genes  contains  13  exons,  which  encode  a  503-amino  acid 
CYP3A  protein  (Wojnowski,  2004).  The  CYP3A  family  consists  of'  four  members; 
CYP3A4,  CYP3A5,  CYP3A7  and  CYP3A43  (FIGURF  1.6;  Kuehl  el  al.,  2001). 
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FIGURE  1.6.  The  location  of  the  ('YP3A  gene  locus  on  Chromosome  7  and 
arrangement  of'CYP3A  genes  in  the  locus.  Adapted  from  Wojnowski  (2004). Chapter  1:  General  Introduction 
1.7.2.3  Genetics  and  common  polymorphisms  of  CYP3A4 
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Genetic  polymorphisms  in  the  flanking,  intronic  and  exonic  regions  of  the  CYP3A4 
gene  may  influence  its  level  of  expression  and  function.  In  the  5'-flanking  region  of 
CYP3A4  gene  alone,  at  least  six  different  SNPs  have  been  identified  (Lamba  et  al., 
2002b).  The  polymorphic  alleles  of  the  CYP3A4  present  at  a  lower  frequency  in 
Caucasians  than  Oriental  populations,  except  for  CYP3A4  g.  747C>G  (Hamzeiy  et  al., 
2002)  and  CYP3A4  g.  -392A>G  (Sata  et  al.,  2000;  Kuehl  et  al.,  2001;  Gracia-Martin  et 
al.,  2002;  Hamzeiy  et  al.,  2002).  The  CYP3A4  g.  -392A>G  polymorphism,  previously 
known  as  CYP3A4-V,  is  a  SNP  in  the  promoter  region  of  the  CYP3A4  gene  and  was 
first  described  in  association  with  the  risk  of  developing  prostate  carcinoma  (Rebbeck  et 
al.,  1998). 
1.7.2.4  Genetics  and  common  polymorphisms  of  CYP3A5 
Clear  polymorphic  CYP3A5  expression  is  found  in  the  adult  liver,  small  intestine  and 
other  organs,  with  individuals  presenting  a  low  level  of  protein  (Ilaehner  et  al.,  1996; 
Kuehl  eta!.,  2001;  Lin  et  a!.,  2002).  The  most  recognised  polymorphism  of  CYP3A5  is 
the  g.  6986A>G  transition  (FIGURE  1.7),  a  SNP  within  intron-3  which  creates  a  cryptic 
splice  site  leading  to  the  insertion  of  exon-313  into  the  mRNA  (Ilustert  et  al.,  2001; 
Kuehl  et  al.,  2001;  Lamba  et  al.,  2002a).  This  SNP  prematurely  produces  a  stop  codon 
and  terminates  the  expression  of  CYP3A5  protein  (Kuehl  et  al.,  2001).  This  explains  the 
absence  of  CYP3A5  protein  in  some  individuals.  The  nonfunctional  homozygous 
CYP3A5  6986G/G  genotype  is  present  in  70-87%  of  Caucasians  (van  Schaik  et  a!., 
2002;  Lee  et  at.,  2003;  King  et  al.,  2003;  Schuetz  et  al.,  2004). Chapter  1:  General  Introduction 
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FIGURE  1.7.  Distribution  of  polymorphisms  in  the  CYP3A5  gene.  Boxes  I  to  13 
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Hepatic  CYP3A4  protein  expression  varies  as  much  as  90-fold  among  individuals 
(Hustert  et  al.,  2001).  The  high  interindividual  variation  observed  in  CYP3A4  levels  is 
believed  to  be  genetically  related  (Chelule  et  al.,  2003;  Ingelman-Sundberg,  2004).  The 
functional  significance  of  CYP3A4  gene  variants  for  AED  metabolism  is  unknown.  For 
substrates  such  as  nifedipine  and  alphatoxin  B1,  the  significance  of  genetic  variability  in 
CYP3A4  activity  has  been  demonstrated  among  Japanese  and  Caucasian  populations 
(Shimada  et  al.,  1994).  This  is  further  supported  by  a  meta-analysis  of  16  studies 
employing  10  different  CYP3A4  substrates,  which  revealed  strong  genetic  control  on 
the  variability  of  CYP3A4-dependent  metabolism  of  adriamycin,  ethylestradiol, 
erythromycin,  midazolam,  nifedipine  and  nitrendepine  (Ozdemir  et  al.,  2000).  Some 
additional  'evidence  to  support  the  importance  of  CYP3A4  gene  variants  in  drug 
metabolism  has  also  been  reported.  For  example,  a  significant  difference  in  the  systemic 
clearance  of  midazolam,  statins,  tacrolimus  and  docetaxel  has  been  demonstrated 
between  the  carriers  of  the  CYP3A4  -392A  and  -392G  alleles  (Wandel  et  al.,  2000; 
Hesselink  et  al.,  2003;  Goto  et  al.,  2004;  Kajinami  et  al.,  2004;  Tran  et  al.,  2006). 
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The  second  most  highly  expressed  CYP3A  protein,  CYP3A5,  provides  another  potential 
avenue  for  exploration.  Some  studies  suggest  that  CYP3A5  might  not  directly 
contribute  to  CYP3A  variability  due  to  its  low  protein  expression  in  the  liver  (Westlind- 
Johnsson  et  al.,  2003).  Nevertheless,  some  investigators  have  demonstrated  positive 
findings.  It  has  been  reported  that  some  Caucasian  subjects  with  the  CYP3A5  6986A 
allele  are  able  to  express  CYP3A5  protein  at  a  level  which  corresponds  to  50%  of  the 
total  hepatic  CYP3A  content  (Kuehl  et  al.,  2001).  Therefore,  polymorphisms  of 
CYP3A5  may  influence  the  total  CYP3A  activity  (Kuehl  et  al.,  2001)  and  there  is 
evidence  to  support  this  hypothesis.  A  significant  influence  of  CYP3A5  polymorphisms 
has  been  demonstrated  on  the  efficacy  of  drugs  which  undergo  CYP3A5-dependent 
metabolism,  such  as  lovastatin,  simvastatin,  artovastatin  (Kivisto  et  al.,  2004)  and 
saquinavir  (Frohlich  et  al.,  2004).  Carriers  of  the  CYP3A5  6986G  allele  were  found  to 
possess  a  lower  midazolam  clearance  (Wong  et  al.,  2004).  However,  a  similarly 
designed  study  in  a  Korean  population  failed  to  reproduce  this  finding  (Yu  et  al.,  2004). 
These  conflicting  results  might  be  explained  by  ethnic  differences  between  studies, 
which  are  not  uncommon,  and  further  investigation  is  required  for  clarification. 
The  degree  of  linkage  disquilibrium  between  common  polymorphisms  in  CYP3A4  and 
CYP3A5  appears  to  be  high  (>90%)  when  calculated  from  all  concordant  homozygous 
and  heterozygous  genotypes  (Dally  et  al.,  2004).  A  60%  homology  between  the  5'- 
flanking  region  of  CYP3A5  and  the  corresponding  region  of  CYP3A4,  from  nucleotide 
-1  to  -1432  (Jounaidi  et  al.,  1994),  appears  to  contribute  to  this  association.  Linkage 
may  play  an  important  role  in  the  overall  activities  of  the  CYP3A  protein  (Lamba  et  al., 
2002b;  Wilkinson,  2004).  For  substrates  that  are  metabolised  mainly  by  one  of  the 
CYP3A  enzymes,  effects  of  the  CYP3A5  g.  6986A>G  polymorphism  are  usually 
opposed  to  the  effects  of  the  CYP3A4  g.  -392A>G  (Saito  et  al.,  2004). Chapter  1:  General  Introduction  57 
The  importance  of  inducer  effects  on  CYP3A4  and  CYP3A5  gene  polymorphisms  has 
been  demonstrated  in  a  handful  of  studies.  Subjects  who  were  treated  with  rifampicin 
and  who  carry  the  CYP3A4  -392A  and  CYP3A5  6986G  polymorphisms  appear  to 
demonstrate  higher  midazolam  clearance  (Floyd  et  al.,  2003).  The  extent  of  induction 
was  also  found  to  be  approximately  50%  greater  in  subjects  with  the  CYP3A5  6986G/G 
genotype  (Floyd  et  al.,  2003).  This  evidence  suggests  that  genetic  polymorphisms  can 
significantly  influence  the  pharmacological  induction  of  drug  metabolism. 
1.7.3  Cytochrome  P450  1A2 
1.7.3.1  Functions  and  tissue  distribution  of  CYP1A2 
CYPIA2  is  a  DME  that  catalyzes  the  hydroxylation  of  xenobiotics  such  as  caffeine, 
theophylline,  clozapine  and  CBZ  (Pelkonen  et  al.,  2001).  Some  of  the  metabolites 
produced  via  the  CYPIA2  pathway  can  be  mutagenic  and  carcinogenic  to  human  cells. 
In  mammals,  CYPIA2  is  constitutively  expressed  in  the  liver  and  the  olfactory  mucosa 
(Zhang  et  al.,  2000).  CYP1A2  represents  approximately  13%  of  human  liver  CYP450 
(Shimada  et  al.,  1994).  Interestingly,  CYPIA2  was  found  to  be  more  active  in  men  than 
in  women  (Rasmussen  et  al.,  2002).  CYPIA2  activity  can  be  induced  by  drugs  such  as 
CBZ  (Parker  et  al.,  1998). 
1.7.3.2  Genetics  and  common  polymorphisms  of  CYPIA2 
The  CYP1A  gene  locus  is  located  on  Chromosome  15q24.1  of  the  human  genome 
(FIGURE  1.8).  The  CYP  1A  locus  contains  two  genes,  CYP  1A1  and  CYP  I  A2.  The 
CYPIA2  gene  comprises  7  exons  that  encode  515  amino  acids.  It  also  contains  an 
upstream  region  of  about  3  kb  (Quattrochi  et  al.,  1986).  The  CYP  IA2  gene  is  separated 
by  23  kb  from  the  CYPIAI  gene  in  the  CYPIA  locus.  These  two  genes  are  orientated  in Chapter  I:  General  Introduction  58 
opposite  directions  with  respect  to  one  another,  and  share  a  common  5'flanking  region, 
which  contains  the  xenobiotic  response  elements  and  hepatic  transcription  factors, 
including  hepatic  nuclear  J  'actors  (I  INFs;  Corchero  ei  (il.,  2001). 
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FIGURE  1.8.  The  location  of  the  CYPIA  gene  locus  on  Chromosome  15  and 
distribution  of  polymorphisms  in  the  CYP  I  A2  gene.  Boxes  I  to  7  represent  the 
exons.  The  *  11'  symbolizes  the  g.  5734C>A  polymorphism. 
Currently,  more  than  13  polymorphisms  of  CYPIA2  have  been  identilicd  (Human 
Cytochrome  P450  (CYP)  Allele  Nomenclature  Conunittce,  2001).  Amon;  these 
polymorphisms  only  the  CYPIA2  g.  -2467del"1'  and  ('YP  I  A2  g.  5734C--A  arc  commonly 
found  in  Caucasian  populations  (Sachse  et  al.,  2003;  Pavancllo  c!  (Il.,  2005).  CYPIA2 
g.  -2467del1'  is  believed  to  he  under  strong  linkage  with  ('YPIA2  g.  5734('  A  in Chapter  1:  General  Introduction  59 
Caucasians  (Sachse  et  al.,  2003).  Little  is  known  about  the  influence  of  CYPIA2 
variants  on  its  metabolic  activity,  except  in  the  case  of  the  CYPIA2  g.  5734C>A 
substitution,  where  the  CYPIA2  5734A  allele  has  been  reported  to  be  highly  inducible 
(Sachse  et  al.,  1999)  and  capable  of  adjusting  the  risk  of  developing  disease  (Cornelis  et 
al.,  2005;  Moonen  et  al.,  2005).  The  allele  frequency  of  CYP1A2  5734A  is believed  to 
be  approximately  70%,  with  only  minor  differences  between  ethnic  populations  (Hamdy 
et  al.,  2003a;  Obase  et  al.,  2003;  Moonen  et  al.,  2005). 
1.7.3.3  Phenotype  profile  of  common  CYP1A2  variants 
Distribution  of  a  urinary  ratio  of  caffeine  metabolites  among  smokers  and  non-smokers 
demonstrates  the  presence  of  genetic  control  over  CYP1A2  activity  (Schrenk  et  al., 
1998).  This  is  further  supported  by  a  study  of  caffeine  metabolism  in  twin  subjects 
(Rasmussen  et  al.,  2002).  The  CYPIA2  gene  variants  show  phenotype  differences  only 
in  the  presence  of  xenobiotics  or  environmental  pollutants,  such  as  cigarette  smoking,  in 
which  the  CYPIA2  5734A  allele  shows  higher  metabolic  activity  (Sachse  et  al.,  1999; 
Sachse  et  al.,  2003).  A  study  using  omeprazole  as  an  inducer  has  established  that 
variation  in  CYPIA2  induction  is  also  associated  with  the  presence  of  the  CYPIA2 
5734C>A  polymorphism  (Han  et  al.,  2002).  This  phenomenon  may  be  applicable  to  the 
study  of  CBZ  because  it  has  the  potential  to  significantly  induce  CYPIA2  activity,  as 
demonstrated  in  the  drug-drug  interaction  involving  concomitant  use  of  CBZ  with 
clozapine  and  olanzapine  (Jerling  et  al.  1994;  Lucas  et  al.  1998). 
1.7.4  Microsomal  epoxide  hydrolase 
The  epoxide  hydrolases  are  categorised  under  a  broad  group  of  hydrolytic  enzymes, 
which  include  esterases,  proteases,  dehalogenases  and  lipases  (de  Vries  &  Janssen, Chapter  1:  General  Introduction  60 
2003).  Epoxide  hydrolases  play  an  important  function  in  the  activation  and 
detoxification  of  exogenous  chemicals,  such  as  polycyclic  aromatic  hydrocarbons.  At 
least  five  forms  of  epoxide  hydrolases  are  present  in  mammalian  species.  These  are 
microsomal  cholesterol  5,6-oxide  hydrolase,  hepoxilin  A3  hydrolase,  leukotriene  A4 
hydrolase,  and  soluble  and  microsomal  epoxide  hydrolases  (Fretland  &  Omiecinski, 
2000).  The  first  four  hydrolases  participate  in  the  metabolism  of  endogenous 
compounds.  In  contrast  to  other  epoxide  hydrolases,  mEH  activity  is  geared  more 
towards  the  metabolism  of  xenobiotic  agents  (Fretland  &  Omiecinski,  2000). 
1.7.4.1  Tissue  distribution  and  structure  of  microsomal  epoxide  hydrolase 
mEH  has  been  found  in  all  tissues  studied  to  date.  The  highest  expression  of  mEH 
protein  is  in  the  liver  followed  by  prostate,  lung  and  kidney  (Rebhan  et  al.,  1997).  mEH 
is  also  present  in  brain  tissue  and  may  have  an  important  role  in  the  metabolism  of  drugs 
that  penetrate  the  BBB,  such  as  AEDs. 
The  first  description  of  epoxide  hydrolase  structure  was  based  on  protein  derived  from 
Agrobacterium  radiobacter  AD1  (FIGURE  1.9;  Nardini  et  al.,  1999).  It  consists  of  2 
domains:  the  first  or  the  core  domain  shows  a  typical  feature  of  the  a/ß  hydrolase-fold 
topology  and  the  second  or  the  cap  domain  is  primarily  comprised  of  a-helices. 
Substrates  enter  the  active  site  through  a  long  tunnel  that  is  filled  with  water  molecules. 
The  tunnel  is  located  between  the  core  domain  and  the  cap  domain.  The  back  of  the 
tunnel  or  the  active  site  of  epoxide  hydrolase  replenishes  the  water  molecules  after  the 
metabolic  reaction  (Nardini  et  al.,  1999;  de  Vries  &  Janssen,  2003). ('harter  1:  General  Introduction 
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FIGURE  1.9.  A  schematic  view  of'  the  secondary  structure  of'  the  epoxide 
hydrolase  protein.  Epoxide  hydrolase  is  built  From  a-helices,  ti-strands  and  coils, 
and  has  a  narrow  hydrophobic  active  site  (black  arrow).  Source  from  Nardini  ei  a!. 
(1999). 
1.7.4.2  Microsonial  epoxide  hydrolase  activity 
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mEH  catalyzes  the  trans-addition  of  water  to  a  broad  range  of  epoxide  substrates  such  as 
xenobiotic  alkene  and  arene  oxides.  mEl  I  substrates  are  quite  selective,  with  little  or  no 
metabolism  by  other  epoxide  hydrolases  (Freiland  &  Omiecinski,  2000).  The  narrow 
hydrophobic  tunnel  of  the  active  site  limits  the  ability  ofml:  l  I  to  catalyze  the  hydrolysis 
of  large  epoxide  molecules  (Fretland  &  Omiecinski,  2000).  'T'ypical  nrllI  substrates 
include  toxic  and  procarcinogenic  compounds,  as  well  as  epoxide  metabolites  ofAEI)s. 
In  an  animal  study,  mEH  activity  was  significantly  increased  by  PB  treatment  (Slawson 
et  at.,  1996).  1lowever,  the  level  ofml;  l I  induction  is  moderate  compared  to  C'YP450s 
(Pirmohamed  et  al.,  1994;  Hassett  et  cit.,  1998).  A  study  employing  human  lymphocytes 
also  demonstrated  that  mEH  activities  varied  by  3.3-fold  and  4.74old  in  control  subjects 
and  patients  receiving  enzyme  inducing  drugs,  respectively  (Pirmohamed  et  al.,  1994). Chapter  1:  General  Introduction  62 
Indirect  pharmacokinetic  evidence  in  human  and  animal  studies  suggests  that  hepatic 
mEH  is  also  inducible  by  CBZ  (Eichelbaum  et  al.,  1985;  Regnaud  et  al.,  1988; 
Kudriakova  et  al.,  1992). 
In  a  study  employing  CBZ-E  as  a  substrate  for  mEII,  it  was  demonstrated  that  the 
median  log  metabolic  ratio  of  transdihydrodiol  to  epoxide  was  slightly  greater  in 
chronic  PB  and  PHT  treated  subjects,  compared  to  subjects  not  treated  with  inducing 
agents  (Kroetz  et  al.,  1993).  However,  the  distribution  of  the  log  metabolic  ratios  did 
not  differ  significantly  from  normality  (Kroetz  et  al.,  1993).  These  findings  indicate  that 
the  rate  of  CBZ-E  metabolism  is  not  significantly  influenced  by  the  induction  of  mEH. 
As  such,  although  CBZ  may  induce  mEH  activity,  it  is  unlikely  to  enhance  the 
elimination  of  CBZ-E. 
1.7.4.3  Genetics  and  common  polymorphisms  of  EPHX1 
A  single  functional  gene,  EPHXI,  located  at  the  g42.1  of  chromosome  1,  encodes  the 
human  mEH  protein  (FIGURE  1.10;  Skoda  et  al.,  1988;  Hassett  et  al.,  1994a).  The 
EPHXI  gene  contains  nine  exons,  although  the  first  exon  is  noncoding.  Protein  coding 
begins  with  the  sixth  nucleotide  of  the  second  exon  (Hassett  et  al.,  1994a).  As  many  as 
33  polymorphisms  in  EPHXI  have  been  reported  (Saito  et  al.,  2001).  Two 
polymorphisms  that  have  been  studied  most  extensively  are  the  substitution  of 
c.  337T>C  on  exon-3  and  c.  416A>G  on  exon-4,  and  particularly,  in  relation  to  the  risk 
of  developing  cancer  (Jourenkova-Mironova  et  al.,  2000;  Zhou  et  al.,  2001;  Lebailly  et 
al.,  2002;  Sonzogni  et  al.,  2002;  Cajas-Salazar  et  al.,  2003),  emphysema  (Smith  & 
Harrison,  1997;  Budhi  et  al.,  2003)  and  liver  disease  (Sonzogni  et  al.,  2002).  The 
frequency  distribution  reported  for  the  337C  allele  is  much  higher  in  Oriental 
populations  (45-56%;  Takeyabu  et  al.,  2000;  Budhi  et  al.,  2003;  Zhang  et  al.,  2003) Chapter  I:  General  Introduction 
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compared  to  African  and  Caucasian  populations  (21-41%;  Jourcnkova-Mironova  et  (11., 
2000;  London  el  al.,  2000;  Wong  el  al.,  2000),  while  the  416(  allele  is  observed  at  a 
frequency  of  around  I5-24%  in  most  populations  (Jourcnkova-Mironova  cat  al.,  2000; 
Wong  el  al.,  2000;  Lebailly  et  al.,  2002). 
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FIGURE  1.10.  The  location  of  the  EPI  IX  I  gene  locus  on  Chromosome  1.  Boxes 
I  to  9  represent  the  exons.  The  *3  and  *4  symbolize  the  c.  337'1'->('  and  c.  416A>G 
polymorphisms,  respectively. 
1.7.4.4  Phenotype  profile  of  common  E  PI  IX  1  variants 
In  vita  eflccts  of  EPI  IX  I  variants  have  been  demonstrated  in  some  cases  ofcancer,  and 
in  lung  and  liver  diseases,  especially  in  the  presence  of'  xenobiotic  or  environmental 
factors  (London  el  al.,  2000;  Wong  el  al.,  2000;  Ulrich  el  a/.,  2001;  Zhou  el  al.,  2001; 
Cajas-Salazar  el  al.,  2003;  Lin  el  al.,  2006).  The  gene-disease  association  is  believed  to 
be  related  to  the  ability  of  EPI  IX  I  variants  to  convert  a  less  active  compound  to  a  more 
active  compound  in  individuals  with  416(;  (fast  nºetaboliser)  or  a  more  active 
compound  to  a  less  active  compound  in  individuals  with  337('  (slow  nºetaholiser).  It  has Chapter  1:  General  Introduction  64 
been  proposed  that  polymorphic  expression  of  EPHX  1  may  also  contribute  to  the 
deficiency  in  mEH,  which  could  be  partly  responsible  for  AED-induced  idiosyncratic 
reactions  such  as  those  observed  with  CBZ-E  (Pirmohamed  et  al.,  1992). 
mEH-mediated  hydrolysis  of  benzo[a]pyrene-4,5-epoxide  varied  8.5-  and  7-fold 
between  liver  samples  at  low  and  high  substrate  levels,  respectively  (Hassett  et  al., 
1997).  This  variation  might  be  due  to  polymorphic  expression  of  the  EPIIXI  gene.  It 
has  been  reported  that  the  activity  of  mEH  is  reduced  by  50%  in  carriers  of  337C,  and 
increased  by  25%  in  carriers  of  416G  (Hassett  et  al.,  1994b).  In  addition,  a  study  of 
EPHXI  variant  activity  in  cultures  of  COS-1  cells  demonstrated  that  expression  and 
activity  of  the  EPHXI  416G-containing  enzyme  were  28%  and  40%  higher  than  the 
EPHX1  416A-containing  enzyme,  respectively  (Maekawa  et  al.,  2003).  Using  cis- 
stilbene  oxide  and  benzo[a]pyrene-4,5-oxide  as  substrates,  the  hydrolysis  reaction  rates 
of  mEH  were  significantly  lower  for  the  337C/416G  allele  than  for  other  EPHX1 
variants  (Hosagrahara  et  al.,  2004).  In  many  studies,  diplotypes  of  337T>C  and 
416A>G  polymorphisms  are  commonly  used  to  predict  the  levels  of  net  mEH  activity 
(Smith  &  Harrison,  1997;  Sarmanova  et  al.,  2000;  Takeyabu  et  al.,  2000;  Zhou  et  al., 
2001;  Sonzogni  et  al.,  2002;  Lebailly  et  al.,  2002;  Cajas-Salazar  et  at.,  2003).  Using 
these  diplotypes,  the  net  mEH  activity  can  be  categorised  as  low,  medium  or  high. 
1.7.5  UDP-glucuronosyltransferases 
Conjugation  reactions  may  involve  glucuronidation,  sulphation,  glutathionation, 
acetylation  and  methylation.  The  glucuronidation  process  is  mediated  by  UGTs.  To 
date,  15  functionally  active  human  UGTs  have  been  identified.  UGTs  catalyze  the 
biotransformation  of  a  vast  array  of  structurally  diverse  endogenous  compounds  and 
xenobiotics.  Substrates  of  UGT  are  conjugated  with  glucuronic  acid  from  a  sugar  donor. Chapter  1:  General  Introduction  65 
Glucuronidation  can  affect  both  parent  compounds  and  metabolites.  Other  than  a 
deactivation  property,  UGTs  may  also  generate  bioactive  and  even  toxic  compounds 
(Radominska-Pandya  et  al.,  2001). 
1.7.5.1  UDP-glucuronosyltransferase  2B7:  Functions  and  tissue  distribution 
UGT2B7  is  an  important  isoform  that  participates  in  glucuronidation  of  physiologically 
important  endogenous  compounds  and  variety  of  clinically  used  drugs  (Turgeon  et  al., 
2001;  Court  et  al.,  2003;  Staines  et  al.,  2004).  Examples  of  UGT2B7  substrates  include 
estrogens,  catecholestrogens,  bile  acids,  3'-azido-3'-deoxythymidine,  opioids,  and  CBZ. 
The  UGT2B7  protein  is  highly  expressed  in  liver  and  kidney;  however,  it  is  also 
detected  in  mammary  gland,  small  intestine,  lungs  and  brain  tissue  (King  et  al.,  1999; 
Turgeon  et  al.,  2001). 
1.7.5.2  Genetics  and  common  polymorphisms  of  UGT2B7 
At  present,  the  human  UGT2B  subfamily  includes  7  genes;  UGT2B4,  UGT2B7, 
UGT2B  10,  UGT2B  11,  UGT2B  15,  UGT2B  17  and  UGT2B28  (Riedy  et  al.,  2000; 
Levesque  et  al.,  2001).  Most  of  the  UGT2B  genes  are  believed  to  be  located  in  one  gene 
locus  on  Chromosome  4g13.2  (FIGURE  1.11;  Riedy  et  al.,  2000).  The  UGT2B7  gene 
comprises  6  exons  that  encode  529  amino  acids  (Carrier  et  al.,  2000;  Riedy  et  al.,  2000). 
More  than  80  SNPs  have  been  reported  for  the  UGT2B7  gene  (National  Center  for 
Biotechnology  Information,  National  Library  of  Medicine,  Bethesda,  USA; 
http:  //www.  ncbi.  nlm.  nih.  gov/).  Of  these  SNPs,  the  UGT2B7  c.  802C>T  polymorphism 
has  been  reported  to  be  present  at  a  significant  level  in  many  populations.  This 
polymorphism  occurs  in  exon-2  of  the  UGT2B7  gene,  and  leads  to  replacement  of 
histidine  by  tyrosine  at  codon  268.  The  presence  of  the  UGT2B7  802T  allele  is  higher  in Chapter  1:  General  Introduction  66 
Caucasian  populations  than  other  ethnic  groups,  ranging  between  49%  -  54'%,  (13hasker 
et  al.,  2000;  Lampe  et  al.,  2000).  Although  the  tJ(i'  2f37  802C%  I'  substitution  causes  an 
amino  acid  change,  its  functional  significance  in  terms  of'  elidogcnous  substrate  and 
xenobiotic  metabolisms  is  unclear. 
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FIGURE  1.11.  The  location  of  the  UG"12U  gene  locus  on  Chromosome  4  and 
distribution  of  polymorphisms  in  the  UG"I'2137  gene.  Boxes  I  to  6  represent  the 
exons.  The  *2  symbolizes  the  c.  802C--T  polymorphism. 
1.7.5.3  Phenotype  profile  of  common  tJGT2137  variants 
Several  studies  have  been  pcrlormed  to  determine  the  eficets  of  the  I  I(  i"I'2137  802('-1'1' 
polymorphism  on  xenobiotic  metabolism,  hoNvcver,  none  of  these  studies  directly 
examined  AEI)  metabolism.  An  in  vitro  investigation  using  two  types  of  cell  culture  has 
concluded  that  the  c.  802C>T  substitution  may  not  he  responsible  liar  the  variability  in Chapter  1:  General  Introduction  67 
plasma  and  urine  concentrations  of  opioid  compounds,  menthol,  oxazepam,  propranolol 
or  androgens  (Coffman  et  al.,  1998).  The  UGT2B7  802T  allele  also  appears  to  lack  a 
functional  effect  on  morphine  3-glucuronidation  (Bhasker  et  al.,  2000;  Holthe  et  al., 
2003).  Nevertheless,  the  carriers  of  the  802T  allele  have  been  shown  to  possess  a 
significantly  lower  UGT2B7  activity  in  morphine-6-glucuronidation  compared  to 
carriers  of  the  802C  allele  (Sawyer  et  al.,  2003).  This  phenomenon  may  be  associated 
with  the  specificity  of  UGT2B7  in  catalysing  glucuronidation  of  morphine  at  position-6 
(Soars  et  al.,  2004). 
Although  the  UGT2B7  802T  allele  has  been  identified  as  a  lower  activity  variant,  a 
recent  study  has  demonstrated  a  contrary  finding,  with  the  UGT2B7  802T  allele 
exhibiting  a  2-fold  higher  intrinsic  clearance  in  conjugating  4-hydroxy- 
catecholestrogens  (Thibaudeau  et  al.,  2006).  Structural  differences  between  substrates 
may  explain  the  conflicting  findings  between  these  studies  (Ekins  et  al.  2001;  Ekins  et 
al.,  2003;  Thibaudeau  et  al.,  2006). 
1.7.6  Drug  Transporter  Proteins 
DTPs  can  be  important  determinants  of  drug  absorption,  distribution  and  excretion.  The 
functional  significance  of  DTPs  is  dependent  upon  their  expression,  and  this  can  be 
modulated  by  genes  and  many  substances  (Ishikawa  et  al.,  2004).  DTPs  are  known  to  be 
involved  in  drug-drug  interactions,  for  example  between  CBZ  and  talinolol  (Lowe  et 
al.,  1997;  Kim,  2002a;  Giessmann  et  al.,  2004). 
DTPs  have  also  been  associated  with  non-responsiveness  to  AEDs,  as  they  significantly 
influence  intestinal  drug  absorption  and  BBB  drug  permeability  (Huai-Yun  et  al.,  1998, 
Potschka  et  al.,  2001;  Potschka  et  al.,  2002).  Some  hepatic  DTPs  such  as  P-gp  may Chapter  I:  General  Introduction  68 
affect  the  influx  of  AEI)s  into  hepatocytes,  and  the  efflux  of  All)  metabolites  into  the 
biliary  system,  which  subsequently  influences  the  rate  and  extent  of  AEI)  metabolism 
(FIGURE  1.12).  The  expression  of  intestinal  P-gp  can  also  be  induced  by  drugs  such  as 
C13Z  (Giessmann  et  al.,  2004).  This  phenomenon  may  further  reduce  drug  absorption 
and  enhance  clearance. 
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FIGURE  1.12.  A  postulated  model  representing  drug  and  metabolite  movement 
in  the  intestinal  epithelium  and  hepatocyte.  OATP  Organic  Anion  Transporter 
Protein,  P-gp  =  P-glycoprotein,  MRP  Multidrug  Resistance  Associated  Protein. 
Adapted  from  Kim  (2002h). 
Drug  distribution  into  brain  tissues  is  determined  by  a  host  of  factors  including  barrier 
systems  such  as  the  131313,  physicochemical  properties  of  the  drugs  themselves,  cerebral 
blood  flow,  drug  metabolism,  and  pathological  conditions  (dc  Lange  &  I)anhofl  2002). 
Expression  of  P-gp  at  the  luminal  membrane  of'  ccrebrovascular  endothelial  cells  and 
within  the  brain  parenchyma  has  been  suggested  to  restrict  drug,  accumulation  at Chapter  I:  General  Introduction  69 
neuronal  target  sites  (FIGURE  1.13;  Tsuji  &  Tamai,  1997;  Marchi  e1  al.,  2004).  P-gp 
has  also  been  reported  to  reduce  the  penetration  of'  several  AI?  I)s  into  the  brain 
(Potschka  el  al.,  2002).  These  findings  support  the  functional  relevance  of  P-gp  in 
influencing  the  distribution  of'AEl)s  into  brain  tissue. 
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FIGURE  1.13.  A  postulated  model  representing  the  location  of  A13('13l  11- 
glycoprotein  in  the  blood-brain  harrier  and  brain  parcnchynrr.  Adapted  from 
Marchi  ei  al.,  2004). 
1.7.6.1  P-glycoprotein 
In  the  1970s,  a  surface  glycoprotein  was  first  identified  on  ('Irinesc  hamster  ovary  cells 
with  altered  permeability  to  colchicine  (Juliano  &  Ling,  1976).  "I'he  170  kI) 
glycoprotein  was  then  designated  as  P-gp.  The  N-terminus  of  the  I'-gp  molecule Chapter  1:  General  Introduction  70 
contains  6  transmembrane  domains,  followed  by  a  large  cytoplasmic  domain  with  an 
ATP  binding  site,  and  then  a  second  section  with  6  transmembrane  domains  and  a 
further  ATP  binding  site  which  shows  over  65%  amino  acid  homology  with  the  first 
half  of  the  polypeptide  (FIGURE  1.14).  P-gp  has  been  studied  extensively  with  regard 
to  its  role  in  chemotherapy  disposition  and  resistance  (Chan  et  al.,  2004). 
c.  3435C>T 
0844 
FIGURE  1.14.  The  putative  2-D  structure  of  ABCB  1  P-glycoprotein  with  the 
sites  of  common  polymorphisms.  Adapted  from  Pastan  et  al.  (1991). 
1.7.6.2  Functions  and  tissue  distribution  of  P-gp 
P-gp  is  an  ATP-dependent  transmembrane  efflux  pump  with  a  wide  range  of 
amphipathic  hydrophobic  substrates  (Kim,  2002a).  P-gp  transports  substances  with 
diverse  chemical  structures,  such  as  anticancer  agents,  cardiac  drugs,  I1IV  protease 
inhibitors,  immunosuppressants,  ß-adrenoceptor  antagonists,  AEDs  and  also  drug 
metabolites  (Potschka  et  al.,  2002;  Schwab  et  al.,  2003).  Usually,  CYP3A  generated 
metabolites  undergo  subsequent  sulfation  and  glucuronidation.  In  humans,  P-gp  is 
commonly  co-localised  and  co-regulated  with  CYP3A  in  many  tissues.  Thus,  P-gp ('hapter  I:  General  Introduction 
substrates  were  originally  speculated  to  include  most  drug  sulfates  and  glucuronides 
(Thu,  1999).  P-gp  may  serve  as  a  tünctional  barrier  against  drug  entry.  P-gp  knock-out 
mice  demonstrate  significant  elevation  in  the  disposition  of  P-gp  substrates  (Schinkcl  ei 
at.,  1996).  P-gp  can  be  detected  in  many  tissues  such  as  the  intestine,  liver,  kidney, 
adrenal  gland  and  brain  (Kim,  2002a;  Marchi  el  at.,  2004).  It  can  also  he  Bond  in  the 
apical  membrane  of  many  barrier  tissues  such  as  the  13ßI3  and  blood-placenta  harrier 
(Cascorbi,  2006). 
1.7.6.3  Genetics  and  common  polymorphisms  of  AB('BI 
P-gp  belongs  to  the  transporter  supcrI  roily  of  the  ATP-hinding  cassette  (ABC).  In 
humans,  the  ABCB  I  gene  encodes  P-gp  (Borst,  1997;  Kusuhara  &  Sugiyama,  2001). 
The  total  length  of  the  A13CB  1  gene  is  approximately  209  kb,  which  consists  of  a  core 
promoter  region  and  29  exons  (FIGURE  1.15;  13odor  el  al.,  2005).  The  gene  encodes  a 
1280-amino  acid  transporter  (Kim,  2002a;  Schwab  el  eil.,  2003). 
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FIGURE  1.15.  The  location  ot'AI3CU  genes  on  Chromosome  4. Chapter  1:  General  Introduction  72 
More  than  35  SNPs  have  been  identified  in  the  ABCB  1  gene,  of  which  eight  SNPs 
cause  non-synonymous  amino  acid  changes  (Cascorbi,  2006).  In  many  populations,  the 
highest  allele  frequencies  have  been  documented  for  the  c.  1236C>T  (21  -  41%), 
c.  2677G>T/A  (10  -  44%)  and  c.  3435C>T  (10  -  54%)  transitions  (Pauli-Magnus  & 
Kroetz,  2004;  Cascorbi,  2006).  Significant  ethnic  differences  exist  in  the  frequency  of 
allele  and  genotype  distributions  of  the  3435C>T  polymorphism  of  ABCBI  (Schwab  et 
al.,  2003).  In  a  Japanese  study,  strong  association  was  demonstrated  between 
c.  2677G>T/A  and  c.  3435C>T  alleles  (Tanabe  et  al.,  2001).  Carriers  of  the  ABCB  1  *2 
variant,  which  signified  the  haplotype  of  1236T-2677T-3435T  were  more  commonly 
found  among  European  Caucasians  (62%)  and  South  East  Asians  (40%)  than  African- 
Americans  (13%;  Kim  et  al.,  2001;  Tang  et  al.,  2002;  Tang  et  al.,  2004). 
1.7.6.4  Phenotype  profile  of  common  ABCB1  variants 
Among  the  SNPs  that  have  been  documented  for  the  ABCB  1  gene,  polymorphisms  of 
c.  1236C>T,  c.  2677G>T/A  and  c.  3435C>T  have  been  studied  extensively  (Kim,  2002a). 
However,  study  findings  are  inconsistent.  Some  investigations  have  shown  that  the 
3435T  allele  is  associated  with  lower  P-gp  expression  and  activity,  while  others  have 
demonstrated  opposite  findings.  Lower  expression  of  duodenal  P-gp  was  found  to 
correlate  with  the  3435T  allele,  resulting  in  higher  digoxin  plasma  levels  (Hoffmeyer  et 
al.,  2000).  Collectively,  haplotypes  of  ABCB  1  harboring  the  3435T  allele  were  also 
associated  with  higher  digoxin  concentrations  (Johne  et  al.,  2002).  However,  a  large 
study  has  shown  no  significant  difference  in  digoxin  absorption  between  the  3435C  and 
3435T  alleles  and  other  variants  (Gerloff  et  al.,  2002).  A  similar  conflict  was  also 
observed  with  studies  related  to  epilepsy.  A  higher  prevalence  of  the  ABCB  1  3435C/C 
genotype  was  found  among  poor-responders  to  AED  treatment  (Siddiqui  et  al.,  2003), 
suggesting  that  the  3435C/C  genotype  was  associated  with  drug  resistant  epilepsy. Chapter  1:  General  Introduction  73 
However,  three  subsequent  studies  examining  this  polymorphism  failed  to  confirm  the 
original  finding  (Tan  et  al.,  2004a;  Sills  et  al.,  2005;  Kim  et  al.,  2006).  Some  further 
investigations  have  suggested  that  haplotypes  of  these  three  loci  might  be  more  useful  in 
predicting  drug  resistance  in  epilepsy  (Hung  et  al.,  2005)  In  this  regard,  a  study 
focusing  on  CBZ  has  shown  that  the  T-T-T  haplotype  at  the  1236,2677  and  3435 
positions  of  the  ABCB  1  gene  was  associated  with  a  better  response  to  CBZ  therapy 
(Seo  et  al.,  2006a). 
1.7.7  Voltage-gated  Sodium  Channels 
Voltage-gated  sodium  channels  play  a  crucial  role  in  the  initiation  and  propagation  of 
action  potentials  in  neurones  and  other  electically  excitable  cells  (Goldin,  2003).  The 
channel  protein  consists  of  a  complex  of  a  260  kDa  a-subunit  in  association  with  one  or 
more  auxiliary  ß-subunits  (Goldin,  2003;  Yu  &  Catterall,  2003).  The  sodium  channel  a- 
subunit  folds  into  4  domains  (I-IV),  which  are  similar  to  one  another  and  each  domain 
contains  6  a-helical  transmembrane  segments  (Sl-S6;  FIGURE  1.16).  The  S4  region 
acts  as  the  channel's  voltage  sensor.  When  stimulated  by  a  change  in  transmembrane 
voltage,  this  region  moves  towards  the  extracellular  side  of  the  cell  membrane  allowing 
the  channel  to  become  permeable  to  sodium  ions.  A  re-entrant  loop  between  S5  and  S6 
is  embedded  into  the  transmembrane  region  of  the  channel  to  form  a  narrow,  ion- 
selective  filter  at  the  extracellular  end  of  the  channel.  The  cytoplasmic  loop  linking 
domains  III  and  IV  is  important  for  channel  function.  This  loop  plugs  the  channel  after 
prolonged  activation  and  contributes  to  its  inactivation.  A  total  of  nine  a-subunits 
(Na,,  1.1-Na￿1.9)  have  been  functionally  characterized  (Yu  &  Catterall,  2003). 
The  essential  properties  that  enable  voltage-gated  sodium  channels  to  carry  out  their 
physiological  roles  include  rapid  voltage-dependent  activation,  which  opens  the Chapter  I:  General  Introduction  74 
channel,  and  inactivation,  which  closes  the  channel  until  recovery  (Goldin,  2003).  The 
inactivation  process  determines  the  frequency  of'  neuronal  action  potential  firing.  In 
general,  the  inactivation  process  can  he  divided  to  two  phases,  mast  and  slow.  Fast 
inactivation  occurs  when  the  cytoplasmic  loop  occludes  the  channel.  On  the  other  hand, 
slow  inactivation  does  not  involve  the  cytoplasmic  loop.  The  slow  inactivation  process 
is  believed  to  involve  a  conformational  change  of  the  channel.  Many  drugs  including 
AEDs  affect  sodium  channel  inactivation. 
u-subunit  11  subunit 
FIGURE  1.16.  Schematic  diagram  of  u-  and  fl-subunits  of  sodium  channel 
Na,.  I.  2.  The  a-subunit  gene  has  four  repeats  (domains  I-  IV).  Fach  of  the  repeats 
has  six  membrane  regions  (S  I  -S6).  The  S4  region  is  the  voltage  sensor.  The  grey 
circle  represents  the  position  of  the  amino  acid  substitution  (R  I9K)  which  results 
from  the  c.  56G>A  polymorphism.  Adapted  from  Goldin  (2003). Chapter  1:  General  Introduction 
1.7.7.1  Tissue  distribution  of  voltage-gated  sodium  channels 
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Consistent  with  a  distinct  role  for  each  channel  in  human  physiology,  sodium  channels 
have  differential  expression  profiles  during  development  and  different  sub-cellular 
localization  in  adulthood  (Mandel,  1992).  Na,,  l.  1  and  Na￿1.3  are  localised  to  the  soma 
of  the  neurone,  where  they  control  neuronal  excitability.  Na￿1.2  is  expressed  in 
unmyelinated  axons  where  action  potential  conduction  takes  place.  Na,,  1.7,  Na,,  1.8  and 
Na,,  1.9  are  the  most  abundantly  expressed  in  the  peripheral  nervous  system  (PNS). 
Na,,  l.  l  and  Na￿1.6  are  also  significantly  expressed  in  the  PNS.  Finally,  Na,,  1.4  and 
Na,,  1.5  are  muscle  sodium  channels  that  control  the  excitability  of  skeletal  and  cardiac 
myocytes,  respectively. 
Within  the  CNS,  the  expression  of  Na￿1.1  is  abundant  in  medulla  oblongata  and  spinal 
cord.  In  contrast,  the  expression  of  Na￿  1.2  is  highest  in  the  hippocampus  and  cerebral 
cortex  (Gordon  et  al.,  1987).  These  are  the  major  seizure  generating  regions  of  human 
brain  and,  on  the  basis  of  this  observation,  it  is  likely  that  the  NaJ.  2  sodium  channel  is 
involved  in  epileptic  discharges  and  their  responsiveness  to  sodium  channel  blocking 
AEDs 
1.7.7.2  Genetics  and  common  polymorphisms  of  SCN2A 
The  a-subunit  is  the  principal  subunit  of  neuronal  sodium  channels  and  is  expressed  by 
at  least  5  genes  in  human  brain,  namely  SCNIA,  SCN2A,  SCN3A,  SCN8A  and  SCN9A 
(Kohling,  2002).  In  general,  the  clusters  of  genes  encoding  sodium  channels  are  located 
on  chromosomes  2  and  3.  The  SCN2A  gene  that  encodes  the  Na￿  1.2  protein  is  located 
on  Chromosome  2q24.3  (FIGURE  1.17).  This  gene  covers  approximately  120  kb  of 
g.  DNA,  contains  29  exons,  and  encodes  a  2005  amino  acid  protein  (Kasai  et  al.,  2001). Chapter  I:  General  Introduction 
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FIGURE  1.17.  The  location  ofthe  SCN2A  gene  on  Chromosome  2. 
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Several  SCN2A  SNPs  have  been  identified  (Kaplan  &  Lacey,  1983;  Kasai  ('1  a/.,  2001; 
heron  et  al.,  2002;  Berkovic  et  al.,  2004).  however,  data  regarding  the  prevalence  of 
these  polymorphisms  is  limited.  The  c.  56G>A  substitution  in  SCN2A  is  a  well  known 
non-synonymous  polymorphism  (Ito  et  al.,  2004).  The  c.  56G  -A  polymorphism  which 
results  in  an  amino  acid  substitution  at  codon-  19  of'the  Na￿  1.2  protein  has  been  reported 
to  have  a  minor  allele  (56A)  frequency  at  6%  in  a  Japanese  population  (Nakayama  ei 
al.,  2002). 
1.7.7.3  Phenotype  profile  of  common  SCN2A  variants 
Several  non-synonymous  SNPs  in  the  SCN2A  gene,  including  the  c.  56(i  ýA 
substitution,  have  been  associated  with  paediatric  seizure  disorders  such  as  lehrile 
seizure  and  benign  familial  neonatal  inlänlile  seizures  (Su`gawara  el  al.,  2001;  Ileron  ei 
al.,  2002;  13crkovic  et  (il.,  2004).  The  56A  allele  was  found  to  be  more  frequent  in 
children  with  febrile  seizure  than  healthy  controls  (Sugawara  ci  al.,  2001).  The 
mechanism  by  which  this  polymorphism  alters  the  predispotion  of'seizures  is  unknown. 
However,  any  significant  modification  of  sodium  channel  structure  night  reasonably 
explain  seizure  generation  and  could,  in  theory,  influence  the  response  to  A1;  1) 
treatment  (Ramachandran  &  Shorvon,  2003). Chapter  1:  General  Introduction 
1.8  Study  Aims 
The  aims  of  this  thesis  are  listed  as  follows: 
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1.  To  identify  the  prevalence  of  alleles  and  genotypes  of  common  CYP3A4, 
CYP3A5,  CYP1A2,  EPHX1,  UGT2B7,  ABCB1  and  SCN2A  polymorphisms  in 
a  West  of  Scotland  epilepsy  population. 
2.  To  establish  an  association  between  common  polymorphisms  in  SCN2A, 
CYP3A4,  CYP3A5,  CYPIA2,  EPHX1,  UGT2B7  genes  and  the  optimal  dose  of 
CBZ. 
3.  To  establish  an  association  between  common  polymorphisms  in  CYP3A4, 
CYP3A5,  CYP1A2,  EPHX1  and  UGT2B7  genes  and  CBZ  adverse  effects. 
4.  To  establish  an  association  between  common  polymorphisms  in  ABCB  I  and 
SCN2A  genes  and  the  response  to  LTG  monotherapy. 
5.  To  establish  an  association  between  common  polymorphisms  in  ABCßl  and 
SCN2A  genes  and  the  optimal  dose  of  LTG. 
6.  To  establish  the  influence  of  common  ABCB  1  gene  polymorphisms  on  the 
pharmacokinetics  of  LTG  in  newly  diagnosed  epilepsy  patients. 
Studies  exploring  aim  (1)  are  presented  in  Chapter  3,  studies  exploring  aims  (2)  and  (3) 
are  described  in  Chapter  4,  and  studies  exploring  aims  (4),  (5)  and  (6)  are  presented  in 
Chapter  5. CHAPTER  2 
Materials,  Experimental  Principles  and  Recurrent 
Methods Chapter  2:  Materials,  Experimental  Principles  &  Recurrent  Methods 
2.1  Materials 
2.1.1  Chemicals  and  reagents 
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Promega®  wizard  DNA  purification  kit  was  purchased  from  Promega  (Southampton, 
UK).  Bromophenol  blue,  ethylene  diamine  tetraacetic  acid  (EDTA),  ethanol,  ethidium 
bromide,  glacial  acetic  acid,  isopropanol,  tris  base  (Trizma®),  and  xylene  cyanole  FF 
were  obtained  from  Sigma-Aldrich  Co.  Ltd.  (Poole,  UK).  Chlorine  tablets  were 
purchased  from  Prime  Source  (Birmingham,  UK).  Deoxyribonucleotide  triphosphates 
(dNTP  mix),  magnesium  chloride  (MgCl2),  lOx  PCR  buffer  (200  mM  Tris  HCl  &  500 
mM  KCI),  and  Taq  polymerase  were  purchased  from  Invitrogen  Ltd.  (Paisley,  UK). 
Molecular  biology  grade  water  was  obtained  from  Eppendorf  AG  (Hamburg,  Germany). 
PCR  primers  were  purchased  from  MWG-Biotech  (Ebersberg,  Germany). 
Agarose  powder  was  obtained  from  BioGene  Ltd.  (Kimbolton,  UK).  Bovine  serum 
albumin  (100x),  lOx  NE  buffer,  restriction  enzymes  (DdeI,  DpnIl,  EcoO1091,  EcoRV, 
FokI,  PspOMI,  Pstl  and  Rsal),  and  DNA  ladders  (25  and  50  bp)  were  bought  from  New 
England  Biolabs  (Hitchin,  UK).  AMPure®  system,  DYEnamic  ET  Terminator  Cycle 
Sequencing  Kit  and  DYEnamic®  ET  Terminator  dilution  buffer  were  purchased  from 
Beckman  Coulter  Ltd.  (High  Wycombe,  UK).  Ethyl  acetate  and  methanol  were  bought 
from  Rathburn  Chemicals  Ltd.  (Walkerburn,  UK).  Sodium  hydroxide  was  purchased 
from  Fisher  Scientific  UK  Ltd.  (Loughborough,  UK). Chapter  2:  Materials,  Experimental  Principles  &  Recurrent  Methods 
2.1.2  Pharmaceuticals 
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LTG  and  the  internal  standard  (BWA725C)  for  high  performance  liquid 
chromatography  (HPLC)  were  obtained  from  Glaxo  Smith  Kline  (Stevenage,  UK). 
2.1.3  Materials  for  gel  electrophoresis 
2.1.3.1  Electrophoresis  buffer 
A  total  of  3.7224  g  of  EDTA  was  dissolved  in  I  litre  of  distilled  water.  The  p11  of  the 
EDTA  solution  was  adjusted  to  7.0  by  slow  addition  of  5N  sodium  hydroxide.  In  a 
separate  container,  48.4  g  of  tris  base  (Trizma®)  was  dissolved  in  5  litres  of  distilled 
water.  The  Tris  Base  solution  was  then  added  to  the  EDTA  solution.  The  p1!  of  the  final 
solution  was  slowly  adjusted  to  8.0  with  glacial  acetic  acid.  Finally,  distilled  water  was 
added  to  a  total  volume  of  10  litres. 
2.1.3.2  Agarose  gel 
Appropriate  quantities  of  agarose  powder  (2.0,2.5  and  3.0  g)  were  dissolved  in  100  ml 
of  electrophoresis  buffer  to  make  2.0,2.5  and  3.0%  gels,  respectively.  The  mixture  was 
boiled  in  a  microwave  oven.  After  the  agarose  powder  was  completely  dissolved,  0.5  µl 
of  ethidium  bromide  (10  mg/ml)  was  added  and  mixed  thoroughly.  The  mixture  was 
poured  into  a  gel  tray  and  allowed  to  set  for  approximately  1  hour. 
2.1.3.3  Loading  dye 
Small  pinches  (approximately  1  mg)  of  both  bromophenol  blue  and  xylene  cyanole  FF 
were  mixed  with  20  ml  of  50%  glycerol/water  solution. Chapter  2:  Materials,  Experimental  Principles  &  Recurrent  Methods 
2.1.4  Equipment 
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Centrifugation:  Blood  samples  were  centrifuged  in  a  ALC®  PK130  centrifuge  (DJD 
Labcare  Ltd.,  Newport  Pagnell,  UK). 
DNA  quantification:  genomic  DNA  samples  were  quantified  using  a  WPA  Biotech 
photometer  model  UV  1101  (Biochrom  Ltd.,  Cambridge,  UK) 
DNA  storage:  The  genomic  DNA  samples  were  stored  in  a  NapCOIL  UF400  -80°C 
freezer  (Jencons-PLS,  Forrest  Row,  UK). 
Direct  sequencing  assay:  The  sequencing  equipment  consisted  of  MegaBACE  1000 
DNA  Analysis  System  and  SPRIPIate  96R®  plate  (Beckman  Coulter  Ltd.,  High 
Wycombe,  UK) 
LTG  assay:  The  experimental  equipment  consisted  of  Shimadzu  SIL-9A  autosampler, 
Shimadzu  SPDF-6A  UV  detector,  Shimadzu  LC-IOAT  pump  (Shimadzu  UK  Ltd., 
Milton.  Keynes,  UK)  and  Heto  Maxi  Dry  Plus  vacuum  centrifuge  (Iieto-Holten  A/S, 
Allered,  Denmark).  The  HPLC  column  was  a  Zorbax  sil  column  (250  x  4.6  mm; 
DuPont  UK  Ltd.,  Stevenage,  UK) 
Polymerase  chain  reaction:  PCR  was  performed  in  a  PxE  2.0  Thermal  Cycler®  (Thermo 
Electron  Co.,  Basingstoke,  UK) 
Restriction  fragment  length  polymorphism  assay:  Separation  of  DNA  fragments  was 
performed  in  a  Sub-cell®  GT  tank.  A  PowerPac  Basic  was  used  as  a  power  system  for 
the  electrophoresis  process.  Separation  of  DNA  fragments  was  visualised  under 
ultraviolet  light  using  Gel  Doc  1000  system  (all  Bio-Rad  Laboratories  Ltd.,  Hemel 
Hempstead,  UK). Chapter  2:  Materials,  Experimental  Principles  &  Recurrent  Methods 
2.2  Experimental  Principles 
2.2.1  Polymerase  chain  reaction 
82 
PCR  provides  a  sensitive  means  of  amplifying  small  quantities  of  DNA.  PCR  was 
invented  by  Kary  B.  Mullis  in  1983  (Rabinow,  1996).  The  discovery  of  polymerase 
derived  from  the  bacterium  Thermus  aquaticus  (Taq)  which  is found  in  the  region  of  hot 
springs  makes  this  method  feasible.  Taq  polymerase  is  stable  at  the  high  temperatures 
required  to  perform  the  amplification,  whereas  other  polymerases  would  denature.  The 
concept  of  PCR  is  based  on  the  fundamentals  of  natural  DNA  polymerization  reaction. 
2.2.1.1  Polymerase  chain  reaction  components 
PCR  requires  several  basic  components  which  include  a  DNA  template  that  contains  the 
region  of  the  DNA  to  be  amplified,  two  primers  which  are  complementary  to  the  DNA 
regions  at  the  5'  and  3'  ends  of  the  DNA  sequence  to  be  amplified,  a  DNA  polymerase 
(Taq  polymerase)  used  to  synthesize  a  DNA  copy,  dNTPs  from  which  the  DNA 
polymerase  builds  new  DNA,  buffer  solution  which  provides  a  suitable  chemical 
environment  for  optimum  activity  and  stability  of  the  DNA  polymerase,  and  the 
divalent  cation  magnesium  which  is  a  necessary  cofactor  for  Taq  polymerase  activity. 
Magnesium  concentration  is  a  crucial  factor  that  can  affect  the  success  of  the 
amplification.  Template  DNA  concentration,  dNTP  concentration  and  the  presence  of 
proteins  can  affect  the  amount  of  free  magnesium  in  the  reaction.  In  the  absence  of 
adequate  free  magnesium,  Taq  polymerase  is  inactive.  In  contrast,  excess  free 
magnesium  reduces  enzyme  fidelity  and  may  increase  the  level  of  nonspecific 
amplification Chapter  2:  Materials,  Experimental  Principles  &  Recurrent  Methods 
2.2.1.2  PCR  primer  design 
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Good  primer  design  is  essential  for  successful  reactions.  A  number  of  criteria  have  been 
proposed  for  optimal  primer  design.  A  primer  length  of  18-24  bases  is  appropriate  for 
most  PCR  applications.  Shorter  primers  lead  to  amplification  of  nonspecific  PCR 
products.  The  specificity  of  PCR  depends  strongly  on  the  primer  melting  temperature 
(Tm),  a  temperature  at  which  half  of  the  primer  has  annealed  to  the  DNA  template. 
Usually,  optimal  amplification  is  achieved  when  the  Tm  for  both  primers  is  between  52- 
58°C.  The  G  and  C  nucleotide  content  of  a  primer  should  be  between  40  and  60%.  To 
assist  in  fulfilling  these  criteria,  several  online  resources  and  software  programmes  have 
been  created,  such  as  Primer3  (Rozen  &  Skaletsky,  2000)  and  GeneFisher  (Giegerich  et 
al.,  1996).  The  template  DNA  sequence  that  is  required  by  these  programmes  can  be 
obtained  from  established  DNA  databases,  such  as  GenBank  (National  Center  for 
Biotechnology  Information,  National  Library  of  Medicine,  Bethesda,  USA; 
http:  //www.  ncbi.  nlm.  nih.  gov/Genbank/).  The  specificity  of  a  primer  produced  by  these 
programmes  can  be  examined  using  Basic  Local  Alignment  Search  Tool  (BLAST; 
National  Center  for  Biotechnology  Information,  National  Library  of  Medicine, 
Bethesda,  USA;  http:  //www.  ncbi.  nlm.  nih.  gov/BLAST/).  This  evaluation  program 
compares  the  primer  sequence  to  DNA  sequences  available  in  a  comprehensive 
genomic  database  and  calculates  the  statistical  significance  of  matches  between  primer 
and  targeted  DNA  sequence. 
2.2.1.3  Polymerase  chain  reaction  assay 
There  are  three  major  steps  in  a  PCR,  which  are  repeated  for  30  to  40  cycles.  This  is 
done  on  an  automated  thermocycler,  which  can  heat  and  cool  PCR  tubes  within  a  very 
short  period  of  time.  It  is  common  that  additional  denaturation  and  extension  steps  are Chapter  2:  Materials,  Experimental  Principles  &  Recurrent  Methods  84 
included  before  and  after  the  PCR  cycles,  respectively.  In  each  cycle,  the  DNA  template 
is  denatured  at  94°C,  the  primers  are  annealed  to  the  target  sequence  at  50-60  °C  and  the 
two  new  strands  are  extended  by  Taq  polymerase  at  72  °C,  doubling  the  amount  of 
DNA  present  in  a  single  cycle.  The  PCR  is  usually  terminated  with  soaking  at  4  °C  to 
prevent  any  further  reaction  before  the  PCR  product  undergoes  further  sequence 
analyses. 
During  the  denaturation,  the  double  strand  melts  open  to  single  stranded  DNA,  and  all 
enzymatic  reactions  stop.  During  the  annealing  stage,  ionic  bonds  are  constantly  formed 
and  broken  between  the  single  stranded  primer  and  the  single  stranded  template.  The 
more  stable  bonds  last  a  little  longer  (especially  where  primers  that  fit  exactly)  and  on 
that  piece  of  double  stranded  DNA  (template  and  primer),  the  polymerase  can  attach 
and  start  to  copy  the  template.  Once  3  to  4  dNTPs  are  incorporated,  the  ionic  bond 
between  template  and  primer  is  sufficiently  strong  to  prevent  further  breakage.  During 
the  extension  phase,  primers  have  a  stronger  ionic  attraction  to  the  template  than  the  any 
forces  attempting  to  break  these  attractions.  Primers  in  positions  with  no  exact  match 
are  loosely  bound  and  do  not  support  extension.  The  dNTPs  are  successively  coupled  to 
the  primer  in  the  5'  to  3'  direction  and  in  direct  complementary  to  the  DNA  template. 
Approximately  1000  dNTPs  can  be  linked  to  form  a  complementary  DNA  sequence  in  I 
minute  at  72°C. 
2.2.1.4  Examining  the  PCR  product 
The  PCR  product  has  to  be  examined  before  it  is  used  in  further  applications.  Not  every 
PCR  is  successful.  There  is  a  possibility  that  the  quality  of  amplified  DNA  is  poor 
because  one  of  the  primers  was  poorly  designed,  there  were  too  many  annealing  site  for 
the  primers  or  that  the  annealing  temperature  or  magnesium  concentration  was  not Chapter  2:  Materials,  Experimental  Principles  &  Recurrent  Methods  85 
optimised.  It  is  also  possible  that  there  is  a  PCR  product  but  of  incorrect  size.  In  this 
case,  one  of  the  primers  likely  anneals  to  a  part  of  the  gene  closer  (or  further)  than 
expected.  It  is  also  possible  that  both  primers  might  anneal  to  a  totally  different  gene.  In 
some  cases,  it  is  possible  that  the  primers  anneal  firmly  to  the  desired  locations,  but  also 
to  other  locations  in  the  genome.  In  this  case,  multiple  DNA  fragments  will  be  formed. 
Multiple  DNA  fragments  can  also  produced  if  a  lower  than  optimal  annealing 
temperature  is  employed.  In  such  cases,  the  primers  anneal  in  a  non-specific  manner  to 
the  DNA  template.  Examination  of  PCR  product  is  tarried  out  by  gel  electrophoresis. 
The  size  of  the  PCR  product  should  be  known  in  advance  and  can  be  confirmed  by  a 
DNA  ladder  which  is  included  in  the  electrophoresis  process.  For  successful  DNA 
sequence  analysis,  a  single  PCR  product  of  uniform  size  should  be  produced. 
2.2.2  Identification  of  single  nucleotide  polymorphisms 
SNPs  can  be  detected  using  many  methods,  including  hybridization,  primer  extension, 
oligonucleotide  ligation,  allele-specific  PCR  and  restriction  enzyme  cleavage.  However, 
each  of  these  methods  has  its  advantages  and  disadvantages  (Syvanene,  2001;  Zhang  et 
al.,  2005). 
2.2.2.1  Restriction  fragment  length  polymorphism  assay 
RFLP  assays  are  based  on  the  principle  of  restriction  enzyme  cleavage  to  identify  the 
individual  alleles  of  a  genetic  polymorphism.  This  method  is  classic,  relatively 
inexpensive  and  reliable  (Zhang  et  al.,  2005).  However,  it  is  not  recognised  as  a  high- 
throughput  technique. 
RFLP  is  a  technique  in  which  genotypes  are  differentiated  by  analysis  of  fragments 
derived  from  cleavage  of  a  larger  DNA  fragment  by  restriction  enzyme.  The  restriction Chapter  2:  Materials,  Experimental  Principles  &  Recurrent  Methods  86 
enzyme  makes  two  incisions,  one  through  each  of  the  sugar-phosphate  backbones  of  the 
double  helix  without  damaging  the  nitrogenous  bases.  Any  SNP  that  alters  the 
recognition  sequence  of  a  restriction  enzyme  can  be  genotyped  by  RFLP. 
When  the  SNP  does  not  alter  the  enzyme  recognition  sequence,  mismatched  PCR-RFLP 
can  be  employed  to  introduce  an  artificial  restriction  enzyme  site  (Haliassos  et  al., 
1989).  This  method  requires  the  careful  selection  of  restriction  enzymes  and  the  design 
of  appropriate  mismatched  PCR  primers.  Mismatched  PCR-RFLP  uses  a  primer 
containing  an  additional  mismatched  nucleotide  or  nucleotides  adjacent  to  the  SNP  site. 
This  allows  restriction  recognition  sequences  to  cover  the  mismatch  base  and  SNP  site. 
The  artificial  restriction  enzyme  recognition  site  is  introduced  in  just  one  of  the  two 
allelic  sequences. 
The  presence  of  genetic  polymorphisms  is  responsible  for  the  variation  in  the  length  of 
DNA  fragments  created  by  the  restriction  enzyme  digest  of  PCR  products.  The 
restriction  enzyme  is  selected  such  that  its  recognition  sequence  contains  the  nucleotide 
of  interest  and  that  the  enzyme  cuts  the  target  DNA  at  only  one  of  the  two  possible 
alleles.  Suitable  restriction  enzymes  for  a  SNP  site  can  be  identified  using  online 
resources,  such  as  RestrictionMapper  (http:  //www.  restrictionmapper.  org)  and  NEB 
cutter  (http:  //tools.  neb.  com/NEBcutter2/index.  php;  Vincze  et  al.,  2003).  The  restriction 
enzyme  recognises  specific  sequences  and  cuts  the  amplified  DNA  strand  into  series  of 
fragments  of  different  lengths.  The  length  of  the  fragments  can  be  analysed  by  gel 
electrophoresis.  The  pattern  of  DNA  fragments  is  used  to  differentiate  one  allele  from 
another.  This  is  a  key  tool  in  DNA  fingerprinting,  reflecting  the  existence  of  different 
alleles  in  the  individual. Chapter  2:  Materials,  Experimental  Principles  &  Recurrent  Methods 
2.2.2.2  Gel  electrophoresis 
87 
Gel  electrophoresis  is  a  method  that  separates  macromolecules,  either  nucleic  acids  or 
proteins,  on  the  basis  of  size  and  electric  charge.  The  term  electrophoresis  describes  the 
migration  of  charged  particles  under  the  influence  of  an  electric  field.  DNA  has  a 
negative  charge  in  solution,  so  it  will  migrate  to  the  anode  in  an  electric  field.  Agarose 
and  polyacrylamide  are  the  most  common  separation  media  used  in  gel  electrophoresis. 
In  gel  electrophoresis,  the  DNA  is  forced  to  move  through  a  sieve  of  molecular 
proportions.  The  end  result  is  that  large  pieces  of  DNA  move  more  slowly  than  small 
pieces.  The  DNA  fragments  in  the  gel  are  visualised  by  the  inclusion  of  ethidium 
bromide.  This  compound  binds  to  DNA  and  the  complex  DNA  and  ethidium  bromide 
fluoresces  under  ultraviolet  light.  A  digital  image  can  be  obtained  as  a  permanent  record 
of  the  gel  electrophoresis. 
2.2.2.3  Direct  sequencing 
The  direct  sequencing  method  is  a  valuable  complement  to  other  methods  of 
polymorphism  identification  such  as  PCR-RFLP  (Yandell  &  Dryja,  1989).  One  of  the 
advantages  of  direct  sequencing  is  that  it  detects  all  polymorphic  sites  within  amplified 
sequence  (Engelke  et  al.,  1988).  For  a  small-scale  study  with  a  limited  number  of 
targeted  polymorphism  sites,  direct  sequencing  can  be  expensive.  In  recent  years,  direct 
sequencing.  of  DNA  has  undergone  vast  development  (Yandell  &  Dryja,  1989).  The 
latest  sequencing  procedures  involve  hybridisation  of  an  oligonucleotide  primer  to  a 
clean  DNA  template  fragment,  extension  of  the  primer  with  DNA  polymerase  and 
energy  transfer  dye-terminator  reagent,  resolution  of  the  DNA  fragment  using  capillary 
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processes  are  now  undertaken  by  a  fully  automated  system  (Innis  et  al.,  1988).  These 
are  high-throughput  and  increasingly  economical. 
2.2.3  Methods  of  assessing  the  response  to  antiepileptic  drug 
treatment 
The  most  common  difficulty  in  pharmacogenetic  studies,  particularly  in  epilepsy,  is  the 
ability  to  identify  an  unequivocal  drug  response  phenotype.  Phenotypes  related  to  AED 
treatment  can  be  pharmacokinetic  or  pharmacodynamic  in  nature  and  can  include  drug 
dose,  plasma  drug  concentration,  response  to  treatment  (efficacy)  and  occurrence  of 
adverse  effects  (toxicity).  Individual  drug  response  can  be  affected  by  both 
environmental  and  genetic  factors  (Terwilliger  &  Weiss,  1998).  In  population-based 
studies,  AED  response  phenotypes  can  also  be  influenced  by  many  clinical  and 
experimental  factors  that  are  directly  and  indirectly  associated  with  AED  treatment, 
such  as  circadian  variability  in  pharmacokinetics,  ethnicity,  population  size, 
heterogeneity  of  epilepsy,  gradations  of  response,  drug  interactions,  life-style  and 
methods  of  assessing  outcome  (Sills  et  al.,  2005;  French,  2006).  Non-genetic  factors 
such  as  renal  and  hepatic  impairments  may  directly  influence  variability  in  drug 
pharmacokinetics,  especially  for  drugs  that  are  mainly  eliminated  through  both  of  these 
organs.  Ethnicity  is  usually  associated  with  genetic  heterogeneity  but  also  variability  in 
diet  and  life-style,  and  thus,  populations  with  mixed-ethnicity  may  also  have  a  broad 
heterogeneity  in  terms  of  environmental  interaction.  Population  size  can  influence 
selection  and  randomisation  biases  and  epilepsy  type  may  demonstrate  different  levels 
of  response  to  a  given  AED,  such  that  differences  in  the  distribution  of  epilepsy 
syndromes  between  studies  may  contribute  to  conflicting  findings.  Finally,  drug-drug 
interactions  can  influence  the  effective  dose  and  concentration  of  AEDs,  and  thus, 
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Assessing  the  response  to  AED  treatment  is  complicated,  however  various  methods 
have  been  proposed.  AED  treatment  response  phenotypes  are  commonly  evaluated  by 
two  sets  of  measures  related  to  efficacy  and  to  safety.  The  primary  outcome  measures 
related  to  efficacy  are  seizure  frequency  and  seizure  severity,  whereas  the  primary 
outcome  measures  related  to  safety  are  the  incidence  of  adverse  drug  effects  (Perucca, 
1997;  Gilliam,  2005). 
2.2.3.1  Assessing  the  efficacy  of  antiepileptic  drugs 
In  clinical  practice,  the  response  of  an  individual  patient  to  a  specific  AED  cannot  be 
known  in  advance;  there  is  no  treatment  that  is  universally  effective  or  universally 
ineffective.  As  such,  it  is difficult  to  establish  whether  a  particular  treatment  is  likely  to 
be  effective  for  a  particular  patient.  The  most  attractive  indicator  of  treatment  success  is 
complete  seizure  control  (Perucca,  1997;  Gilliam,  2005;  French,  2006).  However,  the 
probability  of  achieving  seizure-freedom  varies  greatly  depending  on  the  severity  of  the 
seizure  disorder,  pre-treatment  seizure  frequency  and  duration  of  the  assessment  period 
(Kwan  &  Brodie,  2000;  Gilliam,  2005).  The  hidden  difficulty  in  using  such  a  definition 
is  the  time  factor.  How  long  the  patient  must  be  treated  with  the  medication  before 
complete  seizure  control  can  be  established  or  discounted?  It  is  important  that  the 
duration  of  follow-up  is  sufficiently  long  to  ensure  optimal  individualisation  of  dosage 
and  meaningful  assessment  of  response  at  that  dosage.  Individuals  with  low  frequency 
pre-treatment  seizure  frequencies  may  have  to  be  observed  for  considerably  longer  than 
those  with  higher  frequencies. 
Other  useful  endpoints  include  the  percentage  change  in  seizure  frequency  for  the  group 
as  a  whole,  as  well  as  the  proportion  of  patients  achieving  at  least  50%  reduction  in 
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However,  this  approach,  while  statistically  sound,  has  less  practical  applicability  as  it  is 
arguable  that  a  50%  reduction  in  seizure  frequency  may  not  be  adequate  to  produce  a 
significant  improvement  in  quality  of  life.  Counting  of  seizures  can  be  done  directly  by 
the  patient  or  less  common  by  an  external  observer.  Self-reported  seizure  frequency 
may  be  inaccurate  as  some  patients  are  not  aware  of  their  seizures.  Patients  with  the 
lowest  self-reported  seizure  frequency  often  have  the  highest  proportion  of 
unrecognised  seizures  (Gilliam,  2005).  In  addition,  those  with  newly  diagnosed  epilepsy 
may  not  have  had  a  sufficient  number  of  seizures  to  permit  a  reliable  definition  of 
seizure  frequency;  in  such  circumstances,  the  measurement  of  reduction  in  seizure 
frequency  can  be  meaningless.  Another  potential  measurement  of  treatment  efficacy  is 
the  reduction  in  seizure  severity  (French,  2006).  Seizure  severity  requires  a  definition 
that  takes  several  factors  into  account  and  physiological  consequences  of  the  seizure 
must  be  quantified.  The  most  obvious  factors  include  fall,  loss  of  consciousness,  and 
intensity  or  duration  of  postictal  effect.  It  is  clear  for  the  above  that  variability  in  the 
techniques  of  assessing  the  efficacy  of  AED  treatment  can  contribute  to  the  variation  in 
phenotype  characterization. 
2.2.3.2  Assessing  the  adverse  effects  of  antiepileptic  drugs 
Evaluation  of  adverse  effects  is  fraught  with  difficulties.  One  of  these  is  the  lack  of 
current  standardisation  in  the  methodology  for  the  detection  and  categorisation  of 
adverse  events.  Recording  of  adverse  effects  is  often  based  on  spontaneous  reporting  by 
the  patient,  physical  examination,  laboratory  tests  or  a  combination  thereof. 
Spontaneous  reporting  has  clear  advantages  in  highlighting  effects  which  are  clinically 
relevant,  but  it  is  associated  with  distinct  variability  in  the  accuracy  of  detection  and 
with  significant  under-reporting  (Perucca,  1997;  Gilliam,  2005).  Patients  may  not  be 
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(Gilliam,  2005).  An  alternative  to  the  reliance  on  spontaneous  reporting  is  the  use  of 
standardised  procedures  with  respect  to  clinical  questioning  and  physical  examination. 
Of  course,  a  further  problem  is  the  ability  to  quantitatively  assess  the  severity  of  adverse 
symptoms,  especially  for  CNS-related  adverse  effects  (Perucca,  1997;  Gilliam,  2005). 
Another  important  issue  is  the  need  to  obtain  information  about  the  time  course  of  a 
given  adverse  effect,  as  there  is  a  difference  in  the  relative  importance  between  acute, 
transient  and  chronic  effects  which  persist  throughout  the  treatment  period. 
In  clinical  practice,  the  assessment  of  adverse  effects  may  be  considered  as  "biological", 
and  "cognitive"  or  "behavioral".  Biological  adverse  effects  are  those  that  are  objective 
and  evident  by  examination  or  measured  by  clinical  tests.  This  category  of  adverse 
effects  includes-  rash,  hair  loss,  liver  failure,  or  nephritis.  Supplemental  tests  may  be 
required  when  the  clinical  history  indicates  a  particular  possibility.  Biological  adverse 
effects  can  be  divided  into  acute  and  chronic  events.  Acute  effects  are  generally 
idiopathic  and  by  definition  cannot  be  predicted  or  anticipated  for  an  individual  patient, 
for  example  aplastic  anaemia,  hepatitis,  nephritis,  or  Stevens-Johnson  syndrome. 
Chronic  effects  include  disorders  such  as  folate  deficient  anemia,  AED-induced  rickets, 
neuropathy,  gingival  hyperplasia,  and  cerebellar  degeneration.  Chronic  adverse  effects 
appear  to  be  related  more  to  cumulative  toxicity. 
Individual  sensitivities  to  the  cognitive  and  behavioral  side  effects  of  AEDs  are 
commonly  reported  by  patients  and  their  families.  Behavior  and  cognition  are  altered  by 
many  aspects  of  the  epileptic  disorder  and  these  may  be  confused  with  medication 
effects  (Gilliam,  2005).  In  clinical  practice,  measuring  a  change  in  the  patient's 
personality  or  behavior  is  almost  never  objective.  There  is  almost  no  area  of  clinical 
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with  efficacy,  variability  in  the  techniques  of  assessing  adverse  effects  of  AEDs  may 
contribute  significantly  to  the  variation  in  phenotype  characterization. 
2.3  Recurrent  Methods 
2.3.1  Study  subjects 
Approvals  to  obtain  a  peripheral  blood  sample  for  the  extraction  and  pharmacogenetic 
analysis  of  DNA  from  all  appropriate  patients  with  epilepsy  was  granted  by  the  West 
Research  Ethics  Committee  (North  Glasgow  University  Hospitals  NHS  Trust;  Ref 
02/119(2))  in  September  2002.  All  patients  attending  the  Epilepsy  Unit  at  the  Western 
Infirmary,  Glasgow,  Scotland  were  invited  to  participate.  The  first  400  patients  (201 
male;  median  age  40  years,  range  14  to  85  years)  who  provided  informed  consent 
contribute  to  the  experiments  described  in  this  thesis.  Among  these  patients,  398  self- 
identified  as  being  of  European  ancestry  and  the  other  two  subjects  were  of  Asian 
origin.  The  400  DNA  samples  were  collected  continuously  from  September  2002  until 
December  2005.  Throughout  this  thesis,  this  group  of  400  patients  is  denoted  as  the 
"400-strong  study  population".  A  flow  chart  showing  the  distribution  of  these  400 
patients  to  each  individual  project  is  presented  in  FIGURE  2.1. 
2.3.2  Control  DNA  samples 
A  total  of  10  control  DNA  samples  were  obtained  from  members  of  staff  of  the 
Epilepsy  Unit.  All  of  these  subjects  self-identified  as  being  of  European  ancestry.  These 
samples  were  employed  for  the  purposes  of  assay  optimisation  and  validation  and 
thereafter  as  control  samples  of  known  genotype  in  individual  analyses. Chapter  2:  Materials,  Experimental  Principles  &  Recurrent  Methods 
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A  total  of  16  ml  (4  ml  x4  tubes)  of  venous  blood  was  collected  in  EDTA-coated  tubes 
by  qualified  clinical  personnel  and  stored  at  4  T.  Genomic  DNA  was  extracted  from 
leukocytes  using  the  Promega®  Wizard  DNA  purification  kit  as  describe  below. 
The  DNA  extraction  was  started  with  lysis  of  the  red  blood  cells  and  separation  of  the 
white  blood  cells.  A  total  of  30  ml  of  cell  lysis  solution  was  placed  in  a  50  ml  centrifuge 
tube  and  10  ml  of  whole  blood  added.  The  solution  was  mixed  by  inversion  and  then 
incubated  at  room  temperature  (20°C)  for  10  minutes.  The  mixture  was  then  centrifuged 
at  2000  xg  for  10  minutes  at  room  temperature  (20°C).  The  supernatant  was  removed 
and  discarded  into  a  waste  container  containing  a  chlorine  tablet,  leaving  approximately 
1.4  ml  of  residual  liquid  and  a  white  pellet.  These  steps  were  repeated  if  the  pellet 
appeared  red  in  color. 
The  next  step  was  to  release  the  DNA  from  the  nucleus  of  the  white  blood  cells.  The 
centrifuge  tube  containing  the  white  pellet  was  vortexed  to  resuspend  the  white  blood 
cells.  A  10  ml  aliquot  of  nuclei  lysis  solution  was  added  to  the  tube  and  mixed  using  a 
pasteur  pipette.  The  resulting  solution  was  then  incubated  at  37  °C  for  approximately  2 
hours.  The  next  step  was  to  remove  the  cellular  proteins  by  a  salt  precipitation 
technique.  A  3.3  ml  aliquot  of  protein  precipitation  solution  was  added  to  the  nuclear 
lysate  and  vortexed  for  10  -  20  seconds.  The  solution  was  then  centrifuged  at  2000  xg 
for  10  minutes  at  room  temperature  (20°C)  to  separate  the  cellular  protein  (dark  brown 
pellet). 
The  final  step  was  to  concentrate  and  desalt  the  DNA.  Without  disturbing  the  cellular 
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isopropanol.  This  solution  was  then  mixed  by  inversion  until  the  white  "thread-like" 
DNA  strands  formed  a  visible  mass.  Following  that,  the  solution  was  centrifuged  at 
2000  xg  for  3  minutes  at  room  temperature  (20°C)  and  the  DNA  emerged  as  a  small 
white  pellet.  The  supernatant  was  discarded  and  10  ml  of  70%  ethanol  was  added  to  the 
DNA  pellet.  The  pellet  was  resuspended  and  the  tube  washed  by  several  inversions.  The 
solution  was  again  centrifuged  at  2000  xg  for  3  minutes  at  room  temperature  (20°C). 
The  ethanol  was  decanted,  the  tube  was  inverted  on  clean  absorbent  paper,  and  the 
pellet  allowed  to  air-dry  for  10  -  15  minutes.  A  200  pl  volume  of  molecular  biology 
grade  water  was  added  to  rehydrate  the  DNA  and  left  overnight  prior  to  quantification. 
Thereafter,  the  dissolved  DNA  was  transferred  to  a  250  µl  cryovial  using  a  sterile 
pipette  and  stored  frozen  at  -80  °C. 
2.3.4  DNA  quantification 
The  concentration  of  DNA  was  quantified  using  ultraviolet  spectroscopy.  A1  µl  aliquot 
of  DNA  solution  was  diluted  with  70  µl  of  molecular  biology  grade  water  in  a 
polystyrene  cuvette.  The  optical  density  (O.  D.  )  of  the  DNA  solution  was  determined  at 
a  wavelength  of  260  nm.  The  genomic  DNA  concentration  was  calculated  using  the 
following  equation: 
genomic  DNA  (µg/µ1)  =  0.05  *  O.  D.  *  dilution  factor 
2.3.5  Polymerase  chain  reaction 
2.3.5.1  PCR  primers 
Primer  sequences  were  usually  obtained  from  existing  publications,  however,  on 
occasion,  an  online  software  package,  Primer3  (Rozen  &  Skaletsky,  2000),  was  used  to Chapter  2:  Materials,  Experimental  Principles  &  Recurrent  Methods  96 
design  the  PCR  primers.  Some  characteristics  were  standardised  for  all  primer  design, 
such  as  length  of  primers  (18  -  24  bp),  GC  content  (50%)  and  primer  Tm  (55°C).  The 
genetic  sequence  of  interest  was  obtained  from  GenBank.  The  specificity  of  the  primers 
was  evaluated  using  BLAST. 
2.3.5.2  Optimization  of  polymerase  chain  reaction  assay 
All  PCR  assays  were  optimised  using  a  standard  protocol.  A  total  of  10  control  DNA 
samples  were  employed  for  this  purpose.  The  initial  PCR  assay  was  performed  in  a  30 
µl  reaction  volume  containing  100  ng  of  genomic  DNA,  1U  of  Taq  polymerise,  20 
pmol  of  each  PCR  primer,  1.5  mM  MgC12,3  µl  of  IOx  PCR  buffer  and  0.25  mM  dNTP 
mix,  and  the  final  reaction  volume  adjusted  with  molecular  biology  grade  water.  The 
initial  PCR  conditions  consisted  of  denaturation  at  94°C  for  5  minutes;  followed  by  35 
cycles  at  94°C  for  30  seconds  (denaturation),  55°C  for  30  seconds  (annealing),  72°C  for 
30  seconds  (extension),  and  thereafter  a  final  extension  at  72°C  for  5  minutes  and 
soaking  at  4°C.  The  initial  annealing  temperature  was  close  to  the  mean  Tm  of  both 
PCR  primers.  The  amplified  DNA  fragment  was  separated  using  2.0%  agarose  gel 
electrophoresis  at  80V  for  60  minutes  and  then  visualised  under  ultraviolet  light.  The 
size  of  amplified  DNA  fragment  was  estimated  relative  to  a  DNA  ladder  of  known  size 
(25  bp  or  50  bp)  that  was  incorporated  in  each  electrophoresis.  The  size  of  observed 
DNA  fragment  was  compared  with  the  size  of  expected  fragment  obtained  from  the 
primer  design  tool.  The  quantity  of  amplified  PCR  product  was  assessed  based  on  the 
brightness  of  the  band  under  ultraviolate  light.  PCR  assays  with  poor  DNA 
amplification  were  systematically  modified  and  re-evaluated.  The  annealing 
temperature  was  adjusted  in  a  stepwise  manner  without  changing  any  other  initial  PCR 
conditions.  In  the  case  of  low  quantities  of  PCR  amplification,  the  annealing 
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annealing  temperature  was  increased  by  1  degree  each  time.  The  annealing  temperature 
was  typically  evaluated  between  50  and  60°C.  The  magnesium  concentration  was 
adjusted  as  a  second  step  of  optimisation  once  the  optimal  annealing  temperature  has 
been  identified.  In  the  case  of  low  quantities  of  PCR  product,  the  magnesium 
concentration  was  increased  in  a  stepwise  manner  by  0.5  mM.  In  the  case  of  multiple 
bands,  the  magnesium  concentration  was  reduced  in  a  stepwise  manner  by  0.5  mM.  The 
magnesium  concentration  was  typically  evaluated  between  0.5  and  2.5  mM.  The  PCR 
conditions  were  adjusted  until  a  bright  and  reproducible  PCR  product  band  was 
identified  on  gel  electrophoresis. 
2.3.5.3  Quality  control  of  polymerase  chain  reaction  assay 
To  assess  risk  of  contamination,  two  blank  samples  were  included  in  each  analysis,  in 
which  the  DNA  template  was  replaced  by  1  µl  of  molecular  biology  grade  water.  Each 
batch  of  PCR  analyses  consisted  of  18  reaction  tubes  (16  patient  samples  and  2  blanks). 
Blanks  were  randomly  located  across  the  thermal  cycler  block  and  also  randomly 
assigned  to  lanes  on  gel  electrophoresis.  The  blank  samples  were  not  expected  to 
produce  any  DNA  amplification. 
2.3.6  Restriction  fragment  length  polymorphism  assay 
2.3.6.1  Choosing  suitable  restriction  enzymes 
An  online  restriction  enzyme  mapping  software,  NEB  cutter  (http:  //tools.  neb.  com/ 
NEBcutter2/index.  php),  was  utilised  to  identify  suitable  restriction  enzymes  for  a  given 
SNP  site.  On  occasion,  restriction  enzymes  were  identified  from  existing  publications. Chapter  2:  Materials,  Experimental  Principles  &  Recurrent  Methods 
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Each  of  the  RFLP  assays  developed  in  this  project  was  optimised  using  a  standard 
procedure.  PCR  products  from  10  control  DNA  samples  were  employed  for  this 
purpose.  Each  restriction  digest  was  performed  in  a  10  pl  volume  containing  5  µl  of 
PCR  product,  1  µl  x  lOx  NE  buffer,  restriction  enzyme  (2.5,5  to  7.5  U)  and  the  final 
reaction  volume  adjusted  with  molecular  biology  grade  water.  These  reaction  mixtures 
were  incubated  at  37°C  for  up  to  4  hours.  At  the  end  of  2  and  4  hours  incubation  time, 
an  aliquot  of  digest  product  (5  µl)  was  removed  from  reaction  tube  and  each  mixed  with 
a  small  quantity  of  loading  dye  (1  µl),  and  immediately  loaded  onto  a  2.0%  agarose  gel. 
A  DNA  ladder  of  known  size  (25  bp  or  50  bp)  and  one  sample  of  undigested  PCR 
product  (5  µl)  were  also  included  in  each  electrophoresis  run.  The  electrophoresis 
conditions  were  set  at  80V  for  60  to  120  minutes.  At  the  end  of  electrophoresis,  the 
agarose  gel  was  visualised  under  ultraviolet  light.  The  expected  size  of  digested 
fragments  was  estimated  relative  to  the  DNA  ladder.  Incomplete  digestion  was 
evaluated  by  digesting  the  PCR  product  in  a  high  concentration  of  restriction  enzyme 
(10  U)  and  a  longer  incubation  period  (24  hours).  In  the  case  of  poor  resolution  between 
fragments,  the  electrophoresis  was  repeated  using  a  higher  agarose  concentration 
(increased  in  a  stepwise  manner  by  0.5%)  to  permit  clearer  separation  of  digest 
fragments. 
2.3.6.3  Quality  control  of  restriction  fragment  length  polymorphism  assay 
Each  batch  of  RFLP  analysis  comprised  one  DNA  ladder  (25  or  50  bp),  2  water  blanks, 
16  patient  samples,  one  undigested  control  sample  (PCR  product),  and  three  control 
DNA  samples  of  known  genotype,  corresponding  to  each  of  the  expected  genotypes  in Chapter  2:  Materials,  Experimental  Principles  &  Recurrent  Methods  99 
the  population.  Once  all  400  patients  had  been  genotyped,  5%  were  selected  randomly 
and  re-genotyped  for  confirmatory  purposes. 
2.3.7  Statistical  analyses 
MINITAB  TM  Statistical  Software  Release  13.32  (Minitab  Ltd.,  Coventry,  UK)  was  used 
to  perform  all  statistical  analyses.  Logistic  regression  analysis  was  used  to  assess  the 
association  between  genetic  predictors  and  the  response  to  AED  therapy.  The  odds  ratio 
(OR)  together  with  its  95%  confidence  interval  (95%  Cl)  and  p-value  were  used  to 
evaluate  the  strength  of  association.  Genetic  predictors  for  optimal  dose  of  AEDs  were 
identified  and  characterised  using  univariate  and  multivariate  linear  regression  analyses. 
To  explore  interaction  effects,  cross-product  terms  were  added  as  independent  variables. 
A  goodness-of-fit  (r)  value  more  than  0.8  indicates  a  strong  predictive  model. 
Pearson's  correlation  (r)  value  more  than  0.8  indicates  a  strong  association  between 
variables.  For  this  analysis,  p-values  less  than  0.05  indicate  a  significant  association  or 
significant  predictor  effect.  No  formal  power  calculation  and  multiple  testing 
corrections  were  undertaken  for  the  statistical  analysis;  therefore,  the  research  projects 
presented  in  this  thesis  are  considered  to  be  exploratory  in  an  effort  to  generate  research 
hypothesis. CHAPTER  3 
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3.1  The  Prevalences  of  Common  Polymorphisms  in  the 
Drug  Metabolizing  Enzyme,  Drug  Transporter  Protein 
and  Sodium  Channel  Genes  in  a  West  of  Scotland 
Epilepsy  Population 
3.1.1  Introduction 
In  keeping  with  the  aims  of  this  research  project,  genes  of  interest  were  derived  from 
current  knowledge  regarding  the  pharmacokinetics  and  pharmacodynamics  of  CBZ  and 
LTG.  Potentially  functional  variants  of  these  genes  were  then  selected  from  previously 
published  information  (as  presented  in  section  1.7).  The  common  genetic 
polymorphisms  evaluated  in  this  project  are  listed  in  TABLE  1.6.  In  a  population  based 
pharmacogenetic  study,  the  prevalence  of  variant  genotypes  is  expected  to  adhere  to 
Hardy-Weinberg  Equilibrium  (HWE)  conditions  (Xu  et  al.,  2002).  HWE  is  based  on  the 
assumption  that,  under  constant  conditions  after  a  generation  of  random  mating, 
genotype  frequencies  throughout  a  population  at  a  specified  gene  locus  become  fixed  at 
a  specific  equilibrium  value  (Hosking  et  al.,  2004).  The  HWE  test  is  carried  out  by 
comparing  the  genotype  distribution  of  each  SNP  against  the  genotype  distribution  that 
is  predicted  by  HWE  at  that  locus.  Deviation  from  HWE  can  be  the  result  of  one  or 
more  of  five  violations.  The  first  violation  is  inbreeding,  which  causes  an  increase  in 
homozygosity  for  all  genes.  The  second  violation  is  assortative  mating,  which  causes  an 
increase  in  homozygosity  only  for  those  genes  involved  in  the  trait  that  is  assortatively 
mated.  The  third  violation  is  the  occurrence  of  new  mutations.  The  fourth  violation  is 
gene  flow  through  migration  in  or  out  of  the  population.  The  fifth  violation  is  related  to 
population  size,  which  causes  a  random  change  in  genotypic  frequencies,  particularly  if 
the  population  is  very  small.  This  is  due  to  a  sampling  effect,  and  is  known  as  genetic 
drift  (Xu  et  al.,  2002).  Testing  for  HWE  is  also  commonly  used  for  the  quality  control Chapter  3:  DME  &  DTP  Gene  Polymorphisms  102 
of  large-scale  genotyping  and  is  one  of  the  few  methods  which  can  be  useful  to  identify 
systemic  genotyping  errors  in  unrelated  individuals  (Xu  et  al.,  2002;  Hosking  et  al., 
2004;  Salanti  et  al.,  2005;  Wittke-Thompson  et  al.,  2005). 
3.1.2  Aims 
The  aim  of  this  project  was  to  evaluate  the  prevalences  of  common  gene  polymorphisms 
(TABLE  1.6)  in  a  West  of  Scotland  epilepsy  population  and  to  compare  the  allele  and 
genotype  distributions  with  previously  published  data  from  different  ethnic  groups.  The 
genotype  distribution  was  further  examined  using  the  HWE  test  as  an  early  quality 
control  measure  for  the  genotyping  methodology. 
3.1.3  Methods 
3.1.3.1  DNA  samples  and  extraction 
A  total  of  400  DNA  samples  from  the  study  population  described  in  section  2.3.1  were 
utilised  in  this  project.  DNA  extraction  was  performed  following  the  method  described 
in  section  2.3.3. 
3.1.3.2  PCR-RFLP  optimization 
Each  PCR-RFLP  methods  presented  below  have  been  optimised  using  the  method 
described  in  Chapter  2  (sections  2.3.5.2  and  2.3.6.2). 
3.1.3.3  Identification  of  CYP3A4  g.  -392A>G  polymorphism  by  PCR-RFLP 
The  method  described  by  van  Schaik  et  al.  (2000)  was  modified  for  the  purposes  of  this 
study.  Modification  was  undertaken  to  optimise  the  yield  of  PCR  product  which Chapter  3:  DME  &  DTP  Gene  Polymorphisms  103 
included  alteration  in  the  total  reaction  volume,  the  quantity  of  reagents  and  the 
annealing  temperature  (as  described  in  section  2.3.5.2).  The  5'-flanking  promoter  region 
of  the  CYP3A4  gene  containing  the  g.  -392A>G  polymorphism  was  amplified  using 
forward,  5'-GGA  CAG  CCA  TAG  AGA  CAA  CTG  CA-3'  and  reverse,  5'-CTT  TCC 
TGC  CCT  GCA  CAG-3'  primers.  A  PCR  product  containing  the  CYP3A4  -392G  allele 
with  restriction  site  for  the  Pstl  enzyme  was  produced  by  incorporating  the  underlined 
mismatched  nucleotides  into  the  forward  primer.  The  PCR  assay  was  performed  in  a  30 
pl  reaction  volume  containing  100  ng  of  genomic  DNA,  1U  of  Taq  polymerase,  20 
pmol  of  each  primer,  2  mM  MgCI2,3  pl  of  lOx  PCR  buffer,  0.25  mM  dNTP  mix,  and 
an  appropriate  volume  of  molecular  biology  grade  water. 
The  PCR  conditions  consisted  of  an  initial  denaturation  at  94°C  for  7  minutes;  35  cycles 
of  94°C  for  1  minute  (denaturation),  56°C  for  1  minute  (annealing),  72°C  for  1  minute 
(extension);  and  followed  by  a  final  extension  at  72°C  for  7  minutes  and  soaking  at  4°C. 
A  PCR  product  with  a  size  of  334  bp  was  expected  from  the  amplification. 
The  CYP3A4  -392A  allele  was  discriminated  from  the  -392G  allele  by  digesting  the 
PCR  product  with  PstI  endonuclease.  The  PCR  product  was  digested  for  at  least  2  hours 
at  37°C  in  a  20  µl  reaction  volume  containing  15  µl  of  PCR  product,  5U  of  Pstl 
restriction'enzyme,  2  pl  of  lOx  NE  buffer,  0.2  pl  of  100x  BSA  (10  mg/ml)  and  an 
appropriate  volume  of  molecular  biology  grade  water.  Pstl  cut  the  PCR  product  at 
position  5'-CTGCA/G-3',  and  produced  220-bp,  81-bp  and  33-bp  fragments  for  the 
CYP3A4  -392A  allele;  and  199-bp,  81-bp,  33-bp  and  21-bp  fragments  for  the  CYP3A4 
-392G  allele. 
A  total  of  5  µl  of  digest  product  was  mixed  with  1  µl  of  loading  dye  and  loaded  on  a 
2.5%  agarose  gel  containing  300  ng/ml  ethidium  bromide.  The  gel  electrophoresis Chapter  3:  DMI,  &  DIT  Gene  Polymorphisms  104 
conditions  were  set  at  100  V  for  100  minutes.  A  digital  image  of'  the  agarose  gel  was 
captured  at  the  end  of'  the  electrophoresis  process  under  ultraviolet  transillumination 
(FIGURE  3.1). 
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FIGURE  3.1.  Electrophoresis  patterns  tür  CYI'3A4  g.  -392A  -(i  genotypes 
analysed  with  PCR-RFLP  assay. 
3.1.3.4  Identification  of  CYI'3A5  g.  6986A>C  polyroorphisnI  by  I'('R-RFI.  I' 
The  method  described  by  Fukuen  et  cd.  (2002)  was  modified  for  the  purposes  of  this 
study.  Modification  was  undertaken  to  optimise  the  yield  of'  PUR  product  which 
included  alteration  in  the  total  reaction  volume,  the  quantity  of  reagents  and  the 
annealing  temperature  (as  described  in  section  2.3.5.2).  The  intronic  region  of  the 
CYP3A5  gene  containing  the  g.  6986A>G  polymorphism  was  amplified  using  förward, 
5'-CTT  TAA  AGA  GCT  CTT  'IT(;  TC'l'  CT  C  A-3'  and  reverse,  5'-('('A  GGA  AGC 
CAC;  ACT  'FI'G  Ai'-3'  primers.  A  PCR  product  containing  the  ('YP3A5  69866  allele 
with  restriction  site  tür  the  Dclet  enzyme  was  produced  by  incorporating  tile  tilidellned 
mismatched  nucleotide  into  the  lörward  primer.  The  P('l(  assay  was  pert  rmed  in  a  30 Chapter  3:  DME  &  DTP  Gene  Polymorphisms  105 
pl  reaction  volume  containing  100  ng  of  genomic  DNA,  1U  of  Taq  polymerase,  20 
pmol  of  each  primer,  1.5  mM  MgCIZ,  3  µl  of  lOx  PCR  buffer,  0.25  mM  dNTP  mix,  and 
an  appropriate  volume  of  molecular  biology  grade  water. 
The  PCR  conditions  consisted  of  an  initial  denaturation  at  95°C  for  10  minutes;  35 
cycles  of  94°C  for  30  seconds  (denaturation),  56°C  for  30  seconds  (annealing),  72°C  for 
30  seconds  (extension);  and  followed  by  a  final  extension  at  72°C  for  5  minutes  and 
soaking  at  4°C.  A  PCR  product  with  a  size  of  200  bp  was  expected  from  the 
amplification. 
The  CYP3A5  6986A  allele  was  discriminated  from  the  6986G  allele  by  digesting  the 
PCR  product  with  DdeI  endonuclease.  The  PCR  product  was  digested  for  at  least  2 
hours  at  37°C  in  a  10  µl  reaction  volume  containing  5  µl  of  PCR  product,  5U  of  DdeI 
restriction  enzyme,  1  pl  of  lOx  NE  buffer  and  an  appropriate  volume  of  molecular 
biology  grade  water.  DdeI  cut  the  PCR  product  at  position  5'-C/TNAG-3',  and 
produced  129-bp  and  71-bp  fragments  for  the  CYP3A5  6986A  allele;  and  107-bp,  71-bp 
and  22-bp  fragments  for  the  CYP3A5  6986G  allele. 
A  total  of  5  µl  of  digest  product  was  mixed  with  1  µl  of  loading  dye  and  loaded  on  a 
3.0%  agarose  gel  containing  300  ng/ml  ethidium  bromide.  The  gel  electrophoresis 
conditions  were  set  at  100  V  for  80  minutes.  A  digital  image  of  the  agarose  gel  was 
captured  at  the  end  of  the  electrophoresis  process  under  ultraviolet  transillumination 
(FIGURE  3.2). Chapter  3:  I)ME  &  UTP  Gene  Polyniorphisms 
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FIGURE  3.2.  I:  Icctrophuresis  patterns  for  (')"I';  n5  g.  09S(,  A  (i  ýcnýýtyIýý.  ti 
analysed  with  PCR-RFTP  assay. 
3.1.3.5  Identification  of  CYPIA2  g.  5734C>A  polymorphism  by  P('R-RFLP 
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A  new,  self-designed  PCR-RFLP  method  for  the  identification  of  CYP  I  A2  g.  5734C  -A 
was  utilised  in  this  study.  The  intron-  I  region  of  the  CYPIA2  gene  containing  the 
g.  5734C>A  polymorphism  was  amplified  using  forward,  5'-C('('  T  'l  (i  (i(i'U  A"I'A  '1'G(  i 
AAG  GTA-3'  and  reverse,  5'-C"f'"I'  GAG  CAC  CCA  GAA  'I'AC  ('A-3'  primers.  The 
PCR  assay  was  performed  in  a  30  pl  reaction  volume  containing  100  ng  of  genomic 
DNA,  IU  of  Taq  polymerase,  20  pmol  of  each  primer,  2  mM  Mg('I  3  µl  of  I  Ox  PCR 
buffer,  0.25  mM  dNTP  mix,  and  an  appropriate  volume  of  molecular  biology  grade 
water. 
The  PCR  conditions  consisted  ol'an  initial  denaturation  at  94°('  I'm  5  minutes;  35  cycles 
of  94°C  for  30  seconds  (denaturation),  56°C  für  30  seconds  (annealing),  72"('  für  I Chapter  3:  I)MFId.  DTP  Gene  I'olynuirhhisnu  107 
minute  (extension);  and  followed  by  it  final  extension  at  72°C  fi-  5  minutes  and  soaking 
at  4°C.  A  PCR  product  with  it  size  of'5I8  hp  was  expected  Irom  the  amplification. 
The  CYP  I  A2  5734C  allele  was  discriminated  from  the  5734A  allele  by  digesting  the 
PCR  product  with  PspOM  I  endonuclcase.  The  PCR  product  was  digested  four  at  least  2 
hours  at  37°C  in  a  10  pl  reaction  volume  containing  5  pi  of*  P('R  product,  5U  of 
PspOM  I  restriction  enzyme,  I  pl  of  IOx  NI?  huller  and  an  appropriate  volume  of' 
molecular  biology  grade  water.  PspOM  I  cut  the  l'CR  product  at  position 
3'  and  produced  268-bp  and  250-bp  fragments  for  the  ('YP  I  A2  5734('  allele.  The  518- 
hp  PCR  product  remained  uncut  for  the  ('YP  I  A2  5734A  allele  (11(  it  IRE  3.3). 
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FIGURE:  3.3.  I.  lectruhhoresis  Patterns  Iiir  1,11.1  I(  A  ,  1&  II  ý  pc 
analysed  with  PCR-RFLP  assay.  The  268-bp  and  250-hp  li'agments  did  [lot 
resolve  clearly  aller  45  minutes  electrophoresis  on  a  2.0%  agarose  rel. 
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A  total  of  5  µl  of  digest  product  was  mixed  with  I  pl  of  loading  dye  and  loaded  on  a 
2.0%  agarose  gel  containing  300  ng/mI  ethidium  bromide.  The  gel  electrophoresis Chapter  3:  DME  &  DTP  Gene  Polymorphisms  108 
conditions  were  set  at  90  V  for  45  minutes.  A  digital  image  of  the  agarose  gel  was 
captured  at  the  end  of  the  electrophoresis  process  under  ultraviolet  transillumination. 
The  268-bp  and  250-bp  fragments  did  not  resolve  clearly  after  45  minutes 
electrophoresis,  however,  this  did  not  affect  the  genotype  identification. 
3.1.3.6  Identification  of  EPHX1  c.  337ThC  polymorphism  by  PCR-RFLP 
The  method  described  by  Budhi  et  al.  (2003)  was  modified  for  the  purposes  of  this 
study.  Modification  was  undertaken  to  optimise  the  yield  of  PCR  product  which 
included  alteration  in  the  total  reaction  volume,  the  quantity  of  reagents  and  the 
annealing  temperature  (as  described  in  section  2.3.5.2).  The  exon-3  region  of  the 
EPHX1  gene  containing  the  c.  337T>C  polymorphism  was  amplified  using  forward,  5'- 
GAT  CGA  TAA  GTT  CCG  TTT  CAC  C-3'  and  reverse,  5'-CAA  TGT  TAG  TCT  TGA 
AGT  GAG  GAT-3'  primers.  The  reverse  primer  contains  mismatched  nucleotides  for 
codon  113  (shown  as  bold  and  underlined)  and  codon  119  (shown  as  underlined  only). 
The  mismatched  nucleotide  at  codon  113  was  introduced  to  create  a  restriction  site  for 
the  EcoRV  enzyme  and  recognition  of  the  337T  allele  (Smith  &  Harrison,  1997).  The 
mismatched  nucleotide  at  codon  119  was  introduced  to  eliminate  the  effect  of  the 
adjacent  c.  357G>A  polymorphism,  which  is  reported  to  influence  the  estimation  of 
genotypes  at  codon  113  (Budhi  et  al.,  2003).  The  PCR  assay  was  performed  in  a  30  pl 
reaction  volume  containing  100  ng  of  genomic  DNA,  1U  of  Taq  polymerase,  20  pmol 
of  each  primer,  2  mM  MgC12,3  µl  of  lOx  PCR  buffer,  0.25  mM  dNTP  mix,  and  an 
appropriate  volume  of  molecular  biology  grade  water. 
The  PCR  conditions  consisted  of  an  initial  denaturation  at  94°C  for  7  minutes;  35  cycles 
of  94°C  for  1  minute  (denaturation),  56°C  for  1  minute  (annealing),  72°C  for  1  minute Chapter  3:  DME  &  I1TP  Gcne  Polymorphisms  109 
(extension);  and  followed  by  a  final  extension  at  72°C  fir  7  minutes  and  soaking  at  4°C. 
A  PCR  product  with  a  size  of  164  hp  was  expected  from  the  amplification. 
The  EP  I  IX  1337T  allele  was  discriminated  from  the  337('  allele  by  digesting  the  P('R 
product  with  EcoRV  endonuclease.  The  PCR  product  was  digested  for  at  least  2  hours  at 
37°C  in  a  10  pi  reaction  volume  containing  5  pl  of  PCR  product,  5U  of  EcoRV 
restriction  enzyme,  I  pl  of  lOx  NE  bufirr,  0.1  pl  of  I00x  RSA  (10  mg/ml)  and  an 
appropriate  volume  of  molecular  biology  grade  water.  The  P'eoRV  cut  at  position  5'- 
GAT/ATC-3'  and  produced  140-hp  and  24-hp  fragments  for  the  EPI  IX  1337T  allele. 
The  164-hp  PUR  product  remained  uncut  for  the  EPIIX1  337('  allele  (FIGURE  3.4). 
A  total  of  5  pl  of  digest  product  was  mixed  with  I  µl  of  loading  dye  and  loaded  on  a 
3.0%  agarose  gel  containing  300  ng/ml  ethidium  bromide.  The  gel  electrophoresis 
conditions  were  set  at  80  V  for  100  minutes.  A  digital  image  of  the  agarose  gel  was 
captured  at  the  end  of  the  electrophoresis  process  under  ultraviolet  transillumination. 
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FIGUItI?  3.4.  Electrophoresis  patterns  lor  FTIIXI  c.  337T--('  genotypes  analysed 
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3.1.3.7  Identification  of  EPHX1  c.  416A>G  polymorphism  by  PCR-RFLP 
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The  method  described  by  Smith  &  Harrison  (1997)  was  modified  for  the  purposes  of 
this  study.  Modification  was  undertaken  to  optimise  the  yield  of  PCR  product  which 
included  alteration  in  the  total  reaction  volume,  the  quantity  of  reagents  and  the 
annealing  temperature  (as  described  in  section  2.3.5.2).  The  exon-4  region  of  the 
EPHXI  gene  containing  the  c.  416A>G  polymorphism  was  amplified  using  forward,  5'- 
ACA  TCC  ACT  TCA  TCC  ACG  T-3  and  reverse,  5'-ATG  CCT  CTG  AGA  AGC  CAT- 
3'  primers.  The  PCR  assay  was  performed  in  a  30  µl  reaction  volume  containing  100  ng 
of  genomic  DNA,  1U  of  Taq  polymerase,  20  pmol  of  each  primer,  1.5  mM  MgCl2,3  µl 
of  lOx  PCR  buffer,  0.25  mM  dNTP  mix,  and  an  appropriate  volume  of  molecular 
biology  grade  water. 
The  PCR  conditions  consisted  of  an  initial  denaturation  at  94°C  for  5  minutes;  37  cycles 
of  94°C  for  30  seconds  (denaturation),  56°C  for  30  seconds  (annealing),  72°C  for  30 
seconds  (extension);  and  followed  by  a  final  extension  at  72°C  for  5  minutes  and 
soaking  at  4°C.  A  PCR  product  with  a  size  of  210  bp  was  expected  from  the 
amplification. 
The  EPHXI  416A  allele  was  discriminated  from  the  416G  allele  by  digesting  the  PCR 
product  with  RsaI  endonuclease.  The  PCR  product  was  digested  for  at  least  2  hours  at 
37°C  in  a  10  µl  reaction  volume  containing  5  pI  of  PCR  product,  5U  of  Rsal  restriction 
enzyme,  1  µl  of  lOx  NE  buffer  and  an  appropriate  volume  of  molecular  biology  grade 
water.  Rsal  cut  the  PCR  product  at  position  5'-GT/AC-3'  and  containing  the  EPHXI 
416G  allele  and  produced  164-bp  and  46-bp  sized  fragments  for  the  EPHXI  416G 
allele.  The  210-bp  PCR  product  remained  uncut  for  the  EPHXI  416A  allele. Chapter  3:  UMI:  &DTP  (jene  Polymorphisms  III 
A  total  of  5  µl  of  digest  product  was  mixed  with  I  il  of  loading  dye  and  loaded  on  a 
2.5%  agarose  gel  containing  300  ng/ml  ethidium  bromide.  The  gel  electrophoresis 
conditions  were  set  at  80  V  for  80  minutes.  A  digital  image  of'  the  agarose  gel  was 
captured  at  the  end  of  the  electrophoresis  process  under  ultra\  iuIet  truisillunºination 
(FI(iURE  3.5). 
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FIGURE  3.5.  I:  Icctrophoresis  patterns  for  I:  I'I  IX  I  c.  41  6A  -(  igcnotyprs  euialvsrd 
by  PCR-RFLP  assay. 
3.1.3.8  Identification  of  UGT2137  c.  802('>"1'  polymorphism  by  I'('It-Itl'I,  I' 
The  method  described  by  13hasker  el  ul.  (2000)  was  modified  for  the  purposes  of'  this 
study.  Modification  was  undertaken  to  optimise  the  yield  of'  PUR  product  which 
included  alteration  in  the  total  reaction  volume,  the  quantity  of'  reagents  and  the 
annealing  temperature  (as  described  in  section  2.3.5.2).  The  exon-2  region  of'  the 
UGT2137  gene  containing  the  c.  802C  T  polymorphism  was  amplified  using  forward, 
5'-TGC  CTA  CAT  "I"AT  TCT  AAC  C-3'  and  reverse,  5'-TUT  (1(1  AAA  Al  ('"1'G Chapter  3:  DME  &  DTP  Gene  Polymorphisms  112 
CAC  T-3'  primers.  The  PCR  assay  was  performed  in  a  30  µl  reaction  volume 
containing  150  ng  of  genomic  DNA,  IU  of  Taq  polymerase,  20  pmol  of  each  primer,  2 
mM  MgC12i  3  µl  of  lOx  PCR  buffer,  0.25  mM  dNTP  mix,  and  an  appropriate  volume  of 
molecular  biology  grade  water. 
The  PCR  conditions  consisted  of  an  initial  denaturation  at  94°C  for  5  minutes;  35  cycles 
of  94°C  for  30  seconds  (denaturation),  59°C  for  30  seconds  (annealing),  72°C  for  30 
seconds  (extension);  and  followed  by  a  final  extension  at  72°C  for  5  minutes  and 
soaking  at  4°C.  A  PCR  product  with  a  size  of  579  bp  was  expected  from  the 
amplification. 
The  UGT2B7  802C  allele  was  discriminated  from  the  802T  allele  by  digesting  the  PCR 
product  with  FokI  endonuclease.  The  PCR  product  was  digested  for  at  least  2  hours  at 
37°C  in  a  10  µ1  reaction  volume  containing  6  µl  of  PCR  product,  4U  of  FokI  restriction 
enzyme,  1  µl  of  10x  NE  buffer  and  an  appropriate  volume  of  molecular  biology  grade 
water.  FokI  cut  the  PCR  product  at  position  5'-GGATG(N)9/-3'  and  produced  457-bp, 
79-bp  and  42-bp  fragments  for  the  UGT2B7  802T  allele;  and  346-bp,  II  l-bp,  79-bp  and 
42-bp  fragments  for  the  UGT2B7  802C  allele. 
A  total  of  10  µl  of  digest  product  was  mixed  with  I  µl  of  loading  dye  and  loaded  on  a 
2.5%  agarose  gel  containing  300  ng/ml  ethidium  bromide.  The  gel  electrophoresis 
conditions  were  set  at  80  V  for  45  minutes.  A  digital  image  of  the  agarose  gel  was 
captured  at  the  end  of  the  electrophoresis  process  under  ultraviolet  transillumination 
(FIGURE  3.6). Chapter  3:  DME  &  DTP  Gene  Polymorphisms 
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FIGURE  3.6.  Electrophoresis  patterns  for  UGI'2137  c.  802C-.  T  genotypes  analysed  with 
PCR-RFLP  assay 
3.1.3.9  Identification  of  ABC131  c.  1236C>T  polymorphism  by  I'CR-RFLI' 
The  method  described  by  Tang  et  al.  (2002)  was  modified  fir  the  purposes  ot'this  study. 
Modification  was  undertaken  to  optimise  the  yield  of'  PCR  product  which  included 
alteration  in  the  total  reaction  volume,  the  quantity  of  reagents  and  the  annealing 
temperature  (as  described  in  section  2.3.5.2).  The  exon-12  region  of  the  AI3C13I  gene 
containing  the  c.  1236C>T  polymorphism  was  amplified  using  forward,  5'-TCF  "I'TG 
TCA  CU'  TAT  CCA  GC-3'  and  reverse,  5'-'1'("I'  CAC  ('Al'  'C('('  CT  CC  'l'(i"1'-3' 
primers.  The  PCR  assay  was  performed  in  a  20  pl  reaction  volume  containing  100  ng  of' 
genomic  DNA,  IU  ofTaq  polymerase,  20  pmol  ol'each  primer,  1.5  mM  MgCI,,  2  pl  of 
lOx  PCR  buffer,  0.25  mM  dNTI'  mix,  and  an  appropriate  volume  of  molecular  biology 
grade  water. 
The  PCR  conditions  consisted  of  an  initial  denaturation  at  94°('  I'or  10  n.  inutes;  35 
cycles  of  94°C  for  30  seconds  (denaturation),  60°C  Im-  30  seconds  (annealing),  72°C  I'm Chapter  3:  1)ME  &  DTP  Gene  Polymorphisms  114 
30  seconds  (extension);  and  followed  by  a  final  extension  at  72°C  firr  5  minutes  and 
soaking  at  4°C.  A  PCR  product  with  a  size  of  502  hp  was  expected  from  the 
amplification. 
The  A13CBI  1236C  allele  was  discriminated  fi-om  the  12361'  allele  by  digesting  the 
PCR  product  with  EcoOl091  endonuclease.  The  PCR  product  was  digested  fir  at  least 
2  hours  at  37°C  in  a  20  p1  reaction  volume  containing  10  fil  of  PCR  product,  5U  of 
F.  coOl091  restriction  enzyme,  2  pl  of  I  Ox  NE  huficr,  0.2  pI  of  I  ()Ox  13SA  (10  mg/mI) 
and  an  appropriate  volume  of  molecular  biology  grade  water.  EcoOlO91  cut  the  PCR 
product  at  position  5'-RG/GNCCY-3'  and  produced  380-bp  and  122-hp  fragments  1*6r 
the  ABCBI  1236C  allele.  The  502-bp  PCR  product  remained  uncut  fior  the  A13C13I 
1236T  allele  (FIGURE  3.7). 
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A  total  of  5  µl  of  digest  product  was  mixed  with  I  µI  of'  loading  dye  and  loaded  on  a 
2.5%  agarose  gel  containing  300  ng/mI  ethidium  bromide.  I  he  f_'CI  electrophoresis Chapter  3:  DME  &  DTP  Gene  Polymorphisms  115 
conditions  were  set  at  80  V  for  90  minutes.  A  digital  image  of  the  agarose  gel  was 
captured  at  the  end  of  the  electrophoresis  process  under  ultraviolet  transillumination. 
3.1.3.10  Identification  of  ABCB1  c.  2677G>T/A  polymorphism  by  PCR-RFLP 
The  method  described  by  Cascorbi  et  al.,  (2001)  was  modified  for  the  purposes  of  this 
study.  Modification  was  undertaken  to  optimise  the  yield  of  PCR  product  which 
included  alteration  in  the  total  reaction  volume,  the  quantity  of  reagents  and  the 
annealing  temperature  (as  described  in  section  2.3.5.2).  The  exon-21  region  of  the 
ABCB  I  gene  containing  the  c.  2677G>T/A  polymorphism  was  amplified  using  two  PCR 
assays,  one  for  the  identification  of  the  2677A  allele  (PCRI)  and  the  other  for  the 
identification  of  the  2677T  allele  (PCR2).  PCRI  was  performed  using  forward,  5'-TGC 
AGG  CTA  TAG  GTT  CCA  GG-3'  and  reverse,  5'-GTT  TGA  CTC  ACC  TTC  CCA  G- 
3'  primers.  PCR2  was  performed  using  the  same  forward  primer  as  PCRI,  together  with 
the  reverse,  5'-TTT  AGT  TTG  ACT  CAC  CTT  CCC  G-3'  primer.  A  mismatched 
nucleotide  (underlined)  in  the  reverse  primer  of  PCR2  was  employed  to  introduce  a 
restriction  site  for  the  Banl  enzyme. 
PCRI  and  PCR2  reaction  components  and  conditions  were  identical.  The  PCR  assay 
was  performed  in  a  20  µl  reaction  volume  containing  100  ng  of  genomic  DNA,  IU  of 
Taq  polymerase,  20  pmol  of  each  primer,  2  mM  MgC12,2  µl  of  I  Ox  PCR  buffer,  0.25 
mM  dNTP  mix,  and  an  appropriate  volume  of  molecular  biology  grade  water. 
The  PCR  conditions  consisted  of  an  initial  denaturation  at  94°C  for  2  minutes;  35  cycles 
of  94°C  for  30  seconds  (denaturation),  62°C  for  30  seconds  (annealing),  72°C  for  30 
seconds  (extension);  and  followed  by  a  final  extension  at  72°C  for  7  minutes  and 
soaking  at  4°C.  A  PCR  product  with  a  size  of  220  bp  was  expected  from  the  PCRI Chapter  3:  DME  &  DTP  Gene  Polymorphisms  116 
amplification.  A  PCR  product  with  a  size  of  224  bp  was  expected  from  the  PCR2 
amplification. 
The  ABCB  1  2677non-A  allele  was  discriminated  from  the  2677A  allele  by  digesting  the 
product  of  PCR1  with  Rsal  endonuclease.  The  PCR1  product  was  digested  for  at  least  2 
hours  at  37°C  in  a  10  pl  reaction  volume  containing  5  µl  of  PCR1  product,  5U  of  RsaI 
restriction  enzyme,  1  µl  of  lOx  NE  buffer  and  an  appropriate  volume  of  molecular 
biology  grade  water.  Rsal  cut  the  PCR1  product  at  position  5'-GT/AC-3',  and  produced 
118-bp  and  102-bp  fragments  for  the  ABCB  1  2677non-A  allele;  and  I18-bp,  82-bp  and 
20-bp  fragments  for  the  ABCB  12677A  allele. 
The  ABCB  1  2677non-T  allele  was  discriminated  from  the  2677T  allele  by  digesting  the 
product  of  PCR2  with  Banl  endonuclease.  The  PCR2  product  was  digested  for  at  least  2 
hours  at  37°C  in  a  10  µl  reaction  volume  containing  5  µl  of  PCR2  product,  5U  of  Ban! 
restriction  enzyme,  1  µl  of  lOx  NE  buffer  and  an  appropriate  volume  of  molecular 
biology  grade  water.  BanI  cut  the  PCR2  product  at  position  5'-G/GYRCC-3',  and 
produced  198-bp  and  26-bp  fragments  for  the  ABCB  1  2677non-T  allele.  The  224-bp 
product  of  PCR2  remained  uncut  for  the  ABCB  1  2677T  allele. 
The  electrophoresis  conditions  for  both  PCR1  and  PCR2  assays  were  identical.  A  total 
of  5  µl  of  digest  product  was  mixed  with  I  µl  of  loading  dye  and  loaded  on  a  3.0% 
agarose  gel  containing  300  ng/ml  ethidium  bromide.  The  gel  electrophoresis  conditions 
were  set  at  80  V  for  120  minutes.  A  digital  image  of  the  agarose  gel  was  captured  at  the 
end  of  the  electrophoresis  process  under  ultraviolet  transillumination.  Images  from  both 
PCR1  and  PCR2  were  analysed  simultaneously  to  determine  one  of  the  6  possible 
genotypes  (GIG,  G/T,  T/T,  G/A,  A/A,  T/A;  FIGURE  3.8). Chapter  3:  I)MI::  &  DIT  (  iene  I'ulynxphisnu 
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FI(;  Uit1?  3.8.  FIcctnophoýresis  patterns  for  i1li('I31  c.  207-1(  j  -I/n  gcnut)pcs 
analysed  by  PCR-RI  l  assay.  I'CR  I  and  I'('R2  were  carried-om  in  two  separate 
reactions.  The  product  of  PC'R  I  was  digested  by  Bain  and  the  product  of'  P('R2 
was  digested  by  Rsal.  Digital  images  of'  the  gels  from  both  Pt.  R-RI:  IT  assays 
were  examined  simultaneously  to  determine  the  genotype.  No  liagment  for  the 
2677A  allele  was  observed  in  either  gel.  SI  to  SS  represent  individual  subjects, 
their  respective  electrophoresis  patterns,  and  A13('U  I  c.  2677(i  -'I  /A  genotypes. 
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3.1.3.11  Identification  of  ABCB1  c.  3435C>T  polymorphism  by  PCR-RFLP 
118 
The  method  described  by  Hamdy  et  al.  (2003b)  was  modified  for  the  purposes  of  this 
study.  Modification  was  undertaken  to  optimise  the  yield  of  PCR  product  which 
included  alteration  in  the  total  reaction  volume,  the  quantity  of  reagents  and  the 
annealing  temperature  (as  described  in  section  2.3.5.2).  The  exon-26  region  of  the 
ABCBI  gene  containing  the  c.  3435C>T  polymorphism  was  amplified  using  forward, 
5'-ACT  CTT  GTT  TTC  AGC  TGC  TTG-3'  and  reverse,  5'-AGA  GAC  TTA  CAT  TAG 
GCA  GTG  ACT  C-3'  primers.  The  PCR  assay  was  performed  in  a  20  µl  reaction 
volume  containing  100  ng  of  genomic  DNA,  1U  of  Taq  polymerase,  20  pmol  of  each 
primer,  1.5  mM  MgCl2,2  µl  of  lOx  PCR  buffer,  0.25  mM  dNTP  mix,  and  an 
appropriate  volume  of  molecular  biology  grade  water. 
The  PCR  conditions  consisted  of  an  initial  denaturation  at  94°C  for  5  minutes;  33  cycles 
of  94°C  for  30  seconds  (denaturation),  56°C  for  30  seconds  (annealing),  72°C  for  30 
seconds  (extension);  and  followed  by  a  final  extension  at  72°C  for  5  minutes  and 
soaking  at  4°C.  A  PCR  '  product  with  a  size  of  231  bp  was  expected  from  the 
amplification. 
The  ABCB  13435C  allele  was  discriminated  from  the  3435T  allele  by  digesting  the 
PCR  product  with  DpnII  endonuclease.  The  PCR  product  was  digested  for  at  least  2 
hours  at  37°C  in  a  20  µl  reaction  volume  containing  10  pI  of  PCR  product,  5U  of  DpnII 
restriction  enzyme,  2  pl  of  lOx  NE  buffer  and  an  appropriate  volume  of  molecular 
biology  grade  water.  DpnII  cut  the  PCR  product  at  position  5'-/GATC-3'  and  produced 
163-bp  and  68-bp  fragments  for  the  ABCBI  3435T  allele.  The  231-bp  PCR  product 
remained  uncut  for  the  ABCB  13435C  allele. Chapter  3:  I)MI":  &  I)"Il'  Gene  Polymorphisms  lI  1> 
A  total  of  5  µl  of  digest  product  was  mixed  with  I  µl  of  loading  dye  and  loaded  on  a 
2.5%  agarosc  gel  containing  300  ng/ml  ethidium  hronºide.  The  gel  electrophoresis 
conditions  were  set  at  HO  V  for  120  minutes.  A  digital  image  of'  the  agarose  gel  was 
captured  at  the  end  of  the  electrophoresis  process  under  ultraviolet  transillumination 
(FIGURE  3.9). 
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analysed  by  I'C'R-RFI.  P  assay. 
3.1.3.12  Identification  of  SCN2A  c.  56(;  >;  k  pol.  N  nºurphisnº  h)  I1('ll-IlI-I.  1' 
The  method  described  by  Nakayama  ei  <1/.  (2002)  as  modified  Iii[-  the  purpose,  it  Iiis 
study.  Modification  was  undertaken  to  optimise  the  yield  of  I'('l(  product  which 
included  alteration  in  the  total  reaction  volume,  the  yu:  uºtity  of'  reagents  and  the 
annealing  temperature  (as  described  in  section  2.3.5.2).  'I  he  exon-2  region  of  the 
SC'N2A  gene  containing  the  c.  56(i  -A  polymorphism  was  amplified  using  forward,  5'- 
AA"I'  CAC  ('III'  FA  'F  l'('  'IAA  'I'(i(i  '1'('-3'  and  re\  erse,  5'-('A(L  'I'(jA  A66  ('AA Chapter  3:  DME  &  DTP  Gene  Polymorphisms  120 
CTT  GAC  TAA  GA-3'  primers.  The  PCR  assay  was  performed  in  a  20  µl  reaction 
volume  containing  100  ng  of  genomic  DNA,  IU  of  Taq  polymerase,  20  pmol  of  each 
primer,  1.5  mM  MgC12,2  µl  of  lOx  PCR  buffer,  0.25  mM  dNTP  mix,  and  an 
appropriate  volume  of  molecular  biology  grade  water. 
The  PCR  conditions  consisted  of  an  initial  denaturation  at  95°C  for  10  minutes;  35 
cycles  of  94°C  for  30  seconds  (denaturation),  60°C  for  30  seconds  (annealing),  72°C  for 
30  seconds  (extension);  and  followed  by  a  final  extension  at  72°C  for  7  minutes  and 
soaking  at  4°C.  A  PCR  product  with  a  size  of  400  bp  was  expected  from  the 
amplification. 
The  SCN2A  56G  allele  was  discriminated  from  the  56A  allele  by  digesting  the  PCR 
product  with  ScrFI  endonuclease.  The  PCR  product  was  digested  for  at  least  2  hours  at 
37°C  in  a  20  µl  reaction  volume  containing  10  µl  of  PCR  product,  5U  of  ScrFI 
restriction  enzyme,  2  µl  of  lOx  NE  buffer  and  an  appropriate  volume  of  molecular 
biology  grade  water.  ScrFI  cut  the  PCR  product  at  position  5'-CC/NGG-3',  and 
produced  178-bp,  130-bp,  64-bp  and  28-bp  fragments  for  the  SCN2A  56G  allele;  and 
206-bp,  130-bp  and  64-bp  fragments  for  the  SCN2A  56A  allele. 
A  total  of  5  pl  of  digest  product  was  mixed  with  1  pl  of  loading  dye  and  loaded  on  a 
3.0%  agarose  gel  containing  300  ng/ml  ethidium  bromide.  The  gel  electrophoresis 
conditions  were  set  at  80  V  for  120  minutes.  A  digital  image  of  the  agarose  gel  was 
captured  at  the  end  of  the  electrophoresis  process  under  ultraviolet  trans  illumination 
(FIGURE  3.10). Chapter  3:  I)M1:  &  DIT  Gene  Polymorphism 
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FIGURE  3.10.  Electrophoresis  patterns  for  SCN2A  c.  56G'-A  genotypes  analysed 
by  PCR-RFLP  assay. 
3.1.3.13  Identification  of  EPIIXI  c.  337T>C  polymorphism  by  direct  sequencing 
121 
The  genotype  distribution  of  EPHXI  c.  3371'>C  identified  by  PCR-RFLP  assay  (section 
3.1.3.6)  was  not  consistent  with  IIWE'  (p  <  0.05).  ']'his  was  believed  to  be  the  result  of 
the  close  proximity  of  a  polymorphism  at  codon  119,  and  its  consequent  influence  on 
the  accuracy  of  genotyping  by  the  R11 
, 
I)  technique.  For  this  reason,  a  newly  designed 
direct  sequencing  assay  was  employed  to  re-analyse  all  400  1)NA  samples.  Four  steps  of 
sample  preparation  are  required  before  the  DNA  fragment  can  he  analysed  by  the 
automated  MegaBACE  1000  "  DNA  Analysis  System 
PCR  amplification  of  the  target  DNA  fragment:  Forward  (5'-(i"I'A  (iCC  AG'l'  (iAT 
GTG  (1-3')  and  reverse  (5'-CAT  G'I'A  "I(  i"f  (ill'  ('('"1'  G('('  TA-3')  primers  were  used 
to  amplify  a  DNA  fragment  of  exon-3  of  the  I:  I'I  lX  I  gene.  The  I'CR  assay  was 
performed  in  a  30  pl  reaction  volume  containing  100  ng  of"genomic  I)NA,  IU  of'Yaq Chapter  3:  DME  &  DTP  Gene  Polymorphisms  122 
polymerase,  20  pmol  of  each  primer,  2  mM  MgC12,3  pl  of  IOx  PCR  buffer,  0.25  mM 
dNTP  mix  and  an  appropriate  volume  of  molecular  biology  grade  water. 
The  PCR  conditions  consisted  of  an  initial  denaturation  at  94°C  for  5  minutes,  followed 
by  35  cycles  of  94°C  for  30  seconds  (denaturation),  60°C  for  30  seconds  (annealing), 
72°C  for  30  seconds  (extension)  and  finally  followed  by  72°C  for  5  minutes  (final 
extension)  and  soaking  at  4°C.  A  PCR  product  with  a  size  of  542  bp  was  expected  from 
the  amplification. 
Purification  of  PCR  product:  The  purification  step  was  based  on  protocol  000601v024 
published  by  Agencourt  Bioscience  Corporation,  Beverly,  MA,  USA 
(http:  //www.  agencourt.  com).  The  purification  reaction  was  performed  in  a  96-well 
plate.  In  each  well,  a  total  of  15  µl  of  PCR  product  was  mixed  with  27  pl  of  a  magnetic 
bead  solution  (AMPure).  The  reaction  was  mixed  thoroughly  by  vortexing  for  30 
seconds.  The  reaction  mixtures  were  then  left  to  incubate  for  3-5  minutes  at  room 
temperature  (20°C).  The  magnetic  beads  were  separated  from  the  reaction  mixture  by 
placing  the  plate  onto  a  magnetic  plate  (SPRIP1ate  96R)  for  5-10  minutes.  The 
supernatant  was  aspirated  from  the  reaction  plate  and  discarded.  With  the  reaction  plate 
remaining  on  the  SPRIPIate  96R®,  200  µl  of  70%  ethanol  was  dispensed  into  each  well 
and  the  plate  incubated  for  a  further  30  seconds  at  room  temperature  (20°C).  A  total  of 
two  washes  were  performed  using  70%  ethanol.  The  reaction  plate  was  then  placed  on 
the  bench  to  air-dry,  before  40  µl  sterile  water  was  added  to  each  well  for  elution  of  the 
purified  PCR  product.  The  plate  was  vortexed  for  30  seconds  to  promote  maximum 
elution.  The  eluant  was  then  used  in  the  sequencing  PCR  step. 
Sequencing  PCR:  The  sequencing  PCR  process  was  based  on  DYEnamic  ET 
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Biosciences  (http:  //www4.  gelifesciences.  com/aptrix/uppOI077.  nsf/content/).  A  96-well 
plate  was  used  to  run  the  sequencing  PCR.  The  PCR  was  performed  in  a  10  µl  reaction 
volume  containing  4  µl  of  purified  DNA  template,  5  pmol  of  the  reverse  primer  (5'- 
CAT  GTA  TGT  GTT  CCT  GCC  TA-3'),  1  µl  of  DYEnamic®  ET  Terminator  reagent,  3 
µl  of  DYEnamic®  ET  Terminator  dilution  buffer  and  I  µl  of  sterile  water.  The  PCR 
conditions  consisted  of  25  cycles  of  95°C  for  20  seconds  (denaturation),  50°C  for  15 
seconds  (annealing)  and  60°C  for  60  seconds  (extension).  The  sequencing  PCR  product 
was  then  cleaned  using  C1eanSEQ®  system  (Agencourt  Bioscience  Corporation, 
Beverly,  MA,  USA). 
Removal  of  dye-terminator:  The  dye-terminator  removal  process  was  based  on  protocol 
000600vO31  published  by  Agencourt  Bioscience  Corporation,  Beverly,  MA,  USA 
(http:  //www.  agencourt.  com).  The  cleanup  reaction  was  performed  in  a  96-well  plate.  In 
each  well,  5  µl  of  the  sequencing  PCR  product  was  mixed  with  10  µl  of  magnetic  bead 
solution  (C1eanSEQ®)  and  31  pl  of  85%  ethanol.  The  magnetic  beads  were  separated 
from  the  reaction  mixture  by  placing  the  plate  onto  a  SPRIPIate  96R®  for  3  minutes.  The 
clear  supernatant  was  aspirated  from  the  reaction  plate  and  discarded.  With  the  reaction 
plate  remaining  on  the  SPRIPlate  96R®,  100  µl  of  85%  ethanol  was  dispensed  into  each 
well  and  the  plate  incubated  for  30  seconds  at  room  temperature  (20°C).  The  ethanol 
was  then  aspirated  from  the  reaction  plate  and  discarded.  A  total  of  two  washes  with 
85%  ethanol  were  performed.  After  the  washes,  the  reaction  plate  was  placed  on  the 
bench  to  air-dry,  before  20  µl  of  sterile  water  was  added  to  each  well  for  elution.  The 
eluant  was  then  used  in  the  MegaBACE  1000TM  sequencing  analysis. 
MegaBACE  1000TMsequencing  analysis:  MegaBACE  1000TM  DNA  Analysis  System 
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the  capillaries  with  linear  polyacrylamide,  a  separation  matrix.  Eluant  was  loaded  into 
the  analyser  in  a  96-well  plate  and  a  electrical  current  was  established  at  the  tip  of  each 
capillary,  where  it  came  into  contact  with  the  sample.  Samples  were  electro-kinetically 
injected  into  the  linear  polyacrylamide  and  travelled  the  length  of  the  capillary  during 
the  course  of  the  run.  All  sequencing  samples  were  automatically  base-called  and 
presented  as  DNA  sequencing  chromatograms.  The  DNA  sequencing  signals  for  each 
genotype  of  the  EPHX1  c.  337T>C  polymorphism  are  presented  in  FIGURE  3.11. 
3.1.3.14  Predicting  the  net  activity  of  mEH 
The  net  activity  of  mEH  was  predicted  on  the  basis  of  an  association  between  EPHX1 
gene  variants  and  in  vitro  activity  of  mEH  described  by  Hassett  et  al.  (1994b). 
Individuals  who  carry  the  337  +  416  diplotypes  of  C/C  +  A/A,  C/C  +  A/G,  TIC  +  A/A 
and  C/C  +  GIG  were  predicted  as  having  the  low  activity  mEH,  those  with  337+416 
diplotypes  of  T/T  +  A/A,  T/C  +  A/G  and  TIC  +  GIG  were  predicted  to  have  medium 
activity  mEH,  and  those  with  337+416  diplotypes  of  T/T  +  GIG  and  T/T  +  A/G  were 
predicted  to  have  high  activity  mEH.  This  categorical  method  was  also  described  by 
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FIGURE  3.11.  DNA  sequencing  signals  of  the  four  nucleotides  around  the  EPHXI 
c.  337T>C  polymorphism  for  the  T/T,  T/C,  and  C/C  genotypes. 
3.1.3.15  Comparison  of  allele  and  genotype  distributions  between  ethnic  groups 
Allele  and  genotype  distributions  identified  in  the  current  study  population  were 
compared  with  data  from  other  populations  that  are  available  in  the  literature.  Fisher's 
Exact  test  or  X2  test  was  employed  for  this  purpose.  A  p-value  of  greater  than  0.05 Chapter  3:  DME  &  DTP  Gene  Polymorphisms  126 
indicated  that  no  significant  differences  in  the  allele  and  genotype  distributions  between 
study  populations. 
3.1.3.16  Hardy-Weinberg  Equilibrium  test 
The  HWE  test  is  one  of  the  quality  control  measures  for  genotyping  method  as 
suggested  by  several  authors  (Xu  et  al.,  2002;  Hosking  et  al.,  2004;  Salanti  et  al.,  2005; 
Wittke-Thompson  et  al.,  2005).  Adherence  to  HWE  was  tested  using  an  online 
calculator,  freely  available  on  an  established  website  (The  Online  Encyclopedia  for 
Genetic  Epidemiology,  available  from  <http:  //www.  genes.  org.  uk/software/hardy- 
weinberg.  shtml>).  The  online  calculator  compared  the  genotype  distribution  identified 
in  the  current  study  with  a  distribution  predicted  by  HWE  using  X2  test.  A  p-value  of 
greater  than  0.05  indicated  that  the  observed  genotype  distribution  was  consistent  with 
HWE  assumptions. 
3.1.4  Results 
3.1.4.1  Allele  and  genotype  distributions  of  CYP3A4  g.  -392A>G  and  CYP3A5 
g.  6986A>G  polymorphisms 
Allele  and  genotype  distributions  of  the  CYP3A4  g.  -392A>G  and  CYP3A5  g.  6986A>G 
polymorphisms  in  comparison  with  other  populations  are  presented  in  TABLE  3.1  and 
TABLE  3.2,  respectively.  The  CYP3A4  -392A  and  CYP3A5  6986G  alleles  were 
predominant  in  the  400-strong  study  population,  with  allele  frequencies  of  96.5%  and 
92.6%,  respectively.  Only  one  individual  was  homozygous  for  the  CYP3A4  -392G/G 
genotype  and  four  individuals  were  homozygous  for  the  CYP3A5  6986A/A  genotype. 
The  allele  and  genotype  distributions  of  CYP3A4  g.  -392A>G  and  CYP3A5  g.  6986A>G 
polymorphisms  observed  in  the  current  study  were  consistent  with  UWE  (p  >  0.05)  and Chapter  3:  DME  &  DTP  Gene  Polymorphisms  127 
comparable  (p  >  0.05)  with  other  Caucasian  populations  but  different  (p  <  0.05)  from 
previously  published  Oriental  and  African-American  populations. 
TABLE  3.1.  Allele  and  genotype  distributions  of  the  CYP3A4  g-392A>G 
polymorphism  in  comparison  to  previously  published  data  from  different 
populations. 
Frequency 
Allele  Genotype 
Study  AG  A/A  A/G  GIG  Ref. 
Current  studyt,  n=  400  0.965  0.035  0.932  0.065  0.003 
Chinese  &  Japanese:,  n=  80  1.000  0.000  1.000  0.000  0.000  1 
Hispanics,  n=  121  0.890  0.110  0.800  0.180  0.020  1 
African-Americans,  n=  116  0.455  0.545  0.190  0.530  0.280  1 
Caucasian  (German)°,  n=  432  0.971  0.029  0.944  0.054  0.002  2 
Caucasian  (American)°,  n=  230  0.935  0.065  0.891  0.087  0.022  3 
African-American#,  n=  64  0.477  0.523  0.281  0.391  0.328  3 
to  vs  G,  0.965  vs  0.035  (95%  CI,  0.024  -  0.050);  HWE:  X2  =  0.57,  p=0.752; 
Allele  and  genotype  distributions  in  comparison  with  current  study  findings,  tp  < 
0.05  and  °p  >  0.05;  References:  1=  Paris  et  al.  (1999),  2=  Dally  et  al.  (2003),  3= 
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TABLE  3.2.  Allele  and  genotype  distributions  of  the  CYP3A5  g.  6986A>G 
polymorphism  in  comparison  to  previously  published  data  from  different 
populations. 
Frequency 
Allele  Genotype 
Study  AG  A/A  A/G  G/G  Ref. 
Current  studyt,  n=  400  0.074  0.926  0.010  0.128  0.862 
Japanesel,  n=  400  0.232  0.768  0.070  0.325  0.605  1 
Caucasian  (German)°,  n=  432  0.063  0.937  0.002  0.121  0.877  2 
Caucasian  (American)°,  n=  230  0.048  0.952  0.011  0.073  0.915  3 
African-Americans,  n=  64  0.638  0.362  0.446  0.385  0.169  3 
to  vs  G,  0.074  vs  0.926  (95%  CI,  0.906  -  0.942);  HWE:  X2  =  1.78,  p=0.410; 
Allele  and  genotype  distributions  in  comparison  with  current  study  findings,  tp  < 
0.05  and  °p  >  0.05;  References:  1=  Sata  et  al.  (2000),  2=  Dally  et  al.  (2003),  3= 
Zeigler-Johnson  et  al.  (2004). 
3.1.4.2  Allele  and  genotype  distributions  of  CYPIA2  g.  5734C>A  polymorphism 
Allele  and  genotype  distributions  of  the  CYPIA2  g.  5734C>A  polymorphism  in 
comparison  with  other  populations  are  presented  in  TABLE  3.3.  Most  (93.2%)  of  the 
400-strong  study  population  carried  at  least  one  5734A  allele.  Only  small  numbers  were 
homozygous  for  the  5734C  allele  (6.8%).  The  allele  and  genotype  distributions  of  the 
CYP1A2  g.  5734C>A  polymorphism  observed  in  the  400-strong  study  population  were Chapter  3:  DME  &  DTP  Gene  Polymorphisms  129 
consistent  with  HWE  (p  >  0.05),  and  comparable  (p  >  0.005)  with  other  Caucasian 
populations. 
TABLE  3.3.  Allele  and  genotype  distributions  of  the  CYPIA2  g.  5734C>A 
polymorphism  in  comparison  to  previously  published  data  from  different 
populations. 
Frequency 
Allele  Genotype 
Study  CA  C/C  A/C  A/A  Ref. 
Current  studyt,  n=  400  0.275  0.725  0.068  0.415  0.517 
Caucasian  (German)°,  n=  236  0.322  0.678  0.102  0.441  0.457  1 
Caucasian  (Italian)°,  n=  95  0.332  0.668  0.095  0.474  0.431  2 
Caucasian  (Dutch)°,  n=  94  0.280  0.720  0.080  0.400  0.520  3 
Egyptian°,  n=  212  0.320  0.680  0.108  0.420  0.472  4 
Hispanic  &  Mestizo°,  n=  932  0.300  0.700  0.090  0.420  0.490  5 
Japaneset,  n=  159  0.386  0.614  0.163  0.447  0.390  6 
tC  vs  A,  0.27  vs  0.73  (95%  CI,  0.69  -  0.77);  HWE:  X2  =  0.66,  p=0.717;  Allele 
and  genotype  distributions  in  comparison  with  current  study  findings,  tp  <  0.05 
and  °p  >  0.05;  References:  1=  Sachse  et  al.  (1999),  2=  Pavanello  et  al.  (2005),  3 
=  Moonen  et  al.  (2005),  4=  Hamdy  et  al.  (2003a),  5=  Cornelis  et  al.  (2005),  6= 
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3.1.4.3  Allele  and  genotype  distributions  of  EPIIXI  c.  337T>C  and  c.  416A>G 
polymorphisms 
When  analysed  with  PCR-RFLP,  the  genotype  distribution  of  EPHX1  c.  337T>C  was 
inconsistent  with  HWE  (p  <  0.05).  This  was  believed  to  be  the  result  of  the  close 
proximity  of  a  polymorphism  at  codon  119,  and  its  consequent  influence  on  the 
accuracy  of  genotyping  by  the  RFLP  technique.  For  this  reason,  the  400-strong  study 
population  was  re-analysed  by  direct  sequencing.  The  genotype  distribution  of  EPHX1 
c.  337T>C  identified  this  method  was  consistent  with  FHWE  (p  >  0.05),  was  deemed  to 
be  accurate,  and  has  subsequently  been  reported  and  employed  in  the  remainder  of  this 
thesis. 
Allele  and  genotype  distributions  of  the  EPHX1  c.  337T>C  and  EPHX1  c.  416A>G 
polymorphisms  in  comparison  with  other  populations  are  presented  in  TABLE  3.4  and 
TABLE  3.5,  respectively.  The  allele  and  genotype  frequencies  of  EPHX  1  337T>C  and 
EPHX1  416A>G  polymorphisms  were  consistent  with  HWE  (p  >  0.05)  and  comparable 
(p  >  0.05)  to  those  of  other  Caucasian  populations.  Most  of  study  subjects  were 
predicted  to  carry  low  and  medium  net  activities  of  mEH,  accounting  for  39.5%  and 
40.5%  of  the  400-strong  study  population,  respectively  (FIGURE  3.12).  Patients  who 
carried  a  diplotype  of  337T/T  and  416A/A  dominated  the  medium  mEII  activity  group 
(69.8%). 
3.1.4.4  Allele  and  genotype  distributions  of  UGT2B7  c.  802C>T  polymorphism 
Allele  and  genotype  distributions  of  the  UGT2B7  c.  802C>T  polymorphism  in 
comparison  with  other  populations  are  presented  in  TABLE  3.6.  The  genotype 
distribution  of  the  UGT2B7  c.  802C>T  polymorphism  in  the  400-strong  study 
population  was  consistent  with  UWE  (p  >  0.05)  and  comparable  (p  >  0.05)  with  other Chapter  3:  DME  &  DTP  Gene  Polymorphisms  131 
Caucasian  populations.  Allele  frequency  of  the  UGT2137  c.  802C>T  polymorphism 
approached  equivalence  (50%)  for  the  C  and  T  substitutions.  The  802C/T  genotype 
(54.7%)  was  the  most  common  genotype  observed  in  the  study  population. 
TABLE  3.4.  Allele  and  genotype  distributions  of  the  EPHXI  c.  337T>C 
polymorphism  in  comparison  to  previously  published  data  from  different 
populations. 
Frequency 
Allele 
Study 
Current  study§,  n=  400 
(PCR-RFLP) 
Current  studyt,  n=  400 
(Direct  Sequencing) 
Caucasian  (American)°,  n=  458 
African-Americana,  n=  242 
Caucasian  (Australian)°,  n=  496 
Chinese$,  n=  252 
Japanese$,  n=  172 
TC 
0.640  0.360 
0.689  0.311 
0.718  0.282 
0.791  0.209 
0.672  0.328 
0.443  0.557 
0.558  0.442 
Genotype 
T/T  T/C  C/C  Ref. 
0.468  0.345  0.187 
0.482  0.413  0.105 
0.517  0.402  0.081  1 
0.632  0.318  0.050  1 
0.452  0.439  0.109  2 
0.302  0.282  0.416  3 
0.326  0.465  0.209  4 
The  genotype  distribution  identified  by  PCR-RFLP  was  inconsistent  with  IIWE 
(X2  =  25.26,  p<0.001)  and  was  reanalysed  using  direct  sequencing;  tT  vs  C,  0.69 
vs  0.31  (95%  CI,  0.28  -  0.34);  HWE:  X2  =  0.57,  p=0.750;  Allele  and  genotype 
distributions  in  comparison  with  current  study  findings,  tp  <  0.05  and  °p  >  0.05; 
References:  1=  London  et  al.  (2000),  2=  Gsur  et  a!.  (2003),  3=  Zhang  et  al. 
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TABLE  3.5.  Allele  and  genotype  distributions  of  the  EPIHXI  c.  416A>G 
polymorphism  in  comparison  to  previously  published  data  from  different 
populations. 
Frequency 
Allele  Genotype 
Study  AG  A/A  A/G  GIG  Ref. 
Current  studyt,  n=  400  0.806  0.194  0.650  0.312  0.038 
Caucasian  (American)°,  n=  458  0.806  0.192  0.659  0.297  0.044  1 
African-Americana,  n=  242  0.709  0.291  0.492  0.434  0.074  1 
Caucasian  (Australian)°,  n=  496  0.822  0.178  0.677  0.290  0.032  2 
Japanese°,  n=  172  0.848  0.152  0.744  0.209  0.067  3 
to  vs  G,  0.81  vs  0.19  (95%  Cl,  0.17  -  0.22);  HWE:  X2  <  0.0  1,  p=0.999;  Allele 
and  genotype  distributions  in  comparison  with  current  study  findings,  tp  <  0.05 
and  °p  >  0.05;  References:  1=  London  et  al.  (2000),  2=  Gsur  et  al.  (2003),  3= 
Budhi  et  al.  (2003). Chapter  3:  DME  &  DTP  Gcnc  Polymorphisms 
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FIGURE  3.12.  The  distribution  of  predictive  net  activity  of  mFII  in  the  400-strong 
study  population.  The  net  activity  of  ml;  l I  was  predicted  using  a  series  of  diplotypes 
derived  from  the  EPHX  I  c.  337T>C  and  EPl  lX  l  c.  410A  (i  polymorphisms.  Low 
activity  mEH  =  C/C+A/A,  C/C+A/G,  'I'/C  f  A/A  and  ('/C  f  G/(i,  medium  activity  mEl  I 
T/C+A/G,  T/T+A/A  and  T/C+G/G,  and  high  activity  ml-I'll  '1'/I  f  A/(i  and  '1/I'  I  G/(i. 
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TABLE  3.6.  Allele  and  genotype  distributions  of  the  UGT2B7  c.  802C>T 
polymorphism  in  comparison  to  previously  published  data  from  different 
populations. 
Frequency 
Allele  Genotype 
Study  CT  C/C  C/T  T/T  Ref. 
Current  studyt,  n=  400  0.476  0.524  0.203  0.547  0.250 
Caucasian  (American)  °,  n=  202  0.463  0.537  0.218  0.490  0.292  1 
Caucasian  (Australian)  °,  n=  91  0.511  0.489  0.275  0.472  0.253  2 
Japanese,  n=  84  0.732  0.268  0.512  0.440  0.048  2 
Chinese,  n=  218  0.675  0.325  0.440  0.470  0.090  3 
tC  vs  T,  0.48  vs  0.52  (95%  CI,  0.47  -  0.57);  HWE:  X2  =  3.80,  p=0.149;  Allele 
and  genotype  distributions  in  comparison  with  current  study  findings,  tp  <  0.05 
and  °p  >  0.05;  References:  I=  Lampe  et  al.  (2000),  2=  Bhasker  et  al.  (2000),  3= 
Lin  et  al.  (2005). 
3.1.4.5  Allele  and  genotype  distributions  of  ABCB1  c.  1236C>T,  c.  2677G>T/A 
and  c.  3435C>T  polymorphisms 
Allele  and  genotype  distributions  of  the  ABCB  1  c.  1236C>T,  ABCB  I  c.  2677G>T/A  and 
ABCB  1  c.  3435C>T  polymorphisms  in  comparison  with  other  populations  are  presented 
in  TABLE  3.7,  TABLE  3.8  and  TABLE  3.9,  respectively.  The  allele  and  genotype 
distributions  of  the  ABCB  1  c.  1236C>T,  ABCB  1  c.  2677G>T/A  and  ABCB  I  c.  3435C>T 
polymorphisms  in  the  400-strong  study  population  were  consistent  with  HWE  (p  > 
0.05)  and  comparable  (p  >  0.05)  to  those  of  other  Caucasian  populations.  The  majority Chapter  3:  DME  &  DTP  Gene  Polymorphisms  135 
of  patients  were  heterozygous  for  these  polymorphisms  (47.0%  for  1236C/T,  44.3%  for 
2677G/T  and  48.5%  for  3435C/T). 
TABLE  3.7.  Allele  and  genotype  distributions  of  the  ABCBI  c.  1236C>T 
polymorphism  in  comparison  to  previously  published  data  from  different 
populations. 
Frequency 
Study 
Allele  Genotype 
CT  C/C  C/T  T/T  Ref. 
Current  studyt,  n=  400  0.520  0.480  0.285  0.470  0.245 
Caucasian  (American)°,  n=  100  0.540  0.460 
African-Americans,  n=  100  0.805  0.195 
Chinesen,  n=  92  0.380  0.620 
Malays,  n=  92  0.375  0.625 
Indians,  n=  95  0.347  0.653 
1 
1 
I 
I 
I 
Japanese:,  n=  69  0.348  0.652  0.101  0.493  0.406  2 
tC  vs  T,  0.52  vs  0.48  (95%  CI,  0.43  -  0.53);  HWE:  X2  =  1.37,  p=0.504;  Allele 
and  genotype  distributions  in  comparison  with  current  study  findings,  tp  <  0.05 
and  °p  >  0.05;  `-'  mark  indicates  unavailable  data;  References:  1=  Tang  et  al. 
(2004),  2=  Goto  et  al.  (2002). 136 
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TABLE  3.9.  Allele  and  genotype  distributions  of  the  ABCB  1  c.  3435C>T 
polymorphism  in  comparison  to  previously  published  data  from  different 
populations. 
Frequency 
Allele  Genotype 
Study  CT  C/C  C/T  T/T  Ref. 
Current  studyt,  n=  400  0.425  0.575  0.183  0.485  0.332 
Caucasian  (Scottish)°,  n=  190  0.480  0.520  0.240  0.480  0.280  1 
Japanesel,  n=  69  0.557  0.443  0.304  0.507  0.188  2 
Chinese:,  n=  98  0.460  0.540  0.240  0.440  0.320  3 
Malays:,  n=  99  0.480  0.520  0.250  0.460  0.280  3 
Indians:,  n=  93  0.380  0.620  0.180  0.390  0.430  3 
tC  vs  T,  0.42  vs  0.58  (95%  CI,  0.53  -  0.63);  HWE:  X2  =  0.02,  p=0.988;  Allele 
and  genotype  distributions  in  comparison  with  current  study  findings,  Tp  <  0.05 
and  °p  >  0.05;  References:  I=  Ameyaw  et  al.  (2001),  2=  Goto  et  al.  (2002),  3= 
Balram  et  al.  (2003). 
3.1.4.6  Allele  and  genotype  distributions  of  SCN2A  c.  56G>A  polymorphism 
Allele  and  genotype  distributions  of  the  SCN2A  c.  56G>A  polymorphism  in  comparison 
with  a  Japanese  population  are  presented  in  TABLE  3.10.  The  genotype  distribution  of 
the  SCN2A  c.  56G>A  polymorphism  in  the  400-strong  study  population  was  consistent 
with  HWE  (p  >  0.05)  and  comparable  (p  >  0.05)  with  the  reported  Japanese  population. Chapter  3:  DME  &  DTP  Gene  Polymorphisms  138 
The  56G/G  genotype  (87.5%)  was  the  most  common  genotype  observed  in  the  study 
population. 
TABLE  3.10.  Allele  and  genotype  distributions  of  the  SCN2A  c.  56G>A 
polymorphism  in  comparison  to  previously  published  data  from  a  different 
population. 
Frequency 
Allele  Genotype 
Study  GA  GIG  G/A  A/A  Ref. 
Current  studyt,  n=  400  0.931  0.069  0.875  0.112  0.013 
Japanese°,  n=  100  0.940  0.060  0.880  0.120  0.000  1 
tG  vs  A,  0.93  vs  0.07  (95%  CI,  0.05  -  0.10);  HWE:  p=0.052;  Allele  and 
genotype  distributions  in  comparison  with  current  study  findings,  °p  >  0.05; 
References:  1=  Nakayama  et  al.  (2002). 
3.1.5  Discussion 
3.1.5.1  The  prevalence  of  common  polymorphisms  in  DME,  DTP  and  sodium 
channel  genes  in  comparison  with  other  ethnic  groups 
The  frequencies  of  minor  alleles  ranged  between  3.5%  (CYP3A4  -392G)  and  48.0% 
(ABCBI  1236T).  A  relatively  low  frequency  of  the  CYP3A4  g.  -392G  allele  has  also 
been  observed  in  many  other  studies  (Paris  et  al.,  1999;  Sata  et  a!.,  2000;  Kuehl  et  a!., 
2001;  Gracia-Martin  et  al.,  2002;  Hamzeiy  et  al.,  2002;  Dally  et  al.,  2003;  Zeigler- Chapter  3:  DME  &  DTP  Gene  Polymorphisms  139 
Johnson  et  al.,  2004).  This  low  frequency  may  indicate  that,  in  Caucasian  populations,  a 
large  sample  size  is  required  to  identify  a  statistically  meaningful  association  between 
the  CYP3A4  g.  -392A>G  variant  and  any  respective  phenotype.  The  g.  -392A>G  allele 
and  genotype  frequencies  for  the  400-strong  study  population  were  distinct  from 
previously  published  data  in  Asian,  Hispanic  and  African-American  populations  (Paris 
et  al.,  1999;  Chelule  et  al.,  2003;  Zeigler-Johnson  et  al.,  2004).  In  contrast,  the  non- 
functional  CYP3A5  genotype  (6986G/G)  has  been  identified  at  a  high  frequency  (30  - 
87%)  in  many  populations  (Fukuen  et  al.,  2002;  van  Schaik  et  al.,  2002;  King  et  al., 
2003;  Lee  et  al.,  2003;  Schuetz  et  al.,  2004),  including  the  current  study  population. 
These  CYP3A5  variant  allele  and  genotype  frequencies  are  similar  to  those  of  other 
studies  performed  in  Caucasian  populations  (van  Schaik  et  al.,  2002;  King  et  al.,  2003; 
Lee  et  al.,  2003;  Schuetz  et  al.,  2004),  but  different  to  those  of  Japanese  and  African- 
American  populations  (Fukuen  et  al.,  2002;  Zeigler-Johnson  et  al.,  2004).  These 
findings  may  signify  that,  in  most  Caucasian  individuals,  including  the  current  400- 
strong  study  population,  CYP3A  activity  is  mainly  dependent  on  CYP3A4.  However,  a 
contribution  of  the  CYP3A5  protein  to  overall  CYP3A  activity  may  be  important  in 
around  14%  of  individuals  who  carry  at  least  one  CYP3A5  6986A  allele. 
The  g.  5734C>A  polymorphism  is  the  most  studied  CYPIA2  gene  variant  (Saclise  et  al., 
1999;  Moonen  et  al.,  2005;  Pavanello  et  al.,  2005).  In  the  current  study  population,  the 
genotype  distribution  of  the  CYPIA2  g.  5734C>A  polymorphism  is  almost  identical  to 
that  of  other  populations.  The  high  frequency  of  the  5734A  allele  observed  in  our  study 
was  similarly  reported  for  other  Caucasian,  Egyptian  and  Hispanic  populations  (Sachse 
et  al.,  1999;  Hamdy  et  al.,  2003a;  Cornelis  et  al.,  2005;  Pavanello  et  al.,  2005).  In 
contrast,  a  study  performed  in  Japanese  subjects  has  reported  a  much  higher  5734C/C 
frequency  than  in  other  ethnic  populations  (Obase  et  al.,  2003). Chapter  3:  DME  &  DTP  Gene  Polymorphisms  140 
mEH  plays  a  vital  role  in  metabolising  drugs  and  detoxifying  environmental  pollutants 
(de  Vries  &  Janssen,  2003).  The  common  EPHXI  gene  variants,  c.  337  >C  and 
c.  416A>G,  that  express  polymorphic  mEH  have  been  associated  with  the  risk  of 
developing  several  types  of  cancers  and  other  diseases  (London  et  al.,  2000;  Wong  et 
al.,  2000;  Ulrich  et  al.,  2001;  Zhou  et  al.,  2001;  Cajas-Salazar  et  al.,  2003).  The  EPHXI 
337T  and  EPHX1  416A  alleles  predominate  in  the  majority  of  patients  in  the  current 
study  population.  EPHX1  c.  337T>C  and  c.  416A>G  allele  and  genotype  distributions 
observed  in  the  400-strong  study  population  were  similar  to  those  of  other  Caucasian 
populations  (Smith  &  Harrison,  1997;  London  et  al.,  2000;  Zhou  et  al.,  2001;  Cajas- 
Salazar  et  al.,  2003;  Gsur  et  al.,  2003).  However,  the  337C  allele  frequency  was 
different  from  that  of  previously  published  Chinese,  Japanese  and  African-American 
populations  (Takeyabu  et  al.,  2000;  Budhi  et  al.,  2003;  Zhang  et  al.,  2003),  whereas  the 
416G  allele  frequency  was  different  only  to  that  of  an  African-American  population 
(London  et  al.,  2000). 
It  has  been  shown  that  the  expression  and  activity  of  mEH  is  influenced  by  the 
c.  337T>C  and  c.  416A>G  polymorphisms  (Hassett  et  al.,  1994b;  Maekawa  et  al.,  2003). 
Therefore,  diplotypes  of  these  polymorphisms  have  been  used  to  predict  the  net  activity 
of  mEH  (Smith  &  Harrison,  1997;  Sarmanova  et  al.,  2000;  Takeyabu  et  al.,  2000;  Zhou 
et  al.,  2001;  Lebailly  et  al.,  2002;  Sonzogni  et  al.,  2002;  Cajas-Salazar  et  al.,  2003). 
Most  of  the  400-strong  study  population  were  predicted  to  have  low  and  medium 
activity  mEH,  which  associates  mainly  with  the  T/C-A/A  and  T/T-A/A  diplotypes, 
respectively.  However,  the  frequency  of  patients  with  high  net  mEll  activity  may  be 
important  as  they  accounted  for  up  to  20%  of  the  study  population.  The  implications  of 
this  are  on  the  clinical  pharmacology  of  drugs  which  are  metabolised  by  this  pathway. Chapter  3:  DME  &  DTP  Gene  Polymorphisms  141 
The  most  studied  UGT2B7  variant  is  the  c.  802C>T  polymorphism  (Sawyer  et  al.,  2003; 
Wiener  et  al.,  2004;  Lin  et  al.,  2005;  Thibaudeau  et  al.,  2006).  Allele  and  genotype 
distributions  of  the  UGT2B7  c.  802C>T  polymorphisms  in  the  current  study  population 
were  comparable  with  other  Caucasian  populations  from  two  different  continents,  North 
America  and  Australia  (Bhasker  et  al.,  2000;  Lampe  et  al.,  2000).  However,  the 
prevalence  of  the  802C/C  genotype  was  2-fold  higher  in  the  present  study  than  that 
reported  in  Oriental  populations  (Bhasker  et  al.,  2000;  Saeki  et  al.,  2004;  Lin  et  al., 
2005). 
The  most  widely  investigated  ABCB  1  gene  variants  are  the  c.  1236C>T,  c.  2677G>T/A 
and  c.  3435C>T  polymorphisms.  In  the  400-strong  study  population,  the  1236T, 
2677T/A  and  3435C  were  identified  as  the  minor  alleles.  The  variant  allele  and 
genotype  distributions  were  similar  to  those  reported  in  other  Caucasian  populations 
(Hoffineyer  et  a!.,  2000;  Tan  et  al.,  2004b;  Tang  et  a!.,  2004),  but  different  from  those 
in  Asian  populations  (Goto  et  al.,  2002;  Balram  et  al.,  2003;  Park  et  al.,  2007).  A 
previous  study  employing  a  non-epileptic  Scottish  population  reported  distributions  of 
c.  3435C>T  alleles  and  genotypes  that  were  comparable  to  the  current  study  (Ameyaw  et 
al.,  2001).  A  significant  difference  in  allele  and  genotype  distributions  of  the  ABCB1 
c.  1236C>T  polymorphism  is  observed  between  Caucasians  and  African-Americans 
(Tang  et  al.,  2004).  Although  pharmacogenetic  studies  in  epilepsy  have  focused  on 
these  specific  polymorphisms,  the  functional  significance  of  ABCB  I  variants  remains 
controversial  (Siddiqui  et  al.,  2003;  Tan  et  al.,  2004a;  Sills  et  al.,  2005;  Kim  et  al., 
2006).  Nevertheless,  several  studies  have  suggested  that  haplotypes  based  on  these  three 
SNPs  may  be  useful  in  predicting  drug  resistance  in  epilepsy  (Hung  et  al.,  2005)  An 
investigation  focusing  specifically  on  CBZ  has  shown  that  the  T-T-T  haplotype  at  the 
1236,2677  and  3435  positions  of  the  ABCB  1  gene  was  associated  with  a  better 
response  to  CBZ  treatment  (Seo  et  al.,  2006a). Chapter  3:  DME  &  DTP  Gene  Polymorphisms  142 
The  SCN2A  c.  56G>A  polymorphism  has  previously  been  associated  with  febrile 
seizures  in  children  (Nakayama  et  al.,  2002).  Information  regarding  the  prevalence  of 
SCN2A  c.  56G>A  variants  is limited,  especially  in  Caucasian  populations.  In  the  current 
study,  the  56A  allele  was  identified  in  just  1.3%  of  the  population.  Unlike  most  other 
SNPs  reported  here,  the  SCN2A  c.  56G>A  allele  and  genotype  distributions  in  the  400- 
strong  study  population  were  comparable  with  a  Japanese  population  (Nakayama  et  al, 
2002). 
Differences  in  allele  and  genotype  distributions  between  ethnicities  are  not  uncommon 
(Tishkoff  &  Kidd,  2004).  In  general,  most  of  the  variant  allele  and  genotype 
distributions  identified  in  the  400-strong  study  population  were  different  from  those 
reported  for  non-Caucasian  populations.  Greater  differences  were  observed  between 
populations  of  Caucasian  and  African  ancestry  than  between  Caucasian  and  Asian 
populations.  This  might  be  explained  by  the  length  of  genetic  divergence,  which  is 
approximately  twice  as  long  between  Caucasoid  and  Negroid  than  between  Caucasoid 
and  Mongoloid  (Ameyaw  et  al.,  2001).  Genetic  divergence  is  the  process  of  one  species 
diverging  over  time  into  more  than  one  species:  Passing  small  random  characteristic 
changes  over  time  from  one  generation  to  the  next  generations.  Genetic  divergence 
operates  on  a  genetic  level  favoring  2  or  more  alleles  or  2  or  more  mix  of  alleles  over 
the  original  mixture  of  alleles  in  a  population.  There  is  increasing  evidence  that  different 
ethnic  groups  demonstrate  significant  differences  in  SNP  distribution  and  linkage 
disequilibrium  profiles  (Tishkoff  &  Kidd,  2004).  Furthermore,  the  frequency  of  minor 
alleles  observed  for  CYP3A4  g.  -392A>G,  CYP3A5  g.  6896A>G  and  SCN2A  c.  56G>A 
is  low,  which  suggests  that  a  large  sample  size  is  required  to  obtain  sufficient  statistical 
power  in  any  study  comparing  the  effects  of  the  major  and  minor  alleles  at  these  loci. Chapter  3:  DME  &  DTP  Gene  Polymorphisms 
3.1.5.2  Hardy-Weinberg  equilibrium  test 
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With  the  exception  of  the  PCR-RFLP  derived  data  for  EPHX  1  c.  337T>C,  the  genotype 
distributions  of  all  polymorphisms  reported  in  this  project  were  consistent  with  IIWE. 
This  would  indicate  that  the  distribution  of  variant  genotypes  in  the  400-strong  study 
population  did  not  violate  HWE  assumptions  and  that  there  was  no  apparent  systematic 
error  in  the  genotyping  assays  (Xu  et  at.,  2002;  Hosking  et  al.,  2004;  Salanti  et  al., 
2005).  As  reported  in  section  3.1.4.3,  the  genotype  distribution  of  EPIHXI  c.  337T>C 
polymorphism  identified  by  PCR-RFLP  assay  was  inconsistent  with  IIWE.  Re-analysis 
using  a  direct  sequencing  technique  redressed  this  inconsistency.  This  would  suggest 
that  the  PCR-RFLP  assay  is  not  the  optimal  method  for  identification  of  EPHXI 
c.  337T>C  polymorphisms.  Other  investigators  have  reported  similar  difficulties  in 
detecting  this  polymorphism  by  PCR-RFLP  (Takeyabu  et  al.,  2000;  Gsur  et  al.,  2003; 
Godderis  et  al.,  2004).  It  is  believed  that  the  recognition  site  for  the  EcoRV  restriction 
enzyme  may  be  altered  when  the  mismatched  reverse  primer  anneals  to  another  SNP 
(c.  357G>A)  adjacent  to  the  c.  337T>C  polymorphism  (Takeyabu  et  al.,  2000;  Gsur  et 
al.,  2003).  As  a  result,  the  DNA  fragment  amplified  loses  the  recognition  site  for  EcoRV 
and  the  prevalence  of  the  337C/C  genotype  is  overestimated.  A  modified  reverse  primer 
containing  a  second  mismatched  nucleotide  for  the  c.  357G>A  site  has  been  suggested  to 
improve  the  performance  of  PCR-RFLP-based  analysis  (Budhi  et  al.,  2003).  However, 
the  effectiveness  of  this  second  mismatched  nucleotide  in  improving  the  accuracy  of  the 
assay  remains  questionable.  This  was  the  approach  employed  in  the  current  study 
without  significant  advantage.  Any  conclusions  from  previous  studies  which  utilised  a 
PCR-RFLP  assay  to  identify  the  EPHX1  c.  337T>C  polymorphism  may  be  undermined 
and  should  be  interpreted  with  caution. Chapter  3:  DME  &  DTP  Gene  Polymorphisms  144 
3.1.6  Conclusion 
The  prevalences  of  common  polymorphisms  in  genes  encoding  DMEs,  DTPs  and  a 
voltage-gated  sodium  channel  in  a  West  of  Scotland  epilepsy  population  are  comparable 
with  data  previously  reported  for  other  Caucasian  populations.  The  heredity  of  common 
polymorphisms  in  DME,  P-gp  and  sodium  channel  genes  are  consistent  with  HWE 
assumptions.  Based  on  HWE,  no  apparent  systematic  errors  in  the  genotyping  assays 
were  identified,  except  in  the  PCR-RFLP  assay  for  EPHXI  c.  3371>C. CHAPTER  4 
PHARMACOGENETICS  OF  CARBAMAZEPINE Chapter  4:  Pharmacogenetics  of  Carbamazepine 
4.1  Genetic  Predictors  of  Carbamazepine  Optimal  Dose 
4.1.1  Introduction 
146 
The  response  to  CBZ  therapy  varies  from  patient  to  patient;  some  will  have  full  seizure 
control  and  others  will  fail  to  show  any  response.  Finding  the  optimal  dose  of  CBZ  that 
maintains  complete  seizure  control  with  minimal  side  effects  is  a  challenge.  The  CBZ 
optimal  dose  is  commonly  reached  by  dosage  adjustment  based  on  the  level  of  clinical 
response,  the  occurrence  of  side  effects,  and  the  effects  of  autoinduction.  Patients  that 
show  modest  but  progressive  seizure  reductions  might  undergo  continuous  dosage 
adjustment  for  more  than  1  year  before  the  optimal  dose  is  finally  found.  Within  this 
period,  quality  of  life  might  be  compromised  by  ongoing  seizures.  Most  patients  are 
controlled  on  600  mg/day  but  some  patients  may  require  up  to  1600  mg/day  of  CBZ  to 
attain  complete  seizure  control  (Kwan  &  Brodie,  2001).  Patients  with  a  high  dose 
requirement  are  not  easily  distinguished  from  complete  non-responders.  Therefore,  it 
may  be  useful  to  determine  the  individual  CBZ  dosage  requirement  in  order  to  limit 
unnecessary  or  unreasonable  titration  to  high  doses  of  CBZ. 
Some  studies  have  reported  that  optimum  treatment  response  and  target  therapeutic 
concentrations  of  CBZ  are  achieved  with  a  broad  range  of  doses  (200  -  1600  mg/day; 
Brodie  et  al.,  1995;  Chadwick,  1999;  Kwan  &  Brodie,  2001).  The  variability  in  dosage 
requirement  is  believed  to  be  associated  with  interindividual  differences  in  CBZ 
pharmacokinetics  and  pharmacodynamics.  CBZ  pharmacokinetics  are  predominantly 
influenced  by  the  DMEs  (Browne,  1998;  Kim,  2002b;  Ramachandran  &  Shorvon, 
2003),  while  on  the  other  hand,  CBZ  pharmacodynamics  are  primarily  affected  by  the 
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Polymorphisms  in  genes  that  encode  DMEs  and  Na￿1.2  sodium  channel  could  alter  the 
expression  and  function  of  their  respective  proteins  (as  described  in  Chapter  3)  and,  in 
turn,  affect  CBZ  metabolism  and  the  conformation  of  the  sodium  channel.  These  may 
consequently  influence  CBZ  concentrations  in  plasma  and  in  brain  and  sodium  channel 
sensitivity  to  CBZ.  As  such,  common  polymorphisms  in  the  DME  and  SCN2A  genes 
may  be  able  to  predict  the  optimal  dose  of  CBZ. 
4.1.2  Aims 
This  study  was  designed  to  evaluate  the  association  between  common  polymorphisms  in 
CYP3A4,  CYP3A5,  CYP1A2,  EPHXI,  UGT2B7  and  SCN2A  genes  and  the  optimal 
dose  of  CBZ.  Clinical  factors  such  as  age  and  gender  were  also  evaluated  as  additional 
candidate  predictors. 
4.1.3  Methods 
4.1.3.1  Definitions 
The  optimal  dose  was  defined  as  the  final  dose  given  to  a  patient  that  successfully 
maintained  optimal  seizure  control  without  intolerable  side  effects.  Optimal  seizure 
control  was  defined  as  complete  seizure  freedom  or  a  significant  (>_  50%)  reduction  in 
pre-treatment  seizure  frequency  which  was  maintained  over  a  period  of  at  least  12 
months. 
4.1.3.2  Study  subjects 
From  the  400-strong  study  population,  124  patients  were  identified  as  being  treated  with 
CBZ  monotherapy.  Through  retrospective  evaluation  of  individual  medical  records, Chapter  4:  Pharmacogenetics  of  Carbamazepine  148 
fifteen  patients  were  excluded  due  to  insufficient  clinical  and  CBZ  dosage  information. 
Five  patients  that  had  been  referred  from  other  centres  or  from  primary  care  did  not 
have  sufficient  information  on  the  outcome  of  therapy.  Thirty-four  of  the  remaining  104 
patients  with  complete  outcome  information  did  not  respond  to  CBZ  (n  =  20)  or 
experienced  intolerable  side  effects  (n  =14)  which  resulted  in  the  premature  withdrawal 
of  medication.  These  patients  were  excluded  from  the  study  because  an  optimal  dose 
could  not  be  established.  As  a  result,  70  patients  with  optimal  seizure  control  on  CBZ 
monotherapy  and  with  complete  information  on  dosage  regimen  and  relevant  clinical 
data  were  available  for  analysis.  Information  on  the  clinical  response  of  these  patients 
was  confirmed  by  an  experienced  clinician  prior  to  data  analysis.  None  of  these  patients 
were  concomitantly  treated  with  other  AEDs  or  non-AEDs  that  may  have  influenced 
CBZ  metabolism.  Most  of  the  patients  (91.4%)  were  treated  with  a  sustained  release 
formulation  and  only  a  minority  (8.6%)  received  standard  release  tablets. 
4.1.3.3  Genotype  analysis  and  phenotype  assessment 
Genotypes  of  the  common  CBZ-related  DME  and  SCN2A  polymorphisms  were 
identified  using  the  PCR-RFLP  and  direct  sequencing  assays  described  in  Chapter  3. 
Genotype  determination  for  the  DME  and  SCN2A  polymorphisms  was  completed  on 
February  2006.  Phenotype  assessment  was  started  on  March  2006  and  completed  on 
April  2006. 
4.1.3.4  Statistical  analysis 
Clinical  and  demographic  differences  between  the  CBZ  cohort  and  the  400-strong  study 
population  were  investigated  using  the  X2  test.  The  distribution  of  age  was  compared 
using  Student's  t-test.  The  possibility  of  genotype  selection  bias  was  explored  by 
comparing  the  distribution  of  individual  polymorphisms  between  the  CBZ  cohort  and Chapter  4:  Pharmacogenetics  of  Carbamazepine  149 
the  overall  400-strong  study  population  using  the  X2  test.  Differences  in  the  mean 
optimal  dose  of  CBZ  in  relation  to  predictors  such  as  gender  and  genotype  of  individual 
DME  polymorphisms  were  initially  compared  by  Student's  t-test  and/or  analysis  of 
variance  (ANOVA). 
To  fit  the  genetic  information  into  the  regression  database,  a  specific  score  was  assigned 
to  the  genotype  of  each  polymorphisms  according  to  the  number  of  substituting  alleles; 
no  substituting  allele  was  given  score  1,  one  substituting  allele  was  given  score  2  and 
two  substituting  alleles  was  given  score  3.  Interaction  between  polymorphisms  in  a 
single  gene  or  genomic  region  was  identified  by  correlation  test,  represented  by  the 
multiplicative  value  of  polymorphism  scores,  and  denoted  "SNP  interaction". 
Significant  predictors  of  CBZ  optimal  dose  were  then  identified  using  univariate  and 
multivariate  linear  regression  analysis.  An  additive  model  was  used  in  the  analysis  with 
an  assumption  that  the  combined  effects  of  genetic  alleles  at  two  or  more  gene  loci  are 
equal  to  the  sum  of  their  individual  effects.  SNP  interactions  were  added  to  the 
multivariate  analysis  and  acted  as  a  non-linear  component.  Predictors  were  added  into 
or  taken  out  from  the  predictive  model  using  a  stepwise  approach,  depending  on  the 
degree  of  impact  indicated  by  the  p-value.  Data  transformation  was  employed  to 
optimise  the  regression  modelling,  specifically  transformation  from  linear  to  natural 
logarithmic  form.  Regression  coefficients  of  predictors  that  significantly  influenced  the 
predictive  model  were  used  to  construct  the  CBZ  optimal  dose  predictive  equation. 
Pearson's  correlation  (r-value)  was  used  to  evaluate  the  linearity  of  the  predictive  model 
by  correlating  the  observed  CBZ  optimal  dose  and  the  predicted  CBZ  optimal  dose.  A 
p-value  less  than  0.05  indicated  the  presence  of  a  strong  predictor  effect.  Both  Pres;  d￿  al, 
which  represented  the  p-value  of  residual  analysis,  and  r2,  that  represented  the 
goodness-of-fit,  indicated  how  well  the  data  fitted  the  predictive  model. Chapter  4:  Pharmacogenetics  of  Carbamazepine 
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Demographic  information  for  all  70  patients  included  in  the  CBZ  cohort  is  presented  in 
TABLE  4.1.  Distributions  of  gender  (p  >  0.05)  and  epilepsy  syndromes  (p  >  0.05)  were 
comparable  with  the  400-strong  study  population.  The  median  age  of  patients  in  the 
CBZ  cohort  was  34  years  (range  14  to  72).  In  16%  of  the  CBZ  cohort  the  optimal  dose 
of  CBZ  was  less  than  the  maximum  dose  to  which  those  patients  had  been  exposed. 
Thus,  the  optimal  dose  represents  a  composite  measure  of  efficacy  and  tolerability. 
FIGURE  4.1  shows  that  increasing  age  was  associated  with  a  modest  reduction  in  CBZ 
optimal  dose,  however  this  effect  was  not  statistically  significant  (r  =  -0.171,  p=0.156). 
Gender  and  epilepsy  syndrome  were  not  associated  with  mean  CBZ  optimal  dose  (p  > 
0.05;  FIGURE  4.2  and  4.3,  respectively). 
4.1.4.2  Genetic  predictors  of  carbamazepine  optimal  dose 
Genotype  distributions  for  all  of  the  common  DME  gene  polymorphisms  were  similar 
between  the  CBZ  cohort  and  the  400-strong  study  population  (p  >  0.05,  TABLE  4.2).  A 
total  of  2  SNP  interactions  were  identified,  between  CYP3A4  c.  -392A>G  and  CYP3A5 
c.  6986A>G  (r  =  -0.285,  p=0.017)  and  between  EPHXI  c.  337T>C  and  EPIIXI 
c.  416A>G  (r  =  -0.261,  p=0.029). Chapter  4:  Pharmacogenetics  of  Carbamazepine 
TABLE  4.1.  Patient  demographics  and  carbamazepine  doses. 
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400-strong 
study 
CBZ  cohort  population 
(n  =  70)  (n  =  400)  p-value 
Gender  Male  48.6%  50.3%  0.796 
Female  51.4%  49.7% 
Age  (years)  Median  34  40  0.343 
Min  14  14 
Max  72  85 
Epilepsy  syndrome  IGE  27.1%  29.5%  0.689 
LRE  71.5%  67.5% 
UNC  1.4%  3% 
Optimal  Dose  (mg/day)  Mean  874.3 
Median  800 
Min  300 
Max  2000 
Min  =  minimum;  Max  =  maximum;  IGE  =  idiopathic  generalised  epilepsy;  LRE  = 
localisation  related  epilepsy;  UNC  =  unclassified  epilepsy.  Statistical  significance 
was  determined  by  X2  test.  The  p-value  represents  the  comparison  between  the 
WSEP  and  CBZ  cohort. Chapter  4:  Pharmacogenetics  of  Carbamazepine  152 
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FIGURE  4.1.  Correlation  between  carbamazepine  optimal  dose  and  age  of  the 
patient  at  the  time  optimal  dose  was  attained.  Correlation  was  determined  by 
Pearson's  correlation  test.  Dotted  line  represents  the  linear  correlation  between 
variables. Chapter  4:  Pharmacogenetics  of  Carbamazepine 
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FIGURE  4.2.  Distribution  of  carbamazepine  optimal  dose  between  genders. 
Statistical  significance  was  determined  by  Student's  t-test.  Dotted  line  represents 
the  mean  CBZ  optimal  dose. 
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syndromes.  Statistical  significance  was  determined  by  Student's  t-test.  IGE  _ 
idiopathic  generalised  epilepsy,  LRE  =  localisation  related  epilepsy  and  UNC  = 
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TABLE  4.2.  Genotype  distribution  comparison  between  the  carbamazepine 
cohort  and  the  400-strong  study  population. 
Genotype  frequency 
Variant  Sample  p-value 
Minor  Hetero  -  Major 
SCN2A  c.  56G>A  SSP  0.013  0.112  0.875  0.606 
CBZ  0.000  0.100  0.900 
CYP3A4  g.  -392A>G  SSP  0.003  0.065  0.932  0.333 
CBZ  0.000  0.100  0.900 
CYP3A5  g.  6986A>G  SSP  0.010  0.128  0.862  0.290 
CBZ  0.014  0.171  0.815 
CYP1A2  g.  5734C>A  SSP  0.068  0.415  0.517  0.792 
CBZ  0.057  0.457  0.486 
EPHX1  c.  337T>C  SSP  0.105  0.412  0.483  0.748 
CBZ  0.086  0.386  0.528 
EPHX1  c.  416A>G  SSP  0.038  0.312  0.650  0.417 
CBZ  0.057  0.243  0.700 
UGT2B7  c.  802C>T  SSP  0.202  0.548  0.250  0.061 
CBZ  0.157  0.457  0.386 
Statistical  significance  was  determined  by  X2  test  or  Fisher's  Exact  test.  SSP  = 
400-strong  study  population;  CBZ  =  CBZ  cohort  with  70  patients;  Minor  = 
homozygous  for  minor  allele;  Hetero  =  heterozygous  for  major  and  minor  alleles; 
Major  =  homozygous  for  major  allele.  The  p-value  represents  the  comparison 
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Univariate  linear  regression  analysis  showed  that  none  of  the  candidate  predictors  was 
significantly  associated  with  CBZ  optimal  dose  (TABLE  4.3).  A  multivariate  predictive 
model  (Model  1)  incorporating  all  candidate  predictors  (gender,  age,  genotypes  of  7 
DME  and  SCN  polymorphisms  and  2  SNP  interactions)  identified  age  as  the  only 
predictor  of  CBZ  optimal  dose  (p  =  0.026).  However,  the  overall  model  fit  was  not 
statistically  significant  (r2  =  19.3%,  Presidual  =  0.270,  TABLE  4.4).  Remodelling  of 
Model  1  using  stepwise  regression  analysis  produced  Model  2  which  identified  age, 
EPHXI  c.  337T>C  and  EPHX1  c.  416A>G  as  potential  predictors  (p  =  0.023  to  0.059) 
with  a  significant  overall  model  fit  (r2  =  13.3%,  Presidual  =  0.023).  Enhancement  of 
Model  2  using  simple  data  transformation  (from  linear  form  to  natural  logarithmic  form) 
further  improved  the  overall  model  fit  (r2  =  15.50%,  Presidual  =  0.011)  and  revealed  3 
significant  predictors  (age,  p=0.023;  EHPX1  c.  337  >C,  p=0.019;  EPHX1  c.  416A>G, 
p=0.027;  TABLE  4.4). 
A  predictive  equation  for  optimal  dose  of  CBZ  was  constructed  from  the  constant  value 
and  regression  coefficients  given  by  Model  3.  The  predictive  equation  is  presented 
below: 
lnODcBz  =  6.477  -  0.006*Age  +  0.156*Polyl  +  0.164*Poly2 
Where  InODCBZ  is  the  natural  logarithm  of  the  optimal  dose  (mg/day)  of  CBZ,  Polyl  is 
the  genotype  score  for  EPHX1  c.  337T>C  (T/T  =  1,  T/C  =  2,  C/C  =  3),  and  Poly2  is  the 
genotype  score  for  EPHX1  c.  416A>G  (A/A  =1,  A/G  =  2,  GIG  =  3). 
The  correlation  between  the  observed  CBZ  optimal  doses  and  the  predicted  CBZ 
optimal  doses  generated  by  the  predictive  equation  was  statistically  significant  (p  = 
0.002)  but  moderate  in  strength  (r  =  0.362,95%CI  0.14  to  0.55;  FIGURE  4.4). Chapter  4:  Pharmacogenetics  of  Carbamazepine  157 
TABLE  4.3.  Summary  of  univariate  regression  analysis  of  variables  predicting 
the  optimal  dose  of  carbamazepine. 
Predictor 
Gender 
Age 
Coef.  r2  (%)  p-value 
-55.72  0.8  0.460 
-3.581  2.9  0.156 
SCN2A  c.  56G>A  -82.5  0.0  0.512 
CYP3A4  g.  -392A>G  76.2  0.5  0.545 
CYP3A5  g.  6986A>G  -57.58  0.6  0.508 
CYPIA2  g.  5734C>A  -5.11  0.0  0.935 
EPHXI  c.  3377>C  95.75  4.0  0.098 
EPHXI  c.  416A>G  80.71  2.3  0.208 
UGT2B7  c.  802C>T  55.66  1.6  0.301 
The  relative  impact  of  each  predictor  is  denoted  by  the  coefficient  value  (Coef.  ). 
The  goodness-of-fit  value  (r2)  indicates  how  well  the  individual  predictors  fit  the 
model.  The  p-value  indicates  the  probability  that  the  predictor  influences  CBZ 
optimal  dose. Chapter  4:  Pharmacogenetics  of  Carbamazepine 
TABLE  4.4.  Summary  of  hierarchical  multivariate  regression  analysis  of 
variables  predicting  the  optimal  dose  of  carbamazepine.  Models  were  developed 
in  a  stepwise  manner  from  Model  1  to  Model  3. 
Model  3 
Model  1  Model  2 
Predictor  (natural  log) 
Coef.  p-value  Coef.  p-value  Coef.  p-value 
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Constant  173.10  0.856  649.50  <0.001  6.477  <0.001 
Gender  -93.63  0.249  ---- 
Age  -6.36  0.026  -4.68  0.059  -0.006  0.023 
SCN2A  c.  56G>A  -148.90  0.263  ---- 
CYP3A4  g.  -392A>G  591.10  0.402  ---- 
CYP3A5  g.  6986A>G  174.60  0.603  ---- 
CYP3A  SNP  interaction  -189.30  0.497  ---- 
CYP1A2  g.  5734C>A  25.57  0.695  ---- 
EPHXI  c.  337T>C  255.40  0.172  132.79  0.023  0.156  0.019 
EPHX1  c.  416A>G  283.80  0.181  127.77  0.035  0.164  0.027 
EPHXI  SNP  interaction  -115.8  0.435  ---- 
UGT2B7  c.  802C>T  27.72  0.637  ---- 
r2  (%)  19.3  13.3  15.5 
PresiAual  0.270  . 
0.023  0.011 
The  relative  impact  of  each  predictor  is  denoted  by  the  coefficient  value  (Coef.  ).  The  p- 
value  indicates  the  probability  that  the  predictor  influences  CBZ  optimal  dose.  The 
goodness-of-fit  value  (r)  indicates  how  well  the  individual  predictors  fit  the  predictive 
model.  The  significance  of  model  fitting  is  represented  by  the  p-value  of  residual 
analysis  (presiduai)"  `-'  mark  represents  a  predictor  that  was  eliminated  by  stepwise 
regression  analysis. Chapter  4:  Pharmacogenetics  of  Carbamazepine 
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FIGURE  4.4.  Correlation  between  the  observed  and  predicted  CBZ  optimal  doses 
based  on  the  optimal  multivariate  regression  model.  Correlation  was  determined 
by  Pearson's  correlation  test.  Dotted  line  is  the  linear  correlation  between 
observed  and  predicted  doses. 
4.1.5  Discussion 
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The  main  objective  of  epilepsy  pharmacotherapy  is  to  achieve  complete  seizure  control 
without  apparent  adverse  effects.  The  ability  to  predict  the  required  CBZ  dose  for  an 
individual  patient  may  improve  the  CBZ  dosage  decision  in  patients  who  are 
responders,  and  limit  the  inevitable  titration  of  CBZ  in  patients  who  may  be  refractory. Chapter  4:  Pharmacogenetics  of  Carbamazepine  160 
Therefore,  early  prediction  of  the  CBZ  optimal  dose  may  shorten  the  time  to  achieve 
optimal  seizure  control  and  reduce  unnecessary  exposure  to  a  high  CBZ  doses. 
The  optimal  dose  of  CBZ  is  determined  by  individual  pharmacokinetic  and 
pharmacodynamic  characteristics.  Both  characteristics  are  regulated  by  many  factors 
including  physiological  and  genetic  factors.  Candidate  genetic  predictors  of  optimal 
dose  of  CBZ  were  identified  from  current  knowledge  regarding  the  pharmacokinetics 
and  pharmacodynamics  of  the  drug.  The  ability  of  each  candidate  to  predict  optimal 
dose  of  CBZ  was  examined  through  regression  modelling.  This  analysis  was  not  only 
able  to  identify  potential  predictors,  but  also  to  describe  how  much  each  predictor 
contributed  to  interindividual  variation  in  the  optimal  dose  of  CBZ. 
This  study  revealed  that  increasing  age  was  associated  with  a  reduction  in  the  required 
CBZ  dose.  A  similar  observation  has  been  reported  in  a  study  examining  the 
relationship  between  CBZ  dose  and  plasma  concentrations  (Battino  et  al.,  2003).  These 
investigators  found  that  elderly  patients  required  less  CBZ  to  achieve  the  recommended 
therapeutic  concentration.  Increasing  age  is  known  to  influence  multiple  physiological 
functions,  including  the  drug  elimination  process,  most  likely  as  a  result  of  decreased 
function  of  excretory  organs  such  as  liver  and  kidney  (Bourdet  et.  al.,  2001).  Advancing 
age  may  also  increase  individual  sensitivity  to  drugs  and  increase  the  risk  of  developing 
side  effects  (Bourdet  et.  al.,  2001).  Therefore,  elderly  patients  are  likely  to  require  a 
lower  amount  of  drug  to  achieve  a  similar  response  to  that  of  younger  patients. 
Genetic  factors  influencing  both  pharmacokinetics  and  pharmacodynamics  contribute  to 
the  overall  CBZ  pharmacogenetic  profile.  Interindividual  differences  in 
pharmacokinetics  are  commonly  associated  with  DME  and  DTP  gene  polymorphisms. 
However,  the  role  of  DTPs,  such  as  P-gp,  in  CBZ  disposition  is  controversial  (Owen  et Chapter  4:  Pharmacogenetics  of  Carbamazepine  161 
al.,  2001)  and  potentially  minimal  as  the  CBZ  molecule  is highly  non-polar,  easily  able 
to  penetrate  cell  membranes  and  distributed  well  in  many  body  tissues  (Spina,  2002).  A 
previous  study  failed  to  demonstrate  any  correlation  between  a  common  polymorphism 
in  the  ABCB  1  gene  encoding  P-gp  and  the  maximum  dose  of  CBZ  (Tate  et  al.,  2005). 
For  this  reason,  the  present  study  focused  solely  on  genetic  polymorphisms  of  DMEs  as 
potential  contributors  to  interindividual  variability  in  CBZ  pharmacokinetics. 
In  this  study,  only  two  common  polymorphisms  in  the  EPHXI  gene  were  identified  as 
significant  predictors  of  CBZ  optimal  dose  when  included  in  a  predictive  model 
incorporating  patient  age.  It  is  possible  that  polymorphisms  in  other  DMEs  do  not 
significantly  influence  the  expression  and  activity  of  their  respective  proteins  or  that 
these  proteins  do  not  play  a  principal  and/or  irredeemable  role  in  the  metabolism  of 
CBZ. 
The  g.  -392A>G  transition  is  the  most  widely  studied  polymorphism  in  the  CYP3A4 
gene.  The  CYP3A4  -392G  allele  has  also  been  associated  with  a  reduced  capacity  to 
metabolise  drugs  such  as  nifedipine  and  tacrolimus  (Shimada  et  al.,  1994;  Hesselink  et 
al.,  2003).  The  g.  6986A>G  substitution  is  the  most  commonly  recognised 
polymorphism  in  the  CYP3A5  gene.  Variation  in  CYP3A5  metabolic  capacity 
associated  with  the  g.  6986A>G  polymorphism  has  been  observed  for  drugs  such  as 
midazolam,  statins,  alprazolam  and  tacrolimus  (Hesselink  et  al.,  2003;  Goto  et  a!.,  2004; 
Kivisto  et  al.,  2004;  Wong  et  al.,  2004;  Park  et  al.,  2006).  The  present  study,  did  not 
identify  any  significant  difference  in  the  mean  optimal  dose  of  CBZ  between  individual 
genotypes  of  CYP3A4  g.  -392A>G  and  CYP3A5  g.  6986A>G.  Even  in  the  multivariate 
regression  analysis,  both  polymorphisms  failed  to  predict  CBZ  optimal  dose.  The  reason 
why  these  polymorphisms  do  not  appear  to  influence  CBZ  dosing  is  unclear,  however, 
one  possible  explanation  may  be  related  to  the  strong  linkage  between  these  SNPs.  In Chapter  4:  Pharmacogenetics  of  Carbamazepine  162 
Caucasian  populations,  the  CYP3A4  -392G  allele  is  usually  co-localised  with  the 
CYP3A5  6986A  allele  and  vice  versa  (Dally  et  al.,  2003).  Low  activity  of  CYP3A4 
associated  with  the  -392G  allele  is  therefore  balanced  out  by  possession  of  a  functional 
CYP3A5  enzyme  in  carriers  of  the  6986A  allele  (Ohmori  et  al.,  1998;  Huang  et  al., 
2004).  Thus,  there  is  some  degree  of  redundancy  in  the  genetic  influences  on  CYP3A- 
mediated  metabolism,  at  least  in  the  Caucasian  population.  This  redundancy  is  not 
observed  in  Japanese  subjects,  who  do  not  express  the  CYP3A4  -392G  allele  (Paris  et 
al.,  1999;  Seo  et  al.,  2006b).  In  the  resulting  absence  of  compensatory  linkage  between 
CYP3A  polymorphisms,  the  CYP3A5  c.  6986A>G  variant  is  associated  with 
interindividual  variability  in  CBZ  pharmacokinetics  in  this  population  (Seo  et  al., 
2006b). 
The  CYPIA2  5734A  allele  has  been  reported  to  be  highly  inducible  especially  among 
smokers  (Sachse  et  al.,  1999),  and  is  capable  of  affecting  the  risk  of  developing  heart 
disease  and  cancer  (Cornelis  et  al.,  2005;  Moonen  et  al.,  2005;  Pavanello  et  al.,  2005). 
Although  hydroxylation  of  CBZ  involves  the  CYP1A2  enzyme,  the  present  study  did 
not  find  any  association  between  the  CYPIA2  g.  5734C>A  polymorphism  and  the  CBZ 
optimal  dose.  Up  to  25%  of  the  parent  CBZ  compound  undergoes  hydroxylation,  but  at 
least  4  DMEs  other  than  CYPIA2  have  been  reported  to  catalyze  the  hydroxylation 
pathway  (FIGURE  1.2;  Pelkonen  et  al.,  2001).  Thus,  the  contribution  of  CYPIA2  to 
CBZ  hydroxylation  is  potentially  very  minor,  reducing  the  likelihood  of  detecting  any 
association  between  CYP  I  A2  variants  and  CBZ  dose. 
The  importance  of  mEH  in  the  metabolism  of  CBZ  can  be  predicted  from  the  CBZ 
metabolic  pathway  (FIGURE  1.2;  Pelkonen  et  al.,  2001).  mEH  may  be  responsible  for 
more  than  30%  of  overall  CBZ  metabolism.  The  EPHXI  c.  337T>C  transition  causes 
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transition  causes  substitution  of  histidine  to  arginine  at  codon-139.  In  an  in  vitro  study, 
these  amino  acid  changes  were  shown  to  influence  the  stability  of  mEli  (Bassett  et  at., 
1994b).  As  a  potential  consequence  of  this  alteration  in  mEH  stability,  and  its 
recognised  ability  to  metabolise  several  carcinogens,  both  polymorphisms  have  been 
associated  with  an  adjusted  risk  of  developing  cancers  and  other  diseases  (Smith  & 
Harrison,  1997;  Jourenkova-Mironova  et  at.,  2000;  Sonzogni  et  al.,  2002;  Budhi  et  at., 
2003).  Studies  employing  benzo(a)pyrene-4,5-epoxide  and  cis-stilbene  oxide  as 
substrates  have  shown  that  EPHX1  337C  and  EPHX1  416G  alleles  are  associated  with 
lower  and  higher  mEH  activities,  respectively  (Hassett  et  al.,  1994b;  Hassett  et  al., 
1997).  Interestingly,  the  opposite  was  observed  in  a  study  employing  CBZ-E  as  a 
substrate  (Nakajima  et  at.,  2005).  This  would  indicate  that  the  influence  of  EPHX1 
variants  on  enzyme  activity  is  substrate-specific.  This  is  supported  by  an  investigation 
which  examined  the  hydrolytic  activity  of  mEH  on  three  substrates:  cis-stilbene,  CBZ- 
E,  and  naphthalene  oxide,  in  a  panel  of  microsome  samples  obtained  from  human  livers 
(Kitteringham  eta!.,  1996).  Thus,  the  functional  significance  of  EPHX1  variants  and  the 
percentage  of  mEH  involvement  in  CBZ  metabolism  would  support  the  notion  that 
polymorphisms  of  EPHX1  gene  are  potential  predictors  of  CBZ  optimal  dose.  The 
predictive  model  that  was  constructed  in  the  current  study  further  strengthens  this 
postulation.  A  significant  alteration  in  the  capacity  for  CBZ-E  metabolism  has  been 
demonstrated  in  patients  with  haplotypes  of  EPHX1  harbouring  both  337C  and  416G 
alleles  (Nakajima  et  at.,  2005).  As  CBZ-E  is  commonly  associated  with  the  occurrence 
of  adverse  effects  arising  from  CBZ  therapy  (Ramsay  &  Wilder,  2002)  and  mEH  is  the 
major  determinant  of  CBZ-E  metabolism,  these  EPHX1  polymorphisms  may  also  be 
useful  in  predicting  the  maximum  tolerable  dose  which  should  not  be  exceeded  when 
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Approximately  15%  of  parent  CBZ  compound  undergoes  glucuronidation  which  is 
predominantly  mediated  by  UGT2B7.  The  c.  802C>T  substitution  is  a  recognised 
polymorphism  in  the  UGT2B7  gene,  but  its  functional  significance  is  controvesial.  The 
802T  allele  has  been  associated  with  an  altered  capacity  for  the  metabolism  of  morphine 
and  4-hydroxy-catecholestrogens  (Sawyer  et  al.,  2003;  Thibaudeau  et  al.,  2006),  but 
other  substrates  such  as  oxazepam,  propranolol  and  androgens  are  unaffected  (Coffman 
et  al.,  1998).  In  the  present  study,  the  c.  802C>T  polymorphism,  did  not  significantly 
predict  the  optimal  dose  of  CBZ,  suggesting  that  this  variant  does  not  significantly 
influence  the  role  of  UGT2B7  in  the  glucuronidation  of  CBZ. 
CBZ  acts  predominantly  on  voltage-gated  sodium  channels  to  exert  its  antiepileptic 
effects.  Changes  in  the  structure  of  sodium  channels  may  influence  their  sensitivity  to 
CBZ.  In  the  current  study,  there  was  no  association  between  the  SCN2A  c.  56G>A 
polymorphism  and  the  optimal  dose  of  CBZ.  This  might  suggest  that  the  SCN2A 
c.  56G>A  polymorphism  does  not  significantly  affect  the  function  of  the  Na,,  1.2  protein 
or  its  sensitivity  to  blockade  by  CBZ.  Of  course,  CBZ  can  also  act  on  other  voltage- 
gated  sodium  channels,  potentially  compensating  for  any  functional  or  structural  defect 
in  the  Na,,  1.2  protein.  A  previous  study  has  reported  that  the  maximum  dose  of  CBZ  is 
significantly  associated  with  a  polymorphism  located  within  intron-5  of  SCN1A  gene 
(Tate  et  al.  2005).  However,  there  was  a  clear  difference  in  the  definition  of  dose 
between  the  Tate  et  al.  (2005)  study  and  the  current  investigation.  The  measure  of 
optimal  dose  considers  both  efficacy  and  tolerability  to  CBZ  treatment,  whereas 
maximum  dose  reflects  tolerability  alone.  Nevertheless,  this  SCN1A  polymorphism  is  a 
potential  candidate  for  future  pharmacogenetic  investigations  of  CBZ  optimal  dose  and 
may  be  able  to  explain  additional  interindividual  variability  in  the  CBZ  dose 
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The  predictive  model  of  CBZ  optimal  dose  proved  statistically  relevant  only  when  a 
physiological  factor  (age)  was  combined  with  genetic  predictors.  When  each  candidate 
predictor  was  analysed  in  isolation,  none  showed  significant  ability  to  predict  the 
optimal  dose,  indicating  that  individual  dosing  requirement  are  determined  by  multiple 
factors,  many  of  which  remain  to  be  discovered.  The  present  study  showed  that 
potentially  important  predictors  for  CBZ  optimal  dose  include  patient  age  and 
polymorphisms  in  the  EPHX1  gene.  Although  the  model  revealed  a  significant 
correlation  between  predicted  and  observed  optimal  doses,  the  strength  of  the  prediction 
was  not  sufficient  for  application  in  clinical  practice.  The  small  size  of  the  CBZ  cohort 
and  the  retrospective  design  of  this  study  have  influenced  its  findings  and  their 
applicability.  This  study  has  revealed  an  intriguing  and  potentially  significant  role  of 
EPHX1  SNPs  in  individual  CBZ  dose  requirements,  however  it  should  be  repeated 
independently  and  prospectively.  The  predictive  model  that  was  established  in  this  study 
may  serve  as  a  springboard  for  future  studies  of  SNP-based  prediction  of  optimal  drug 
doses. 
4.1.6  Conclusion 
None  of  the  input  factors,  gender,  age,  and  polymorphisms  in  DME  and  SCN2A  genes 
can  be  used  as  a  single  predictor  for  CBZ  optimal  dose.  However,  the  EPIIXI 
c.  337T>C  &  c.  416A>G  polymorphisms  appear  to  be  potential  predictors  for  optimal 
dose  in  a  predictive  model  incorporating  age.  More  candidate  predictors  in  a  larger 
population  are  required  to  strengthen  the  model.  The  additional  candidate  predictors 
may  include  factors  that  influence  CBZ  pharmacodynamics  such  as  polymorphisms  in 
genes  encoding  other  voltage-gated  ion  channels  that  represent  the  pharmacological 
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4.2  A  Preliminary  Genetic  Analysis  of  Drug  Metabolising 
Enzymes  in  Patients  with  Carbamazepine  Adverse 
Effects 
4.2.1  Introduction 
Major  adverse  drug  reactions  associated  with  CBZ  treatment  can  be  divided  into  two 
categories;  CNS  toxicity  and  idiosyncratic  reactions.  Several  mechanisms  have  been 
proposed  to  explain  the  occurrence  of  CBZ  adverse  effects.  One  hypothesis  is  that  CNS 
toxicity  is  dependent  on  CBZ  dose  and  concentration  (Delcker  et  al.,  1997).  The 
severity  of  adverse  effects  has  been  reported  to  be  directly  associated  with  increasing 
plasma  CBZ  concentrations  (Weaver  et  al.,  1988;  Semah  et  al.,  1994).  In  addition,  this 
has  also  been  demonstrated  by  the  relationship  between  intermittent  CNS  effects  and  the 
dosing-interval  fluctuation  in  CBZ  concentrations  at  steady-state  (Tomson,  1984).  In 
some  patients,  CNS  related  adverse  effects  are  experienced  at  modest  CBZ  doses  (less 
than  600  mg/day),  suggesting  that  these  individuals  possess  low  activity  DMEs,  which 
result  in  higher  plasma  CBZ  concentrations.  Polymorphisms  in  genes  that  encode  DMEs 
may  be  responsible  for  this  phenomenon.  Another  hypothesis  is  that  CNS  related 
adverse  effects  are  associated  with  the  rate  of  rise  in  plasma  CBZ  concentrations  (Lesser 
et  al.,  1984;  Wildin  et  al.,  1993;  Delcker  et  al.,  1997).  An  adaptation  effect  of  the  brain 
in  response  to  changes  in  CBZ  concentration  is  believed  to  be  responsible  for  the 
occurrence  of  these  adverse  effects  (Lesser  et  al.,  1984). 
Idiosyncratic  reactions  are  independent  of  CBZ  dose  and/or  concentration.  Rashes  are 
the  most  common  cutaneous  manifestation  of  CBZ  idiosyncratic  reactions,  and  a 
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result  of  cross-sensitivity  to  other  AEDs  (Shear  &  Spielberg,  1988;  Moss  et  al.,  1999). 
Although  a  relatively  small  proportion  of  patients  experience  idiosyncratic  reactions, 
unattended  cases  can  result  in  severe  morbidity  and  even  fatality  (Shear  &  Spielberg, 
1988;  Moss  et  al.,  1999;  Rzany  et  al.,  1999;  Maldonado  et  al.,  2002;  Pirmohamed  & 
Park,  2003).  Idiosyncratic  reactions  are  believed  to  be  associated  with  an  increased 
activation  and/or  decreased  deactivation  of  reactive  intermediate  metabolites 
(Pirmohamed  &  Park,  2003).  In  an  animal  model,  the  production  of  reactive  metabolites 
of  CBZ  such  as  arene  oxides  and  quinones  is  mediated  by  CYP450  isoenzymes  such  as 
CYP3As  and  CYPIA2  (Madden  et  al.,  1996;  Pearce  et  al.,  2002).  In  contrast,  the 
deactivation  process  is  largely  mediated  by  mEH  and  UGTs  (Green  et  al.,  1995;  Maggs 
et  al.,  2000). 
Evidence  suggests  that  polymorphisms  in  DME  genes  are  able  to  alter  enzyme  activity 
(as  described  in  Chapter  3).  Polymorphisms  in  genes  that  encode  activation  and 
deactivation  enzymes  for  CBZ  may  be  causal  in  the  precipitation  of  adverse  drug 
effects.  Together  with  other  physiological  and  immunological  factors,  genetically 
compromised  DMEs  may  contribute  to  the  generation  of  both  categories  of  CBZ-related 
adverse  effects.  Collectively,  these  polymorphisms  may  produce  a  unique  adverse  effect 
phenotype.  As  a  result,  common  genetic  polymorphisms  of  DMEs  that  are  involved  in 
CBZ  metabolism  were  examined  as  potential  genetic  markers  of  CBZ  adverse  effects. 
4.2.2  Aims 
In  an  effort  to  identify  a  potentially  unique  phenotype  of  CBZ  adverse  effects,  the 
incidence  of  common  DME  polymorphisms  in  patients  experiencing  intolerable  CBZ 
adverse  effects  was  investigated. Chapter  4:  Pharmacogenetics  of  Carbamazepine 
4.2.3  Methods 
4.2.3.1  Study  subjects 
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From  the  400-strong  study  population,  104  patients  treated  with  CBZ  monotherapy  and 
possessing  sufficient  outcome  data  were  identified  and  retrospectively  screened  for  any 
incidence  of  adverse  effects.  A  total  of  14  patients  had  experienced  at  least  one 
intolerable  adverse  effect  that  led  to  CBZ  withdrawal  (9  CNS-related,  5  idiosyncratic). 
The  remaining  90  patients  did  not  experience  any  adverse  effect  of  sufficient  severity  to 
necessitate  drug  withdrawal,  despite  at  least  6  months  exposure  to  CBZ.  These  patients 
were  employed  for  control  purposes  and  randomely  assigned  to  one  of  two  distinct 
control  groups  using  an  online  random  number  generator  (http:  //www.  randomizer. 
org/form.  htm).  A  total  of  five  individuals  were  selected  at  random  from  control  group  1 
and  employed  for  comparison  with  those  patients  experiencing  idiosyncratic  reactions 
with  CBZ.  Control  group  2  was  first  pared  to  include  only  those  patients  who  had  been 
exposed  to  CBZ  at  doses  above  800  mg/day  and  then  nine  individuals  were  selected  at 
random  for  comparison  with  those  patients  experiencing  intolerable  CNS-related 
adverse  effects.  Applying  a  minimum  dose  exposure  criterion  ensured  that  control  group 
2  was  relatively  free  from  dose-related  adverse  events  and  sufficiently  distinct  from 
those  patients  who  discontinued  CBZ  due  to  CNS-related  adverse  effects  and  who  had 
done  so  at  a  median  maximum  dose  of  just  400  mg/day. 
4.2.3.2  Adverse  reaction  documentation 
Major  adverse  effects  were  divided  into  two  categories,  CNS-relatcd  effects  and 
idiosyncratic  reactions.  Information  regarding  CBZ  adverse  effects  was  obtained 
retrospectively  from  patient  medical  records.  None  of  the  patients  was  concomitantly 
treated  with  other  medications  (AEDs  or  non-AEDs)  at  the  time  of  CBZ  adverse  effect. Chapter  4:  Pharmacogenetics  of  Carbamazepine 
4.2.3.3  Genotype  analysis  and  phenotype  assessment 
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The  genotypes  of  recognised  polymorphisms  in  DMEs  associated  with  CBZ  metabolism 
were  identified  using  the  PCR-RFLP  and  direct  sequencing  assays  described  in  section 
3.1.3.  Genotype  determination  for  the  DME  polymorphisms  was  completed  on  February 
2006.  Phenotype  assessment  was  started  on  March  2006  and  completed  on  April  2006. 
4.2.3.4  Genotype-phenotype  analysis 
Minor  alleles  were  chosen  as  potential  genetic  markers  for  CBZ  adverse  effects.  The 
minor  alleles  were  represented  by  the  CYP3A4  -392G,  CYP3A5  6986A,  CYPIA2 
5734C,  EPHX1  337C,  EPHX1  416G  and  UGT2B7  802C  variants.  CYP3A4,  CYP3A5 
and  CYP1A2  were  regarded  as  potential  activation  enzymes  in  the  precipitation  of 
CBZ-related  idiosyncratic  reactions,  whereas  UGT2B7  and  EPHXI  were  regarded  as 
potential  deactivation  enzymes.  The  incidence  of  the  minor  alleles  of  the  recognised 
polymorphisms  in  DME  genes  was  compared  between  the  adverse  effects  groups  and 
their  respective  control  groups  by  the  method  proposed  by  Green  et  al.  (1995). 
4.2.3.5  Statistical  analysis 
The  distributions  of  gender  and  epilepsy  syndromes  were  initially  compared  by  X2  test. 
The  pattern  of  genetic  polymorphisms  was  evaluated  by  allelic  term.  The  distribution  of 
minor  and  major  alleles  between  adverse  effect  and  respective  control  groups  was 
compared  using  an  appropriate  contingency  table  test  (Fisher's  Exact  test  or  X2  test).  P- 
values  less  than  0.05  represented  a  significant  difference  in  the  distribution  of  minor  and 
major  allele  between  the  two  groups. Chapter  4:  Pharmacogenetics  of  Carbamazepine 
4.2.4  Results 
4.2.4.1  Patient  characteristics  and  adverse  effect  profile 
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There  was  no  significant  difference  in  the  distribution  of  gender  (p  =  0.388)  or  epilepsy 
syndrome  (p  =  0.503)  between  adverse  effect  and  control  groups  (TABLE  4.5).  In  the 
majority  of  cases,  adverse  effects  were  observed  at  lower  median  CBZ  doses  (400 
mg/day)  than  was  employed  in  the  population  as  a  whole  (800  mg/day;  p=0.001; 
TABLE  4.5). 
TABLE  4.5.  Demographic  profile  of  patients  who  experienced  intolerable 
carbamazepine  adverse  effects. 
Intolerable  Adverse  Events 
Yes,  n=l4  No,  n=90  p-value 
Gender  Male  60%  48%  0.388 
Female  40%  52% 
Epilepsy  Syndrome  IGE  13%  28%  0.503 
LRE  87%  70% 
UNC  0%  2% 
CBZ  maximum  dose  (mg/day)  Median  400  800  0.001 
Min  400  300 
Max  1200  2000 
IGE,  idiopathic  generalised  epilepsy;  LRE,  localisation  related  epilepsy;  UNC, 
unclassified  epilepsy.  Statistical  significance  was  determined  by  X2  test  for  gender 
and  epilepsy  syndrome,  and  Student's  t-test  for  CBZ  maximum  dose.  Thep-value 
represents  the  comparison  between  patients  who  experienced  intolerable  CBZ  and 
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Drowsiness  and  dizziness  (6  out  of  14  cases)  and  rash  (5  out  of  14  cases)  were  the  most 
common  intolerable  adverse  effects  leading  to  CBZ  withdrawal.  Some  patients 
experienced  more  than  one  adverse  event  simultaneously.  In  all  patients,  the  adverse 
effects  resolved  with  discontinuation  of  CBZ. 
4.2.4.2  The  pattern  of  polymorphisms  in  drug  metabolising  genes  in  patients 
with  carbamazepine  adverse  effects 
The  incidence  of  common  polymorphisms  in  DME  genes  are  presented  in  TABLE  4.6 
and  TABLE  4.7  for  the  CNS-related  adverse  effects  and  idiosyncratic  reaction  groups, 
respectively.  For  CNS  related  adverse  effects,  there  was  a  marginally  lower  incidence  of 
minor  alleles  in  the  adverse  effect  group  compared  to  the  control  group  (total  =  20  vs  25 
alleles,  p=0.402).  For  idiosyncratic  reactions,  the  presence  of  minor  alleles  in  DME 
genes  was  similar  between  adverse  effect  and  control  groups  (total  =  10  vs  11  alleles,  p 
=  0.882).  The  presence  of  minor  alleles  in  activation  DMEs  was  comparable  between 
the  idiosyncratic  reaction  group  and  controls  (3  vs  2  alleles,  p=0.999)  and  there  was 
similarly  no  difference  in  the  distribution  of  minor  alleles  in  the  deactivation  DME 
genes  between  the  idiosyncratic  reaction  group  and  respective  control  group  (7  vs  9 
alleles,  p=0.559).  Overall,  there  was  no  single  polymorphism  that  was  evidently 
related  to  the  occurrence  of  CBZ  adverse  effects. 
4.2.5  Discussion 
The  risk  of  developing  adverse  drug  effects  has  been  associated  with  several 
polymorphisms  in  DME  genes,  such  as  CYP2C9  and  CYP2D6  (Royer,  1997).  The 
expression  and  activity  of  DMEs  may  be  decreased  or  increased  by  the  effects  of 
genetic  polymorphisms.  A  decrease  in  DME  activity  may  result  in  higher  plasma  drug 
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dependent  adverse  effects.  This  low  activity  phenotype  may  also  be  associated  with 
accumulation  of  reactive  metabolites  that  could  in  turn  be  responsible  for  idiosyncratic 
reactions.  In  contrast,  the  high  activity  phenotype  may  also  be  partly  responsible  for  the 
development  of  idiosyncratic  reactions  through  increased  production  of  reactive 
metabolites  (Shear  &  Spielberg,  1988;  Green  et  al.,  1995;  Royer,  1997;  Pirmohamed  & 
Park,  2003).  Accordingly,  polymorphisms  in  genes  encoding  DMEs  that  mediate  CBZ 
metabolism  were  hypothesised  to  be  causal  factors  in  the  development  of  CBZ  adverse 
effects.  However,  there  was  no  clear  association  between  the  incidence  of  common 
polymorphisms  in  DME  genes  and  CBZ  adverse  effects  that  might  be  considered  as  the 
sole  determinant  of  treatment  withdrawal.  Common  polymorphisms  in  DME  genes  such 
as  CYP3A4,  CYP3A5,  CYP1A2,  EPHX1  and  UGT2B7  are  unlikely  to  be  a 
predominant  factor  in  the  development  of  CBZ  adverse  reactions.  It  is  more  likely  that 
other  factors  acting  concurrently  with  DMEs  may  be  responsible  in  predisposing  an 
individual  to  CBZ  adverse  effects.  The  overall  balance  between  physiological  factors, 
bioactivation,  detoxification  and  immune  responsiveness  probably  determines  whether 
an  adverse  effect  will  occur. 
In  many  studies,  the  occurrence  of  CNS-related  adverse  effects  is  associated  with  the 
rate  of  rise  in  plasma  CBZ  concentration  (Lesser  et  al.,  1984;  Wildin  et  al.,  1993;  Oiling 
et  al.,  1999).  The  CNS  symptoms  are  manifested  when  the  brain  attempts  to  adapt  to  the 
increasing  CBZ  concentrations  (Lesser  et  al.,  1984;  Wildin  et  a!.,  1993).  The  rising 
phase  of  plasma  CBZ  concentration  is  controlled  by  three  principle  factors,  absorption, 
distribution  and  elimination.  The  influence  of  absorption  is  most  pronounced  in  the 
immediate  aftermath  of  drug  intake,  early  in  the  dosing  interval  and  when  the  rate  of 
rise  in  concentration  is  at  its  greatest.  Therefore,  factors  that  affect  the  rate  of  CBZ 
absorption  may  be  more  responsible  for  the  generation  of  CNS-related  adverse  effects 
than  those  which  influence  distribution  and  elimination. r-  n 
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Factors  that  affect  the  rate  of  absorption  include  gastrointestinal  function  and  drug 
formulation  (Wildin  et  al.,  1993;  Oiling  et  al.,  1999).  Any  given  CBZ  formulation  is 
subject.  to  high  interindividual  variability  in  the  rate  of  absorption  (Cotter  et  al.,  1977; 
Perucca  et  al.,  1980a;  Oiling  et  al.,  1999),  highlighting  important  differences  in 
gastrointestinal  function  between  individuals.  Gastrointestinal  disease  may  also  alter 
intestinal  motility  and  the  potential  for  drug  absorption.  The  pattern  of  dosing-interval 
fluctuation  in  plasma  CBZ  concentrations  can  also  be  affected  by  formulation  (May  & 
Rambeck,  1989;  Stevens  et  al.,  1998)  and  is  closely  associated  with  the  intensity  of 
adverse  effects  (Tomson,  1984).  The  dosing-interval  fluctuation  in  concentrations 
observed  with  extended-release  formulations  is  lower  than  that  observed  with  standard 
release  tablets  and  consequently  fewer  adverse  effects  are  noted  (Miller  et  al.,  2004). 
Idiosyncratic  reactions  may  be  associated  with  the  imbalance  between  activation  and 
deactivation  of  reactive  metabolites  of  CBZ,  and  also  immune  responsiveness  (Shear  & 
Spielberg,  1988;  Green  et  al.,  1995;  Royer,  1997;  Pirmohamed  &  Park,  2003).  The 
reactive  metabolites,  arene  oxides,  can  precipitate  cellular  damage  if  not  sufficiently 
deactivated  (Madden  et  al.,  1996).  Low  molecular  weight  drugs  and  reactive 
metabolites  bind  covalently  to  cellular  proteins  and  form  haptens  that  trigger  an 
immunological  response  (Svensson  et  al.,  2000).  The  isoforms  of  CYP450  involved  in 
CBZ  metabolism  are  present  in  human  skin  (Wolkenstein  et  al.,  1998)  and  stable 
binding  between  reactive  metabolites  of  CBZ  and  skin  CYP450s  has  been  demonstrated 
(Wolkenstein  et  al.,  1998).  The  hapten  produced  can  precipitate  a  cutaneous  reaction. 
As  a  result,  the  production  of  hapten  has  been  postulated  as  one  possible  explanation  for 
the  occurrence  of  CBZ  cutaneous  reactions.  The  presence  of  anti"CYP450  antibodies  in 
patients  who  suffer  hypersentivity  reactions  further  supports  this  hypothesis  (Leeder  et 
al.,  1992).  The  findings  of  the  current  study  suggest  that  common  DME  polymorphisms Chapter  4:  Pharmacogenetics  of  Carbamazepine  176 
do  not  significantly  influence  the  pathway  of  activation/deactivation  or  the  binding 
between  DMEs  and  reactive  metabolites. 
Previous  studies  have  also  failed  to  demonstrate  any  association  between 
polymorphisms  in  the  EPHX1  gene  and  CBZ  hypersensitivity  (Green  et  al.,  1995; 
Pirmohamed  &  Park,  2003).  Polymorphisms  in  genes  that  express  DMEs  may  be  less 
important  than  those  that  express  immunological  factors.  The  human  major 
histocompatibility  complex  (MHC)  which  determines  immune  system  recognition  and 
which  responds  to  CBZ-related  antigen  production  is  a  possible  causal  immunological 
factor.  Expression  of  genetically  polymorphic  MHCs  has  been  identified  (Leeder  et  al., 
1992).  Furthermore,  haplotypes  of  MHC  and  other  immunological  factors  such  as 
tumour  necrosis  factor  have  been  associated  with  the  severity  of  drug  hypersensitivity 
reactions  (Pirmohamed  et  al.,  2001). 
The  present  study  should  be  considered  as  preliminary  because  of  the  limited  number  of 
patients  who  experienced  intolerable  CBZ-related  adverse  effects.  In  addition,  the  study 
findings  may  also  be  influenced  by  the  method  of  assessing  adverse  effects  as  described 
in  section  2.2.3.2.  Most  of  the  adverse  effects  documented  in  this  study  arose  from 
spontaneous  reporting.  Spontaneous  reporting  has  advantages  in  highlighting  effects 
which  are  clinically  relevant,  but  is  associated  with  extreme  variability  in  the  accuracy 
of  detection  and  with  significant  under-reporting  (Perucca,  1997;  Gilliam,  2005).  The 
retrospective  nature  of  this  study  may  have  further  compromised  the  accurate' 
identification  and  recording  of  relevant  adverse  effects.  Accordingly,  this  study  focused 
only  on  those  adverse  effects  which  were  sufficiently  severe  to  necessitate  CBZ 
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4.2.6  Conclusion 
This  preliminary  study  failed  to  reveal  any  association  between  CBZ  adverse  effects  and 
common  polymorphisms  in  DME  genes.  A  large  prospectively  designed  study  is 
required  to  establish  whether  there  is  any  functional  relevance  of  DME  gene 
polymorphisms  in  the  development  of  CBZ  adverse  effects.  Genetic  variability  in  drug 
absorption  and  in  proteins  which  contribute  to  the  immune  response  should  be  targeted 
as  potentially  causal  precipitants  of  CBZ  adverse  effects  in  future  explorations. CHAPTER  5 
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5.1  Association  between  ABCB1  and  SCN2A  gene 
polymorphisms  and  the  Response  to  Lamotrigine 
Therapy  in  Newly  Diagnosed  Epilepsy  Patients 
5.1.1  Introduction 
Partially  responsive  and  non-responsive  epilepsy  patients  may  try  a  number  of  AEDs 
over  a  long  period  of  time  before  they  are  definitely  identified  as  being  refractory.  This 
may  result  in  an  increased  exposure  to  adverse  drug  effects,  seizure  progression  and  an 
elevation  in  the  cost  of  treatment  (Elger,  2003).  Resistance  to  AED  treatment  remains  as 
a  major  therapeutic  challenge,  despite  the  increasing  numbers  of  AEDs  in  routine 
clinical  use.  Two  major  theories  have  been  proposed  to  explain  the  phenomenon  of 
therapeutic  failure  in  epilepsy  (Elger,  2003;  Loscher,  2005),  both  arising  from  a  basic 
knowledge  of  clinical  pharmacology.  Firstly,  the  pharmacokinetic  hypothesis  suggests 
that  AEDs  do  not  reach  the  epileptic  focus  in  sufficient  concentration  (Elger,  2003; 
Loscher,  2005;  Szoeke  et  al.,  2006),  and  secondly,  the  pharmacodynamic  hypothesis 
suggests  that  alteration  in  the  subunit  composition  of  ion  channels  and  neurotransmitter 
receptors  reduces  their  sensitivity  to  AEDs  (Elger,  2003;  Loscher,  2005). 
The  pharmacokinetic  profile  of  AEDs  is  predominantly  determined  by  the  activities  of 
DMEs  and  DTPs.  Brain  tissue  obtained  from  patients  with  medically  intractable 
seizures  has  been  shown  to  express  a  higher  level  of  the  efflux  transporter  protein,  P-gp 
(Tishler  et  al.,  1995;  Marchi  et  al.,  2004)  and  several  AEDs  are  believed  to  be  substrates 
for  P-gp-mediated  transport  (Potschka  et  al.,  2002).  Overexpression  of  P-gp  may  result 
in  an  insufficient  penetration  of  AEDs  into  brain  tissue  (Ramachandran  &  Shorvon, 
2003)  and  has  been  proposed  to  be  responsible  for  the  phenomenon  of 
pharmacoresistance  in  epilepsy.  Seizure  activity  itself  can  increase  the  expression  of  P. Chapter  5:  Pharmacogenetics  of  Lamotrigine  180 
gp  (Rizzi  et  al.,  2002;  van  Vliet  et  al.,  2004),  suggesting  that  any  delay  in  achieving 
optimal  seizure  control  might  increase  the  likelihood  of  long-term  intractability  to  AED 
treatment. 
A  significant  percentage  of  newly  diagnosed  epilepsy  patients  have  been  shown  to 
respond  poorly  to  LTG  monotherapy  (Kwan  &  Brodie,  2000)  and  one  could  argue  that 
overexpression  of  P-gp  may  contribute  to  this  poor  response.  It  is  widely  recognised  that 
the  expression  of  P-gp  can  be  influenced  by  polymorphisms  in  the  ABCB  1  gene 
(Hoffineyer  et  al.,  2000;  Tanabe  et  a!.,  2001;  Nakamura  et  a!.,  2002)  and  that  these 
genetic  variants  may  influence  the  ability  of  P-gp  to  transport  substrates  across 
biological  membranes.  Given  that  LTG  is  believed  to  be  a  substrate  for  P-gp  (Potschka 
et  a!.,  2002)  and  that  this  protein  is  up-regulated  in  epileptic  brain  tissue,  it  is  not 
unreasonable  to  suggest  that  common  polymorphisms  in  the  ABCB1  gene  could  impact 
on  the  efficacy  and/or  toxicity  of  LTG  monotherapy  in  newly  diagnosed  epilepsy. 
The  most  commonly  recognised  SNPs  in  the  human  ABCB  1  gene  are  the  c.  1236C>T, 
c.  2677G>T/A  and  c.  3435C>T  substitutions.  Several  studies  have  explored  the 
functional  relevance  of  the  ABCB1  c.  2677G>T/A  and  c.  3435C>T  variants  but 
inconsistent  findings  have  been  reported  when  employing  drug  pharmacokinetics  as  a 
phenotype  (Hoffmeyer  et  al.,  2000;  Kim  et  a!.,  2001;  Nakamura  et  a!.,  2002;  Oselin  et 
al.,  2003).  Other  studies  have  evaluated  the  association  between  the  ABCB  1  c.  3435C>T 
polymorphism  and  response  to  AED  treatment  and  again  have  produced  conflicting 
results  (Siddiqui  et  al.,  2003;  Tan  et  al.,  2004a;  Sills  et  al.,  2005;  Kim  et  a!.,  2006).  The 
3435C  allele  was  initial  associated  with  poor  response  to  AED  treatment  (Siddiqui  et 
al.,  2003),  but  at  least  three  further  studies  have  failed  to  corroborate  this  original 
finding  (Tan  et  a!.,  2004a;  Sills  et  al.,  2005;  Kim  et  al.,  2006).  Rather  than  investigate 
single  genotypes,  some  investigators  have  suggested  that  haplotypes  of  the  three Chapter  5:  Pharmacogenetics  of  Lamotrigine  181 
common  polymorphisms  in  ABCB  1  could  be  more  useful  in  predicting  drug 
responsiveness  in  epilepsy  (Hung  et  al.,  2005;  Seo  et  al.,  2006a). 
Discrepancies  between  the  results  of  individual  studies  may  be  attributed  to  sample  size, 
or  genetic  background  of  the  respective  cohorts,  or  they  may  simply  have  arisen  by 
chance  (Sills  et  al.,  2005).  Differences  in  AED  regimens  between  invidual  studies  may 
have  also  significantly  influenced  the  findings.  Not  all  AEDs  are  believed  to  be 
transported  by  P-gp  (Owen  et  al.,  2001;  Potschka  et  al.,  2004).  Therefore,  examining 
the  association  between  ABCB  I  polymorphisms  and  the  response  to  monotherapy 
treatment  with  an  AED  that  has  been  shown  to  be  a  substrate  of  P-gp  may  be  more 
appropriate. 
In  contrast  to  the  transporter  hypothesis  discussed  above,  the  pharmacodynamic  theory 
of  refractory  epilepsy  suggests  that  variations  in  the  structure  and  subunit  composition 
of  ion  channels  may  be  associated  with  poor  response  to  AED  treatment  (Ramachandran 
&  Shorvon,  2003).  This  phenomenon  may  also  contribute  to  poor  seizure  control  with 
LTG  therapy.  LTG  acts  mainly  on  voltage-gated  sodium  channels  to  exert  its 
antiepileptic  effect  (Zona  &  Avoli,  1997;  Kohling,  2002),  and  any  changes  in  sodium 
channel  structure  may  affect  the  activity  of  LTG.  As  described  in  Chapter  3,  the  SCN2A 
c.  56G>A  substitution,  results  in  a  nonsynonymous  amino  acid  change  from  arginine  to 
lysine  at  codon  19  of  the  Na,  1.2  a-subunit  protein  (Ito  et  al.,  2004).  This  polymorphism 
has  the  potential  to  affect  the  conformation  of  the  sodium  channel  and  consequently  its 
sensitivity  to  LTG.  As  such,  this  SCN2A  variant  may  also  be  associated  with 
interindividual  variability  in  the  responsiveness  to  LTG  treatment. Chapter  5:  Pharmacogenetics  of  Lamotrigine 
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In  light  of  the  pharmacokinetic  and  pharmacodynamic  hypotheses  of  pharmacoresistant 
epilepsy,  the  prevalences  of  the  ABCB  1  c.  1236C>T,  ABCB  I  c.  2677G>T/A,  ABCB  I 
c.  3435C>T  and  SCN2A  c.  56G>A  polymorphisms  were  investigated  in  a  series  of  newly 
diagnosed  epilepsy  patients  in  an  attempt  to  predict  the  response  to  LTG  monotherapy. 
5.1.3  Methods 
5.1.3.1  Study  subjects 
From  the  overall  400-strong  study  population,  118  patients  were  identified  as  being 
treated  with  LTG  monotherapy.  A  total  of  79  patients  from  the  118  patients  received 
LTG  as  their  first  ever  AED,  irrespective  of  seizure  type.  All  of  these  patients  were 
involved  in  a  head  to  head  monotherapy  trial  comparing  LTG  with  VPA  (Stephen  et  al., 
2007).  Each  patient  was  treated  for  at  least  1  year  with  LTG.  Patients  who  withdrew 
from  LTG  therapy  for  any  reason  before  the  end  of  the  12-month  study  period  were 
excluded.  None  of  the  participants  was  concomitantly  treated  with  any  other  medication 
(AEDs  or  non-AEDs)  that  might  have  influenced  LTG  metabolism. 
5.1.3.2  Genotype  analysis  and  phenotype  assessment 
Genotypes  of  the  common  SCN2A  and  ABCBI  gene  polymorphisms  were  identified 
using  the  PCR-RFLP  assays  described  in  Chapter  3.  Genotype  determination  completed 
for  the  SCN2A  polymorphism  on  February  2006  and  for  ABCB  I  polymorphisms  on 
May  2006.  Phenotype  assessment  was  started  on  June  2006  and  completed  on  July 
2006. Chapter  5:  Pharmacogenetics  of  Lamotrigine 
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The  haplotypes  of  ABCB1  polymorphisms  were  inferred  using  THESIAS  software 
(Testing  Haplotype  Effects  In  Association  Studies;  Tregouet  &  Garelle,  2007).  The 
haplotypes  were  presented  in  the  arrangement  of  c.  123  6C>T-c.  2677G>T/A-c.  343  5C>T. 
This  study  was  not  powered  for  this  haplotype  analysis  due  to  limited  sample  size, 
therefore,  the  result  was  considered  observational.  ABCBI  diplotypes  were  inferred 
using  combination  of  genotypes  of  the  c.  1236C>T,  c.  2677G>T/A  and  c.  3435C>T 
polymorphisms,  as  described  by  Coulbault  et  al.  (2006). 
5.1.3.4  Evaluation  of  clinical  response 
Information  regarding  the  outcome  of  LTG  therapy  was  obtained  retrospectively  from 
the  clinical  study  notes.  Response  to  LTG  was  assessed  by  an  experienced  clinician  and 
recorded  in  the  study  folders  and  electronic  database.  Complete  medical  history,  seizure 
type  and  basic  clinical  factors  such  as  height,  weight,  age  and  gender  were  documented 
at  the  first  study  visit.  Progress  was  evaluated  at  study  visits,  scheduled  every  4  to  6 
weeks,  from  the  day  of  treatment  initiation  and  for  at  least  12  months  thereafter. 
However,  patients  are  allowed  to  contact  or  visit  the  clinic  at  anytime  in  cases  of 
worsening  of  seizure  control  and  adverse  drug  reaction.  Records  of  each  study  visit 
included  details  of  seizure  frequency,  adverse  effects,  and  complete  LTG  treatment 
regimen.  Patients  were  categorised  as  seizure  free  if  no  seizure  was  experienced  within 
the  last  6  months  of  the  study  period.  In  contrast,  patients  with  uncontrolled  seizures  or 
those  who  had  experienced  seizure  break-through  within  the  last  6  months  were 
categorised  as  non-seizure  free. Chapter  5:  Pharmacogenetics  of  Lamotrigine 
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Clinical  and  demographic  differences  between  the  seizure  free  and  non-seizure  free 
groups  were  investigated  using  the  X2  test.  The  distributions  of  age  and  maximum  LTG 
dose  were  compared  using  Student's  t-test.  The  possibility  of  genotype  selection  bias 
was  explored  by  comparing  the  distribution  of  individual  polymorphisms  between  the 
LTG  cohort  and  the  overall  400-strong  patient  population  using  the  X2  test. 
The  genotype  distribution  of  each  polymorphism  was  initially  compared  between 
seizure  free  and  non-seizure  free  groups  by  contingency  table  tests.  Logistic  regression 
analysis  was  then  used  to  evaluate  differences  in  the  prevalences  of  ABCB  1 
c.  1236C>T,  c.  2677G>T/A,  c.  3435C>T  and  SCN2A  c.  56G>A  polymorphisms.  The 
analyses  were  conducted  using  allele,  genotype,  diplotype  and  haplotype  frequencies. 
Specifically  for  haplotype  analysis,  the  haplotype  with  the  highest  frequency  was 
selected  as  the  default  reference.  The  odds  ratio  (OR)  together  with  its  95%  confidence 
interval  (95%  CI)  was  used  as  a  measure  of  association  between  the  gene 
polymorphisms  and  response  to  LTG  treatment.  All  reportedp-values  are  two-tailed. 
5.1.4  Results 
5.1.4.1  Patient  demographics  and  lamotrigine  dosage  regimen 
A  total  of  39  patients  became  seizure-free  within  the  first  12  months  of  LTG  treatment, 
while  the  remaining  40  patients  continued  to  experience  seizures  despite  attempts  to 
optimise  LTG  therapy.  The  median  age  of  patients  was  35  years  (range  13  to  80)  and 
there  were  no  significant  differences  in  the  distribution  of  gender  (p  =  0.216),  age  at 
evaluation  (p  =  0.165)  or  epilepsy  syndrome  (p  =  0.332)  between  the  seizure  free  and 
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patients  had  reached  a  significantly  higher  daily  LTG  dose  than  the  seizure  free  patients 
(p  <  0.001;  TABLE  5.1). 
TABLE  5.1.  Patient  demographics  and  lamotrigine  doses. 
Response  to  LTG  Therapy 
Seizure  free  Non-seizure  free 
n=  39  is  =  40  p-value 
Gender  Male  56.4% 
_43,6% 
0.216 
Female  42.5%  57.5% 
Age  at  evaluation  Mean  39.4  34.5  0.165 
Median  36.0  32.5 
Min  13  14 
Max  80  78 
Epilepsy  syndrome  IGE  20.5%  30.0%  0.332 
LRE  79.5%  70.0% 
Maximum  dose  (mg/day)  Mean  180  294  <  0.001 
Median  150  300 
Min  100  150 
Max  400  600 
IGE  =  idiopathic  generalised  epilepsy;  LRE  =  localisation  related  epilepsy. 
Statistical  significance  was  determined  by  X2  test  for  gender,  age  and  epilepsy 
syndrome,  and  Student's  t-test  for  LTG  maximum  dose.  The  p-value  represents 
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5.1.4.2  Associations  between  polymorphisms  in  the  ABCB1  and  SCN2A  genes 
and  the  response  to  lamotrigine  monotherapy 
There  was  no  significant  difference  in  the  genotype  distributions  of  ABCB  I  c.  1236C>T, 
c.  2677G>T/A,  c.  3435C>T  and  SCN2A  c.  56G>A  polymorphisms  between  the  LTG 
cohort  and  the  overall  400-strong  study  population  (p  >  0.05;  TABLE  5.2).  The 
distributions  of  ABCB1  c.  1236C>T,  c.  2677G>T/A,  c.  3435C>T  and  SCN2A  c.  56G>A 
genotypes  were  similar  between  the  seizure  free  and  the  non-seizure  free  patients  (p  > 
0.05;  TABLE  5.3)  and  there  was  no  significant  association  between  the  alleles  or 
genotypes  of  common  ABCB  1  and  SCN2A  polymorphisms  and  the  response  to  LTG 
monotherapy  (p  >  0.05;  TABLE  5.4).  The  distribution  of  ABCB  I  haplotypes  is 
presented  in  TABLE  5.5.  The  major  haplotypes  of  ABCB  I  in  the  LTG  cohort  were  the 
T-T-T  (38.8%)  and  C-G-C  (36.9%;  TABLE  5.5).  There  was  no  significant  difference  in 
the  response  to  LTG  treatment  when  common  ABCBI  haplotypes  were  compared  with 
the  T-T-T  default  reference  haplotype  (p  >  0.05;  TABLE  5.6)  There  was  similarly  no 
association  between  the  major  diplotypes  in  ABCB  I  and  the  response  to  LTG  treatment 
(p  >  0.05;  TABLE  5.7). 
5.1.5  Discussion 
Overexpression  of  P-gp  has  been  postulated  to  be  one  explanation  for  the  poor  response 
to  AED  treatment.  Brain  tissue  from  patients  with  medically  intractable  seizures  has  a 
high  level  of  P-gp  expression  and  several  AEDs  are  believed  to  be  transported  by  this 
protein  (Tishler  et  al.,  1995;  Potschka  et  al.,  2001;  Marchi  et  al.,  2004).  LTG  has  been 
shown  to  be  a  substrate  for  P-gp  (Potschka  et  al.,  2001)  and  thus,  it  is  possible  that  a  P- 
gp-related  mechanism  might  be  responsible  for  any  poor  clinical  response  to  LTG 
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TABLE  5.2.  Genotype  distributions  of  common  SCN2A  and  ABCBI 
polymorphisms  between  the  lamotrigine  cohort  and  the  overall  400-strong  study 
population 
Genotype  frequency 
Polymorphism  Cohort  Minor  Ilelero  Major  p-value 
SCN2A  c.  56G>A  SSP  0.013  0.112  0.875  0.532 
LTG  0.025  0.140  0.835 
ABCB  1  c.  1236C>T  SSP  0.245  0.470  0.285  0.657 
LTG  0.203  0.599  0.278 
ABCB  1  c.  2677G>T/A  SSP  0.23  0.45  0.32  0.457 
LTG  0.10  0.52  0.30 
ABCB1  c.  3435C>T  SSP  0.182  0.485  0.333  0.723 
LTG  0.177  0.532  0.291 
SSP  =  400-strong  study  population  (n  =  400);  LTG  =  LTG  cohort  (n  =  79);  Minor 
=  homozygous  of  minor  allele;  Hetero  =  heterozygous  of  minor  and  major  alleles; 
Major  =  homozygous  of  major  allele.  Statistical  significance  was  determined  by 
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TABLE  5.3.  Comparison  of  the  genotype  distribution  of  common  polymorphisms 
in  SCN2A  and  ABCB  1  between  seizure  free  and  non-seizure  free  groups. 
Seizure  free  Non-seizure  free  p- 
Gene  Polymorphism  Genotype  n=39  n=40  value 
SCN2A  c.  56G>A  GG  34  32  0.755 
GA  47 
AA  11 
ABCB  1  c.  1236C>T  CC  12  10  0.605 
CT  21  20 
TT  6  10 
ABCB  1  c.  2677G>T  GG  13  11  0.908 
GT  19  22 
TT  67 
TA  10 
ABCBI  c.  3435C>T  CC  770.985 
CT  21  21 
TT  11  12 
Statistical  significance  was  determined  by  X2  test  or  Fisher's  Exact  test.  The  p- 
value  represents  the  comparison  of  the  genotype  distribution  between  seizure  free 
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TABLE  5.4.  Logistic  regression  analysis  of  response  to  lamotrigine  monotherapy  on 
the  basis  of  genotype  and  allele  of  common  polymorphisms  in  SCN2A  and  AICB  1 
genes. 
Gene  Polymorphism  Genotype  Allele  Odds  Ratio  95%  Cl  p-value 
SCN2A  c.  56G>A  GG  vs  not  GG  1.70  0.50-5.74  0.393 
GAvsnotGA  0.54  0.14-2.01  0.357 
AA  vs  not  AA  1.03  0.06-17.01  0.986 
GG  vs  AA  1.06  0.06  -17.71  0.966 
G  vs  A  0.66  0.22  -1.94  0.448 
ABCB  1  c.  1236C>T  CC  vs  not  CC  1.33  0.50-3.58  0.568 
CT  vs  not  CT  1.17  0.48-2.82  0.732 
TT  vs  not  TT  0.55  0.18-1.68  0.292 
CCvsTT  2.00  0.54-7.45  0.301 
C  vs  T  0.73  0.39-1.37  0.333 
ABCB  1  c.  2677G>T  GG  vs  not  GG  1.32  0.50-3.45  0.573 
GT  vs  not  GT  0.78  0.32-1.88  0.577 
TT  vs  not  TT  0.86  0.26-2.82  0.800 
GGvsTT  1.38  0.36-5.34  0.642 
G  vs  T  0.97  0.43-2.19  0.941 
ABCB  1  c.  3435C>T  CC  vs  not  CC  1.03  0.32-3.27  0.958 
CT  vs  not  CT  1.06  0.44-2.56  0.905 
TT  vs  not  TT  0.92  0.35-2.42  0.861 
CC  vs  TT  1.09  0.29-4.12  0.898 
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TABLE  5.5.  The  distribution  of  ABCB  1  haplotypes  between  seizure  free  (n  =  39) 
and  non-seizure  free  (n  =  40)  patients. 
Haplotype  frequency 
ABCB  1  haplotype  Seizure  free  Non-seizure  free 
T-T-T  0.368  0.408 
C-G-C  0.393  0.346 
C-G-T  0.142  0.026 
T-G-C  0.054  0.078 
C-T-T  0.041  0.028 
T-T-C  0.001  0.014 
TABLE  5.6.  Logistic  regression  analysis  of  response  to  lamotrigine  monotherapy 
on  the  basis  of  ABCB  1  haplotype.  Only  haplotypes  with  a  frequency  of  more  than 
1%  in  both  seizure  free  and  non-seizure  free  patients  were  examined. 
ABCB  1  haplotype  Odds  ratio 
95%  confidence 
interval  p-value 
T-T-T  1.00  reference 
C-G-C  0.82  0.43  -1.57  0.559 
C-G-T  0.87  0.36-2.14  0.769 
T-G-C  1.42  0.46-4.44  0.545 
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TABLE  5.7.  Logistic  regression  analysis  of  response  to  lamotrigine  monotherapy 
on  the  basis  of  major  diplotype  of  the  ABCB  1  gene. 
Diplotype  of  ABCB1*  Odds  Ratio  95%  Cl  p-value 
CC-GG-CC  vs  not  CC-GG-CC  1.03  0.30-3.52  0.393 
CT-GT-CT  vs  not  CT-GT-CT  1.30  0.52-3.27  0.580 
TT-TT-TT  vs  not  TT-TT-TT  0.83  0.23-2.99  0.780 
CC-GG-CC  vs  TT-TT-TT  1.20  0.23-6.19  0.827 
*Diplotype  arrangement:  ABCB  1  c.  1236C>T-c.  2677G>T/A-c.  3435C>T. 
Variability  in  the  expression  and  activity  of  P-gp  can  be  influenced  by  polymorphisms 
in  the  encoding  gene  (Hoffineyer  et  al.,  2000).  Of  the  three  most  widely  studied 
polymorphisms  in  ABCB  1,  only  the  c.  2677G>T/A  transition  is  known  to  produce  an 
amino  acid  change  which  might  in  turn  be  associated  with  a  functionally  relevant 
phenotype  (Cascorbi,  2006).  The  common  polymorphisms  of  the  ABCB  1  gene  are 
strongly  linked  to  each  other  (Kim  et  al.,  2001;  Tanabe  et  al.,  2001;  Tang  et  al.,  2002; 
Tang  et  al.,  2004),  most  likely  because  they  exist  within  a  single  block  of  linkage 
disequilibrium.  Accordingly,  the  association  between  common  ABCB  1  polymorphisms 
and  the  response  to  LTG  treatment  was  investigated  both  individually  and  in 
combination  analyses  using  allele,  genotype,  haplotype,  and  diplotype  of  the  ABCB  1 
gene. 
This  study  took  advantage  of  an  existing  monotherapy  comparison  between  VPA  and 
LTG  in  order  to  isolate  a  cohort  of  newly  diagnosed  epilepsy  patients  treated  with  a 
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confounding  factors  which  may  have  contributed  to  the  conflicting  results  of  previous 
investigations  (Siddiqui  et  al.,  2003;  Tan  et  al.,  2004a;  Sills  et  al.,  2005;  Basic  et  al., 
2006;  Kim  et  al.,  2006).  Evaluating  the  response  to  AED  treatment  without  considering 
the  spectrum  of  individual  drugs  to  which  the  patients  were  exposed  may  have 
undermined  the  conclusions  of  previous  studies. 
There  is  currently  no  firm  evident  to  suggest  that  all  clinically  used  AEDs  are  substrates 
for  P-gp.  This  is  clearly  emphasised  in  recent  studies  of  both  CBZ  (Owen  et  al.,  2001; 
Potschka  et  al.,  2001)  and  levetiracetam  (Potschka  et  al.,  2004).  It  is  therefore  unlikely 
that  any  changes  in  the  expression  or  activity  of  P-gp  resulting  from  ABCB  i  gene 
polymorphisms  would  influence  the  penetration  of  these  AEDs  into  brain  tissue.  Hence, 
their  inclusion  in  efficacy  studies  would  weaken  or  possibly  mask  any  evidence  of 
association  between  genetic  variants  and  response  to  AED  treatment,  particularly  where 
significant  numbers  of  CBZ  and  levetiracetam  exposed  patients  are  involved.  In 
addition,  AED  polytherapy  is  commonly  used  in  the  management  of  patients  with 
partially  responsive  epilepsy  and  this  fact  could  also  have  affected  study  findings.  The 
concomitant  use  of  multiple  AEDs  may  result  in  unpredictable  interactions  at  the  level 
of  both  DMEs  and  DTPs.  Furthermore,  some  AEDs  have  been  shown  to  stimulate  the 
expression  of  P-gp  (Weiss  et  al.,  2003).  Thus,  drug-drug  and  drug-Pgp  interactions 
could  independently  influence  the  response  to  AED  treatment.  This  underlines  the 
importance  of  performing  such  studies  in  patients  with  newly  diagnosed  epilepsy  treated 
with  AED  monotherapy. 
There  were  no  significant  differences  in  the  distribution  of  clinical  factors  such  as  age, 
gender  and  epilepsy  syndromes  between  seizure  free  and  non-seizure  free  groups.  This 
would  indicate  that  any  variability  arising  from  clinical  factors  was  equally 
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is  symptomatic  of  ongoing  titration  and  excludes  any  suggestion  of  undertreatment  in 
these  poor-reponders.  Almost  50%  of  the  patients  in  the  LTG  cohort  failed  to  achieve 
seizure  free  status  within  the  first  12  months  of  LTG  monotherapy.  This  percentage  is 
higher  than  the  value  previously  reported  in  newly  diagnosed  epilepsy  patients  (Kwan  & 
Brodie,  2000).  Differences  in  the  duration  of  follow-up  may  explain  this  discrepancy. 
No  significant  association  was  observed  between  ABCB  1  c.  1236C>T,  c.  2677G>T/A 
and  c.  3435C>T  polymorphisms  and  the  response  to  LTG  treatment,  irrespective  of 
whether  analyses  were  based  on  allele,  genotype,  haplotype  or  diplotype  frequencies. 
These  findings  would  support  the  observations  reported  previously  by  Tan  et  al. 
(2004a),  Sills  et  a!.  (2005)  and  Kim  et  a!.  (2006).  If  P-gp  expression  and  activity  are 
genuinely  influenced  by  common  polymorphisms  in  the  ABCB  I  gene,  the  current  study 
findings  would  question  the  role  of  P-gp  in  mediating  resistance  to  treatment  with  LTG. 
Either  the  distribution  of  LTG  in  human  brain  is  not  significantly  affected  by  P-gp  or 
the  function  of  P-gp  at  the  BBB  is  not  influenced  by  common  ABCB  I  polymorphisms. 
However,  there  has  been  a  suggestion  that  pathological  overexpression  of  P-gp  in  the 
epileptic  focus  may  overcome  any  genetically  determined  variability  (Sills  et  al.,  2005). 
In  addition,  it  is  reasonable  to  speculate  that  LTG  may  also  be  transported  by  other,  as- 
yet-unidentified  DTPs  (Cascorbi,  2006).  Other  DTPs  could  potentially  compensate  for 
any  deficiency  in  the  function  of  P-gp  related  to  genetic  variability.  As  such,  changes  in 
P-gp  activity  secondary  to  polymorphic  expression  of  the  ABCB  1  gene  might  not  be 
demonstrable  in  a  clinical  study  of  drug  efficacy.  One  must  also  appreciate  that  the 
response  to  LTG  treatment  can  be  influenced  by  a  multitude  of  additional 
pharmacokinetic  and  pharmacodynamic  factors,  such  as  the  conformation  of  voltage- 
gated  sodium  channels  and  the  activity  of  glucuronidation  enzymes. Chapter  5:  Pharmacogenetics  of  Lamotrigine  194 
For  AEDs  such  as  LTG,  which  act  predominantly  on  voltage-gated  sodium  channels, 
changes  in  the  structure  or  function  of  the  sodium  channel  may  significantly  influence 
the  response  to  treatment.  In  this  study,  the  SCN2A  c.  56G>A  polymorphism  did  not 
appear  to  be  associated  with  the  response  to  LTG  treatment.  This  might  suggest  that  the 
SCN2A  c.  56G>A  polymorphism  does  not  significantly  affect  the  expression  or  function 
of  the  Na,,  1.2  protein  in  the  neuronal  tissue  or  its  sensitivity  to  blockade  by  LTG. 
However,  it  is  also  recognised  that  LTG  can  act  on  other  voltage-gated  sodium 
channels,  potentially  compensating  for  any  functional  or  structural  defect  in  the  Na￿l.  2 
protein. 
This  investigation  failed  to  demonstrate  any  association  between  the  ABCBI 
c.  1236C>T,  c.  2677G>T/A,  c.  3435C>T  and  SCN2A  c.  56G>A  polymorphisms  and  the 
response  to  initial  LTG  monotherapy.  Some  common  issues  to  pharmacogenetic  studies 
that  may  influence  their  findings  should  be  considered,  especially  the  consensus  of 
phenotype  criteria.  At  the  very  least,  it  is  important  to  recognise  that  results  are  strongly 
influenced  by  the  duration  of  follow-up  which  was,  in  this  case,  12  months  of  LTG 
therapy.  The  duration  of  follow-up  can  influence  the  number  of  patients  who  are 
categorised  as  seizure  free  and  non-seizure  free.  Hence,  the  conclusions  of  any  such 
study  should  be  considered  alongside  limitations  of  study  design. 
5.1.6  Conclusion 
There  was  no  evidence  of  any  association  between  the  prevalences  of  ABCB  1 
c.  1236C>T,  c.  2677G>T/A,  c.  3435C>T  and  SCN2A  c.  56G>A  polymorphisms  and  the 
response  to  LTG  monotherapy  within  the  first  12  months  of  treatment.  This  study 
included  only  a  small  number  of  patients  which  could  have  had  a  significant  bearing  on 
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prospectively  in  a  considerably  larger  cohort  of  patients  with  newly  diagnosed  epilepsy 
and  treated  with  AED  monotherapy  in  order  that  a  more  definitive  conclusion  can  be 
reached.  In  the  meantime,  any  functional  significance  of  ABCB  1  and  SCN2A  gene 
variants  on  pharmacoresistant  epilepsy  remains  unclear. 
5.2  Genetic  Predictors  of  Lamotrigine  Optimal  Dose 
5.2.1  Introduction 
AED  dosing  is  typically  based  on  a  trial  and  error  approach  allied  to  the  individual 
clinical  experience.  In  the  absence  of  a  rational  approach  to  identify  optimal  dose,  the 
duration  of  uncontrolled  seizures  may  be  prolonged  and  some  patients  may  be  exposed 
to  unnecessarily  high  AED  doses.  A  wide  interindividual  variability  in  dosage 
requirement  has  been  documented  for  most  AEDs.  For  example,  the  effective  doses 
leading  to  seizure  freedom  with  CBZ  range  between  200  and  1600  mg/day,  and  for 
VPA  between  200  and  2500  mg/day  (Kwan  &  Brodie,  2001).  Differences  in  the 
required  dose  between  individuals  are  believed  to  be  linked  to  genetic  variability  in 
genes  associated  with  AED  pharmacodynamics  and  pharmacokinetics.  Genetic  variants 
that  influence  dosing  regimen  have  been  reported  for  both  PIT  and  CBZ,  with 
maximum  doses  of  these  drugs  associated  with  polymorphisms  in  the  SCN1A  and 
CYP2C9  genes  (van  der  Weide  et  al.,  2001;  Tate  et  al.,  2005). 
A  study  by  Kwan  and  Brodie  (2001)  reported  that  a  modest  dose  of  LTG  (100  to  200 
mg/day)  can  provide  complete  seizure  control  in  a  large  number  of  patients.  However, 
some  patients  may  require  doses  up  to  600  mg/day  to  achieve  a  similar  degree  of 
efficacy.  Interindividual  variability  in  LTG  dosage  requirement  is  likely  to  be 
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previous  study  (section  5.1)  failed  to  demonstrate  any  association  between  the  response 
to  LTG  therapy  and  common  SCN2A  and  ABCB  1  polymorphisms,  it  did  not  directly 
investigate  any  association  between  these  genetic  variants  and  LTG  dose.  It  is  important 
to  note  that  the  response  to  LTG  treatment  is  not  correlated  with  plasma  concentration 
or  dose  (Kilpatrick  et  al.,  1996;  Mahmood  et  al.,  1998). 
Thus,  it  is  reasonable  to  speculate  that  the  SNPs  which  were  studied  in  the  previous 
section  may  be  able  to  influence  the  LTG  dose  requirement.  In  this  section,  these 
polymorphisms  were  investigated  in  relation  to  the  dose  of  LTG,  rather  than  its  efficacy. 
5.2.2  Aims 
This  study  was  designed  to  evaluate  the  association  between  common  polymorphisms  in 
the  SCN2A  and  ABCB  1  genes  and  the  optimal  dose  of  LTG.  Basic  clinical  factors  such 
as  age  and  gender  were  also  included  as  potential  predictors  of  optimal  dose. 
5.2.3  Methods 
5.2.3.1  Definitions 
Optimal  dose  was  defined  as  the  final  dose  given  to  a  patient  that  successfully 
maintained  optimal  seizure  control  without  intolerable  side  effects  and  which  was 
maintained  throughout  the  period  of  follow-up  without  the  need  for  adjustment.  Optimal 
seizure  control  was  defined  as  seizure  freedom  for  at  least  1-year  on  LTG  monotherapy. 
5.2.3.2  Study  subjects 
From  the  overall  400-strong  study  population,  a  total  of  118  patients  were  identified  as 
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patient  records,  94  of  these  patients  were  identified  as  having  achieved  seizure  free 
status  for  a  period  of  at  least  1  year.  These  patients  included  those  who  achieved  seizure 
free  within  and  after  the  first  12  months  of  LTG  initiation  and  those  received  LTG  as  a 
second  line  monotherapy  AED.  Complete  information  on  LTG  dosing  regimen  and 
other  basic  clinical  data  was  available  for  all  of  these  individuals.  None  was 
concomitantly  treated  with  any  other  medication  (AEDs  and  non-AEDs)  that  might 
have  influenced  LTG  metabolism. 
5.2.3.3  Genotype  analysis  and  phenotype  assessment 
Genotypes  of  the  common  SCN2A  and  ABCB  1  gene  polymorphisms  were  identified 
using  the  PCR-RFLP  assays  described  in  Chapter  3.  Genotype  determination  completed 
for  the  SCN2A  polymorphism  on  February  2006  and  for  ABCB  1  polymorphisms  on 
May  2006.  Phenotype  assessment  was  started  on  June  2006  and  completed  on  October 
2006. 
5.2.3.4  Statistical  analyses 
Clinical  and  demographic  differences  between  the  LTG  cohort  and  the  400-strong  study 
population  were  investigated  using  XZ  test.  The  distribution  of  age  was  compared  using 
Student's  t-test.  Differences  in  the  mean  LTG  optimal  dose  between  categorical 
variables  (gender  and  epilepsy  syndromes)  were  compared  by  t-test  or  analysis  of 
variance  (ANOVA),  as  appropriate.  The  association  between  age  and  optimal  dose  of 
LTG  was  evaluated  using  Pearson's  correlation  test.  Evidence  of  genotype  selection 
bias  was  investigated  by  comparing  the  distribution  of  each  polymorphism  between  the 
LTG  cohort  and  the  overall  400-strong  study  population. Chapter  5:  Pharmacogenetics  of  Lamotrigine  198 
To  fit  the  genetic  information  into  the  regression  database,  a  score  was  assigned  to  the 
genotype  of  each  polymorphism  according  to  the  number  of  substituting  alleles;  no 
substituting  alleles  was  given  score  1,  one  substituting  allele  was  given  score  2  and  two 
substituting  alleles  was  given  score  3.  Interaction  between  polymorphisms  was 
investigated  by  Pearson's  correlation  test  and  represented  by  the  multiplicative  value  of 
polymorphism  scores. 
Candidate  predictors  included  age,  gender  and  the  genotypes  of  each  polymorphism. 
The  influence  of  each  predictor  on  LTG  optimal  dose  was  analysed  individually  using 
univariate  linear  regression  analysis  and,  in  combination,  using  multivariate  linear 
regression  analysis.  An  additive  model  was  used  in  the  analysis  with  an  assumption  that 
the  combined  effects  of  genetic  alleles  at  two  or  more  gene  loci  are  equal  to  the  sum  of 
their  individual  effects.  SNP  interactions  were  added  to  the  multivariate  model  and 
acted  as  a  non-linear  component.  Predictors  were  added  or  removed  using  a  stepwise 
approach,  depending  on  the  degree  of  impact  indicated  by  the  respective  p-value.  Data 
transformation  from  linear  to  natural  logarithmic  form  was  employed  to  optimise 
regression  modelling.  Coefficients  of  regression  of  the  predictors  which  significantly 
influenced  the  model  were  used  to  construct  a  predictive  equation  for  LTG  optimal 
dose.  Pearson's  correlation  test  was  used  to  evaluate  the  relationship  between  the 
observed  optimal  doses  and  the  optimal  doses  predicted  by  the  equation.  Pearson's 
correlation  value  (r)  of  more  than  0.8  indicated  a  strong  correlation  between  variables. 
A  p-value  of  less  than  0.05  indicated  a  significant  predictor  effect.  Both  Presiduab  which 
represented  the  p-value  of  residual  analysis,  and  r1,  which  represented  the  goodness-of- 
fit,  indicated  how  well  the  model  fitted  the  data. Chapter  5:  Pharmacogenetics  of  Lamotrigine 
5.2.4  Results 
5.2.4.1  Patient  demographics  and  lamotrigine  dosage  regimen 
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Demographic  information  for  patients  in  the  LTG  cohort  is  presented  in  TABLE  5.8. 
Distribution  of  gender  (p  =  0.887)  and  epilepsy  syndromes  (p  =  0.429)  were  comparable 
with  the  400-strong  study  population.  The  median  age  of  patients  in  the  LTG  cohort  was 
38.5  years  (range  16.5  to  85). 
TABLE  5.8.  Patient  demographics  and  lamotrigine  doses. 
LTG  Cohort 
(n  =  94) 
Gender 
400-strong  study 
Population  p-value 
(n  =  400) 
Male  51.0%  50.3%  0.887 
Female  49.0%  49.7% 
Age  (year)  Median  38.5  40  0.460 
Min  16.5  14 
Max  85  85 
Epilepsy  syndrome  IGE  35.1%  29.5%  0.429 
LRE  60.6%  67.5% 
UNC  4.3%  3.0% 
Optimal  dose  (mg/day)  Median  200 
Min  50 
Max  600 
Min  =  minimum,  Max  =  maximum;  IGE  =  idiopathic  generalised  epilepsy;  LRE  = 
localisation  related  epilepsy;  UNC  =  unclassified  epilepsy.  Statistical  significant 
was  determined  by  Student's  t-test  or  X2  test,  where  appropriate.  The  p-value 
represents  the  comparison  between  the  LTG  cohort  and  400-strong  study 
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All  of  the  patients  received  LTG  on  a  twice-daily  basis  with  total  daily  dose  ranging 
from  50  to  600  mg.  Female  patients  received  higher  LTG  doses  in  order  to  achieve 
optimal  seizure  control  (male  vs  female,  201  vs  279  mg/day  respectively,  p=0.002; 
FIGURE  5.1).  There  was  no  significant  association  between  LTG  dose  and  age  of  the 
patients  (r  =  -0.096,  p=0.356;  FIGURE  5.2)  or  epilepsy  syndromes  (p  =  0.674; 
FIGURE  5.4). 
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FIGURE  5.1.  Distribution  of  lamotrigine  optimal  dose  between  genders. 
Statistical  significance  was  determined  by  Student's  t-test.  Dotted  lines  represent 
the  average  optimal  dose  for  respective  gender. 
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FIGURE  5.2.  Distribution  of  lamotrigine  optimal  dose  and  age  at  achieving  12 
months  of  seizure  freedom.  Correlation  was  examined  by  Pearson's  correlation 
test. 
20I Chapter  5:  Pharmacogenetics  of  Lamotrigine 
p=0.674 
600 
500  ý 
400  ý 
300-I 
200  ý 
100 
"  "" 
" 
0  00 
" 
000 
"  00 
000 
of  .....  ýod>..... 
................  00000 
"ýýý"  "ýýý"  "ýý"  "ýýý" 
""""" """"" 
0000 
"*@*" 
"000" 
000000 
"" 
00 
................ 
00 
IGE  LRE  UNC 
Epilepsy  Syndrome 
FIGURE  5.3.  Distribution  of  lamotrigine  optimal  dose  between  epilepsy 
syndromes.  Statistical  significance  was  determined  by  ANOVA.  Dotted  lines 
represent  the  average  optimal  dose  for  respective  epilepsy  syndrome.  IGE  = 
idiopathic  generalised  epilepsy;  LRE  =  localisation  related  epilepsy;  UNC  = 
unclassified  epilepsy. 
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5.2.4.2  Genetic  predictors  of  lamotrigine  optimal  dose 
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There  were  no  significant  differences  in  the  distribution  of  common  polymorphisms  in 
the  ABCB  1  and  SCN2A  genes  between  the  LTG  cohort  and  the  overall  400-strong 
study  population  (TABLE  5.9).  Three  potential  SNP  interactions  were  identified 
between  ABCB  1  c.  1236C>T  and  c.  2677G>T/A  (r  =  0.751,  p<0.00  1),  c.  1236C>T  and 
c.  3435C>T  (r  =  0.549,  p  <  0.001),  c.  2677G>T/A  and  c.  3435C>T  (r  =  0.618,  p  <  0.001). 
Univariate  linear  regression  analysis  demonstrated  that  single  predictors  for  LTG 
optimal  dose  included  gender  (p  =  0.002)  and  genotype  of  ABCB  1  c.  1236C>T  (p  = 
0.010).  However,  the  strength  of  prediction  was  weak  in  both  cases  (r2  <  10%;  TABLE 
5.10).  In  an  effort  to  improve  the  strength  of  prediction,  the  candidate  predictors  were 
evaluated  using  a  multivariate  linear  regression  analysis  (TABLE  5.11).  The  basic 
regression  model  (Model  1)  represents  the  combination  effects  of  all  candidate 
predictors  and  showed  a  better  overall  model  fit  (?  =  11.2%,  p=0.023)  than  any 
individual  univariate  analysis.  Stepwise  multivariate  regression  analysis  identified 
gender  and  the  SNP  interaction  between  ABCB1  c.  1236C>T  and  c.  3435C>T  as  the 
optimal  combination  of  predictors  (r2  =  14.1%,  p  <  0.001;  Model  2).  Transformation  of 
optimal  dose  data  from  linear  to  natural  logarithmic  form  further  improved  the  overall 
model  fit  (r2  =  16.6%,  p<0.001;  Model  3).  A  predictive  equation  for  LTG  optimal  dose 
was  constructed  from  the  regression  constant  and  coefficients  of  Model  3  and  is 
presented  below: 
1nODcrG  =  4.68  +  0.32*Gender  +  0.05  *(AßCß  1  c.  1236C>T*c.  3435C>T) 
where;  InODLTG  =  natural  log  of  LTG  optimal  dose  (mg/day);  scores  for  gender,  1= 
male,  2=  female;  scores  for  ABCB  1  c.  1236C>T  and  c.  3435C>T  genotypes,  I=  C/C,  2 
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A  statistically  significant  correlation  was  observed  between  predicted  and  observed 
LTG  optimal  doses  (p  <  0.001),  however,  the  strength  of  the  association  was  modest  (r 
=  0.400,95%CI  0.22  to  0.56;  FIGURE  5.4). 
TABLE  5.9.  Comparison  of  distributions  of  common  SCN2A  and  ABCBI 
polymorphisms  between  the  lamotrigine  cohort  and  the  400-strong  study 
population. 
Genotype  frequency 
Polymorphism  Cohort  Minor  Hetero  Major  p-value 
SCN2A  c.  56G>A  SSP  0.013  0.112  0.875  0.974 
LTG  0.010  0.106  0.884 
ABCB  1  c.  1236C>T  SSP  0.245  0.470  0.285  0.300 
LTG  0.170  0.521  0.309 
ABCB1  c.  2677G>T/A  SSP  0.230  0.450  0.320  0.147 
LTG  0.140  0.500  0.360 
ABCB  1  c.  3435C>T  SSP  0.182  0.485  0.333  0.305 
LTG  0.181  0.564  0.255 
SSP  =  400-strong  study  population;  LTG  =  LTG  cohort  (94  patients);  Minor  = 
homozygous  for  minor  allele;  Hetero  =  heterozygous  for  minor  and  major  alleles; 
Major  =  homozygous  for  major  allele.  Statistical  significance  was  determined  by 
X2  test.  Thep-value  represents  comparison  of  LTG  and  SSP  data. Chapter  5:  Pharmacogenetics  of  Lamotrigine  205 
TABLE  5.10.  Summary  of  univariate  regression  analysis  of  variables  predicting 
the  optimal  dose  of  lamotrigine. 
Predictor  Coef.  r=  (%  p-value 
Gender  78.31  9.2  0.002 
Age  -0.72  0.9  0.358 
SCN2A  c.  56G>A  -35.07  0.0  0.612 
ABCB  1  c.  1236C>T  47.72  5.9  0.010 
ABCB  1  c.  2677G>T/A  27.81  1.3  0.143 
ABCB1  c.  3435C>T  29.01  1.3  0.135 
The  relative  impact  of  each  predictor  is  presented  by  the  coefficient  value  (Coef.  ). 
The  goodness-of-fit  value  (r2)  indicates  how  well  the  individual  predictors  fit  the 
model.  The  p-value  indicates  the  probability  of  the  predictor  influencing  LTG 
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TABLE  5.11.  Summary  of  hierarchical  multivariate  regression  analysis  of 
variables  predicting  the  optimal  dose  of  lamotrigine. 
Model  3 
Modell  Model  2 
Predictor  (natural  log) 
Coef.  p-value  Coef.  p-value  Coefi  p-value 
Constant  176.30  0.121  74.79  0.077  4.68  <0.001 
Gender  83.11  0.001  76.13  0.002  0.32  0.001 
Age  -0.14  0.853  ---- 
SCN2A  c.  56G>A  -45.15  0.207  ---- 
ABCB  1  c.  1236C>T  -18.12  0.791  ---- 
ABCB  1  c.  2677G>T/A  57.51  0.499  ---- 
ABCB1  c.  3435C>T  -100.0  0.382  ---- 
ABCB  1  1236C>T*2677G>T/At  8.87  0.813 
ABCB  1  1236C>T*3435C>Tt  -4.13  0.923  12.46  0.015  0.05  0.009 
ABCB  1  2677G>T/A*3435C>Tt  22.48  0.591 
r2  (/) 
Presidual 
11.2  14.1  16.6 
0.023  <0.001  <0.001 
The  relative  impact  of  each  predictor  is  presented  by  the  coefficient  value  (Coef.  ). 
The  p-value  indicates  the  probability  of  the  predictor  affecting  LTG  optimal  dose. 
The  goodness-of-fit  value  (r)  indicates  how  well  the  predictors  fit  the  model.  The 
significance  of  model  fitting  is  represented  by  the  p-value  of  residual  analysis 
(presidul)"  `-'  mark  represents  predictors  that  were  eliminated  in  the  stepwise 
regression  analysis.  tSNP  interaction  between  predictors. Chapter  5:  Pharmacogenetics  of  Lamotrigine 
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FIGURE  5.4.  Correlation  between  observed  and  predicted  lamotrigine  optimal 
dose  based  on  the  optimal  multivariate  regression  model.  Statistical  significance 
was  determined  by  Pearson's  correlation  test.  A  single  data  point  (")  may 
represent  more  than  one  value.  Dotted  line  is  the  correlation  between  observed 
and  predicted  doses. 
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5.2.5  Discussion 
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One  of  the  biggest  challenges  in  the  treatment  of  epilepsy  is  the  identification  of  the  best 
dose  of  any  given  AED  for  a  particular  patient.  Conventionally,  optimal  doses  are 
established  through  a  trial  and  error  method.  During  the  period  of  dosing  adjustment, 
quality  of  life  may  be  impacted  by  either  under-treatment  or  over-treatment.  This 
concern  applies  to  all  epilepsy  patients  and  all  AEDs,  including  LTG.  Although 
complete  control  of  seizures  can  be  achieved  with  doses  of  100  to  200  mg/day  of  LTG 
in  a  large  number  of  patients,  higher  doses  of  up  to  600  mg/day  may  be  required  by 
some  individuals  (Kwan  &  Brodie,  2001).  Continuous  titration  of  LTG  may  be 
undertaken  in  an  attempt  to  achieve  complete  seizure  control  and  this  may  expose  non- 
responsive  patients  to  unnecessarily  high  doses  of  LTG,  increasing  the  risk  of  adverse 
effects  and  the  cost  of  treatment.  Prediction  of  LTG  optimal  dose  may  be  useful  in 
guiding  dosing  strategies  and  could  improve  the  usage  of  LTG  by  employing  slow 
titration  and  low  target  doses  in  potentially  sensitive  individuals  and  a  quicker  titration 
and  higher  target  doses  in  less  sensitive  patients. 
In  addition  to  conventional  therapeutic  drug  monitoring,  a  genetic-based  approach  to  the 
optimisation  of  AED  dose  may  be  useful  (Tate  et  a!.,  2005;  Ferraro  &  Buono,  2005). 
Potential  genetic  predictors  of  optimum  dose  are  genes  which  encode  proteins  involved 
in  the  pharmacokinetics  and  pharmacodynamics  of  LTG  such  as  DMEs,  DTPs  and 
voltage-gated  ion  channels.  LTG  has  been  suggested  to  be  a  substrate  for  P-gp 
(Potschka  et  al.,  2002)  and  its  principle  mechanism  of  action  is  believed  to  be  blockade 
of  sodium  channels  (Zona  &  Avoli,  1997;  Kohling,  2002).  Therefore,  polymorphisms  in 
the  ABCBI  gene  that  encodes  P-gp  and  the  SCN2A  gene  which  encodes  the  Naj.  2 
sodium  channel  were  evaluated  as  potential  predictors  of  LTG  optimal  dose.  Basic Chapter  5:  Pharmacogenetics  of  Lamotrigine  209 
clinical  factors  such  as  age  and  gender  were  included  in  the  evaluation  as  additional 
candidate  predictors. 
This  study  failed  to  demonstrate  any  association  between  age  and  LTG  optimal  dose. 
This  is  not  surprising  given  that  a  previous  report  suggested  that  LTG  pharmacokinetics 
were  not  significantly  influenced  by  age  in  an  adult  population  (Hussein  &  Posner, 
1997).  The  SCN2A  c.  56G>A  polymorphism  was  similarly  unrelated  to  LTG  optimal 
dose  when  assessed  either  individually  or  in  combination  with  other  candidate 
predictors.  If  the  function  of  the  Na,,  1.2  sodium  channel  is  genuinely  influenced  by  the 
SCN2A  c.  56G>A  polymorphism,  then  it  is  possible  any  effect  of  this  polymorphism  on 
LTG  dosage  requirement  was  masked  by  the  interaction  of  LTG  with  other  sodium 
channel  subtypes  (Zona  &  Avoli,  1997;  Kohling,  2002).  A  polymorphism  in  the  SCNIA 
gene  has  been  associated  with  maximum  doses  of  both  PHT  and  CBZ  (Tate  et  al.,  2005) 
and  plasma  concentrations  of  PHT  at  maintenance  dose  (Tate  et  al.,  2006).  It  is 
reasonable  to  suggest  that  this  particular  polymorphism  in  the  SCN1A  gene  should  be 
included  in  any  future  search  for  candidate  predictors  of  LTG  optimal  dose. 
Gender  and  the  interaction  between  ABCB  1  c.  1236C>T  and  c.  3435C>T  polymorphisms 
were  shown  to  possess  the  greatest  predictive  capacity  for  the  optimal  dose  of  LTG 
when  employed  together  in  a  multivariate  regression  model.  flow  gender  might 
influence  the  LTG  optimal  dose  is  unclear,  as  the  pharmacokinetics  of  LTG  are  not 
believed  to  differ  between  males  and  females  (Hussein  &  Posner,  1997).  It  is  possible 
that  this  observation  is  based  on  differences  in  body  weight,  fat  composition,  or  in  sex 
hormone  activity  between  the  genders  (Gallagher  et  al.,  1996;  Tanaka,  1999).  Females 
have  a  higher  fat  composition  than  males  (Lemieux  et  al.,  1993;  Gallagher  et  al.,  1996), 
and  this  may  increase  the  Vd  of  lipophilic  drugs  (Mangoni  &  Jackson,  2003;  Thomson, 
2004).  LTG  is highly  lipophilic  in  nature  (Mashru  et  a!.,  2005)  and,  therefore,  a  higher Chapter  5:  Pharmacogenetics  of  Lamotrigine  210 
dose  may  be  required  by  females  to  achieve  a  similar  target  concentration. 
Unfortunately,  the  current  study  did  not  include  measures  of  body  weight,  or  further 
investigate  the  effect  of  fat  composition,  which  may  have  been  enlightening  with  regard 
to  the  relationship  between  dose  and  gender. 
The  association  between  the  ABCB  1  c.  1236C>T  polymorphism  and  LTG  dose  was 
significant,  with  or  without  the-  presence  of  gender  information.  Although  the 
c.  1236C>T  polymorphism  does  not  result  in  an  amino  acid  substitution  in  the  encoded 
protein,  this  polymorphism  may  be  linked  to  an  as  yet  unidentified  causal  variant  which 
could  in  theory  influence  the  activity  of  P-gp  or  indeed  any  other  LTG-related 
pharmacokinetic  and  pharmacodynamic  factor.  Previous  studies  exploring  the 
functional  significance  of  the  ABCB  1  gene  polymorphisms  on  drug  pharmacokinetics 
have  been  largely  inconclusive  (Tanabe  et  al.,  2001;  Goto  et  al.,  2002;  Nakamura  et  al., 
2002),  with  differences  in  substrate  and  study  design  believed  to  be  the  major 
contributing  factor  to  the  conflicting  findings.  The  c.  3435C>T  substitution  is  the  most 
studied  polymorphism  in  the  ABCB  I  gene.  There  is  no  general  consensus  with  regard  to 
the  functional  significance  of  ABCBI  variants  associated  with  the  c.  3435C>T 
polymorphism.  The  3435T  allele  has  been  associated  with  both  higher  and  lower 
expression  of  P-gp  depending  on  substrate  studied  (Hoffmeyer  et  al.,  2000;  Nakamura 
et  al.,  2002).  Elevation  in  P-gp  expression  is  believed  to  decrease  absorption  and 
increase  elimination  of  many  drugs.  These  effects  may  explain  the  association  between 
the  3435T  allele  and  reduced  concentrations  of  fexofenadine  (Kim  et  al.,  2001)  and  also 
the  poor  response  to  chemotherapy  (Sohn  et  al.,  2006).  As  the  3435C>T  and  1236C>T 
polymorphisms  are  strongly  under  linkage  disequilibrium  (Kim  et  al.,  2001;  Tang  et  al., 
2002;  Tang  et  al.,  2004),  a  similar  mechanism  may  also  explain  the  association  between 
LTG  dose  and  the  1236T  allele.  This  would,  in  turn,  explain  why  the  association Chapter  5:  Pharmacogenetics  of  Lamotrigine  211 
between  the  c.  1236C>T  polymorphism  and  optimal  dose  of  LTG  was  much  stronger 
when  the  c.  3435C>T  polymorphism  was  included  in  the  multivariate  analysis. 
The  small  number  of  participants  and  the  retrospective  nature  of  this  study  may  limit  the 
potential  significance  of  the  findings.  A  larger  prospective  study  in  newly  diagnosed 
epilepsy  must  be  undertaken  before  the  clinical  implications  of  these  results  can  be 
realistically  assessed.  With  respect  to  LTG  therapy,  this  study  provides  some 
information  which  may  guide  future  dosing  decisions.  The  combination  of  ABCB  1 
c.  1236C>T-c.  3435C>T  SNP  interaction  and  gender  explains  approximately  17%  of  the 
interindividual  variability  in  LTG  optimal  dose  and  may  be  an  important  clinical 
indicator  of  whether  a  patient  will  require  low  or  high  doses  of  LTG  to  achieve 
complete  seizure  control.  This  could  potentially  prevent  the  under-treatment  of 
responsive  individuals  or  reduce  the  risk  of  unnecessary  exposure  to  high  doses  of  LTG 
in  patients  who  are  non-responders.  Despite  this  encouraging  finding,  more  candidate 
predictors  are  required  to  strengthen  the  model.  These  should  include  polymorphisms  of 
genes  that  encode  other  sodium  channel  subunits  and,  given  that  LTG  metabolism,  is 
primarily  mediated  by  UGT1A4,  any  known  variants  in  the  UGT1A4  gene  (Magdalou 
et  al.,  1992;  Rambeck  &  Wolf,  1993;  Vashishtha  et  al.,  2001). 
5.2.6  Conclusion 
This  study  suggests  that  patient  gender  and  the  genotypes  of  ABCB  1  c.  1236C>T  and 
c.  3435C>T  polymorphisms  are  useful  in  predicting  the  LTG  optimal  dose.  In  contrast, 
there  was  no  significant  association  between  a  common  polymorphism  in  the  SCN2A 
gene  and  doses  of  LTG.  The  use  of  genetic  markers  in  predicting  LTG  optimal  dose 
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further  support  to  the  proposed  involvement  of  the  ABCB  1  gene  and  P-gp  in  epilepsy 
management. 
5.3  The  Effects  of  ABCB1  Gene  Polymorphisms  on  the 
Pharmacokinetics  of  Lamotrigine  Monotherapy 
5.3.1  Introduction 
The  single  and  multiple  dose  pharmacokinetics  of  LTG,  when  used  as  both 
monotherapy  and  polypharmacy  have  been  studied  in  healthy  volunteers  and  patients 
(Jawad  et  al.,  1987;  Ramsay  et  al.,  1991;  Hussein  &  Posner,  1997).  In  general,  drug 
pharmacokinetics  are  affected  by  both  extrinsic  factors,  such  as  concomitant 
medications,  mealtime  and  composition,  chronopharmacology,  and  lifestyle,  and 
intrinsic  factors,  such  as  gender,  age,  body  size,  renal  and  hepatic  function,  phenotype 
and  disease  conditions.  The  influence  of  some  of  these  factors  on  the  interindividual 
variability  in  LTG  pharmacokinetics  has  been  explored  previously,  for  example, 
comedication  with  other  AEDs  and  renal  impairment  (Jawad  et  al.,  1987;  Ramsay  et  al., 
1991;  Wooton  et  al.,  1997). 
Common  and  clinically  significant  pharmacokinetic  parameters  include  clearance,  Vd 
and  Ka.  In  healthy  volunteers,  the  total  apparent  clearance  and  renal  clearance  of  LTG 
have  been  estimated  at  0.5  and  0.043  ml/min/kg,  respectively  (Cohen  et  al.,  1987; 
Wooton  et  al.,  1997).  Renal  impairment  does  not  influence  the  clearance  of  LTG 
(Wooton  et  al.,  1997).  LTG  has  clinically  important  pharmacokinetic  interactions  with 
other  AEDs.  Concomitant  administration  of  LTG  with  enzyme-inducing  AEDs  (PUT, 
CBZ,  primidone  or  PB)  increases  the  clearance  of  LTG  through  induction  of  UGT 
enzymes  (Jawad  et  al.,  1987;  Ramsay  et  al.,  1991),  whereas  co-medication  with  VPA Chapter  5:  Pharmacogenetics  of  Lamotrigine  213 
decreases  the  clearance  of  LTG  through  inhibition  of  glucuronidation  (Jawad  et  a!., 
1987;  Patsalos,  1999;  Perucca,  2001;  Bazil  &  Pedley,  2003).  Consequently,  the  LTG 
concentration/dose  ratio  can  be  altered  by  interactions  with  other  AEDs.  LTG 
concentrations  can  also  be  affected  by  oral  contraceptives  (Sabers  et  a!.,  2001),  which 
are  believed  to  induce  LTG  glucuronidation.  The  apparent  Vd  has  been  reported  in  the 
range  of  1.14  to  1.36  1/kg  (Cohen  et  a!.,  1987;  Ramsay  et  a!.,  1991;  Hussein  &  Posner, 
1997;  Wooton  et  a!.,  1997).  No  significant  relationship  has  been  identified  between  the 
pharmacokinetic  parameters  of  LTG  and  either  age  or  gender  in  adult  population 
(Hussein  &  Posner,  1997).  However,  in  special  populations  such  as  pregnancy,  the 
clearance  of  LTG  is  higher  in  the  second  and  third  trimesters  when  compared  with  the 
preconception  and  postpartum  periods  (Tran  eta!.,  2002;  Petrenaite  et  a!.,  2005). 
To  further  understand  interindividual  variability  in  LTG  pharmacokinetics,  additional 
factors  should  be  considered.  These  should  perhaps  include  genetic  variants  of  P-gp 
since  LTG  has  been  suggested  to  be  a  substrate  for  P-gp-mediated  transport  (Potschka  et 
al.,  2002).  As  P-gp  is  significantly  expressed  in  many  organs  related  to  drug  absorption 
and  elimination  (Kim,  2002a),  alteration  in  the  activity  of  P-gp  may  consequently 
influence  the  pharmacokinetics  of  LTG.  The  expression  and  function  of  P-gp  has  been 
associated  with  polymorphisms  in  the  encoding  gene,  ABCB  I  (Hoffineyer  et  a!.,  2000). 
The  ABCB  1  gene  has  several  common  polymorphisms  including  the  c.  1236C>T, 
c.  2677G>T/A  and  c.  3435C>T  transitions.  However,  conflicting  results  have  been 
reported  regarding  the  association  between  these  polymorphisms  and  their  respective 
phenotypes  (Hoffmeyer  et  al.,  2000;  Kim  et  a!.,  2001;  Gerloff  et  a!.,  2002;  Johne  et  al., 
2002;  Yates  et  a!.,  2003). 
In  the  current  study,  the  effects  of  ABCB  1  c.  1236C>T  and  c.  3435C>T  polymorphisms 
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concentration  data  obtained  during  a  head-to-head  monotherapy  trial  of  LTG  and  VPA 
in  newly  diagnosed  epilepsy  patients  (Stephen  et  al.,  2007).  LTG  pharmacokinetic 
parameters  were  estimated  using  a  population  pharmacokinetic  approach.  A  similar 
approach  has  been  used  to  examine  the  pharmacokinetics  of  other  AEDs  (Ingwersen  et 
al.,  2000;  Jiao  et  al.,  2003). 
5.3.2  Aims 
The  aim  of  this  study  was  to  perform  an  exploratory,  retrospective  evaluation  of:  (1)  the 
population  pharmacokinetics  of  LTG  monotherapy  in  newly  diagnosed  epilepsy 
patients;  and  (2)  the  influence  of  ABCB  1  c.  1236C>T  and  c.  3435C>T  polymorphisms 
on  LTG  pharmacokinetic  parameters  such  as  the  oral  clearance  (CL/F;  where  F= 
bioavailability),  volume  of  distribution  (Vd/F)  and  Ka. 
5.3.3  Methods 
5.3.3.1  Study  subjects 
Subjects  were  identified  from  the  400-strong  study  population.  A  total  of  118  patients 
were  identified  as  treated  with  LTG  monotherapy.  All  of  these  patients  were  drawn 
from  on  going  head  to  head  monotherapy  trial  comparing  LTG  with  VPA  in  newly 
diagnosed  epilepsy  (Stephen  et  al.,  2007).  Study  visits  were  scheduled  every  4  to  6 
weeks,  at  which  demographic  data  such  as  age,  gender  and  body  weight  were 
documented,  efficacy  and  tolerability  was  recorded,  and  venous  blood  samples  were 
obtained.  A  total  of  50  patients  had  sufficient  demographic,  pharmacokinetic  and 
genotypic  data  to  be  included  in  the  pharmacokinetic  analysis.  Routine  biochemical  data 
representing  the  level  of  organ  function  were  not  included  because  blood  samples  were 
not  obtained  for  this  purpose. Chapter  5:  Pharmacogenetics  of  Lamotrigine 
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The  mean  number  of  blood  samples  obtained  from  each  patient"was  3  (range  I  to  4). 
Each  of  these  samples  was  taken  at  a  different  study  visit.  Blood  samples  obtained  in 
this  study  were  collected  at  a  steady-state  concentrations  between  0.9  to  13.5  hours  post 
dose  (mean  3.8;  median  3.0).  Plasma  was  separated  from  whole  blood  by  centrifugation 
at  800  xg  for  10  minutes  and  was  stored  below  -10°C  until  required  for  analysis.  In 
total,  156  blood  samples  were  available  for  drug  concentration  measurement. 
5.3.3.3  ABCB1  c.  1236C>T  and  c.  3435C>T  polymorphism  analysis  and 
phenotype  assessment 
Genotypes  of  common  ABCB  1  gene  polymorphisms  were  identified  using  the  PCR- 
RFLP  assays  described  in  Chapter  3.  Genotype  determination  completed  for  ABCB  1 
polymorphisms  on  May  2006.  Phenotype  assessment  was  started  on  November  2006 
and  completed  on  March  2007. 
5.3.3.4  Lamötrigine  assay 
The  LTG  concentration  was  determined  by  a  modified  version  of  the  method  described 
by  Kilpatrick  et  al.  (1996). 
Standards:  Blank  plasma  obtained  from  drug-free  healthy  volunteers  was  used  as  a 
diluent  for  the  stock  and  standard  solutions.  LTG  stock  solution  was  prepared  by 
dissolving  20  mg  of  LTG  in  20  ml  of  methanol.  The  stock  solution  was  then  diluted  to 
10  mg/I  LTG  with  blank  plasma.  Further  dilution  of  the  10  mg/I  LTG  solution  with 
blank  plasma  was  required  to  achieve  the  full  range  of  calibration  standard  solutions  (1, 
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quality  control  standard.  Internal  standard  solution  (2  mg/1)  was  prepared  by  dissolving 
1  mg  of  BWA725C  in  1  ml  of  methanol  and  diluting  to  500  ml  with  ethyl  acetate.  The 
calibration  and  internal  standard  solutions  were  stored  at  -20°C  for  up  to  seven  days. 
Sample  preparation:  A  10  µl  aliquot  of  the  internal  standard  solution  and  50  µl  of  2M 
sodium  hydroxide  were  added  to  100  µl  of  calibration  standard  solutions  (1,2.5,5,7.5 
and  10  mg/I  LTG),  quality  control  solution  (1  mg/1)  and  patient  plasma  samples  alike. 
The  calibration  standards  were  used  to  construct  a  linear  calibration  plot  that  was  then 
employed  to  estimate  LTG  concentrations  in  the  patient  samples.  Three  of  quality 
control  standards  were  included  in  each  batch  analysis  to  determine  and  monitor  intra- 
and  inter-assay  reproducibility. 
LTG  extraction:  LTG  was  extracted  from  standards  and  patient  samples  into  ethyl 
acetate  under  alkalinised  conditions.  A  total  of  1  ml  of  ethyl  acetate  was  added  to  both 
standards  and  samples  before  vortex-mixing  for  10  seconds.  The  organic  layer  was 
separated  from  the  aqueous  layer  by  centrifugation  at  12  100  xg  for  30  seconds.  The 
organic  layer  was  removed  into  a  conical  centrifuge  tube,  and  the  ethyl  acetate 
evaporated  using  vacuum  centrifuge  (Heto  Maxi  Dry  Plus).  The  residue  was 
reconstituted  with  300  µl  of  flow  solvent.  The  flow  solvent  consisted  of  hexane,  ethanol 
and  35%  ammonia  solution  in  a  ratio  of  79.75/20/0.25  by  volume.  Reconstituted 
standards  and  samples  were  transferred  to  autosampler  microvials  before 
chromatography. 
High-performance  liquid  chromatography:  Chromatography  was  carried  out  at  room 
temperature  (20°C)  on  a  Zorbax  sil  normal-phase  column  (250  x  4.6  mm).  The 
chromatographic  system  consisted  of  a  Shimadzu  LC-IOAT  pump,  a  Shimadzu  SIL-9A 
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volume  was  set  at  100  µl.  Flow  rate  was  1.75  ml/min  throughout.  The  detector  was  set 
at  wavelength  306  nm  with  aI  second  rise  time.  The  lower  limit  of  detection  was  0.25 
mg/1  LTG.  The  intra-assay  and  inter-assay  coefficients  of  variation  were  <4%  and  <6% 
at  1  mg/I  LTG,  respectively. 
Calculations:  Chromatograms  were  recorded  and  integrated  on  a-  Jones 
Chromatography  JCL6000  chromatography  data  system  (Crawford  Scientific, 
Strathaven,  UK).  LTG  concentrations  were  determined  by  comparison  of  peak  height 
ratios  of  analyte  to  internal  standard,  quantified  in  relation  to  volume,  and  expressed  in 
mg/l. 
5.3.3.5  Database  construction 
Details  of  the  LTG  dosage  regimen,  the  time  of  last  dose  and  the  time  of  blood  sampling 
were  recorded  in  a  specific  database  that  could  be  read  by  NONMEM®  (Beal  &  Sheiner, 
1992).  All  patients  received  a  twice-daily  LTG  regimen,  which  is  believed  to  be 
associated  with  optimal  compliance.  Where  the  time  of  the  previous  evening  dose  was 
not  available,  a  standardised  dosing  interval  of  12  hours  was  assumed.  The  time  at 
which  the  morning  and  evening  doses  were  taken  is  required  because  daily  LTG  doses 
may  not  be  divided  equivalently.  A  scoring  system  was  employed  to  incorporate 
categorical  data  into  the  database,  such  as,  gender  (1  =  female;  0=  male),  and  genotypes 
of  the  ABCB  1  c.  1236C>T  and  c.  3435C?  T  polymorphisms  (0  =  C/C;  1=  C/T;  2=  T/T). 
5.3.3.6  Population  pharmacokinetic  analysis 
The  population  pharmacokinetic  analysis  of  LTG  was  performed  by  the  NONMEM°D 
software  package,  version  V,  level  1.1  (GloboMax  L.  L.  C.,  Hanover,  USA).  NONMEM 
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absorption  and  first-order  elimination  to  the  LTG  concentration  data.  The  first-order 
conditional  estimation  (FOCE)  algorithm  was  used  throughout  the  modelling  procedure. 
FOCE  uses  conditional  estimates  of  the  random  interindividual  variability  while 
estimating  the  population  parameters.  The  choice  of  a  structural  pharmacokinetic  model 
was  based  on  prior  knowledge  of  LTG  disposition  and  preliminary  data  from  the  present 
study. 
The  base  model  (without  any  covariates)  was  initially  used  to  describe  LTG  plasma 
concentration-time  data  and  to  obtain  initial  estimates  of  CL/F,  Vd/F  and  K,.  Covariate 
modelling  in  NONMEM®  was  undertaken  using  the  following  general  model  structures: 
Base  model:  TVCL  =  OCL 
Linear  model:  TVCL  =  OCL*  WT 
Linear  model  with  intercept:  TVCL  =  OCL*(1  +  OWT  *(WT-median  WT)) 
O 
Nonlinear  model:  TVCL  =  OCL*(WT/median  WT)  "fww 
where:  TVCL  is  the  typical  population  estimate  of  CUF;  0  is  the  population  parameter 
estimate;  WT  is  the  body  weight. 
Typical  values  (TVCL,  TWd  and  TVKa)  represent  the  population  estimates  of  CL/F, 
Vd/F  and  Ka,  respectively.  For  each  patient,  the  magnitude  of  interindividual  variability 
in  parameters,  such  as  CL/F,  was  modelled  as  follows: 
CLL  =  TVCL*exp'b'c` 
where:  CLj  is  the  value  of  CL/F  for  the  j`h  patient;  TVCL  is  the  typical  population 
estimate  of  CL/F;  and  rl;,  cL  was  assumed  to  be  a  random  Gaussian  variable  with  zero 
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estimate  as  predicted  by  the  model.  A  similar  model  was  used  to  estimate  VIF. 
Individual  estimates  of  CL/F  and  Vd/F  were  obtained  from  individual  Tlj  estimates  which 
were  obtained  as  part  of  the  FOCE  analysis. 
The  magnitude  of  the  residual  variability  in  plasma  concentrations  was  modelled  using 
3  error  models: 
Additive  error  model:  Cobs,  ij  =  Cprcd,  ij  +  error, 
Proportional  error  model:  Cobs,  ij  =  Cprcd,  ij  (1  +  error2) 
Combined  error  model:  Cobs,  ij  =  Cpred,  ij  (1  +  error2)  +  error, 
where:  Cobs,  y  is  the  ith  observed  LTG  concentration  in  the  j`h  patient;  CPrca,  ;j  is  the 
predicted  LTG  concentration  corresponding  to  the  ih  observed  LTG  concentration  for 
the  j`h  patient;  error,  is  the  additive  error;  error2  is  the  proportional  error  and  the 
magnitude  of  error  was  assumed  to  be  a  random  Gaussian  variable  with  mean  of  zero 
and  variance  a2.  Additive,  proportional  and  combined  error  models  were  tested  in  this 
study. 
The  potential  influence  of  clinical  factors  on  the  population  parameter  estimates  was 
first  examined  subjectively  using  scatterplots  of  individual  estimates  of  CL/F  against  the 
available  clinical  factors.  Generalised  Additive  Modelling  (GAM)  was  then  used  as  an 
additional  screening  tool  to  objectively  evaluate  the  effect  of  univariate  and  multivariate 
factors  on  the  base  model.  The  Akaike  Information  Criterion  (AIC)  value  produced  by 
the  GAM  analysis  was  compared  between  the  model  that  included  clinical  factors  and 
the  base  model.  A  lower  AIC  value  indicates  a  better  goodness-of-fit  of  the  statistical 
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Various  structural  and  covariate  models  were  analysed  using  NONMEMS.  Covariate 
models  included  body  weight  and  ABCB  1  c.  3435C>T  and  ABCBI  c.  1236C>T 
polymorphisms.  Hierarchical  models  were  compared  by  a  likelihood  ratio  test.  A 
decrease  in  the  value  of  objective  function  (OBJF)  as  a  result  of  structural 
pharmacokinetic  remodeling  or  the  inclusion  of  a  parameter  indicates  a  better  fit.  A 
change  in  OBJF  of  more  than  6.63  and  9.21  are  required  to  reach  statistical  significance 
(p  =  0.01)  for  the  addition  of  1-fixed  or  2-fixed  effects,  respectively.  In  addition  to  the 
above  statistical  condition,  the  following  two  criteria  were  also  required  to  be  met:  good 
fit  in  the  diagnostic  plots  (predicted  versus  measured  concentration  and  weighted 
residuals  versus  predicted  concentration),  and  low  relative  standard  errors  of  the 
parameter  estimates.  The  coefficient  of  variation  (cv)  which  represents  a  measure  of 
dispersion  of  a  probability  distribution  was  calculated  for  each  parameter  estimated. 
5.3.4  Results 
5.3.4.1  Patient  demographics 
The  study  population  consisted  of  50  newly  diagnosed  epilepsy  patients  of  whom  52% 
were  male.  The  mean  age  and  weight  of  the  participants  was  39  years  (range  13.5  to 
80.5  years)  and  75.4  kg  (range  48.3  to  129  kg),  respectively.  There  was  no  association 
between  weight  and  age  (r  =  0.139,  p=0.334),  or  weight  and  genotypes  of  ABCB  1 
c.  1236C>T  (p  =  0.279)  and  c.  3435C>T  (p  =  0.340).  Female  patients  had  a  slightly 
lower  body  weight  than  male  patients  (70.8  kg  vs  79.0  kg;  p=0.057).  The  duration  of 
treatment  from  initiation  of  LTG  to  time  of  final  blood  sample,  was  between  I  and  131 
weeks  (mean  62  weeks).  The  daily  doses  of  LTG  ranged  between  50  mg  and  550  mg 
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5.3.4.2  Genotype  distribution  of  ABCBI  c.  1236C>T  and  c.  3435C>T 
polymorphisms 
The  genotype  frequencies  of  the  ABCB  I  c.  1236C>T  polymorphism  was  14%  C/C,  52% 
C/T,  and  34%  T/T..  The  genotype  frequencies  of  the  c.  3435C>T  polymorphism  was 
28%  C/C,  46%  C/T,  and  26%  T/T.  The  genotype  distributions  of  ABCB  1  c.  1236C>T 
and  c.  3435C>T  polymorphisms  were  consistent  with  HWE  (p  =  0.853  and  p=0.841, 
respectively). 
5.3.4.3  Lamotrigine  population  pharmacokinetics 
The  OBJF  values  for  selected  pharmacokinetic  models  fitted  using  NONMEM®  are 
presented  in  TABLE  5.12.  The  first  pharmacokinetic  model  incorporating  a  combined 
error  model  had  an  OBJF  value  of  257.7  with  an  aborted  covariance  step.  The  OBJF 
value  did  not  significantly  change  when  the  interindividual  variability  in  K.  was  fixed  to 
zero,  however,  the  covariance  step  managed  to  achieve  completion.  This  simpler  model 
was  chosen  as  the  base  model  (Model  2)  and  provided  the  following  initial  estimates  of 
population  values  (mean  value  with  relative  standard  error  expressed  as  a  percentage): 
OCL  =  2.46  Uh  (7.5%)  cvn,  =  45.3%  (22.4%) 
Ov  =  51.51(41.0%)  cv￿  =  132%  (62%) 
OKa  =  1.57  /h  (73.0%) 
Plots  of  individual  estimates  of  CL/F  versus  clinical  factors  are  presented  in  FIGURE 
5.5.  There  was  no  significant  correlation  between  the  individual  estimates  of  CIJF  and 
the  clinical  factors,  except  for  body  weight  (r  =  0.490,  p<0.001).  Plots  of  individual 
estimates  of  CL/F  versus  genotypes  of  the  ABCB  1  c.  1236C>T  and  c.  3435C>T 
polymorphisms  are  presented  in  FIGURE  5.6.  There  was  no  significant  difference  in Chapter  5:  Pharmacogenetics  of  Lamotrigine  222 
individual  estimates  of  CL/F  between  genotypes  of  either  ABCB  1  c.  1236C>T  (p  = 
0.690)  or  c.  3435C>T  (p  =  0.384). 
The  GAM  analysis  produced  similar  results  to  those  obtained  with  the  scatterplots 
(FIGURE  5.7).  None  of  the  factors  tested  improved  the  AIC  value  of  the  base  model 
(Model  2),  except  body  weight.  Addition  of  other  factors  into  the  model  did  not  improve 
the  AIC  value  in  the  presence  of  weight.  These  analyses  indicated  that  weight  was  the 
only  factor  that  was  likely  to  improve  the  population  model  fit. 
A  linear  effect  of  weight  on  the  population  value  of  CL/F  improved  the  pharmacokinetic 
model  fit  (Model  3)  and  reduced  the  interindividual  coefficient  of  variation  in  clearance 
from  45%  to  37%.  There  was  no  advantage  in  using  a  non-linear  model  to  describe  the 
influence  of  weight.  Although  no  influence  of  weight  could  be  detected  on  Vd/F,  this 
was  deemed  to  be  physiologically  appropriate  and  therefore  included  (Model  4;  TABLE 
5.12).  The  residual  error  was  adequately  described  using  a  proportional  error  model. 
Model  4  was  therefore  used  to  evaluate  the  effects  of  ABCB  1  gene  polymorphisms  on 
LTG  pharmacokinetics.  Addition  of  ABCBI  e.  1236C>T  and  c.  3435C>T  genotype 
scores  into  model  4,  either  individually  or  in  combination,  did  not  significantly  improve 
the  OBJF  value  (Models  5&6;  TABLE  5.12).  The  model  fitting  was  consistent  with 
the  results  of  GAM  analysis  and  visual  examination  of  the  scatterplots. ý 
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The  optimal  pharmacokinetic  model  for  LTG  provided  the  following  estimates  of 
population  values  (mean  value  with  relative  standard  error  expressed  as  a  percentage; 
TABLE  5.13): 
OcL  =  0.0334  1/h/kg  (6.4%)  cvCý  =  37.8%  (22.4%) 
Ov  =  0.5151/kg  (37.0%)  cv￿  =  136%  (46.4%) 
OKa  =  0.681  /h  (37.0%) 
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Both  the  estimates  of  Vd/F  and  K$  were  poorly  characterised  with  relative  standard 
errors  of  37%  and  the  interindividual  variability  in  Vd/F  had  an  estimated  cv  of  136%, 
which  again  indicates  wide  interindividual  variability. 
The  measured  versus  population  predicted  and  individual  predicted  LTG  concentration 
plots  of  the  base  and  optimal  models  are  presented  in  FIGURE  5.8.  The  plots  indicate  a 
slightly  better  fit  with  the  optimal  model  for  measured,  compared  to  population 
predicted,  concentrations,  with  less  scatter  around  the  line  of  identity.  There  was  no 
difference  between  the  models  when  the  individual  predictions  were  used.  This  is 
expected  since  the  structural  model  was  identical. 
5.3.5  Discussion 
Given  the  wide  variability  in  interindividual  pharmacokinetics,  these  findings  may 
improve  current  understanding  of  the  clinical  pharmacology  of  LTG.  This  investigation 
complements  previous  traditional-type  studies  that  have  been  performed  in  standardised 
populations  receiving  monotherapy  or  polytherapy  regimens  (Cohen  et  al.,  1987; 
Ramsay  et  al.,  1991;  Bartoli  et  al.,  1997;  Hussein  &  Posner,  1997;  Armijo  et  al.,  1999), 
but,  in  addition,  has  uniquely  examined  the  effects  of  ABCB  I  gene  polymorphisms  on 
LTG  pharmacokinetics. Chapter  5:  Pharmacogenetics  of  Lamotrigine  228 
TABLE  5.13.  Lamotrigine  pharmacokinetic  parameter  estimates  and  their  relative 
standard  errors  (RSE)  using  various  models. 
Model 
Parameter  23456 
Base  model  Optimal  model 
OcL  2.46  0.033  0.0334  0.0324  0.0329 
RSE  OCL  7.5%  6.3%  6.4%  8.5%  7.4% 
Ovd  51.5  42.1  0.515  0.529  0.508 
RSE  OW  41.0%  38.0%  37.0%  37.0%  37.0% 
OKa  1.57  0.709  0.681  0.657  0.691 
RSE  OKa  73.0%  35.0%  37.0%  40.0%  38.0% 
OAdd  NG  0.0974  --- 
RSE  OAdd  -  428%  --- 
OPro  0.276  0.262  0.265  0.267  0.264 
RSE  OPro  8.5%  10.0%  7.7%  7.7%  7.7% 
OPo11  ---0.132 
RSE  OPo11  --- 
136%  - 
OPo12  ---0.0552 
0.0319 
RSE  OPo12  --- 
237%  398% 
cva  45.3%  37.3%  37.8%  36.9%  37.8% 
RSE  CVCL  22.4%  22.9%  22.4%  22.2%  21.9% 
cvvd  132%  141%  136%  138%  134% 
RSE  cv.  62%  24.5%  46.4%  49.6%  47.7% 
0,  population  value;  CL,  oral  clearance;  Vd,  volume  of  distribution;  Ka,  rate 
constant  of  absorption;  cv,  coefficient  of  variation;  Poll,  polymorphism  of 
ABCB1  c.  3435C>T;  Po12,  polymorphism  of  ABCBI  c.  1236C>T;  Add,  additive 
error;  Pro,  proportional  error;  NG,  negligible. Chapter  5:  Pharmacogenetics  of  Lamotrigine 
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Population  pharmacokinetic  analysis  methods,  such  as  NONMEM®,  were  originally 
designed  for  the  analysis  of  the  type  of  sparse  data  that  is  routinely  collected  in  a 
clinical  setting.  However,  these  approaches  have  also  been  shown  to  be  useful  in 
analyzing  rich  data  sets  collected  in  an  experimental  setting.  The  advantages  of  using 
NONMEM®  include  the  ability  to  estimate  pharmacokinetic  parameters  for  individuals, 
to  correctly  handle  differing  numbers  of  data  points  per  patient,  to  investigate  the 
influence  of  clinical  factors  on  pharmacokinetic  parameters,  and  to  separate  random 
effects  into  interindividual  variability  in  pharmacokinetic  parameters  and  residual  error 
in  concentration  measurements. 
When  compared  with  published  data,  only  the  population  estimates  of  CUF  were 
consistent  with  previous  results.  The  estimate  of  Vd/F  was  half  that  of  previous  reports 
and  K.  was  one  third  of  the  value  that  has  been  reported  elsewhere  (Cohen  et  al.,  1987; 
Ramsay  et  al.,  1991;  Hussein  &  Posner,  1997;  Wooton  et  al.,  1997).  Both  of  these  latter 
parameters  were  poorly  characterised  (relative  standard  error  37%)  and  interindividual 
variability  in  Vd/F  was  high.  Poor  quality  data  obtained  during  the  absorption  phase  up 
to  the  time  of  peak  concentration  might  have  contributed  to  the  inadequate  estimation. 
The  time  to  peak  concentration  for  individual  LTG  doses  in  a  chronic  treatment  regimen 
has  been  reported  to  range  between  0.5  and  4.0  hours  (Cohen  et  al.,  1987).  In  this  study, 
the  majority  of  samples  (67.3%)  were  collected  within  4  hours  of  the  last  dose  and 
would  thus  have  been  influenced  by  variability  in  CUF,  Vd/F  and  K.  To  estimate  all 
parameters  effectively  with  sparse  data  collection  in  the  absorption  and  distribution 
phases  is  difficult.  In  addition  to  the  high  interindividual  variability  and  narrow  range  of 
time  to  peak  concentration,  any  small  inaccuracy  in  recording  the  time  of  last  dose  and 
the  time  of  blood  sampling  could,  in  theory,  have  influenced  the  estimates  of  Vd/F  and 
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In  this  study,  the  optimal  population  estimate  for  CL/F  was  0.033  1/h/kg  or  2.5  1/h  based 
on  a  mean  population  body  weight  of  75  kg.  This  is  in  agreement  with  previously 
published  values  (Cohen  et  al.,  1987;  Hussein  &  Posner,  1997;  Wooton  et  a!.,  1997). 
The  magnitude  of  interpatient  variability  in  CL/F  was  38%,  which  indicates  significant 
unexplained  interindividual  variation. 
Although  the  estimate  of  CL/F  was  consistent  with  a  previous  report  (Hussein  &  Posner, 
1997),  it  failed  to  demonstrate  any  association  with  the  duration  of  therapy.  This  is 
probably  because  most  of  the  blood  samples  (73%)  were  taken  after  at  least  8  weeks  on 
therapy,  which  is  beyond  the  expected  time  of  completion  of  the  autoinduction  process 
with  LTG.  It  is  believed  that  the  autoinduction  process  is  complete  within  2  weeks  after 
LTG  initiation  (Hussein  and  Posner,  1997),  and  that  the  short  duration  of  autoinduction 
with  LTG  is  unlikely  to  be  clinically  significant  (Rambeck  &  Wolf,  1993). 
The  interindividual  variability  in  CL/F  was  reduced  slightly  when  body  weight  was 
included  in  the  model.  This  finding  is  consistent  with  a  previous  study  by  Hussein  & 
Posner,  (1997)  who  found  that  a  higher  body  weight  was  associated  with  a  higher  CUF. 
This  may  be  explained  by  the  proposed  correlation  between  body  weight  and  liver  size. 
Some  studies  have  demonstrated  a  significant  correlation  between  body  weight  and  liver 
size  (Andersen  et  al.,  2000)  and  for  drugs  that  are  principally  metabolised  in  the  liver, 
there  is  a  clear  association  between  systemic  clearance  and  lean  body  mass  (Morgan  & 
Bray,  1994).  Studies  exploring  the  relationship  between  liver  size  and  AED  clearance 
are  limited.  A  single  study  in  children  and  adolescents  receiving  CBZ  demonstrated  that 
clearance  was  correlated  with  liver  volume  (Reith  et  al.,  2000).  The  present  study  lends 
further  weight  to  the  proposed  association  between  body  weight  and  the  clearance  of 
AEDs  which  undergo  hepatic  metabolism. Chapter  5:  Pharmacogenetics  of  Lamotrigine  232 
The  wide  tissue  distribution  and  disparate  list  of  compounds  that  are  transported  by  P- 
gp  indicate  its  potentially  important  role  in  drug  absorption,  distribution,  and 
elimination.  Genetic  polymorphisms  that  alter  the  drug  transport  capacity  of  P-gp 
therefore  have  the  potential  to  affect  the  pharmacokinetics  of  many  therapeutic  agents. 
The  most  commonly  studied  ABCB  1  polymorphisms  are  c.  123  6C>T,  c.  2677G>T/A  and 
c.  3435C>T  substitutions.  Significant  linkage  disequilibrium  between  these 
polymorphisms  has  been  reported  in  both  Oriental  and  Caucasian  populations  (Kim  et 
al.,  2001;  Tang  et  al.,  2002).  Although  the  functional  significance  of  ABCB  1  variants 
remains  controversial,  genotypes  and  haplotypes  of  ABCB  1  polymorphisms  have  been 
associated  with  alterations  in  the  pharmacokinetics  of  drugs  such  as  digoxin  (11offineyer 
et  al.,  2000),  fexofenadine  (Kim  et  al.,  2001)  and  cyclosporin  (Yates  et  al.,  2003). 
The  current  study  suggests  that  ABCB  1  c.  1236C>T  and  c.  3435C>T  polymorphisms  do 
not  significantly  influence  the  clearance  of  LTG.  The  most  obvious  explanations  for  this 
observation  include  the  possibility  that  LTG  may  be  not  a  substrate  for  P-gp,  or  that  the 
polymorphisms  investigated  do  not  significantly  influence  the  expression  or  activity  of 
P-gp.  However,  it  is  reasonable  to  speculate  that  the  level  of  expression  of  P-gp  in  the 
intestine  and  any  genetic  variability  therein  may  not  be  sufficient  to  influence  the 
pharmacokinetics  of  a  drug  with  high  oral  bioavailability  such  as  LTG  (Patsalos,  1999). 
Equally,  P-gp  efflux  transport  capacity  may  be  saturable,  leading  to  substrate  overload, 
and  absorption  of  LTG  by  passive  diffusion  or  active  influx  transport  (Cascorbi,  2006). 
Either  of  these  alternative  mechanisms  could  potentially  mask  any  deficiency  in  P-gp 
transport  capacity  resulting  from  genetic  polymorphisms.  A  study  with  cyclosporin  has 
shown  that  the  effect  of  the  ABCB1  3435C>T  polymorphism  on  CL/F  can  be  largely 
attributed  to  altered  absorption  rather  than  hepatic  clearance  (Yates  et  al.,  2003).  In 
addition,  a  study  with  digoxin  has  also  highlighted  the  important  effect  of  the  ABCB  I 
3435C>T  polymorphism  on  the  extent  of  absorption  rather  than  the  rate  of  renal Chapter  5:  Pharmacogenetics  of  Lamotrigine  233 
clearance  (Johne  et  al.,  2002).  Accordingly,  the  current  study  may  indirectly  indicate 
that  the  effect  of  ABCB1  c.  1236C>T  and  c.  3435C>T  polymorphisms  on  the  absorption 
of  LTG  is  negligible. 
There  was  a  large  variation  in.  LTG  CL/F  within  each  ABCB  I  genotypic  group.  This 
might  indicate  the  presence  of  other  confounding  factors,  including  as  yet  undetected 
SNPs  or  dietary  and  environmental  contributors.  It  is  also  possible  that  the  overall  rate 
of  LTG  clearance  is  predominantly  influenced  by  physiological  factors,  rather  than 
genetic  polymorphisms.  Other  than  the  sample  size  issue,  the  variability  in  estimated 
pharmacokinetic  parameters  can  be  attributed  collectively  to  model  mis-specification, 
assay  variability,  intraindividual  variability  and  non-compliance  with  medication.  Some 
of  this  variability  may  also  be  related  to  the  assumption  of  a  12-hour  dosing  interval  in 
subjects  with  incomplete  dosing  records. 
5.3.6  Conclusion 
The  population  pharmacokinetic  parameter  estimate  of  CL/F  during  LTG  monotherapy 
was  in  good  agreement  with  the  findings  of  previous  studies.  Steady-state  plasma  LTG 
concentrations  can  be  affected  by  the  influence  of  body  weight  on  clearance.  There  was 
no  clear  evidence  to  support  the  functional  involvement  of  ABCB  i  c.  1236C>T  and 
c.  3435C>T  polymorphisms  in  the  CL/F  of  LTG.  The  current  study  findings  need  to  be 
verified  in  a  large,  prospective,  purposely-designed  pharmacokinetic  study. CHAPTER  6 
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The  objective  of  this  programme  of  work  was  to  examine  the  influence  of  genetic 
variability  in  DME,  DTP  and  voltage-gated  sodium  channel  genes  on  the  clinical 
pharmacology  of  CBZ  and  LTG.  The  individual  projects  which  comprise  this  thesis  are 
to  a  certain  extent  diverse,  although  not  unrelated.  While  the  general  introduction 
endeavours  to  summarise  present  understanding  of  epilepsy,  its  clinical  treatment, 
variation  in  human  genetics,  the  pharmacogenetics  of  AEDs,  the  clinical  pharmacology 
of  CBZ  and  LTG,  and  the  genes  and  SNPs  of  interest,  the  individual  results  chapters 
developed  particular  aspects  of  the  pharmacogenetics  of  CBZ  and  LTG  in  more  detail. 
Chapter  3  addressed  the  prevalence  of  common  polymorphisms  in  the  genes  of  interest 
and  the  validity  of  the  methods  used  to  identify  these  genetic  variants.  Next,  in  chapter 
4,  an  attempt  to  study  the  influence  of  common  polymorphisms  in  DME  and  sodium 
channel  genes  on  the  optimal  dose  and  adverse  effect  profile  of  CBZ  (sections  4.1  and 
4.2).  Finally,  in  chapter  5,  a  series  of  studies  was  conducted  to  investigate  the  influence 
of  common  polymorphisms  in  ABCB  1  and  sodium  channel  genes  on  the  treatment 
response,  optimal  dose  and  pharmacokinetic  parameters  of  LTG  (sections  5.1  -  5.3). 
Individual  results  are  discussed  in  detail  in  the  relevant  sections,  both  in  relation  to  their 
particular  limitations  and  in  their  consistency  with  previously  published  work.  This 
general  discussion  attempts  to  summarise  individual  aspects  of  this  project  and  to 
highlight  those  of  particular  interest. 
Interindividual  variability  in  the  response  to  drug  treatment  is  the  fundamental  basis  of 
pharmacogenetic  studies.  Pharmacogenetics  offers  a  systematic  approach  to  the 
evaluation  of  genetic  influences  on  the  response  to  individual  drug  treatments.  With  this Chapter  6:  Discussion  &  Conclusion  236 
in  mind,  this  project  has  attempted  to  improve  the  current  understanding  of  the  clinical 
pharmacology  of  AEDs.  Previous  studies  in  this  regard  have  tended  to  focus  on  the 
association  between  genetic  variation  and  pharmacokinetic  mechanisms  influencing 
AED  disposition.  Less  emphasis  has  been  given  to  the  potential  influence  of  variation  in 
genes  encoding  AED  targets  (Ferraro  &  Buono,  2005).  Although  this  project  has 
principally  concentrated  on  pharmacokinetic  factors,  efforts  were  also  made  to  examine 
pharmacodynamic  influences. 
The  ability  of  the  body  to  eliminate  AEDs  and  their  metabolites  affects  the  magnitude 
and  duration  of  efficacy  (Perucca,  1999).  Responsiveness  to  AEDs  can  be  influenced  by 
drug  metabolism  in  several  ways.  Under  normal  circumstances,  when  the  parent  drug  is 
the  principle  active  compound,  DME  variants  that  have  relatively  low  activity  may  be 
associated  with  higher  plasma  drug  concentrations  than  might  otherwise  be  expected 
under  standard  dosing  regimens.  This  may  result  in  the  occurrence  of  adverse  effects. 
On  the  other  hand,  DME  variants  with  relatively  high  enzymatic  activity  may  be 
associated  with  lower  plasma  drug  concentrations  than  might  otherwise  be  expected 
under  standard  dosing  regimens.  This  may  result  in  a  lack  of  efficacy.  In  the  case  of 
AEDs  that  are  metabolically  activated,  such  as  oxcarbazepine  (Perucca,  2001), 
relatively  lower  biotransformation  capacity  may  result  in  treatment  failure  due  to 
inadequate  plasma  concentrations  of  the  active  compound,  whereas,  relatively  higher 
bioactivation  may  result  in  the  elevation  of  plasma  concentrations  and  the  risk  of 
adverse  effects.  For  AEDs  that  are  active  as  both  parent  and  metabolite,  for  example 
CBZ,  the  influences  of  variable  DME  activity  are  more  complex  and  dependent  upon 
the  specific  nature  of  the  metabolic  pathway  and  the  relative  contribution  of  individual 
compounds  to  the  efficacy  and  tolerability  profiles.  Thus,  there  are  a  variety  of  potential 
mechanisms  by  which  polymorphisms  in  DME  genes  can  influence  AED 
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In  addition  to  the  above,  the  extent  by  which  AEDs  are  absorbed  and  distributed  to 
various  regions  of  the  brain  influences  their  potency  and  adverse  effect  profile  (Browne, 
1998;  Kim,  2002b;  Ramachandran  &  Shorvon,  2003).  The  absorption  of  AEDs  and  their 
distribution  to  organs  and  tissues  is  determined  not  only  by  the  physicochemical 
properties  of  the  drugs  themselves,  but  also  by  endogenous  molecules  such  as  DTPs  and 
plasma  proteins  (Kim,  2002b;  Patsalos  &  Perucca,  2003).  Several  DTP  systems  have 
been  described  that  are  responsible  for  moving  substrates  both  in  and  out  of  cells,  which 
would  suggest  that  DTPs  can  be  involved  in  drug  pharmacokinetics  from  multiple 
mechanistic  standpoints  (Kim,  2002a;  Kim,  2002b).  The  most  extensively  studied  DTP 
in  the  epilepsy  field  is  P-gp,  which  has  been  proposed  to  transport  several  AEDs 
(Potschka  et  al.,  2002).  Like  DMEs,  the  expression  and  activity  of  P-gp  may  also  be 
affected  by  polymorphisms  in  the  encoding  gene  (Hoffineyer  et  al.,  2000). 
Most  AEDs  have  multiple  mechanisms  of  action  (Kwan  et  al.,  2001),  and  definitive 
evidence  linking  specific  molecular  targets  to  individual  drugs  is lacking.  It  is  likely  that 
the  effects  of  any  given  AED  are  a  composite  of  its  entire  spectrum  of  cellular  actions. 
The  most  common  AED  target  is  the  voltage-gated  sodium  channel  (Kwan  et  al.,  2001), 
an  observation  which  may  be  consistent  with  the  premise  that  epilepsy  can  be  viewed  as 
arising  from  group  of  diverse  ion  channelopathies.  There  is  increasing  evidence  to 
support  the  notion  that  several  forms  of  epilepsy  are  associated  with  common  allelic 
variants  in  SCN  genes  (Ceulemans  et  al.,  2004;  Kamiya,  2004).  Thus,  it  is  possible  that 
disease  susceptibility  variants  may  influence  therapeutic  activity  of  AEDs  and 
potentially  contribute  to  the  phenomenon  of  pharmacoresistant  epilepsy.  This  should  be 
considered  in  the  design  and  analysis  of  drug  target  pharmacogenetic  studies. 
In  section  3.1,  there  were  significant  differences  in  the  prevalences  of  common 
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between  the  400-strong  study  population  and  those  observed  in  previously  published 
non-Caucasian  populations.  The  genotype  distributions  of  these  polymorphisms  were 
consistent  with  those  predicted  by  HWE.  Deviation  from  IIWE  is  often  associated  with 
systematic  error  in  the  genotyping  methodology  (Xu  et  al.,  2002;  Ilosking  et  al.,  2004; 
Salanti  et  al.,  2005;  Wittke-Thompson  et  al.,  2005).  Thus,  HWE  can  be  useful  as  an 
initial  test  to  evaluate  assay  reliability.  In  section  3.1,  the  PCR-RFLP  assay  designed  for 
the  identification  of  EPHX1  c.  337T>C  polymorphisms  produced  a  genotype 
distribution  that  was  inconsistent  with  HWE.  Re-analysis  was  conducted  for  this 
polymorphism  using  direct  sequencing.  The  genotype  distribution  identified  by  direct 
sequencing  was  consistent  with  HWE.  If  one  assumes  that  this  discrepancy  was  a 
reflection  of  the  genotyping  methodology  and  not  a  characteristic  of  the  population 
itself,  then  it  is  reasonable  to  suggest  that  direct  sequencing  is  a  more  reliable  technique 
than  PCR-RFLP  for  the  identification  of  the  EPHXI  c.  337T>C  polymorphism.  Indeed, 
several  studies  employing  a  PCR-RFLP  assay  to  identify  this  polymorphism  have 
reported  a  similar  problem  (Takeyabu  et  al.,  2000;  Gsur  et  al.,  2003;  Godderis  et  al., 
2004). 
Given  that  two  of  the  study  subjects  were  not  European,  population  stratification  can  be 
useful  to  eliminate  the  diversity  in  drug  response  between  ethnics.  Population 
stratification  refers  to  differences  in  allele  frequencies  between  cases  and  controls  due  to 
systematic  differences  in  ancestry  rather  than  association  of  genes  and  disease.  It  has 
been  proposed  that  false  positive  associations  due  to  stratification  can  be  controlled  by 
genotyping  a  few  dozen  unlinked  genetic  markers.  This  available  method  is  also  known 
as  genomic  control.  Further  studies  should  utilise  this  approach  to  address  the 
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Response  to  AED  treatment  can  be  defined  in  terms  of  efficacy  (abolition  of  seizures  or 
reduction  in  their  frequency)  or  in  terms  of  tolerability  (prevalence  and/or  severity  of 
adverse  effects).  However,  it  is  a  challenge  to  establish  a  definite  association  between 
genotype  and  treatment  response  phenotype  because  non-genetic  confounders,  such  as 
drug-drug  interactions,  treatment  compliance  and  patient  lifestyle,  are  difficult  to 
control.  The  AED  response  phenotype  is  highly  complex  and  represents  a  classic 
example  of  the  interaction  between  genetic  and  environmental  factors.  As  a  result, 
understanding  genetic  variation  may  not  fully  explain  the  outcome  of  pharmacological 
treatment.  When  faced  with  such  difficulties  in  defining  responsiveness,  it  may  be  more 
prudent  to  employ  pharmacokinetic  parameters  as  the  principal  phenotypic  definition  in 
AED  pharmacogenetic  studies.  These  are  more  quantifiable  and  more  reliable  than 
measures  of  efficacy  and/or  tolerability  and  a  more  easily  extrapolated  from  patient  to 
patient,  investigator  to  investigator  and  from  research  centre  to  research  centre.  Even 
then,  a  multitude  of  events  and  protein  interactions  occur  from  the  moment  that  an  AED 
is  ingested.  The  fundamental  issues  of  absorption,  distribution,  metabolism  and 
excretion  all  involve  interaction  with  multiple  endogenous  and  exogenous  factors, 
binding  of  drug  to  target  proteins,  and  interactions  of  those  proteins  with  both  other 
proteins  and  DNA  (Spear,  2001;  Clancy  &  Kass,  2003;  Ramachandran  &  Shorvon, 
2003).  Despite  this  enormous  complexity,  it  is  possible  that  identifying  the  relative 
contribution  of  genetic  variation  to  the  phenotype  of  AED  response  will  permit 
preliminary  progress  in  the  field  of  pharmacogenetics. 
Using  a  comprehensive  drug  response  phenotype  definition  and  a  well-defined  study 
population  can  improve  the  quality  of  pharmacogenetic  findings,  and  result  in  a  better 
understanding  of  the  association  between  genotypes  and  phenotypes.  In  the  current 
project,  for  studies  involving  drug  responsiveness  and  clinical  outcome,  inter- 
investigator  variability  in  clinical  practice  and  in  the  assessment  of  individual  patients Chapter  6:  Discussion  &  Conclusion  240 
was  largely  eliminated  by  the  selection  of  subjects  from  research  projects  within  a 
single  centre  and  which  employed  a  similar  procedure  for  the  initiation  of  treatment  and 
clinical  follow-up.  This  ensured  that  all  patients  were  treated  equally.  The  potentially 
confounding  effects  of  drug-drug  interactions  on  drug  response  phenotypes  were 
similarly  eliminated  by  employing  only  those  patients  who  were  treated  with  AED 
monotherapy.  Drug-drug  interactions  can  affect  the  dose  and  concentration  of  each 
individual  compound  in  the  therapy  regimen  (Patsalos  &  Perucca,  2003),  with  a 
consequent  influence  on  treatment  response.  CBZ  and  LTG  were  evaluated  individually 
as  each  drug  has  different  pharmacokinetic  and  pharmacodynamic  characteristics. 
Categorising  patients  according  to  the  severity  of  their  seizures  may  have  helped  to 
optimise  the  phenotype  definition.  However,  given  the  limited  number  of  patients  and 
the  retrospective  nature  of  this  project,  no  sub-analysis  was  performed  in  terms  of 
seizure  severity. 
To  identify  a  pure  association  between  genotype  and  drug  response  phenotype,  one 
should  also  consider  the  clinical  relevance  of  each  phenotypic  definition.  Drug  response 
phenotypic  definitions  that  are  clinically  relevant  have  more  practical  application  and 
thus,  increase  the  value  of  pharmacogenetic  findings.  With  this  in  mind,  in  Chapters  4 
and  5,  OD  was  employed  as  a  composite  measure  of  both  efficacy  and  tolerability  of 
CBZ  and  LTG,  respectively.  The  OD  is  equivalent  to  the  maintenance  dose  and  is  more 
advantageous  than  maximal  tolerated  dose.  Previously,  association  between  genetic 
markers  and  maximal  tolerated  doses  of  PHT  and  CBZ  has  been  reported  by  Tate  et  a!. 
(2005).  The  maximal  tolerated  dose  phenotype  has  clinical  implications  with  regard  to 
safety  but  does  not  provide  any  measure  of  efficacy  that  might  have  added  to  the 
clinical  applicability  of  the  findings.  Many  patients,  even  in  a  tertiary  referral  setting, 
become  seizure  free  on  a  modest  dose  and  may  never  reach  their  personal  limit  of 
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dose  on  the  basis  of  genotype  is  of  limited  and  non-existent  value.  In  the  current  study, 
clinical  response  phenotypes  focused  on  two  relevant  outcomes,  namely  seizure 
freedom  and  intolerable  adverse  effects.  These  outcome  measures  demonstrate  the 
efficacy  and  safety  of  AEDs,  respectively.  The  probability  of  achieving  seizure  freedom 
varies  greatly  depending  on  the  effectiveness  of  treatment  and  also  on  seizure  severity, 
pre-treatment  seizure  frequency  and  the  duration  of  the  assessment  period  (Pcrucca, 
1997;  Kwan  &  Brodie,  2000).  Intolerable  adverse  effects  of  AEDs  arc  the  most 
common  reason  for  early  treatment  withdrawal.  In  many  patients,  the  health-related 
quality  of  life  is  affected  more  by  adverse  effects  than  by  seizures  themself  (Perucca, 
1997).  As  such,  evaluation  of  seizure  freedom  and  adverse  effects  represents  an 
important  component  in  the  assessment  of  overall  clinical  outcome. 
In  section  4.1,  the  influence  of  genetic  variability  on  CBZ  dose  requirement  was 
evaluated.  Like  most  AEDs,  CBZ  doses  are  predominantly  determined  by  the  level  of 
response  and  the  occurrence  of  adverse  effects.  Inadequate  seizure  control  necessitates 
an  increase  in  CBZ  dose,  whereas  the  emergence  of  adverse  effects  limits  the  amount  of 
drug  that  can  be  prescribed.  Dosage  adjustment  of  CBZ  is  complicated  due  to  the 
potential  for  drug-drug  interactions  and  the  phenomenon  of  autoinduction.  As  a  result  of 
autoinduction  and  the  onset  of  adverse  effects,  the  maintenance  dose  of  CBZ  will  be 
higher  than  the  initial  dose,  but  often  lower  than  maximum  dose.  Typical  CBZ 
maintenance  doses  have  been  reported  between  200  to  1600  mg/day  (Kwan  &  Brodie, 
2001),  similar  to  the  range  of  doses  observed  in  the  current  project. 
This  project  identified  polymorphisms  in  the  EPHX1  gene  as  potential  predictors  of  the 
OD  of  CBZ.  The  influence  of  DME  variants  on  the  pharmacokinetics  of  CBZ  is 
important  because  CBZ  is  predominantly  metabolised  through  hepatic  enzyme 
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CYP3A4  and  CYP3A5  genes  (Gracia-Martin  et  al.,  2002)  and  the  most  common  of 
these  had  no  influence  on  CBZ  dose.  This  might  suggest  that  any  genetically  determined 
variability  in  CBZ  metabolism  occurs  at  other  stages  of  the  pathway.  It  is  possible  that 
the  rate  of  CBZ-E  hydrolysis  could  determine  the  variability  in  CBZ  metabolism.  This 
hydrolysis  process  is  predominantly  mediated  by  mEH  (Pelkonen  et  al.,  2001). 
Polymorphisms  in  the  EPHX1  gene  are  known  to  affect  the  activity  of  mEll  (Nakajima 
et  al.,  2005)  and  therefore  have  the  potential  to  influence  plasma  concentrations  of  CBZ 
and  its  dose  requirement.  Other  common  DME  polymorphisms  examined  did  not 
predict  the  OD  of  CBZ.  This  might  suggest  that  these  polymorphisms  have  limited 
functional  consequences  or  that  the  enzymes  in  question  are  not  fundamental 
contributors  to  CBZ  metabolism.  On  the  basis  of  this  study,  it  would  appear  that  genetic 
variants  of  the  EPHX1  gene  are  the  strongest  candidate  markers  of  inter-individual 
variability  in  CBZ  dosing. 
In  section  4.2,  the  association  between  polymorphisms  in  DME  genes  and  a  unique 
phenotype  that  may  be  exquisitely  sensitive  to  CBZ  adverse  effects  was  evaluated.  This 
study  failed  to  reveal  any  association  between  common  genetic  polymorphisms  and  the 
proposed  phenotype  in  question.  Previous  studies  examining  the  EPIIXI  gene  have  also 
failed  to  associate  multiple  polymorphisms  with  the  incidence  of  CBZ  hypersensitivity 
reaction  (Gaedigk  et  al.,  1994;  Green  et  al.,  1995).  Two  common  polymorphisms 
(c.  337T>C  and  c.  416A>G)  in  the  EPHX1  gene  have,  however,  been  associated  with 
variation  in  the  plasma  concentrations  of  CBZ-E  (Nakajima  cl  al.,  2005).  If  the 
functional  effect  of  these  polymorphisms  is  genuine  and  if  they  are  associated  with  CBZ 
dose  (as  reported  in  section  4.1),  the  the  current  study  might  question  the  popular  notion 
that  CBZ-E  is  responsible  for  precipitating  many  of  the  adverse  effects  associated  with 
CBZ  treatment  (Ramsay  &  Wilder,  2002).  Although  it  is  dangerous  to  make  such 
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several  previous  investigations  have  indeed  failed  to  demonstrate  any  correlation 
between  CBZ-E  concentrations  and  the  toxicity  of  CBZ  in  epilepsy  patients  (Theodore 
et  al.,  1989;  Semah  et  al.,  1994).  The  current  study  also  suggested  that,  with  the 
exception  of  EPHXI,  the  contribution  of  other  DME  polymorphisms  to  the  risk  of 
developing  CBZ  adverse  effects  is  modest  or  non-existent.  This  would  support  the 
suggestion  that  common  polymorphisms  in  these  genes  do  not  significantly  influence 
the  activity  of  their  respective  enzymes. 
As  with  other  AEDs,  response  to  LTG  treatment  is  likely  to  be  significantly  influenced 
by  the  activity  of  DMEs,  DTPs  and  sodium  channels.  LTG  is  predominantly 
metabolised  by  UGT1A4  (Magdalou  et  al.,  1992;  Vashishtha  et  al.,  2001)  and  is 
believed  to  be  transported  by  P-gp  (Potschka  et  al.,  2002).  As  such,  the  major 
determinants  of  LTG  pharmacokinetics  are  likely  to  be  UGTIA4  and  P-gp.  The 
mechanism  of  action  of  LTG  is  similar  to  that  of  many  other  AEDs,  such  as  CBZ  and 
PHT,  and  is  mediated  by  inhibition  of  voltage-gated  sodium  channels.  Thus,  any 
alteration  in  the  expression  or  activity  of  UGTIA4,  P-gp  and  voltage-gated  sodium 
channels  has  the  potential  to  impact  on  LTG  pharmacokinetics  and  pharmacodynamics. 
Such  alterations  include  polymorphisms  in  the  respective  encoding  genes.  The  influence 
of  UGTIA4  variants  was  not  examined  in  this  project  because  polymorphisms  in  this 
gene  are  rare  and  no  functional  variants  had  been  reported  in  the  Caucasian  population 
at  the  time  this  project  was  planned.  As  a  result,  only  polymorphisms  in  the  ABCB  1  and 
SCN2A  genes  were  evaluated  in  relation  to  the  LTG  treatment  response  phenotype. 
The  findings  reported  in  section  5.1  suggest  that  ABCB  1  and  SCN2A  variants  do  not 
significantly  influence  the  response  to  LTG  monotherapy.  There  are  several  potential 
explanations  for  this  observation.  Firstly,  LTG  may  not  be  a  strong  substrate  for  P-gp,  in 
which  case  LTG  distribution  in  the  brain  might  not  be  significantly  influenced  by  P-gp- Chapter  6:  Discussion  &  Conclusion  244 
mediated  efflux  transport.  This  is  plausible  because  LTG  is  known  to  be  highly 
lipophilic  (Mashru  et  al.,  2005).  Secondly,  common  polymorphisms  in  ABC131  and 
SCN2A  genes  may  not  be  functional,  and  thus  may  not  affect  the  expression  or  activity 
of  P-gp  or  Na,,  1.2  proteins,  respectively.  Even  if  they  were  functional,  the  modification 
in  protein  structure  or  function  may  not  be  of  sufficient  magnitude  to  influence  the 
response  to  LTG  treatment.  Finally,  it  is  important  to  remember  that  LTG  may  act  on 
other  subtypes  of  voltage-gated  sodium  channel  and  may  be  transported  by  other  DTPs. 
One  should  also  be  aware  that  the  response  to  AED  therapy  in  terms  of  efficacy  is  easily 
influenced  by  other  clinical  and  environmental  factors,  including  seizure  severity  and 
pathological  causes  (Stephen  et  al.,  2001;  Brodie,  2005). 
In  section  5.1,  it  was  reported  that  patients  who  are  seizure  free  on  LTG  monothcrapy 
have  a  wide  distribution  of  optimal  doses.  Since  the  efficacy  of  LTG  treatment  does  not 
significantly  associate  with  its  plasma  concentration  (Kilpatrick  et  al.,  1996;  Mahmood 
et  al.,  1998),  it  is  possible  that  the  diversity  in  dose  requirement  might  be  influenced  by 
inter-individual  variability  in  P-gp  function  and  the  resulting  ability  of  LTG  to  cross  the 
BBB.  Polymorphisms  in  the  ABCB  1  gene  that  have  the  potential  to  alter  the  expression 
and  activity  of  P-gp  were  postulated  to  be  responsible  for  the  spread  of  individual  LTG 
dose  requirements.  This  hypothesis  was  confirmed  (section  5.2)  with  the  association 
between  common  polymorphisms  in  the  ABCBI  gene  and  the  OD  of  LTG.  This  is  an 
interesting  finding  and  one  which  may  help  to  dismiss  concerns  about  whether  LTG  is  a 
substrate  for  P-gp  mediated  transport. 
The  influence  of  ABCB  1  variants  on  LTG  pharmacokinetics  was  further  examined  in  an 
effort  to  understand  the  relationship  between  polymorphisms  in  this  gene  and  LTG 
dose,  as  reported  in  section  5.2.  This  additional  investigation  failed  to  identify  any 
association  with  the  clearance  of  LTG,  suggesting  that  the  influence  of  dose  is  most Chapter  6:  Discussion  &  Conclusion  245 
likely  related  to  some  other  as-yet  unidentified  pharmacokinetic  or  pharmacodynamic 
factors.  P-gp  is  believed  to  be  expressed  in  a  tissue-specific  or  disease-specific  manner 
(Croop  et  al.,  1989).  For  example,  epileptic  brain  tissue  has  been  shown  to  have  a 
higher  expression  of  P-gp  than  normal  brain  (Marchi  et  al.,  2004;  Volk  et  al.,  2004).  It 
is  possible  that,  in  epilepsy  patients,  the  expression  of  P-gp  in  the  gastrointestinal  tract, 
kidney  and  liver  is  relatively  lower  than  that  observed  at  the  BBB.  The  effect  of  ABCB  I 
variants  may  be  enhanced  in  conditions  where  P-gp  is  over-expressed  whereas  genetic 
variability  would  have  less  impact  in  conditions  or  in  tissues  where  P-gp  expression  is 
low  or  normal.  This  would  explain  how  ABCB  1,  polymorphisms  can  associate  with 
LTG  dose  (by  influencing  BBB  transfer)  but  not  LTG  clearance,  which  is  a  more 
peripheral  phenomenon  and  not  necessarily  subject  to  disease  mediated  augmentation. 
The  studies  presented  in  this  thesis  have  revealed  some  previously  unrecognised  factors 
that  may  influence  individual  AED  dose  requirement.  The  predominant  application  of 
these  pharmacogenetic  findings  is  in  AED  dosing  strategies.  Polymorphisms  in  the 
SCN1A  gene  have  previously  been  identified  as  useful  predictors  for  CBZ  and  PUT 
dose  (van  der  Weide  et  al.,  2001;  Tate  et  al.,  2005;  Tate  et  al.,  2006).  This  observation, 
together  with  the  intriguing  findings  presented  in  this  thesis,  provide  a  theoretical 
direction  for  future  clinical  investigations  to  assess  whether  pharmacogenetic  profiling 
can  improve  dosing  decisions.  There  is  clear  clinical  benefit  in  determining  the  optimal 
titration  rate  and  target  dose  for  an  individual  patient.  Those  who  require  a  lower  dose 
and  a  slower  titration  rate  can  be  identified  before  the  initiation  of  treatment,  and  any 
unnecessary  exposure  to  high  doses  of  AEDs  can  be  prevented,  thereby  minimizing  the 
risk  for  adverse  effects.  Similarly,  patients  with  a  high  dosing  requirement  can  be 
titrated  faster  in  order  to  avoid  prolonged  periods  of  under-exposure  and  a  consequent 
lack  of  efficacy.  Pharmacogenetic  profiling  may  also  be  more  useful  than  therapeutic 
drug  monitoring  in  determining  the  dose  of  AEDs,  particularly  for  those  AEDs  that  have Chapter  6:  Discussion  &  Conclusion  246 
a  poor  plasma  concentration-response  relationship  (Patsalos,  2001).  Finally, 
pharmacogenetic  testing  can  be  utilised  prospectively,  before  the  AED  is  started  and 
only  a  small  amount  of  blood  sample  or  a  cheek-swab  sample  is  required  for  genotypic 
analysis. 
These  findings  represent  another  step  in  the  ongoing  effort  to  improve  understanding  of 
the  role  of  pharmacogenetics  in  epilepsy  management.  Knowledge  of  AED  mechanisms 
of  action  and  awareness  of  genetic  factors  that  determine  treatment  response  should  not 
only  improve  the  use  of  AEDs  but  may  also  allow  AEDs  to  be  designed  for  specific 
targets  in  particular  populations  or  that  avoid  any  detrimental  genetic  variability  in 
therapeutic  response.  The  preponderance  of  genetic  polymorphisms  in  the  human 
genome  suggests  that  pharmacogenetic  variability  will  likely  be  an  issue  for 
consideration  in  almost  all  drug  treatments. 
Pharmacogenetic  research  has  developed  rapidly,  with  recent  advances  in  molecular 
genetics  and  genome  sequencing.  This  is  largely  due  to  the  emergence  of  new 
technologies  that  allow  rapid  screening  for  specific  polymorphisms,  as  well  as  recently 
gained  knowledge  of  genetic  sequence  derived  from  the  Human  Genome  project. 
Epilepsy-related  pharmacogenetic  research  is  beginning  to  take  advantage  of  this  new 
information  in  order  to  enhance  current  understanding  of  epilepsy  therapeutics.  This 
new  found  knowledge  can  be  employed  effectively  in  two  main  areas:  identification  of 
specific  genes  and  gene  products  associated  with  various  forms  of  epilepsy  and  which 
may  act  as  targets  for  new  AEDs  and  identification  of  genes  and  allelic  variants  of 
genes  that  can  influence  the  response  to  current  AEDs. 
We  are  still  a  long  way  from  having  a  pharmacogenetic  test  that  clinicians  can  routinely 
use  to  identify  the  most  appropriate  AED  for  any  particular  patient,  however  there  is Chapter  6:  Discussion  &  Conclusion  247 
increasing  evidence  that  pharmacogenetics  will  be  important  in  clinical  practice.  In  the 
future  it  may  be  considered  unethical  not  to  perform  such  tests  routinely  to  avoid 
exposing  individuals  to  doses  of  AEDs  that  could  be  harmful.  The  ability  to  identify 
sensitive  or  insensitive  individuals  before  commencing  AED  treatment  would  also  be  of 
economic  importance.  AED  treatment  based  on  genetic  profile  might  avoid  the  current 
empiricism  associated  with  matching  the  most  appropriate  AED,  at  its  optimal  dose,  to 
each  patient.  The  development  of  pharmacogenetics  as  a  scientific  discipline  should 
offer  a  departure  from  current  empirical  prescribing  and  a  move  towards  more 
individualised  AED  treatment. 
6.2  Future  Research  Directions 
The  recent  advances  in  genetic  technology  encourage  a  rapid  development  of 
pharmacogenetic  research.  The  relatively  high  prevalence  of  seizure  disorders,  limited 
number  of  drugs,  relatively  poor  success  rate  and  the  broad  range  of  interindividual 
responses  make  epilepsy  an  ideal  target  for  pharmacogenetic  research  and  its 
application  in  clinical  practice.  To  date,  pharmacogenetie  studies  in  epilepsy  have 
predominantly  explored  the  association  between  genetic  polymorphisms  and  either  the 
pharmacokinetics  of  specific  AEDs  (i.  e.  PHT)  or  the  efficacy  of  AEDs  in  general 
(irrespective  of  individual  treatments).  Other  established  drugs  such  as  CBZ,  VPA,  PB 
and  ethoxusimide,  and  newer  AEDs  such  as  LTG,  topiramate  and  levetiracetam  have 
not  yet  been  investigated  in  any  significant  detail.  Drugs  with  single  mechanisms  of 
action  (i.  e.  levetiracetam)  or  single  metabolic  pathways  may  be  the  best  place  to  start. 
Levetiracetam  does  not  appear  to  act  via  conventional  AED  mechanisms  such  as, 
GABAergic  facilitation,  inhibition  of  voltage-gated  sodium  channels  or  modulation  of 
voltage-gated  calcium  channels.  In  contrast,  it  would  appear  to  bind  to  synaptic  vesicle 
protein  SV2A,  which  is  ubiquitously  found  in  the  mammalian  CNS  (Lynch  et  al.,  2004). Chapter  6:  Discussion  &  Conclusion  248 
As  such,  genetic  polymorphisms  in  the  SV2A  gene  are  potential  contributors  to 
variability  in  the  response  to  levetiracetam  treatment.  This  is  a  single  example  of  the 
enormous  potential  which  exists  for  the  exploration  of  pharmacogenetics  in  epilepsy  in 
an  effort  to  better  understand  the  clinical  pharmacology  of  both  established  and  modern 
AEDs. 
The  OD  predictive  models  that  were  developed  for  CBZ  and  LTG  in  this  project 
explained  less  than  20%  of  the  dose  variation  between  individuals.  More  genetic  and 
non-genetic  variables  are  clearly  required  to  improve  the  predictability  of  this  approach. 
Polymorphisms  in  genes  which  encode  voltage-gated  sodium  channels,  other  DMEs  and 
other  DTPs  that  are  related  to  the  pharmacokinetics  and  pharmacodynamics  of  CBZ  and 
LTG  may  be  the  most  appropriate  place  to  start.  Polymorphisms  of  the  SCNIA  gene 
that  have  been  reported  to  be  associated  with  the  maximum  dose  of  CBZ  (Tate  et  al., 
2005)  should  almost  certainly  be  included  in  any  such  predictive  model  of  CBZ  OD  or 
LTG  OD,  as  both  drugs  act  by  blockade  of  voltage-gated  sodium  channels.  However, 
other  less  obvious  genes  should  not  be  excluded  and  DME  and  DTP  genes  should  be 
subject  to  further  investigation  particularly  with  regard  to  those  SNPs  which  occur  less 
commonly  than  those  reported  here.  Haplotype  studies  may  be  more  appropriate  than 
those  based  on  genotype  and  whole-genome  scans  may  become  available  in  the  near 
future.  However,  the  genotype-based  approach,  as  presented  in  this  project,  has  some 
advantages  over  the  haplotype  strategy.  Genotyping  may  permit  the  identification  of 
causal  variants,  especially  for  rare  SNPs,  which  can  dramatically  alter  the  expression 
and/or  the  activity  of  their  respective  proteins.  This  approach  is  typically  directed  by  the 
notion  that  functional  variants  are  highly  associated  with  SNPs  located  in  the  promoter 
and  coding  regions.  As  such,  the  number  of  SNPs  which  need  to  be  typed  is limited  and 
this  reduces  the  cost  of  genotyping.  In  fact,  these  are  the  variants  to  which  random  SNPs 
searches  are  most  likely  to  lead  and  such  polymorphisms  are  more  likely  to  be  in Chapter  6:  Discussion  &  Conclusion  249 
linkage  disequilibrium  with  the  causal  allele  (Risch,  2000).  Employing  a  haplotypc 
strategy,  on  the  other  hand,  is  useful  for  SNPs  that  have  a  relatively  high  allele 
frequency  (>10%;  Becquemont,  2003)  and  is  entirely  dependent  on  linkage 
disequilibrium  (Roses,  2000).  Linkage  disequilibrium  occurs  when  combinations  of 
alleles  at  different  loci  present  more  frequently  than  would  be  expected  from  random 
association.  Variations  of  several  ordered  SNPs  that  are  close  to,  or  within,  a  particular 
chromosomal  region  are  likely  to  be  inherited  together  when  they  are  in  linkage 
disequilibrium.  As  such,  SNPs  associated  with  a  drug  response  phenotype  can  `mark' 
the  position  on  the  chromosome  where  a  susceptibility  gene  is  located.  The  whole- 
genome  scan  technique  may  enable  the  identification  of  several  multiple  small 
susceptibility  regions,  within  which  the  search  for  genetic  markers  can  be  focused 
(Roses,  2000).  However,  the  haplotype  strategy  is  not  the  best  choice  for  low  frequency 
SNPs  because  it  misses  rare  haplotypes,  which  might  otherwise  be  clinically  relevant. 
To  generate  stronger  research  data,  prospectively  designed  studies  is  preferred  than 
retrospectively  designed  studies,  largely  because  avoidance  of  confounding  variables.  A 
prospective  study  is  designed  before  the  data  is  collected,  which  allows  the  researchers 
several  advantages  over  the  retrospective  study.  Researchers  can  design  a 
pharmacogenetic  study  with  a  control  group,  design  internal  devices  to  eliminate  bias, 
and  follow  subject  throughout  the  length  of  the  study  to  observe  development  of  the 
outcome  in  question.  The  down-sides  of  prospective  studies  are  that  they  are  more 
expensive  and  time-consuming  to  design  and  execute,  and  are  difficult  to  use  to  study 
rare  polymorphisms  as  the  number  of  subjects  is  often  too  low.  Although  studies 
presented  in  this  thesis  have  produced  several  intriguing  findings,  these  have  to  be 
further  explored  in  prospectively  designed  studies  with  formal  power  calculations 
included  and  followed  by  replication  studies. Chapter  6:  Discussion  &  Conclusion 
6.3  Conclusion 
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In  conclusion,  this  series  of  pharmacogenetic  studies  examined  the  clinical 
pharmacology  of  CBZ  and  LTG  and  served  to  identify  polymorphisms  in  genes 
encoding  mEH  and  P-gp  as  potential  predictors  of  CBZ  and  LTG  OD,  respectively. 
Common  genetic  polymorphisms  of  other  DMEs  that  are  responsible  for  CBZ 
metabolism,  namely  CYP3A4  g.  -392A>G,  CYP3A5  g.  6986A>G,  CYPIA2  g.  5734C>A, 
and  UGT2B7  c.  802C>T,  did  not  significantly  associate  with  the  OD  of  CBZ  and  none 
were  associated  with  CBZ  adverse  effects.  Polymorphisms  in  the  ABCB  I  gene 
encoding  P-gp  did  not  prove  useful  in  predicting  the  response  to  LTG  treatment  and  did 
not  appear  to  influence  the  oral  clearance  of  LTG. 
The  experimental  work  contained  in  this  thesis  advances  current  knowledge  of  the 
association  between  genetic  variability  and  the  clinical  pharmacology  of  AEDs.  Positive 
findings  require  confirmation  in  a  prospectively-designed  study  employing  a  larger 
cohort  of  newly  diagnosed  epilepsy  patients.  Characterisation  of  polymorphisms  in 
genes  that  encode  proteins  related  to  AED  pharmacokinetics  and  pharmacodynamics 
may  enable  us  to  predict  efficacy  and  tolerability  of  AEDs  and  to  make  informed 
decisions  with  regard  to  titration  rates  and  target  doses  for  individual  patients.  Fostering 
a  closer  relationship  between  clinical  pharmacology  and  genetics  has  the  potential  to 
make  significant  progress  in  the  treatment  of  epilepsy. LIST  OF  REFERENCES 
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